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Title An exploration of the management of blood glucose in hospital
patients with diabetes at the end-of-life.
Objective Investigate current practice through retrospective medical notes review
and focus group discussion with palliative care, diabetes and generalist 
specialties to explore their perspectives of end-of-life diabetes care. 
The aim is to inform service development guidelines to improve the 
quality of care for patients with diabetes.
Design An evaluation research method using a mixed method approach was
conducted within an acute care setting.
Deceased patient’s records (n=71) were reviewed and data were 
abstracted for Glycaemic variables, advocacy, diabetes and admission 
variables to determine the factors influencing admission and end-of-life 
diabetes management. Descriptive statistics were used to compare the 
management of cancer and non-cancer patients and referral patterns 
to palliative care and diabetes specialists.
Four focus groups were convened from the individual specialities, and 
a final mixed specialty group was convened. The participants were 
predominantly senior medical, nursing, pharmacy and dietician 
professionals within the hospital.
Results The focus group perception of care ideals was not reflected in the 
medical notes. Capillary Blood Glucose (CBG) is not routinely 
managed at the end-of-life due to rapid deterioration and death in the 
majority of patients. Diabetes is apparently treated generically without 
due consideration to its type or in those patients whose survival goes 
beyond 72 hours up to 16 days. Patients and relatives views are not 
routinely sought. The Liverpool Care Pathway (LCP) and limited 
knowledge for the management of diabetes was found to be a barrier 
to personalised diabetes care.
Conclusion Guidelines have been suggested. Education for practice is required for 
optimal end-of-life care for patients hospitalised with diabetes.
Glossary
IV
CBG Capillary Blood Glucose
DH Department of Health
DKA Diabetic Ketoacidosis
DM Diabetes Medicine
DNAR Do Not Attempt Resuscitation
DPA Data Protection Act 1998
DSN Diabetes Specialist Nurse
HbA-ic Glycated Haemoglobin -standard blood test summarising mean 
blood glucose in last 6-12 weeks
HES Hospital Episode Statistics
HHNS Hyperglycaemic Hyperosmolar Non Ketotic State
LCP Liverpool Care Pathway
NICE National Institute of Health and Clinical Excellence
NHS National Health Service
ONS Office for National Statistics
OPD Out Patient Department
PCDB Palliative Care Database
SPSS Statistical Package for the Social Sciences
UK United Kingdom
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CHAPTER ONE CLINICAL BACKGROUND
1.0. Introduction
The research inquiry aims to explore the management of the patient with diabetes in 
the terminal phase at the end-of-life in the hospital setting. This phase is defined as 
the point where clinically the patient is thought to have days or hours to live and in 
this thesis, it refers to the last 72 hours of life.
This chapter will outline background data about the researcher, the research question 
and key clinical literature that contextualises the research inquiry. This includes the 
main features of diabetes that concern the end-of-life glucose management, palliative 
care principles, hospital care of the dying and the policy and evidence-based 
initiatives that influence it.
The researcher is a senior diabetes specialist nurse (DSN) working in a 500 bed 
acute care trust. The purpose of the role is to provide clinical leadership through 
service development initiatives, and the provision of care planning, education and 
advice for patients, their families and all the staff who have responsibility for patient 
care. The patient caseload varies from managing patients in the short term for insulin 
education in newly diagnosed type 1 patients, to more involved care in those who 
have complex needs arising from inter-current illness, and managing the transition of 
their diabetes care plan through to the early discharge period. Few patients are 
referred to the DSN service for end-of-life care, and knowledge around the 
management for this patient group has been limited within my sphere of experience.
1.0.1. Background to the Research Question
The motivation for conducting the present study arose from two co-occurring critical 
events. These were a clinical incident, and a request to present current literature to
the palliative care journal club to inform end-of-life care in patients with diabetes. The 
latter revealed a paucity of literature on the topic.
The clinical impetus for the present study arose from an incident where I was asked 
by nursing colleagues to review a dying patient for palliation of significant 
hyperglycaemic symptoms. This patient and his family were well known to me during 
the preceding 18 months, where I had supported dose adjustments for his type 2 
diabetes as an in-patient. His prior admissions were for palliation of symptoms 
arising from cancer of the prostate. On his final admission, the patient was clearly 
suffering from an acute urinary and chest infection, with symptomatic evidence of 
acute-on-chronic renal failure, dehydration, anorexia, dyspnoea and anxiety. He 
presented in a generally exhausted state, from which he died within 36 hours of 
admission. The patient had agreed to short-term insulin therapy to manage his 
osmotic symptoms and reduce the debilitating effects of hyperglycaemia. However, 
as I was handing over the treatment plan to the team, the senior consultant physician 
of the unit interrupted the discussion and was very clear about not treating his 
hyperglycaemia with insulin, and cancelled the insulin prescription. The reasons 
cited for this consisted of a list of unfavourable clinical investigation results, and the 
view that insulin would add to the burden of treatment (injection) in a patient whose 
life expectancy was predicted to be within days to weeks. He was not persuaded by 
any argument put in favour of treating. The patient was then told that the physician 
thought that his usual tablets would cover the blood glucose, to which the patient 
responded that his terminal state probably did not merit the effort to treat it. The 
implication suggested by the patient was that his physical state was too hopeless to 
bother about, and he accepted the decision. At an intuitive level, I felt this medical 
decision not only disappointed him, but also disempowered him, reduced his hope 
and his self worth. From a professional perspective, this was a distressing, and an
ethically challenging decision that had the hallmarks of abandonment based on the 
notion of medical futility.
These events prompted the research inquiry to explore the questions that this 
incident had raised about clinical practice decisions for patients with diabetes at the 
end-of-life. The scope of the inquiry aims to explore the views, attitudes, and usual 
practices around blood glucose management, by acute care health professionals in 
the diabetes, palliative care and general specialities, who provide care to this cohort 
of patients. The nature of blood glucose values at the end-of-life and what their 
potential contribution to symptom burden may be; the degree to which health care 
providers sought to involve the relatives and patients in the decisions for their 
diabetes management at the end-of-life were of interest.
The research questions that were generated from this critical event were:
‘Is blood glucose management an important component of end-of-life care in 
, patients with diabetes?
What factors influence the clinical management in the acute care setting?’
1.1. Diabetes Mellitus
Diabetes can be considered to be a disorder of energy homeostasis. The lack of 
insulin or its reduced potency (insulin resistance) is a defining feature of diabetes that 
results in hyperglycaemia (Williams & Pickup, 2000). Glucose is an important fuel 
that is stored and released through a complex and exquisite interplay of 
neuroendocrine mechanisms that provide energy or power to operate the body (Holst 
& Deacon, 2005). Insulin is an important hormone required for the maintenance of 
energy homeostasis as blood glucose levels are regulated by it. High blood glucose 
levels stimulate insulin release, which facilitates the uptake of glucose to the cells for 
conversion to stored fuel (glycogen). In situations where blood glucose levels are
reduced (fasting), insulin levels are also suppressed and this enables the release of 
the hormone glucagon which allows glucose to be released back into the blood 
stream to fuel the nervous system, or support an energy response to physiological 
stress, or flight and fright situations (Williams & Pickup, 2000).
In situations where there is a substantially reduced level of insulin (e.g. starvation and 
low blood glucose), the release of fatty acids and protein that are stored under its 
influence occurs to provide an alternate fuel source. In a person with type 1 diabetes, 
or advanced type 2 diabetes, the diminished availability of insulin may invoke acute 
metabolic pathophysiological changes leading to diabetic ketoacidosis (DKA) that 
may be fatal if untreated (Umpierrez et al. 2002).
In summary, diabetes pathophysiology reflects a situation of fuel dysregulation where 
fuel in the form of glucose is available for transfer from the blood stream to the tissue, 
but without sufficient insulin remains in the circulation and can lead to the escalation 
of blood glucose levels (hyperglycaemia). This may lead to pathologic metabolic 
derangements and may result in premature death due to diabetes rather than the 
primary disease process causing admission (Umpierrez et al. 2002). If over treated, 
hypoglycaemia will result and may be fatal if untreated (Cryer, 2002). As long as the 
body is living it will always need fuel to power it until the last breath is drawn, and for 
this reason, due consideration should be given to diabetes across the entire lifespan.
Diabetes mellitus in all its forms is a serious heterogeneous endocrine disorder in 
which hyperglycaemia is a defining feature (de Courten, 2002) and is associated with 
significant complications or comorbidities (see table 1). These complications can be 
categorised as occurring in the short or long-term.
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1.1.1. Long-term Complications
The contribution of chronic hyperglycaemia in the pathogenesis of diabetes 
complications was compellingly demonstrated in two major studies; the Diabetes 
Control and Complications Trial (DCCT, 1993) in patients with type 1 diabetes; and 
the United Kingdom Prospective Diabetes Study (1998) for type 2 diabetes (see table 
1). These studies reported that both types of diabetes have serious consequences, 
and that reducing blood glucose to near-normal levels significantly reduced the 
development and progression of vascular complications.
Diabetes has also been associated with an increased cancer risk. Data from the 
Eindhoven Cancer registry (van de Poll-Franse et al, 2007) reported that 60% of all 
new cancer patients older than 65 years suffered at least one other serious disease. 
Diabetes was found to be the most common (16%) co-morbid condition in newly 
diagnosed cancer patients. This study reported patients with diabetes frequently 
presented with a higher tumour stage in some cancer sites (breast, gut, colon and 
ovary); were more likely to be treated less aggressively, and had a higher mortality 
rate ranging from 0-40% for different types of cancers compared with the non-diabetic 
population. Although palliative care is traditionally associated with cancer, the 
management of long-term conditions should be considered as part of the holistic 
approach to care (Payne et al. 2008). Theoretically, a good understanding of the role 
of glycaemic symptom management by palliative care teams and care providers at 
the end-of-life should be in place for patients with diabetes.
1.1.1.1. The Role of HbAic Testing
Glycated haemoglobin is formed when the protein haemoglobin bonds to glucose. 
The HbAic (Glycated haemoglobin) is a blood test which remains the ‘gold standard’ 
for assessing medium term diabetes control and is a key parameter on which to 
assess the long-term risks and guide the management of diabetes treatment
(Reynolds et al, 2006). In the in-patient setting, the HbAic value can provide a basis 
of assessment of prior glycaemic control to contextualise the hospital point-of-care 
testing readings (Olohan, 2010).
1.1.1.2. Short-Term Complications
The short-term complications have both physiological implications and symptoms 
associated at both extremes of blood glucose fluctuations (below 3.9 mmol/l or above
11.0 mmol/l.). The literature on symptoms is discussed later. Physiological 
implications have been associated with hyperglycaemia in several studies. Clements 
et al, (2004) have summarised these in their consensus guidelines for practice as 
being associated with increased infection rates, procoagulant states, and endothelial 
dysfunction, which may be improved with the achievement of normal blood glucose. 
Laboratory based studies in patients with type 2 diabetes (median diabetes duration 5 
years) by Sommerfield et al, (2004) reported acute hyperglycaemia was associated 
with impaired working memory and attention, adverse effects on mood states with 
reduced levels of happiness, energy and increased levels of anxiety. Therefore, 
decisions around liberalising the blood glucose need to be discussed with patients to 
ensure they are acceptable risks to quality of life for the remaining lifespan.
1.1.1.3. Point of Care Testing
Point of care testing through the measurement of capillary blood glucose (CBG) from 
the finger-tip is an important aspect of diabetes care for some patients. These include 
patients who are managed on oral diabetes medication that may cause 
hypoglycaemia, or on insulin, to allow for dose adjustments (NICE, 2008). The use of 
CBG monitoring represents a paradigm shift in moving towards increased patient 
involvement and ownership of glycaemic control (Wallymahmed, 2007). This 
technological innovation has enabled supported self-management of diabetes and 
the ability of the patient to provide data on their normal blood glucose profiles and
symptom management for hyperglycaemia and hypoglycaemia. In the hospital 
setting, this information can assist setting individualised glycaemic thresholds 
according to patient norms. Studies investigating the accuracy of point of care blood 
glucose testing in the hospital setting have shown a high degree of reliability in a 
range of critically ill patients (Petersen et al, 2008) including hypo-perfusion states 
when compared with venous and arterial sampling methods. This may be relevant to 
interpreting the accuracy of blood glucose readings at the end-of-life as the body 
‘shuts down’ in the dying state.
1.1.1.4. Supported Self-Management & Patient Advocacy
Supported self-management is an important component of diabetes. This strategy is 
underpinned through education to enable patient empowerment (DH, 2001, Funnel & 
Anderson, 2004) through education as lifestyle adjustments in diet, exercise and the 
proactive management of long-term drug therapy. In selected patient cohorts, the 
ability to self manage in the hospital has been supported by ‘Diabetes UK’ (2009). In 
the context of end-of-life care, the patient with mental capacity should be involved in 
the decision for the withdrawal of diabetes treatment or monitoring (Watt, 2000). The 
view of the patient is likely to be an informed one in those who actively self manage, 
and where the ability for self-advocacy is maintained.
However, supporting self-care behaviours may be challenging for many groups of 
patients with diabetes such as the disabled, elderly frail, cognitively impaired or those 
with mental health problems (Forbes et al, 2010). Diabetes affects a significant 
number of elderly patients, where the management of blood glucose and insulin 
becomes more difficult over time (Engelgau et al, 2004). In these patients, the family, 
nurse or relevant healthcare provider may need to undertake the role of patient 
advocate in care decisions around glucose management.
The importance of psychosocial comorbidity is also increasingly being recognised as 
the consequences of diabetes are known to be burdensome (Snoek & Skinner,
2005). This anxiety may have implications for how the family copes and supports the 
patient, which may also impact on end-of-life and bereavement coping. Family 
members may be aware of the patient’s attention to their diabetes and the degree of 
diligence paid to its management (Beverley et al, 2008).
1.1.1.5. Metabolic Emergency Risks of Type 1 & Type 2 Diabetes
The two most common presentations of diabetes are type 1 and type 2 (see table 1). 
Although, the risks and management of diabetes are similar, they differ according to 
type of diabetes. Patients diagnosed with type 1 diabetes are at greater risk in the 
short term for metabolic derangements of DKA and hypoglycaemia than patients with 
type 2 diabetes. As noted in table 1, poorly controlled diabetes may lead to metabolic 
complications that may cause the patient’s death, or cause distressing symptoms that 
are reversible with insulin. The omission of insulin in type 1 patients may be 
perceived as a form of ‘euthanasia’ by relatives (Boyd 1993).
1.2.0. Symptoms and Glycaemic Control
Blood glucose monitoring and management may be important at the end-of-life due to 
the similarity of the symptom profiles in terminally ill and those caused by abnormal 
blood glucose levels (see table 1.2). Ford-Dunn et al, (2006) suggest that for this 
reason, monitoring blood glucose on appearance of symptoms alone may be difficult 
to judge. Homsi et al, (2006) reported that there is a major discrepancy between the 
symptoms that persons with advanced disease experience and what they will 
spontaneously report to their physicians. They concluded that best practice 
comprises an initial systematic assessment of symptoms which should be used as a 
template on which to base continued individualised management of symptoms.
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1.2.1. Origins of Symptoms in Hypoglycaemia and Hypergiycaemia
Normal glucose homeostasis is supported by several hormonal responses that 
maintain euglycaemia (Kruger et al, 2006). These mechanisms include the blood 
glucose lowering effect of insulin, and the glucose raising effect of the counter 
regulatory hormones (cortisol, growth hormone, glucagon and adrenalin). The 
maintenance of homeostasis may be compromised by several factors. These include 
the underlying multi-pathological changes in diabetes, the limitations of diabetes 
pharmacotherapy, use of palliative drugs such as steroids and Octreotide, and the 
impaired glycogen stores associated with liver disease (McAulay et al, 2001). In the 
patient with advanced disease, decreasing appetite, weight loss and gut related 
symptoms and pathologies contribute to the challenges of glycaemic control.
1.2.1.1 Hypoglycaemia
For patients with diabetes, the main defence against severe hypoglycaemia is the 
subjective recognition of the onset of the glucose fall (Baker et al, 1997). 
Hypoglycaemia has been defined as a blood glucose level of 3.9 mmol/l, where the 
threshold for counter regulation is activated (Cryer et al, 2003). Physiological and 
laboratory conducted insulin clamp studies in the early 1990’s in patients with type 1 
diabetes reported that most symptoms of hypoglycaemia are generated through the 
autonomic nervous system (see table 1.2) or through direct effects on the brain, 
(neuroglycopenic symptoms) (Towler et al. 1993; Hepburn et al, 1993). Were it not 
for the barrier of hypoglycaemia, people with diabetes could have normal HbAic 
levels over a lifetime of diabetes (Cryer et al, 2003). Quality of life data from the 
UKPDS (1999) reported no adverse effect of hypoglycaemia on well-being. However, 
at the end-of-life the role of blood glucose monitoring may be important to 
differentiate reversible symptoms.
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1.2.1.2. Hypergiycaemia
A study by Warren et al, (2003) classified their eighteen documented symptoms of 
hypergiycaemia using factor analysis statistical methods. Four categories of 
hypergiycaemia were classified as follows: (1) Osmotic symptoms, (thirst, dry mouth, 
need to urinate, not feeling right, sweet funny taste, weakness) (2) Agitation (feeling 
tense and irritable, restlessness, poor concentration) (3) Neurological (dizziness, 
blurred vision, light-headedness, weakness) (4) Malaise (headache, nausea). This 
study also reported a small group of subjects who experienced symptoms such as 
sweating, myalgia, a flushed or warm sensation, and heavy or stiff limbs, which were 
not included in the above classification. The median blood glucose threshold for 
symptoms was 15.0 mmol/l, however, the reported range at which symptoms 
occurred was between 8-30 mmol/l. This indicates the wide spectrum of patient 
sensitivity to symptom perception and the need to assess at an individualised level.
1.2.1.3. Symptom Perception Issues
The range of symptom manifestation and perception as outlined in table 1.2 and box
1.0 point to the potential communication difficulties that may be imposed on patients 
due to the effects on cognitive receptivity as well as skills of healthcare professionals 
for discriminating cause. The significance of these symptoms requires a good 
knowledge base of palliative and diabetes symptomology. For these reasons, a 
glycaemic history is important when patients are clerked by the admitting physician 
and nurses on admission and for palliative care symptom management.
Amelia (2003) observes generally that in the elderly, vague symptoms are more 
common than acute, and are harder to isolate using classic symptom analysis. The 
majority of patients with diabetes are elderly, and glycaemic symptoms may be 
attenuated, unrecognized, or may be misinterpreted (Oiknine & Mooradian, 2003). 
Factors placing patients at greater risk of hypoglycaemia may be patient-related and
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include the presence of polypharmacy, renal, cognitive and psychiatric disorders 
(Tanwani, 2011). Within the hospital setting, the risk of hypoglycaemia may be 
greater due to changes imposed through hospital routine, limited meal choices, 
interruption of enteral feeding, failure of medical teams to make appropriate 
adjustments to insulin and diabetes treatment in the context of reduced doses of 
steroid therapy, altered nutritional intake, nil-by-mouth states for diagnostic testing, 
acute and debilitated states (Bellam & Braithwaite, 2010). Approaches to the 
prevention of hypoglycaemia include blood glucose monitoring, meal planning, and 
medication adjustment. The attention to managing these issues may be overlooked 
in the hospital setting, as there is a tendency for clinicians to devote their attention to 
the primary diagnosis of their patients (Baumeister et al, 2005). Patients admitted to 
acute care may be cared for by relevant specialists according to their presenting 
complaint and diabetes may take a lower priority.
Box 1.0 Characteristics of glycaemic symptom perception
Not all relevant symptoms are recognised as blood glucose-related (Malerbi & Matos, 2001, 
Gonder-Frederlcketal, 1997).
Situational and physical cues contribute to their detection (Hernandez et al, 1999).
Idiosyncratic and variable in character, pattern and intensity (Pennebaker et al, 1981, Cox et al, 
1993, Weinger et al, 1995).
None of glycaemic symptoms are exclusive to hypoglycaemia alone.
Both hypoglycaemic and hyperglycaemic states can generate physical, mood related (affective), 
and cognitive symptoms, & cognitive-motor disruptions (Cox et al, 2002).
Many patients are poor estimators of their blood glucose level (Weinger et al. 1995).
There is considerable individual variation in the cognitive responses to acute glycaemic 
fluctuations (Draelos et al 1995).
The subjective interpretation of glycaemic symptoms vary over time in the long and short term, 
and are dynamic in nature (McAulay et al, 2001).
Prevailing blood glucose concentrations and number of antecedent hypoglycaemia events 
affect the symptoms perception of subsequent hypoglycaemic events (McAulay, 2001).
Hypo-unawareness occurs in 25% of type 1 diabetes (Pramming et al, 1991).
Hypoglycaemia unawareness causes more profound cognitive dysfunction during acute 
hypoglycaemia, which persisted for longer following blood glucose recovery (Gold et al, 1995).
Age may attenuate symptom perception (Warren et al, 2003).
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1.3. The Acute Care Context
The hospital is important for end-of-life care as the majority of deaths occur in this 
setting. The Office for National Statistics (ONS, 2009) reported that for England & 
Wales over half (56%) of deaths occurred in National Health Service (NHS) hospitals. 
In the context of diabetes, the incidence and prevalence of diabetes increases with 
age, and the elderly, consume more NHS hospital resources (Department of Health, 
(DH) 2000, DH, 2007, DH, 2008). Seale and Cartwright (1994) reported that the 
majority of patients who are in the last year of their life would be elderly, and utilise 
approximately 22% of hospital bed days. Diabetes is a very common condition in 
elderly people affecting 10-25% of the population in Europe, with the highest rates in 
subjects 70-79 years old (Fagot-Campagna et ai, 2005). This suggests that the end- 
of-life diabetes management in the hospital setting will continue to be a common 
challenge.
1.3.1. Hospitalisation and Diabetes
Patients with diabetes have twice the number of annual admissions compared with 
people who are non-diabetic (Donnan et ai, 2000) and suffer increased morbidity and 
mortality (Umpierrez et al, 2007). De Berardis et al (2011) reported an increased 
likelihood of hospitalisation for people with diabetes by an incidence of two to six 
times, for the different causes examined. Papazafiropoulou et al, (2010) 
retrospective analysis of mortality rates in patients with and without type 2 diabetes 
reported higher mortality rates in those with diabetes compared with those without 
(11.2% versus 8.7%, respectively, p<0.001). The age at death did not differ (age+/- 
SD: 77.1+/-9.5 vs. 77.6+/-16.3 years, p=0.73) and the median length of hospital stay 
was higher (p=0.03). End-of-life care in the hospital setting is likely to be common, 
and comprise unexpected premature death or natural deterioration due to advanced
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disease states. Diabetes in the hospital setting may comprise a population of 
patients that require the support of both palliative care and diabetes specialist teams.
1.3.1.1. importance of Managing Hypergiycaemia
The role of blood glucose management in morbidity and mortality studies points to 
hypergiycaemia being an important factor in clinical outcomes and mortality, and 
hypoglycaemia has been identified as a risk marker for patients who may be 
approaching the end-of-life. The identification of patients who may benefit from 
palliative intervention may be complex to identify in patients with diabetes.
Several studies have indicated that hypoglycaemia and hypergiycaemia in the 
hospital setting are associated with disease severity and increased mortality. Studies 
that have investigated hypergiycaemia in hospitalised adult patients with diabetes 
have shown they are an independent predictor for poor outcomes across a wide 
spectrum of acute illness (Clement et al, 2004).
A large observational study by Schnipper et al, (2006) reported that the management 
of diabetes and hyperglycemias in a general medicine service showed several 
deficiencies in process (e.g. limited use of basal and especially nutritional insulin) and 
outcome (i.e. glycaemic control). Predictors of higher glucose readings included 
severe diabetic complications and higher glucose level at admission. The use of an 
insulin sliding scale was associated with worse glycaemic control after extensive 
adjustment for a variety of clinical factors. Schnipper et al, (2006) concluded from 
their data that clinical inertia accounted for lack of treatment adjustment in 
hypergiycaemia and was probably secondary to the fear of causing iatrogenic 
hypoglycaemia.
Studies using survey methods on attitudes to blood glucose management in the 
hospital setting indicate most midlevel providers acknowledged the importance of
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good glucose control but lack the confidence to use insulin in the hospital setting 
(Cook et al. 2008, George et al, 2010). Lack of familiarity with how to use insulin in 
the hospital environment was the most commonly cited reason for not managing 
diabetes effectively.
Spoliett (2006), reports that studies which investigated basic diabetes knowledge in 
nurses in a variety of clinical settings indicate poor clinical knowledge on the basics of 
HbAic test, insulin and oral therapies, hypoglycaemia and self-management. Studies 
in hospital nurses indicated that nurses often overestimate their diabetes knowledge 
and the need for greater input to education and training is required.
1.3.1.2. Importance of Hypoglycaemia in Hospital Setting
Observational studies of hypoglycaemia in the hospital setting have suggested that 
hypoglycaemia is a marker of illness severity and an independent predictor of 
mortality (Shilo et al, 1998; Kagansky et al, 2003; Turchin, et al. 2009). Turchin et al 
(2009) who conducted the largest study to date, noted the odds of inpatient death 
also rose threefold for every 0.5 mmol/l decrease in the lowest blood glucose during 
hospitalisation (P=0.0058). The role of hypoglycaemia was suggested as a risk 
marker for in-patient deterioration and its clinical evaluation may be an important part 
for end-of-life care.
1.3.2. Managing Diabetes in the Acute and Palliative Care Context
Acute care is part of a wider system of healthcare services that are functionalist in 
nature and work to different paradigms of care ranging from supported self-care to 
professionally led care. Acute care is primarily associated with episodic, bio- 
medically focussed care arising from accident, trauma or disease (Walshe & Smith,
2006). National statistics indicate that care of the dying is a core role in acute care 
and this role has been criticised in the literature as being sub-optimal.
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These criticisms have pointed to poor symptom management, lack of comfort care 
plans, and insufficient involvement of patients and their relatives in discussion of the 
end-of-life care preferences (Connors, 1995; Middlewood, 2001; Jacobs et al, 2002; 
van der Heide et al, 2010). These issues have been attributed to the difficulty in 
prognostication, particularly in long-term conditions. Aabom et a! (2005) report that 
the recognition by physicians that a cancer (or chronic disease) course has come to a 
terminal phase is an on-going challenge.
The episodic nature of acute care service provision may hold inherent problems of 
continuity of care. These are due to the role of the acute sector in training 
professionals where the complex duty rosters and rotation through specialities may 
limit the assessment of patient’s progressive decline in long-term conditions (Gadoud 
& Johnson, 2011). Jacobs et a! (2002) reported that senior physicians identified the 
lack of a pre-existing relationship with the patient inhibited the initiation of end-of-life 
conversations with patients and their relatives; and were also influenced by their own 
personal values of care provision in end-of-life decision-making. The lack of clinical 
guidelines and evidence-base knowledge around the withdrawal of medicines in 
patients with multi-comorbidities and its psychological effects, means the sequelae 
are not fully known (Stevenson et al, 2004). These issues and others have been 
influential in the development of The End of Life Care Strategy for England’ (DH,
2008) which has highlighted the delivery and requirements for high-quality end-of-life 
care in acute hospitals as a priority. The strategy idealises the notion of advanced 
planning and collaboration with the multidisciplinary team for preferences of place of 
death and treatment decisions for patients who are identified as being in the last year 
of life. Palliative care has been described as both a philosophy and a practice 
discipline (Mcllfatrick, 2007) and has been defined by the World Health Organisation 
(WHO, 2002; p i) as...
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‘an approach that improves the quality of life of patients and their families 
facing the problem associated with life-threatening illness, through the 
prevention and relief of suffering by means of early identification and 
impeccable assessment and treatment of pain and other problems, 
physical, psychosocial and spiritual’.
The involvement of a multidisciplinary palliative care team is intrinsic to supporting 
quality of life and symptom management within a supportive system. It recognises 
the wider aspects of the patient’s needs in terms of family, spiritual, psychological, 
social and bereavement needs. Implicit to this outcome is the deployment of an 
‘impeccable assessment’ that implies a level of expertise and co-ordination of 
resources to achieve.
The role of the nurse as a patient advocate at the end-of-life was reported as 
important for vulnerable patients in the acute care setting by Thacker, (2008). The 
basic principle of end-of-life and palliative care is symptom control to enable a 
peaceful and comfortable death. In her review of the literature Thacker (2008) 
observed that patient advocacy relies on three key concepts: communication and 
information sharing; accepting prognosis and a sense of well-being. Most patients 
are willing to discuss their end-of-life preferences (Heyland et al, 2003) and the 
opportunity to do so has been found to be important (Fallowfieid et al, 2002, van der 
Heide, et al. 2010). Control and autonomy has been reported to be important up until 
the point of death, but can only be facilitated when power and autonomy are shared 
with the patient (Bottorff et al, 2000). These issues may be important to patients with 
diabetes who have the mental capacity and self-management knowledge to 
participate in their monitoring and treatment decisions at the end-of-life. The 
importance of clarifying the type of diabetes, glycaemic history and thresholds for 
symptoms is an important aspect of the ‘impeccable assessment’ recommended by 
the WHO (2002).
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1.3.2.1. The Liverpool Care Pathway
The Liverpool integrated Care Pathway (LCP) was developed in the UK to manage 
the different dimensions of end-of-life care in those patients with a prognosis of ‘days’ 
(Pugh et al. 2010). The objectives of the LCP are to provide a template for 
appropriate, evidence-based, multidisciplinary care of the dying, designed to replace 
all other documentation and support auditing and outcome measurements 
(Ellershaw, 2007). The key elements of care address physical comfort, psychological 
and spiritual care, anticipatory prescribing of medication and discontinuation of 
inappropriate treatments. The pathway includes goals that support the care of the 
family before and after the patient’s death.
The LCP framework is recognised as the gold standard for care in the End-of Life 
strategy (2008) and NICE (2004) guidelines. It was originally developed to transfer 
the quality of care given to the patient dying with a cancer diagnosis in a hospice 
setting to those with cancer in the hospital and community setting (Douglas et al,
2009). Thus key prescribing decisions for cancer symptom management are 
supported through ‘anticipatory prescribing’ that includes the selective use of 
analgesics, anti-emetic, anti-secretory and anxiolytic / sedatives drug therapies 
(Payment & Ward, 2011 ).
A personalised approach to ‘comfort care’ lies at the heart of the LCP (Ellershaw,
2007). Implicit in this assumption is that the practitioner has personal knowledge of 
the patient’s clinical situation and the clinical expertise on which to base all 
prescribing decisions (Ellershaw & Hayes, 2011, Nunn, 2010) for the management of 
symptoms arising from both cancer and non-cancer conditions. According to 
Payment & Ward, (2011) plans should be put in place to ensure that the patient has a 
‘symptom-free, peaceful and dignified death’; all drugs not providing benefit in the 
immediacy are recommended for withdrawal. This broad directive of ‘benefit’ may be
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complex and subject to the ethics and expertise of the prescriber. Decisions to 
withdraw medications ‘for survival’ such as insulin in type 1 diabetes, or those 
therapies that supplement or compensate altered physiology such as heart failure 
medications have a limited evidence-base on which to confidently provide end-of-life 
care.
1.3.2.1.1. End-of-life care in non-cancer patients
Palliative support for patients with a non-cancer diagnosis has received recognition in 
the end-of-life strategy (DH, 2008) and the Darzi report, (Darzi,2008). It is known that 
disease trajectories and prognosis is inherently difficult to predict in patients with a 
non-cancer diagnosis (Trueman & Trueman, 2011). This fact impacts on optimal 
points for referral for palliative care support in both the community and in-patient 
setting (Stevens et al, 2007). The increasing numbers of patient with multiple co­
morbidities places restraints on the limited resources within the palliative care team 
(Fisher, 2006). Thus, the specific symptoms and patient value issues for the last few 
days of life that may impact on holistic care has not been sufficiently explored in the 
literature.
There is a dearth of research literature that has reported on the transferability of end- 
of-life ‘comfort’ management plans for patients with specific non-cancer diagnoses 
within the LCP framework. One study by Douglas et al. (2009) explored the symptom 
profiles and appropriateness of this ‘anticipatory’ prescribing framework for the LCP 
in dying patients with stage 4 & 5 chronic kidney disease. They concluded from their 
expert (physician) panel and literature review that the four drug classes were relevant 
to this cohort and recommended dose adjustments to avoid adverse side effects that 
may impact on comfort care.
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Several studies have explored the collaborative role for palliative care specialists and 
cardiac teams for symptom management of heart failure, which relies on fluid balance 
and cardiac drug management (Johnson & Houghton, 2006). The authors discuss the 
complex issues of defining acute versus terminal deterioration in symptomatic cardiac 
failure. It was suggested that the use of the LCP should encourage good care without 
requiring cardiac speciality involvement (Johnson & Houghton, 2006). However, the 
work of Zacharias et al, (2011) in the management of end-of-life heart failure in the 
community setting, examined the benefit of adding furosomide (diuretic) to the 
syringe driver to control fluid related symptoms and found that careful patient 
selection was indicated.
Stevens et al (2007) concluded in their literature review that end-of-life palliation for 
stroke patients was complex, and issues around withdrawal of enteral feeding and 
complex symptoms arising from acute and chronic effects of stroke need to be 
addressed. Evans (2009) reported that amendments to the LCP for assessing pain 
management in patients with dementia were needed to supplement comfort for end- 
of-life care. A comparison for several tools to effectively manage pain was discussed.
These issues from the literature suggest that the end-of-life requirements of non­
cancer patients may not be completely addressed by the LCP and are likely to 
require collaboration with acute care specialties and palliative care.
1.4. In Summary
There are many complex factors impacting on the patient with diabetes at the end-of- 
life that die in the hospital setting. The evidence for long-term complications is 
equally serious in type 1 and type 2 diabetes. Supported self-management and 
patient empowerment are the keystones of management and this has implications for 
patient choices in the withdrawal of monitoring and diabetes treatment in the terminal
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phase. The perception of symptoms in individuals with diabetes is idiosyncratic and 
occurs at different thresholds, and may change over time making it complex to 
interpret glycaemic origins of some terminal symptom.
The knowledge, skills and confidence to manage diabetes is limited in health care 
professionals in the hospital setting. The episodic care and limited relationships with 
patient’s in conjunction with the inherent difficulties in prognostication of long-term 
conditions may compromise holism in end-of-life care planning for hospitalised 
patients.
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CHAPTER TWO REVIEW OF THE LITERATURE
2.0. Introduction
This chapter will present and critically discuss the literature and research studies that 
directly address the management of end-of-life care for patients with diabetes. The 
search strategy and findings will be summarised and the gaps in the research 
literature identified and discussed.
2.0.1. Literature Search Strategy
The focus of the research inquiry is to investigate the management of the patient with 
diabetes in the terminal phase at the end-of-life patients in the hospital setting; and to 
explore the attitudes and perceptions about the management of diabetes that help or 
hinder this care.
The purpose of the literature search was to critically review what was already known, 
or considered to be important about the care of the patient with diabetes in the 
terminal stages of their disease and available practice guidelines. A blended 
approach was used to guide the search. This included an initial search through 
‘Google Scholar’, which generated a few direct returns on journal articles and NHS 
websites, and informed key author searches through the reference lists and citation 
searches. This was followed by a systematic search through the following electronic 
databases; PsyclNFO, Cumulative Index to Nursing & Allied Health Literature 
(CINAHL), Medline, Web of Knowledge, and PubMed for the period 1990 to October 
2009. The keywords searched are summarised in table 2.1.
The use of snowball techniques (follow up through reference lists), hand searching 
palliative and diabetes journal and textbooks was part of the systematic searching
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strategy. The search strategy was an iterative process to enable maximal retrieval of 
documents for review.
Table 2.1 Inclusion and exclusion criteria and key words for the literature review
Inclusion criteria Exclusion criteria
Published empirical studies 
peer reviewed journals 
Retrospective Studies 
Surveys 
Humans
Non-empirical studies
Main focus of study - diabetes and terminal /end- 
of-life care
Diabetes Mellitus, Type 1/*therapy 
Diabetes Mellitus, Type 2/*therapy 
Insulin -  Administration and Dosage ;
Therapy Terminal Care 
Terminally III*
Liverpool Care Pathway
End-of-life
Dying /Death*
Blood Glucose Monitoring 
Glycaemic Control 
Hyperglycemia 
Hypoglycemia
Attitude of Health Personnel*
Withholding Treatment
Unpublished doctoral dissertations 
Apoptosis
Glucose homeostasis. 
Pharmacological interactions 
Pharmacological reviews
Study sample settings
- Hospice
- Palliative care
- Hospital /-Hospitalization/*statistics & numerical 
data
- Medical Organizations
- Multidisciplinary Care Team
Children 
Length of Stay 
Home Nursing, Professional 
Terminal Care -  Methods
Research studies reported in English language Research reports not available in English 
language.
Practice beliefs & policy / guidelines 
Practice guidelines as topic/*standards 
Audit
Terminal care standards
Physician's Practice Patterns/*statistics &
numerical data
2.0.2. Summary of Literature Found
After reviewing all abstracts, eight sources were considered to be relevant and the full 
text articles were reviewed. Of the eight sources, four papers were research studies
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(Ford-Dunn, 2004; Ford-Dunn et al, 2006; McCoubrie et al, 2005, Quinn et al, 2006) 
and four were expert opinion based articles (Boyd, 1993, Smyth & Smyth, 2005; Tice, 
2006; Mo Pherson, 2008).
Research had been generated principally from palliative care physician specialists in 
Britain (Ford-Dunn et al, 2004; Ford-Dunn et al, 2006; McCoubrie et al, 2005) and 
specialist diabetes and palliative care nurses in Australia (Quinn et al, 2006). These 
studies have been summarised in table 2.2 and have explored different aspects of 
care in community and hospital settings.
Expert opinion and journal articles suggesting best practice have been published by 
authors experienced in palliative medicine in Canada (Poulson, 1997); pharmacy 
practice (McPherson,2008); nursing in palliative and diabetes specialities in the 
United States of America (USA) (Tice, 2006) and in the UK (Smyth & Smyth, 2005). 
The most cited resource was Poulson, (1997). These commentaries will be briefly 
discussed in section 2.2 below as they may influence practitioner views.
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Ford-Dunn et al. 
(2004) (UK) 
Palliative Care 
Consultant
Ford-Dunn et al.
(2006) (UK)
Palliative Care Consultant
McCoubrie et al. 
(2005) (UK) 
Palliative care 
Registrar
Quinn et al.
(2006) (Australia) 
Palliative / Diabetes 
Nursing
Research
Question
W hat is the natural 
progression of blood 
glucose in type 2 
patients whose 
diabetes treatment 
was stopped at the 
start of terminal 
phase?
(Glycaemic) Management 
of (type 1 ; & tablet and 
insulin controlled type 2) 
diabetes during the last 
days of life: attitudes of 
consultant’s diabetologists 
and palliative physicians in 
the UK
How is diabetes 
managed at the end- 
of-life in cancer 
patients in a general 
hospital
What are the clinical 
experiences of; & 
decision criteria for 
assessment and 
management of diabetes 
in advanced disease & 
does it vary according to 
diabetes type?
Research
Aim
Determine if treatment 
can be stopped 
without adverse effect 
in dying patients
Derive expert consensus 
opinion of the 
management of diabetes 
in the terminal phase
To enable appropriate 
management at end- 
of-life
Describe current 
practice / clinical 
experience of MDT
Research
Method
6 month retrospective 
study of blood glucose 
readings
Semi- structured postal 
questionnaire (non­
validated) vignette based.
Retrospective case 
note audit in 12 month 
period
Cross-sectional survey 
(52 item, non validated) 
& 2 focus groups
Sample
Hospice & hospital 
deaths (1) terminal 
phase apparent (2) 
treatment discontinued 
at onset (3) CBG 
continued to death
217/305 Palliative care 
Consultants (PCC)
111/205 Diabetes 
Consultants (DC)
Deceased patients 
with cancer & 
diabetes: 8(19% ) 
type 1, 34 (81%) type 
2 of which 8% were 
steroid induced. 
Diet=7, tablets=23, 
insulin =12
Purposive:- snowball 
Doctors & Nurse 
specialists in diabetes & 
palliative care GP’s: 
Hospital/Community; 
Regional / Met’politan 
settings.3+ years 
experience.
Sample size 
quantitative
18 cases diet=2 
tablets =12 insulin = 4
328 consultants 71% PCC 
and 54% DC 42 cases 67 /167 questionnaire
Sample size 
qualitative nil
Number responding 
qualitative element not 
reported
nil N=18 (8 Regional)
Blood
glucose
monitoring
practice
2.5 tests (median) -  
(0.3-10.3) per 24 
hours. Average time 
weighted CBG was 
8.9-14.0 mmol/L
Stop? PCC%
DC
% 76% monitored to 
within 24 hours of 
death, 28% (n=12) 
stopped 3-16 days 
prior to death, 
hypoglycaemia n=2 
<3.0 mmol/l 
hypergiycaemia n=6 
>15 mmol/l
Can stop 48 hours pre 
death /decision 
parameters unclear-. No 
known benefits or other 
non CBG methods.
Mixed views re: finger 
prick distress for CBG / 
benefit. Steroid diabetes 
monitored more.
T2 on 
tablets 76 * 63
type 1 27 24
[*P=<0.05] More DC 
would monitor across All 
situations more frequently 
than PCC [ p=<0.001]
Withdrawal 
of diabetes 
treatment 
practice
Stopped at point 
identified as terminal 
stage
Stop? PCC%
DC
% 2 cases discussed 
preferences with team. 
Hypergiycaemia 
preferable to 
hypoglycaemia
Variable practice -  
knowing when is difficult
tablets 76 63
insulin 73 61
type 1 30 25
Type 1 
diabetes
Not applicable Actrapid used by PCC , 
basal insulin by DC
reduced dose insulin maintain treatment
Type 2 
diabetes
Can be stopped safely PCC add in PRN Actrapid 
(P=<0.001)DC used wider 
insulin choices
Treat if >20 mmol/L 
if unconscious stop.
less serious - 
symptomatic treatment
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2.1. Research Studies
The research studies can be categorised as those that investigated the capillary 
blood glucose (CBG) levels and monitoring practices (section 2.1.1); and those that 
examined attitudes and clinical practice decisions parameters (section 2.1.2). These
are critically discussed below.
(
2.1.1. Blood Glucose Levels and Blood Glucose Monitoring
The palliative care physicians (Ford-Dunn et al, 2004; McCoubrie et al, 2005), have 
explored the CBG levels in patients at the end of life through audit methods (see 
table 2.0).
2.1.1.1. Ford-Dunn Study 2004
The study by Ford-Dunn et al, (2004) was motivated to inform the knowledge base on 
the natural progression of CBG in untreated patients with diabetes during the dying 
phase to enable evidence based guidelines to be generated. Eighteen CBG records 
of patients with type 2 diabetes were examined to evaluate the final values in the last 
72 hours in patients whose treatment was stopped. Limitations are the small sample 
size, and the decontextualisations of the patients from their clinical and prior diabetes 
control. It is not clear whether the patients preceding HbAic pre-terminal CBG values 
had been continuously normal. The limitation of background clinical data such as the 
nature of inter-current illness, cancer and non-cancer diagnoses, level of 
consciousness, caloric intake, or why these patients had been monitored to the end- 
of-life was not reported. It is not clear from this poster presentation, what proportions 
of patients were in the hospital or hospice setting. There are more questions 
unanswered in this early research than was answered in order to safely make the 
generalisation for all blood glucose values to be in the normal range in untreated type 
2 patients in the final 72 hours of life.
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2.1.1.2. McCoubrie Study 2004
This hospital based study collected audit data on the management of diabetes in 
cancer patients over a one-year period. The objective was to establish their CBG 
monitoring activity and readings in the last 72 hours. The cancer and diabetes 
disease characteristics and demographics were evaluated in addition to the inclusion 
of the patient or their family for views on continuation of monitoring decisions.
This study concluded that cancer appears to be a more common problem in patients 
with diabetes than in the general population. The prevalence of diabetes in their 
sample of 42 cancer patients was 14.6%. Findings reported an inconsistent 
approach to CBG monitoring and management. A limited number of CBG in the 
hypoglycaemia range of < 3.0 mmol/l (n=2) and >15 mmol/l (n=6) was noted. There 
was no report of any documented symptoms with the CBG derangements.
Blood glucose monitoring data showed that 76% were monitored up until and 
including the date of death, and 24% of patients had their CBG monitoring stopped 
between 72 hours and 16 days pre death. This continuation of monitoring to the end- 
of-life was assumed to be due to a ‘reluctance’ to stop monitoring. There are no data 
to suggest why health care professionals continued to monitor CBG. The clinical 
situation, disease trajectory or imminence of death is not explored to confirm the 
conclusion of ‘reluctance’ to stop. Arguably, at the time when patients are at greatest 
risk for CBG excursions when gastric symptoms, appetite variables and end-of-life 
pharmacy side effects are operational, it could be that some patients may be 
comforted by knowing what their glucose levels are doing while others may not be 
concerned at all. CBG monitoring practice did not address whether active treatment, 
declining appetite or risk of hypoglycaemia was an issue for that patient. It may be 
that the monitoring behaviour was the reason why there were so few abnormal 
readings. The views of patients as perceived by healthcare providers on whether
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patients are distressed by CBG monitoring is not known and this is a current gap in 
the literature.
Two patient’s admissions were for hyperglycaemic emergencies, including one 
occurrence of DKA, and Hyperglycaemic Hyperosmolar Nonketotic Syndrome 
(HHNS), thus confirming reasons to monitor in advanced disease in the pre-terminal 
stage. There were 45% of patients who were managed on steroids ‘at some point’ in 
the admission, but the relationship to CBG results in the terminal phase and 
monitoring patterns for steroids were not reported. Specialist referral was involved in 
a minority of cases, with three referrals to the DSN patients, where one referral 
occurred in the last seventy-two hours.
Only one third of patients were referred to the palliative care team and only two cases 
where documented evidence of patients and relatives involvement in the discussion 
around blood glucose monitoring preferences was reported. The nature of the 
patient’s preferences, or the type of diabetes obtained was not stated in the two 
cases found where the enquiry was documented. This research provided a context 
of the number of cancer patients who died with a comorbidity of diabetes, but there 
was a gap in the knowledge of whether blood glucose is normal in the non-cancer 
population, and the clinical contexts or health care professional’s motivations for 
monitoring were not known. The limitation of audit data is the lack of contextual data 
that explain the motivations of decisions by the clinicians and practitioners who cared 
for the patients.
2.1.2. Attitudes and Clinical Management Issues
The following research studies have investigated attitudes and experience in clinical 
practice using quantitative and qualitative methods. Both the researchers have used 
survey methods, one as a single method (Ford-Dunn et al. 2006) and the other as
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part of a mixed method strategy using two focus groups (Quinn et al, 2006) as 
summarised in table 2.2.
2.1.2.1. Ford-Dunn Study 2006
This semi-structured postal questionnaire was based around three case scenarios 
designed to cover the three main clinical diabetes treatment situations that may 
present in practice (see box 2.0).
Box 2.0 Ford-Dunn et al. (2006) Clinical Scenarios
All treatment scenarios include same options; the first is always modified to the scenario treatment as 
follows:
1. Stop the current treatment
2. Use short acting insulin prn
3. Start twice a day intermediate insulin or mixed insulin
4. Start an intravenous insulin sliding scale
5. Insert a nasogastric tube to administer oral agent.
Case 1. Type 2 on tablets
An 81-year-old female with type 2 diabetes on Gliclazide 80 mgs BD, is admitted with pneumonia. 
Despite treatment, she deteriorates and is now clearly dying. The decision is made to stop all antibiotics 
and all active treatment and ‘keep her comfortable’. She is drowsy, not eating or drinking and is unable 
to take her Gliclazide tablet. Your recommendation would be:
Case 2. Type 2 on insulin
A 77-year-old female with type 2 diabetes on twice-daily Mixtard 30 insulin, is admitted with a dense 
OVA and is initially put on an intravenous sliding scale. She deteriorates further, is unconscious and is 
now dying. The decision is made to stop active treatment and keep the patient comfortable. Your 
recommendation would be:
Case 3. Type 1 diabetes
A 47-year-old man with type 1 diabetes on twice daily Mixtard 30 insulin is admitted with breathlessness 
due to lung cancer. Despite aggressive treatment, he deteriorates and the decision is made to stop 
active treatment. He is drowsy and not eating or drinking much. Your recommendation would be:
The respondents were asked to judge the scenarios and select the answer that 
reflected their opinion, and invited to comment. The vignettes did not specify any 
blood glucose readings. Gould (1996) notes that survey methods in studies of
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attitude, beliefs and norms, are limited by selection of the ‘ideal’ answer. The use of 
vignettes can overcome this limitation and stimulate a more considered response in 
surveys and improve the validity. Hughes & Huby (2002) advise that it is important to 
consider the extent to which vignettes can simulate reality and demonstrate its 
complexity. Case scenario one (see box 2.0) decision looks quite clear-cut. The 
ability of vignettes to simplify selective representations of the real world may help to 
disentangle the complexities and conflicts present in everyday life. For this reason, it 
may be difficult to generalise findings from vignette based data (Hughes & Huby, 
2002).
The majority of doctors stopped treatment in both type 2 diabetes scenarios. The 
discontinuation of treatment in type 2 diabetes is now ‘validated’ as accepted practice 
according to the recent journal literature (Budge, 2010, Angelo et al, 2011, King et al, 
2011). It is uncertain how typical these scenarios are in everyday hospital practice 
for patients at the end-of-life.
This study reported significant practice differences between the palliative care and 
diabetes consultants. In patients with type 2 diabetes, more palliative care 
consultants would stop treatment, and use short-acting insulin initiated at higher 
glucose thresholds than diabetes doctors. Diabetes consultants were reported to be 
more likely (P=0.001) to use a wider range of insulin products, and request more 
blood glucose monitoring than palliative care consultants. Ford-Dunn et al. (2006) 
attributes this divergence of treatment views to the different clinical objectives within 
the specialism’s. Withdrawal of therapy and enhancing the care of the dying was 
seen to be a marker of the ethos of palliative medicine, whereas diabetes consultants 
are clinically focussed to the evidence-base directives on the long-term prevention. 
However, it may be more simply, that diabetes consultants understand their formulary 
for glycaemic treatment options more succinctly than palliative consultants. For
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people with type 1 diabetes, there were fewer consultants who would stop treatment. 
The reasons speculated were the prevailing uncertainty around the ethics of 
withdrawing life sustaining treatments and the benefit versus burden debates.
The qualitative element of the questionnaire (response rate not reported) indicate that 
the key element influencing the continuation of CBG monitoring was contingent on 
the current clinical picture and the clarity of the diagnosis of dying versus reversible 
deterioration. Similar to McCoubrie et al, (2004) iatrogenic hypoglycaemia was
important to avoid, and a tolerance for higher glucose levels was seen as 
appropriate. The views of the patient and family would be influential in the decision­
making process for some clinicians, but the differences between diabetes versus 
palliative care holding this view was not reported. Ford-Dunn et al. (2006) raises the 
complex issue of judging when to test CBG given that many of the symptom profiles 
for hypergiycaemia are similar to those in the dying. It was unclear whether research 
investigating glucose symptom perception in the patient with diabetes was 
transferable in terms of their perception in the end-of-life context.
2.1.2.2. Quinn et al. Mixed Methods Study (2006)
Quinn et al, (2006) aimed to investigate the glycaemic management in advanced 
disease to establish palliative practice guidelines for patients with diabetes. The key 
findings established general agreement that the stage of illness and type of diabetes 
was influential in treatment decisions. Type 1 and steroid induced diabetes are 
priorities to monitor due to their symptomatic risks, whereas type 2 was seen as less 
serious. Glycaemic control should be more liberal for patients in the pre-terminal and 
terminal phases of illness. Blood glucose monitoring frequency was variable across 
different organisations, but a common theme was the lack of treatment planning to 
support monitoring results. Although guidelines were seen as much needed, few 
palliative care specialists undertook any diabetes continuing professional education
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and did not refer to diabetes specialists for advice. Many saw the management of 
blood glucose as important but practice was experience-led and variable. The level 
of confidence to manage diabetes was limited in a third of survey respondents, and 
42% rated the satisfaction with diabetes management as less than 5 on a scale of 10. 
This research while comprehensive was broad ranging in the health provider field. 
There was no sense of the different perspective of the hospital setting versus 
community care of dying patients with diabetes, or the degree of involvement in the 
hospital setting of the patient and relatives.
Given the vast number of dying patients cared for in the hospital setting, there is a 
need to understand the practice issues in this setting, the patient’s clinical contexts, 
the differences of glycaemic control in cancer versus non-cancer patients and the 
degree of involvement of patients and relatives in the end-of-life blood glucose 
management decisions.
2.2. Clinical Journal Articles
These were reviewed briefly as they may be influential to current clinical practice 
behaviours in the generalist setting. The most cited author on this topic is Dr. 
Poulson (1997), a palliative care physician, whose publications gave a 
comprehensive overview on diabetes in advanced cancer. Iatrogenic hypoglycaemia 
was advised to avoid due to the discomfort and the practical difficulties of 
resuscitating severe hypoglycaemia in patients with poor venous access, poor 
glycogen stores or who cannot swallow. The approach to pre-terminal and terminally 
ill diabetes management takes a minimalist approach and draws exclusively on the 
literature of biochemistry and cancer physiology.
There are common core issues raised by doctors, (Boyd, 1993; Usborne & Wilding
(2003) nurses, (Smyth & Smyth, 2005) and a pharmacist (McPherson, 2008) in the
34
opinion based literature, that acknowledges the complexities of managing the 
communication, pharmaceutical and nutrition variables that impact on diabetes 
management at the end-of-life, and the difficulties in defining the terminal phase. The 
lack of guidelines is cited as problematic and contributes to practice variation with all 
the ethical and other issues this may raise. Glucose thresholds range considered 
appropriate varied between 5-20 mmols.
The obvious finding from the literature review is the lack of references written by 
generalists in the community or hospital setting, where the problem has either not 
been recognised or considered important enough. The role of evidence-based 
medicine may be influential as its focus is for generaliseable outcomes rather than 
individualised and values based ones (McCarthy & Grumley, 2010). Healthcare is 
essentially bio-medically focused and ‘body’ focussed. The recognition for the 
supported self-management paradigms of diabetes care where patients may 
contribute to medical management decisions were not addressed. This may be due 
to the preoccupation with the physical body and fear of iatrogenic hypoglycaemia risk. 
It is acknowledged in the literature that both palliative care and hospital based 
professionals have limited knowledge, confidence and skills in diabetes management 
(Quinn et al, 2006, Spollet, 2006; George et al, 2010).
2.3. Research Gaps Identified.
These clinical based studies have laid a foundation of knowledge based on small 
samples, in patients that have advanced cancer, and the methods used have been 
predominantly opinion based. The gaps that have been identified were found to be 
those that contextualise the different hospital healthcare professional’s attitude and 
clinical experience for managing end-of-life issues in patients with diabetes; and the 
degree to which they would involve the patient or relatives in the decision. The 
clinical context of the patient’s admission, their glycaemic history and how it is used.
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the influence of the pre-terminal glucose readings and monitoring experience is not 
known. Further, the socio-demographic factors, and the patient’s clinical and 
glycaemic control context; the ability of the patient or their relatives to advocate for, or 
be involved in their end-of-life decisions in terms of mental and physical capacity is of 
interest but unknown to the problem context.
The method proposed is to extend the findings in the literature to the hospital context 
through the retrospective medical notes review. This method aims to identify the 
patient population contexts of admission (socio-demographic and related advocacy 
factors, admission reasons, diabetes duration and treatment, HbAic) and the hospital 
management of blood glucose (factors influencing CBG at the end-of-life, diabetes 
treatment, symptoms documented in this period and referral patterns for diabetes and 
palliative care advice).
The use of focus groups that reflect the views of palliative care, diabetes and non­
specialist (generalists) perspectives aims to document, analyse, synthesise and 
understand these different practitioner perspectives influencing the end-of-life 
management for patients with diabetes.
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CHAPTER THREE METHODOLOGY
3.0. Introduction
This chapter will critically discuss the theoretical and philosophical stance that 
underpins evaluation research methodology to rationalise the research approach.
The research inquiry aims to establish the nature of blood glucose values, and the 
perceived importance of their management in hospitalised patients with diabetes by 
specialist and non-specialist healthcare providers at the end-of-life. Further, an 
exploration of the factors that influence the clinical management of blood glucose are 
of interest to enable a strategy for evaluating, improving and supporting best clinical 
practice.
The objectives of this research inquiry are to understand the potential for symptom 
burden of capillary blood glucose values at the end-of-life, patient advocacy, and to 
explore the views and practice of healthcare professionals regarding the continuation 
or withdrawal of diabetes monitoring and treatments within the acute care setting 
during the last 72 hours of life.
End-of-life issues are complex, multi-dimensional and traditionally difficult to research 
due to the ethical and practical issues involved in accessing this patient population 
(Teno, 2005). For this reason, and because it is unclear what the clinical 
management influences are, and what comprises clinical practice in the acute care 
setting, the research strategy aims to pursue the inquiry through the healthcare 
professional viewpoint initially. The findings of this research may be used to inform 
future research direction to address the patient issues directly in an informed and 
sensitive way.
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3.1. Evaluation Research
An evaluation research approach was taken because the major goal of evaluation is 
to influence decision-making or policy formulation through the provision of empirically 
driven organisational feedback (Patton, 2002). The key advantage of evaluation 
research is that the research is contextually situated to the particular practice and 
organisational influences and thus offers a pragmatic appeal as a potential change 
management tool. This approach does not restrict the type or style of research 
methodology since the methods employed are largely determined by the research 
question and research context (Robson, 2002). Although evaluation research is 
traditionally associated with outcome-based programme evaluation, different models 
of evaluation have been described in the literature and include needs-based 
evaluation, process evaluation and cost-benefit evaluation (Robson, 2002). Process 
evaluation is the focus of this study as the intention is to establish what actually 
happens in practice and the experiences of those involved. This evaluation aims to 
address the following:
1. Define patient demographic and disease characteristics of patients with 
diabetes to understand the admission contexts and potential for self or other 
advocacy.
2. Establish typical blood glucose values across the hospital episode and last 72 
hours to understand the CBG values pattern influences at end-of-life, and 
their potential contribution to symptom burden, and the monitoring withdrawal 
contexts.
3. Evaluate the degree to which healthcare professionals involve the patient and 
their family in the discussion around the monitoring, treatment and glycaemic 
targets decisions at the end-of-life.
4. Explore the beliefs, practices, perceptions and motivations of specialist and 
non-specialist healthcare professionals who provide care at the end of life, for 
stopping or continuing blood glucose monitoring and diabetes treatment.
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3.1.1. Definition and Purpose of Evaluation Research
Patton, a recognised leader in the field defines evaluation research as:
‘the systematic collection of information about the activities; 
characteristics; and outcomes of programs to make judgements about 
the program; improve the programme effectiveness, and/or inform 
decisions about future programming. When one examines and judges 
accomplishments and effectiveness one is engaged in evaluation, 
when this evaluation of effectiveness is conducted systematically and 
empirically through careful data collection and thoughtful analysis, one 
is engaged in evaluation research’ (Patton,2002:10).
This definition emphasises the application of appropriate research methods to the 
evaluation process and context. Evaluation research is essentially indistinguishable 
from other research in terms of design, data collection and methods of analysis 
(Robson, 2002:204). However, bringing evaluation under the umbrella of research 
brings certain safeguards to the integrity of the enterprise because research requires 
competency and a commitment to ethical standards. It is typically used to answer 
‘how’ or ‘why’ questions and can quite broadly include any effort where the inquiry 
seeks to evaluate whether people are accomplishing what they want to arises 
(Patton, 2002). In this research inquiry, this relates to the achievement of palliative 
care principles with regard to the role of blood glucose monitoring and management 
as part of a holistic approach for the end-of-life care. It is a form of applied research 
that encompasses a wide range of methodologies that are appropriate to research 
objectives within the palliative care context (Ingleton & Davies, 2007). Science is not 
just a body of knowledge but also logic of inquiry, for generating, replenishing and 
correcting knowledge (Burns, 2000:5).
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3.1.2. Theory and Evaluation Research Methodology
Evaluation research has been criticised for being ‘atheoretical’ or a ‘value-free ‘way of 
measuring efficiency or effectiveness (Robson, 2002, Kelly, 2005).
However, no knowledge can be value-free since different conceptual frameworks for 
evaluation emerge in some part from the professional epistemology underlying the 
disciplines or field of interest and values of the researcher (Kelly, 2005). All research 
has a theoretical basis that will influence decisions about methodology and the 
framework used for conceptualising the problem under study. Bryman (2001) 
outlines a number of theoretical considerations that enter into the process of doing 
social research and these are most commonly drawn from the distinctions between 
qualitative and quantitative research paradigms. A paradigm has been defined as the 
“basic belief system or world view that guides the investigation” (Guba & Lincoln, 
1994:105). These paradigms are associated with different ontology’s (nature of 
reality) and epistemologies (what is, or should be, regarded as acceptable knowledge 
in a discipline).
Quantitative and qualitative research approaches can be broadly distinguished 
through their relationship to theory generation in terms of whether theoretical 
considerations were influential at the start of the research as in quantitative research 
(hypothetico-deductive methods) or occurred as an outcome of the research 
(inductive) as in qualitative methodologies. These paradigm differences are 
important because they are politically influential in terms of the acceptability or validity 
of the knowledge generated. Whether findings are adopted for practice, using 
quantitative or qualitative data may depend on different stakeholder views (Fulop el 
al, 2001). The rigour of the research method is an important consideration for the 
evaluation researcher for this reason (Patton, 2002). Inherent in both qualitative and 
quantitative approaches are strengths and weaknesses and these are discussed
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below. Ironically, the ontology of the different paradigms is yet unproven and is 
assumptive and theoretical in nature as no-one can prove what reality is, only what it 
may be.
3.2. Quantitative and Qualitative Research Approach
The quantitative paradigm embodies the ‘scientific’ or ‘empirical’ approach and has 
historically been the dominant paradigm. Inherent in this approach is the belief that 
only one reality exists, and this is seen to lie in the external world-awaiting discovery. 
Quantitative research is also referred to as ‘Positivism’ where the epistemological 
perspective holds that the only authentic knowledge is that which is based on 
experience by the senses and positive verification. The principal assumptions 
underpinning this model are objectivity, generality, reductionism, validity and 
reliability. Theory is generated through the hypothetico-deductive approaches which 
are based on discovering existing truths and this is the logic that drives the data 
gathering process. Quantitative research methods are thus used to establish laws 
and principles which are generalisable and predictable (Burns, 2000). Further, they 
incorporate only questions and phenomena that can be controlled, measured, 
counted, and analysed by statistical methods (Creswell, 2003) and are self-limited by 
the research questions that are amenable to its methods (Gerrish, 2006).
Data collection is made objective through operational definitions and through 
distancing the perspective of the researcher to avoid bias or ‘contamination’ of data. 
The hypotheses is then refuted or confirmed. Confirmatory evidence through this 
process is viewed as authentic and thus generalisable. The quantitative researcher 
is concerned to explore variation in observed values among units of analysis and the 
causes of variation (Bryman & Cramer, 2009). Studies aimed at quantifying 
relationships are of two types: descriptive and experimental.
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In a descriptive study, such as survey methods, no attempt is made to change 
behaviour or conditions, but to measure things as they actually are. In an 
experimental study, pre and post measurements are taken to establish a cause-effect 
relationship following some intervention (Burns, 2000). As this study is exploratory, a 
descriptive approach was used where objective numerical data are collected.
A retrospective medical notes review was taken to provide an objective exploratory 
approach to describing the current clinical practice. The objective stance is 
enhanced as the researcher contamination is limited, as the researcher or the 
research question did not influence the medical notes. The use of data abstraction 
proforma with clear operational definitions for each data variable ensures reliability to 
ensure the same thing is being counted from each set of notes. This quantifies 
practice in terms of what is commonly seen and what variation exists through using 
descriptive or other relevant statistics depending on the findings. The advantage of 
using this method lies in its ability to contextualise practice through objective 
description of the clinical and socio-demographic variables within the patient 
population. Blood glucose values are numerical in nature and these are amenable to 
quantitative analysis to objectively define whether and to what extent the blood 
glucose deviates from normal at the end of life. However, quantitative research 
methods are limited in their ability to explore the motivation, beliefs and influences 
that impacted on the decisions to continue or withdraw blood glucose monitoring and 
diabetes treatment. This limitation can be overcome by using a mixed method 
approach which includes a qualitative data collection component.
3.2.1. Qualitative Research
Qualitative research is a field of research in its own right and encompasses a 
complex interconnected family of terms, concepts and assumptions that have evolved 
over the years (Denzin & Lincoln, 2000:2). Qualitative research methods are also
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referred to as a naturalistic inquiry and were developed within the social and human 
sciences, and refer to theories on interpretation (hermeneutics) and human 
experience (phenomenology) (Gerrish, 2006). Qualitative research methods employ 
strategies for the ‘systematic collection, organisation, and interpretation of textual 
material obtained from talk or observation, which allow the exploration of social 
events as experienced by individuals in their natural context’ (Malterud, 2001 ;397). 
The development of theory or knowledge is inductive and has value in topic areas 
where little is known.
In contrast to the quantitative paradigm, social reality is regarded as a creation of 
individual consciousness, which may reflect multiple, rather than a single reality 
(Burns, 2000). The subject matter of social sciences comprises people and their 
institutions, which are seen as fundamentally different from that of the natural 
sciences, and requires a different logic of research procedures. Reality is seen as 
socially constructed and so is constantly changing. On an epistemological level, 
there is no access to reality independent of our minds, no external referent by which 
to compare claims of truth (Sale & Brazil, 2006). The emphasis is on understanding 
rather than explaining. For this reason, in social research, quantitative approaches 
are seen as having a limited validity as they can lead to assumption that facts are 
true for all people all of the time. According to Burns, (2000) the task of the 
qualitative methodologist is:
‘To capture what people say and do, as a product of how they interpret 
the complexity of their world, to understand events from the view points 
of the participants. It is the ‘life world’ of the participants that constitutes 
the investigative field. ‘Truth’ within this context is bound to humanistic 
caprices. Thus, conventional attempts to emphasise the imperatives of 
science place unrealistic constraints on research’ (p11).
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Burns (2000) explains that qualitative researchers emphasise the socially constructed 
nature of reality, the intimate relationships between the researcher and what is 
studied, as well as the situational constraints that shape the study. In contrast within 
quantitative paradigm, the emphasis is on the measurement and analysis of causal 
relationships between variables, not processes. In essence, qualitative methods are 
concerned with the ‘organic wholeness’ rather than independent variables and with 
meaning versus behavioural statistics, where interest is directed towards context- 
bound conclusions rather than towards ‘scientific’ generalisations’ (Burns, 2000:12).
3.2.2. Pragmatism and Mixed Method Research Approach
According to Creswell (2003), pragmatism derives from many authors and many 
forms exist. For most of them, knowledge claims arise from ‘actions, situations, and 
consequences rather than antecedent conditions’ (p11). There is a concern about 
solutions to problems and instead of ‘methods’ being important, the ‘problem’ is seen 
as being important and researchers use all research approaches to understand the 
problem. Therefore, it is not committed to any one system of philosophy and does 
not see the world in absolute unity. Pragmatism therefore accesses a range of 
methods, worldviews, assumptions and data collection methods and analysis. In the 
context of clinical practice the unity of both paradigms are required to utilise their 
strengths and strategies to overcome their limitations sought. This approach is 
becoming more accepted to a greater number of healthcare professionals as 
Malterud (2001), argues:
‘Although the ideas of evidence-based medicine are widely accepted, clinical 
decisions and methods of patient care are based on much more than just 
results of controlled experiments. Clinical knowledge consists of interpretive 
action and interaction -  factors that involve communication, opinion and 
experiences. The traditional quantitative research methods represent a 
confined access to clinical knowing since they only incorporate only questions 
of phenomenon that can be controlled, measured and counted. The tacit 
knowing of an experienced practitioner should also be investigated, shared and 
contested’ (p357).
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Although differences exist between positivism and naturalism, they are both 
committed to realism but in different ways. The underlying logic of mixing is that 
neither quantitative nor qualitative methods are sufficient in themselves to capture the 
trends and details of the situation (Creswell, 2004). The pragmatic approach, which 
is implicit in evaluation research, requires the researcher to be competent in both 
methods and, or to recognise when to identify expertise from others to support the 
research inquiry to conduct it to a high standard.
3.3. Validity and Reliability
Validity and reliability are conceptualised in different ways in quantitative and 
qualitative research. Much debate on the respective paradigms has centred on 
validity and reliability issues because it is associated with the credibility of the 
research findings. Reliability and validity issues should be considered in all research 
endeavours however; the defining features vary between quantitative and qualitative 
studies. The terms that are used to characterise reproducibility relate to concerns 
about reliability. Whereas, concerns about the scope and meaning of content and the 
generalisability of findings amount to concerns about validity (Brink, 1991; Kidd & 
Parshall, 2000).
3.3.1. Reliability
This is argued to be a difficult criterion to meet in qualitative studies by Bryman
(2004) because the social setting is dynamic and not amenable to replication. 
However, this can be overcome with agreement with observers about what they see 
and hear. This is known as inter-observer consistency, which is similar to the 
quantitative concept of internal reliability. Issues of external reliability or 
generaliseabilty are limited in qualitative studies due to small study size and 
contextual nature of qualitative studies (Bryman, 2004). Lincoln & Guba (1985), 
suggest that different criteria need to be applied to qualitative work, partly because in
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the social sciences there is no single absolute truth being sought, but a spectrum of 
perspectives. They suggest the notion of ‘trustworthiness’ be used, and propose four 
criterion by which this is judged (see box 3.0).
Box 3.0. Reliability & Validity Equivalent Concepts in Qualitative & Quantitative Research (in brackets) 
using Criteria from Lincoln & Guba (1985)
Trustworthiness:
5. Credibility -  (internal validity). Research has been carried out according to best research 
practice and subjects validate that meaning has been correctly interpreted.
6. Transferability -  (external validity) - presentation through dense description that enables 
other researchers to make judgements about ‘transfer’ to other contexts.
7. Dependability -  (reliability) -  provision of an audit trail in all phases of the research, field 
notes to enable third party judgements.
8. Confirmability (objectivity) -  clarity that researcher’s personal values have not influenced the 
research project.
Kidd & Parshall, (2000) find it useful to consider reliability in the conventional terms of 
stability, which is the equivalence to internal consistency. With focus group methods, 
stability can be improved when the same group is convened on more than one 
occasion especially if some members are present and missing on another. In this 
situation, the group can be asked to rank related issues in order of importance on 
each occasion as a means of testing for stability. Alternatively, it may suffice to 
demonstrate a similar range of concerns raised at different times.
3.4. In Summary
This chapter has considered the philosophical differences of qualitative and 
quantitative research paradigms and their use in process evaluation research. Both 
approaches have been compared and it can be concluded that the use of both 
paradigms brings a depth and breadth of knowledge generation to the research 
inquiry. In addition, the strengths and weaknesses of the quantitative and qualitative
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approaches can be overcome in combination to provide a pragmatic approach to the 
knowledge generation. Objective data can be explored in conjunction with subjective 
data to provide rich seams of data to describe current practice. Different governance 
processes to ensure validity and reliability associated with qualitative and quantitative 
methods have been highlighted and followed to ensure the integrity of the research 
data is not compromised.
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CHAPTER FOUR DATA COLLECTION METHODS
4.0. Introduction
The research methods used was a retrospective medical notes review (n-71 case 
notes) influenced by the quantitative paradigm and focus group research (n=4) which 
is aligned to the qualitative paradigm. A Parallel data analysis approach was 
undertaken as described by Ostlund et al (2011). This is where data collection and 
analysis are done separately and then data is compared or consolidated in the 
interpretation stage. This was thought appropriate as the data gathering strategy 
aims to overcome the limitations of both research paradigms in order to describe and 
explain the research findings. The purpose of the quantitative data was to 
characterise the patient cohort, admission circumstances, diabetes history, CBG 
monitoring and treatment withdrawal variables; whereas, the focus groups addressed 
the personal beliefs, clinical contexts and their perceptions (ideal and common 
practice) that may be influencing practice decisions. Both quantitative and qualitative 
data can mutually enable a richer interpretation of practice contexts from which to 
map out care processes to inform and support practice development. The 
development of theoretical frameworks does not form part of the data collection 
objectives.
This chapter will critically discuss the data collection methods with particular 
reference to the development of the data collecting tools and the issues of validity, 
reliability and ethical standards that are associated them. A brief review of data 
analysis is also presented.
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4.1. Ethical Considerations to the Conduct of Research
Research is not a benign endeavour, no matter how altruistic the research idea may 
appear there are likely to be ethical issues that should be addressed at the outset. 
Further, the political nature inherent in evaluation research study requires the 
purpose to be clear, because various stakeholders may hold different views about its 
results (Patton, 2002). This clarity is important for obtaining clearances and 
permissions with gatekeepers to access sources of data (Robson, 2002). 
Submission of the research proposal to ethics and other relevant committees who 
represent a range of interested stakeholders are required as part of the research 
governance processes to minimise harm at a range of levels, such as personal, 
public, moral, legal and organisational accountabilities.
The ethics of any research proposal begins with consideration of the relevance, 
benefit and justification for the inquiry and extends to issues for the design, conduct 
confidentiality and dissemination of the research findings (Farsides, 2003). This has 
been accomplished through the review of the literature, seeking expert and user 
(acute trust patient panel members) opinion and through proposal submission for 
ethical review. A favourable ethical opinion for the research proposal was received 
from all stakeholders relevant to the research prior to data collection. These were 
Surrey Research Ethics Committee, acute hospital trust research and development 
department, and the University of Surrey Ethics Committee (see appendices). The 
ethical considerations relevant to the research methods will be discussed within the 
sections pertinent to the method context in this chapter.
4.2. Retrospective Medical Notes Review
The research objectives for utilising the retrospective medical notes review method 
were to establish a range of contexts that may be influential in the decision-making 
for end-of-life glucose management. These variables can be organised around the
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socio-demographic characteristics, admission reasons and the potential for self- 
advocacy and involvement of relatives in monitoring and treatment decisions, 
diabetes type, duration and HbAic to contextualise experience, potential for advocacy 
and the nature and management of blood glucose at the end-of-life. The medical 
notes review was considered an important data source to map out these variables to 
establish population and care processes.
4.2.1. Retrospective Medical Notes Review Method
Medical records have been defined as ‘informal collections of observations and 
impressions that contain both subjective and objective information obtained during 
the patient care process’ (Panacek, 2007; 206). A retrospective medical notes 
review^ entails abstracting and anonymising patient’s personal and clinical data from 
a set of medical notes in a systematic way (Menon & Cash, 2006). It is a routine and 
efficient method of data collection for clinical databases, audit and clinical research 
(Pan, et al. 2005) and enables healthcare professionals to inform and add to their 
practice (Gearing, 2006). It is an important methodology with distinct advantages 
since all significant clinical events that occur during a patients’ hospitalisation are 
assumed to be recorded in the patient record (Sutherland & Steinum, 2009). It offers 
many advantages in terms of data accessibility, ability to customise data collection in 
scope and detail, clinical richness, low cost, and flexibility in data collection during the 
time the study is conducted (Pan et al. 2005, Wu & Ashton, 1997). Retrospective 
medical notes review are often perceived as easy and potentially expedient data 
collection methods, however creating an effective data abstraction tool takes time, 
planning and piloting (Engle, 2009). Methods to increase validity and reliability of 
data collection need to be carefully considered and tested through pilot work.
 ^Also known as a 'chart review'
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4.2.2. Strengths and Limitations to Validity and Reliability
Although this methodology has many advantages, it also has limitations. The primary 
limitation lies in the fact that the medical record was not generated to produce 
research data, and data within it are of variable quality and accuracy (Hess, 2004). 
By definition, retrospective studies are those in which the events and all other 
relevant observations or data measurements have already occurred before the 
investigator begins the project (Panacek, 2007). Against these advantages of limiting 
researcher bias through ‘distance’, lies a range of other biases from other sources. 
Clinical data comprise objective data (laboratory tests, investigations demographic 
data) and subjective data such as patient interview, observation and physical 
examination where bias can occur. It is not always possible to get a complete story 
from the notes due to the variation of what is told to the health care provider, and of 
these data, what gets noted (Luck, 2000, Schwartz & Panacek, 1996). Other sources 
of bias include missing medical notes and data, unrecoverable information, 
incomplete or unrecorded information and difficulty interpreting subjective information 
(Gearing 2006; Panacek, 2007; Pan et al. 2005). The degree to which information 
loss or degradation has occurred is also impossible to determine. Thus, it can be 
seen that there are issues within the methodology that can lead to quality 
measurements that spuriously overestimate or underestimate the quality of care 
given. To overcome these limitations, a pilot abstraction form was compiled and 
tested on ten medical case notes.
4.2.3. Data Abstraction Instrument Development Process
The framework outlined by Gearing et al. (2006) was used for developing a data 
abstraction proforma and conducting the retrospective medical notes review. These 
steps are outlined in table 4.0. The variables for the data abstraction form were 
informed by the literature review and expertise within the clinical, research, audit, and
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statistics advisory teams, from the hospital trust and university resources. A 
reflective approach using my own expertise to list assumptions and rationalise what 
would comprise evidence of importance for blood glucose management was taken 
and these are summarised in table 4.1. The process of ethical review was also 
influential in the final proforma.
4.2.3.1. Audit Registration & Ethical Considerations
Ethical considerations concerning the use of medical notes beyond the primary 
purpose for which they were created are complex, particularly those of deceased 
patients. These issues mostly concern patient confidentiality which is principally 
protected by common law and the Data Protection Act (DPA) (1998) which 
emphasise that informed consent is of paramount importance (Damschroder et al. 
2007). In the case of accessing identifiable deceased patients medical records, 
where consent is not possible, governance arrangements are in place through 
section 60 of the Health & Social Care Act 2001 (Haynes et al. 2007). This provides 
a legal and advisory framework (Patient Information Advisory Group (PIAG) 
application) for protection of both the patients’ privacy while taking into account the 
wider complexities of justifying access for modern healthcare development and 
research requirements. Without this framework there are complex ethical issues in 
that confidential information may impact on living relatives or partners in cases of 
infectious diseases or psychiatric histories, which may impact on confidentiality of 
relevant others (Haynes et al, 2007, Metcalfe et al, 2008). Therefore consideration to 
purpose, access and confidentiality protocols is crucial.
Section 60 support is not required if information is required for local care pathway 
audit that will directly impact on the quality of care given and the data can be fully 
anonymised (PIAG,2009). PIAG (2009:5) has agreed that consent for audit 
processes is implied as part of consent for treatment as long as there is available
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information provision to enable patients to opt out of audit. With this is mind, the 
retrospective medical notes review audit was registered with the Quality and Clinical 
Effectiveness Department, where advice and support for accessing patient medical 
notes was provided. The 1998 Data Protection Act (DPA) clarifies the legal 
conditions that must be satisfied in order to process medical data (Boyd, 1993). A 
consequentialist view would argue that generally, research methods of this kind are 
qualitatively different from other research because there is limited potential harm to 
the patient and the outcome may improve the quality of care for others (Menon, 
2006). However, in the case of deceased patient’s records, as in any retrospective 
study, there is a requirement to weigh the risks to privacy and confidentiality with the 
potential benefits to existing patients, future patients and the public in general. The 
implementation of confidentiality procedures as specified in the Health & Social Care 
Act (section 60) 2001, and within the organisational protocols within the Trust and the 
university were followed.
4.2.3.1.1. Confidentiality processes for medical notes review
This was enacted by ensuring the data that was to be abstracted was legally 
obtainable without PIAG application by inspection of the data collecting tool by the 
audit team and through ethical procedures. A series of 5-10 medical records were 
obtained and returned, and were kept in a locked cupboard, in a locked office. All 
data abstraction procedures were completed on the hospital premises. Data was 
abstracted directly into SPSS and all patient records were anonymised (alpha- 
numerically coded) at the point of collection. The ‘key’ document identifying coded 
patients was stored as an encrypted file and when data was collected and validated, 
the file was destroyed. All medical records were returned via an audit trail and 
supported by the audit team who supplied and returned the records.
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Table 4.0 Framework for conducting retrospective medical notes review (adapted from 
Gearing et al. 2006)
Step Stage Activity Rationale
1 Conception of 
idea
‘Clinical scan’ through consultation 
with clinical experts.
Determine feasibility and informed 
approach to decisions through research 
stages.
2 Literature
review
Literature review methodology. Generate key variables, operational 
definitions and question validation.
3 Research
Proposal
development
Clear definition of study variables 
Study variables operationally 
defined based on other studies 
definitions.
Check medical notes for structure 
and documentation.
Consistency and clarity, comparability 
with other studies (generalisability).
Provided a standardised baseline for 
retrospective medical notes review
Design data abstraction to align with 
information flows.
4 Data
abstraction
instrument
organisation
Simplicity and clarity to enable 
uniformity.
Data should be organised in a 
logical order and parallel flow of 
heath record.
Consider data management 
storage and analysis.
Improve internal validity and 
reproducibility.
Use of data abstraction software (SPSS) 
that parallels data abstraction instrument.
5 Develop 
protocols and 
guidelines
Coding Manual developed for 
reviewers.
SPSS software used for consistent data 
collection with operational definitions 
cited at point of data collection.
6 Data
Abstraction
Training and management of 
abstractors, protocols. Chart 
procurement procedures, rules for 
accessing data, photocopying 
policies.
Abstractors blinded to study 
hypotheses.
Clarity of procedures and quality control
To decrease reviewer bias that may 
affect study outcome. Maintain 
objectivity.
7 Sample statistician supported
Management of missing data rules 
-  pilot study -  Inclusion & 
exclusion criteria clear.
Pragmatism & requirement for probability 
statistics.
Consider hidden or non-response bias -  
usually cases deleted.
8 Ethics Ethical approval. Confidentiality/consent/data handling 
legalities.
9 Pilot study Ten percent of the overall sample 
recommended
Check inter-rater reliability -  
includes cross checking /  
occasionally checking a single 
abstractor collecting data from a 
chart on 2 separate occasions.
Assess feasibility adequacy of 
instrumentation, assess missing data 
bias, sampling concerns and inclusion 
and exclusion criteria
Reliability should be at least >70% on 
Kappa rating.
4.2.3.2. Pilot Evaluation & Shaping the Question and the Data
Pilot studies allow researchers to assess the feasibility of the planned investigation,
determine the adequacy of the instrumentation and evaluate any potential 
methodological pitfall such as the frequency to which items are missing from the 
notes (Wu & Ashton, 1997). They also provide information to evaluate any potential
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sampling concerns or impact from inclusion and exclusion criteria (Jansen, 2005). In 
retrospective medical notes review studies, a commonly used general guideline for 
reliability is that the pilot studies should target 10% of the overall sample (Jansen, 
2005, Panacek, 2007) and this was the standard used for the study.
A review of the first ten sets of notes was iterative and prolonged. This process 
served to rationalise what data were valid and why, and was helpful in maintaining 
the focus on the blood glucose management decision. Objective data such as age, 
gender, dates, times and numbers, numbers of prescribed medicines on admission 
and number of comorbidities stated on admission were clear, consistently 
documented and validity and reliability issues were non-contentious. The pilot raised 
some themes for data abstraction that were not initially considered but were likely to 
be important. For example, it was noticed that a lot of patients lived alone, and this 
raised issues around advocacy for patient wishes, and the social context was added. 
Some data were not possible to collect easily, or at all, as these were qualitative in 
nature and were not documented in a consistent way. An example of this is the 
random and varied observations on diabetes blood glucose control in the doctor’s 
notes. There was no clear way to operationally define these variables reliably. 
Similar issues were raised in the nursing notes about nutrition, which was a grey area 
that generated an exhaustive list of symptoms. Statements such as ‘refused’ on food 
record chart may be appetite related, menu driven, or too tired to eat. Therefore, it 
was noted directly in the SPSS database as ‘refused food’ and not under ‘poor 
appetite’.
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Table What would imply evidence that blood glucose is an important
4.1 component of end-of-life?
Assumption Indicator
Blood glucose is an important if:-
1. Measured consistently and responded 
to
2. Patients distressing symptoms are 
reversible by diabetes treatment
3. Risk of life threatening acute 
complications of diabetes such as DKA 
/HHNS /  Hypoglycaemia
4. Patient and family think it is
5. Health care professionals think it is 
important
1. Blood glucose monitoring rationalised, recorded 
and treatment thresholds prescribed and given
2. Patients usual symptoms assessed and 
included in a palliative care plan
3. Diagnosis and treatment plan in place when 
critical glucose threshold occurs
4. Patient & family involved in decision noted in 
notes or LCP
5. Documented care plan in place in the Liverpool 
care pathway or notes. LCP /  notes reflect 
views and decisions or referral to diabetes 
expert resources.____________________________
Blood glucose are likely to be 
deranged if:
6. Patients are septic, have an intercurrent 
illness or not receiving adequate 
nutrition or treatment
7. They have cancer versus non-cancer 
diagnosis
8. Patients are on medications likely to 
elevate blood glucose
9. Steroids /feeds are stopped abruptly
10. Sliding scale insulin is used
Admitting diagnosis and key laboratory values, 
date when diet and diabetes treatment stopped
7. Note whether cancer or non-cancer cause for 
admission
8. Document steroid therapy
9. 4/5 Date started/stopped
10. Documentation checked
Patients/relatives are likely to 
contribute to decision making if:
11. They have mental capacity to do so
12. Are symptomatic enough to request 
treatment
13. Consider their diabetes to be important 
enough to become involved
14. Are well enough to be concerned
15. Have had diabetes long enough and are 
aware of symptom origin
16. They have type 1 diabetes and self 
manage their condition well
17. Have family who are willing or 
knowledgeable enough to be an 
advocate
18. If health care professionals involve them
11. Medical notes report dementia /  confusion / 
unresponsive / mental status/not providing 
admission clerking data or notes not specifying 
direct communication of medical plan with 
patient
12. Medical notes symptoms documented
13. Medical notes state involvement
14. Medical notes state/DNAR form/ physical 
dependency
15. Medical notes state duration and concern
16. Diagnosis stated in notes /  HbAic recorded
17. Medical notes state any concerns and patients 
social status -  married etc
18. Medical notes state any concerns
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4.2.3.3. Symptom Data Inclusion
The retrospective medical notes review method generates descriptive quantitative 
data. Associations regarding symptoms and CBG values are likely to be unreliable 
due to the variation of accurate recording of symptoms in the medical notes (deVon 
et al, 2004; Schwartz, 1995), which may be driven by the experience of the clinician 
and by what was reported by the patient at the time. This is a well-known limitation of 
retrospective data (Jansen, 2005). The advice of a palliative care physician was 
sought. It was agreed to limit the data collection in the chart review to a simple list of 
reported symptoms that were noted during the end-of-life to assess what was 
important enough to get noted. Independent advice was also sought from a diabetes 
consultant at a neighbouring hospital who felt that symptom data should be collected 
and to consider some effects of diuretic and cardio-respiratory drug therapy 
withdrawal at end-of-life. A second pilot was conducted and it was found too onerous 
on time available to link in other drug factors, or vital signs (as recommended by the 
local ethics committee). The practicalities of capturing a rich data set against time 
constraints needs to be addressed realistically (Patton, 2002). Therefore, a symptom 
list was thought to be sufficient. For the purposes of the research outcomes, 
theoretically if the blood glucose value data were in the normal range they would be 
unlikely to add to symptom burden.
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Preadmission period Post admission period
Stable
Trajectory 1 
Acute deterioration death
Acute 
, deterioration 
. Comfort careStable
Trajectory 2 
Acute illness
death
Figure 4.0 Deterioration trajectories 
4.2.3.4. Identification of the End-of-Life Phase
The pilot review indicated a consistent clear dated documentation of acute physical 
deterioration occurring in the pre-admission period, and post admission period 
following acute care treatment. Figure 4.0 summarises the two trajectories that occur 
in acute care. Trajectory 1 is acute deterioration that may, or may not be recognised 
as the terminal phase and death occurs in early admission. Trajectory 2 is acute 
illness that is actively managed and is followed by an acute deterioration phase, or 
reaches a point where ‘comfort care’ treatment is declared. The dates when this is 
documented and the date of death will define the end-of-life phase.
The variable affecting the blood glucose monitoring and management, and treatment 
withdrawal practice is measured against this time point of deterioration. The pilot 
phase indicated that in some patients the diabetes drug therapy was stopped prior to 
the date of deterioration secondary to poor oral intake and may not form part of the 
decision to stop treatment as an end-of-life decision.
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4.2.3.S. Conclusion on Process
The process of developing the data abstraction instrument can be likened to peeling 
away layers of an onion to get to the heart of the data in order to establish what can 
be reliably and validly measured. The process is iterative and time consuming, but 
allows the researcher to have clarity of focus during data collection. Those data that 
arose in the data collection period that were seen as important, but were not on the 
abstract form were noted in field notes for reflection in the final analysis.
4.3. Sample
Table 4.2 Research Sample and Purpose for Inclusion.
Sample Source Purpose of Sample
Diabetes Specialist Nurse (DSN) referral 
requests who deceased in 2008.
To learn the ‘who, what, when and why’ 
reasons patients were referred at the end of 
life.
Information department search of Hospital 
Episode Statistics (MES) database to identify 
cancer patients coded as having a 
comorbidity of diabetes.
Cancer patients more likely to be perceived 
as ‘palliative’ than non-cancer conditions; 
useful comparator to identify ‘factors 
influencing’ component of research question.
Palliative Care Patient Data Base (PCDB) 
listings of patients with a comorbidity of 
diabetes provided by palliative care team.
Influence of palliative expertise on 
symptomatic management and holistic 
approach.
A purposive sample of patients who died of any cause in the year 2008 and had a 
comorbidity of diabetes was obtained from three sources. These are summarised in 
table 4.3. Inconsistencies of clinical coding for diabetes has been reported widely in 
the literature particularly when the primary reason for admission is not diabetes 
related (Sutherland & Steinum, 2009, Cox et al, 2003, Humphries, et al. 2000). The 
sample size is thus likely to be an under-estimate of the total number of hospital 
deaths in patients with diabetes.
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4.3.1. Inclusion and Exclusion Criteria
Only adult patients who were documented as having a comorbidity of diabetes, and 
who died in the hospital setting from any cause were included. Patients were 
excluded if the medical notes did not contain a clear documented diagnosis of 
diabetes, or lacked the following documentation: drug charts, glucose record charts, 
nursing notes, medical notes, and vital signs data.
4.3.2. Data Analysis
The data were analysed using SPSS software (version 19) and Microsoft Excel 2007 
to generate descriptive statistical data. Inferential statistics were employed relative to 
data quality.
4.4. Focus Groups - introduction
Focus group data enabled the collection of rich data from acute care professionals 
(doctors, nurses, dieticians, pharmacists and allied health care professionals) who 
had expertise in components of care related to blood glucose management. Views 
were sought for the management of blood glucose from the point where terminal 
deterioration was declared and the prognosis was thought to be ‘days’.
A total of 31 participants provided data across four focus groups (see table 4.4). The 
first group comprised the palliative care team which acted as the pilot. The data from 
this group were included in the data analysis. Three other groups were convened; 
these were: a generalist group representing views from the medical and surgical 
wards, a diabetes group from the diabetes ward staff and specialist nurses from the 
outpatient team. A fourth group was convened and comprised of members from the 
palliative care and generalist group, and three new members volunteered who were 
unable to make any of the dates from the three previous specialist group dates. One 
of whom worked on the diabetes ward. The role of the focus groups was to explore
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the perceptions from each specialism and inform some of the findings from the 
retrospective medical notes review. Richards and Morse (2007) suggest that if the 
topic is complex focus groups are helpful in distinguishing dimensions that matter to 
the participants. Carey (1994;p226) defines focus group technique as comprising ‘a 
semi-structured group discussion, moderated by a leader, held in an informal setting, 
with the purpose of collecting information on a designated topic’. All the focus groups 
were audio-recorded with a digital recorder with the signed consent of all the 
participants.
Table 4.3. Summary of Focus Group Composition and Management
Pilot Group
(palliative) N =7
Generalist
N=7
Diabetes
N=9
All groups N=8
(previous group 
representatives &
3 new participants)
Gender 0 m ale 1 m ale 1 m ale 0 m ale
Doctor 2 14 -3 5 2 15 -2 5 2 7 -1 8 1 14
Nurse 3 2 0 -3 3 3 10 -3 5 6 0.7-38 5 3 -3 3
Pharmacist 1 6 0 0 0 0 0 0
Dietician 1 17 1 7 1 25 0 0
Allied health 
Professional
0 0 1 13 0 0 1 13
Spiritual leader 0 0 0 0 0 0 1 19
^Formal education 
diabetes 1 /7
2 /7 8 /9 2/8
*Formal education 
oncology
2 /7 2 /7 0 /9 3/8
*Formal education 
palliative care
5 /7 4 /7 1 /9 6 /8
*Formal education for 
end-of-life care
6 /7 2 /7 1 /9 5 /8
Years experience in 
speciality
1-20 
(mean 8.9 years)
3-34 
(mean 12.8)
0.7-20  
(mean 9.6)
3-19  
(mean 9.25)
Years experience in 
end-of-life care
1-30 
(mean 9.2)
0-30 
(mean 12.1)
0-18 
(mean 4)
3-19  
(mean 9.25)
MM
Length of discussion 1 hour 1 hour 1 hour 1.5 hours
Digital audio-taped yes yes yes yes
**P rom pt sheet version 1 version 2 version 2 version 2
M oderator researcher (DH) researcher (DH) researcher (DH) researcher (DH)
Co-facilitator present present present present
Transcriber present present present present
1 *W ithin  last 3 years * *  see appendices
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A key advantage of focus group method is the ability to collect a large amount of data 
on a topic in a limited period of time (McLafferty, 2004). This is a pragmatic approach 
because time is a limited resource for busy healthcare professionals. However, for 
the researcher it requires a considerable amount of time for formal planning, 
organising, topic guide development and other organisational tasks (Krueger and 
Casey, 2000). The exploratory nature of the research inquiry favours the use of 
focus group methodology over the individual interview because of its social context 
and focus on interaction between participants (Barbour, 2007, Duggleby et al, 2009). 
Although the social context in a focus group may not be a natural one, (Lambert & 
Loiselle, 2008) it may be a familiar one within the NHS where attending multi­
disciplinary meetings are commonplace and may not be as imposing as an individual 
interview.
4.4.1. Data Collection Objectives
The research aimed to explore the beliefs, practices, perceptions and motivations of 
healthcare professionals around withdrawing or continuing blood glucose monitoring 
or diabetes treatment at the point where irreversible deterioration or comfort 
measures were declared in situations where the prognosis was ‘days’. The inclusion 
and perceptions of the patient and the relatives in shared decisions for diabetes 
management for these decisions were explored.
Of particular interest were the values and perspectives within the diabetes, palliative 
care and general specialties across the trust, set within a multidisciplinary 
perspective. The generalist aspect, and multi-disciplinary specialist focus is a clear 
gap in the literature. A fourth group was convened with the majority of the palliative 
care team and mixed membership from the generalist groups with additional new 
members. The aim of this composition was to generate a rich discussion, enable 
‘sense-making’ and to challenge the differing perspectives from the clinical teams that
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work across the trust. In addition, it presented an opportunity for participants to 
consider the topic and revisit it post reflection. This strategy adds strength to the 
validity of the findings (Kidd & Parshall, 2000).
Interaction data within focus groups is an important data source. It allows the 
researcher not just to observe who says what, but also who speaks out most, which 
kinds of staff dominate, and whose comments are taken seriously (Green & 
Thorogood, 2009, Lambert & Loiselle, 2008). Limited data were also collected on 
professional discipline, years experience and recent formal education in diabetes, 
palliative care, oncology, experience of the focus group participants to provide 
contextual data (see table 4.4). This may add to the knowledge base findings of 
Quinn et al, (2006).
4.4.2. Recruitment
Qualitative research by definition uses non-probability sampling methods (Bryman, 
2009). Within this study, a purposive sample was used from within the acute trust. 
This is in alignment with the pragmatic approach of evaluation research. Purposeful 
sampling aims to recruit participants because of their experience and knowledge that 
is relevant to the inquiry (Richards & Morse, 2007). Hudson (2003) adds that 
sufficient interest in the issue or question to contribute to the discussion is a key 
requirement in the recruitment process. Seniority was seen as important for many 
reasons including their ability to comment on their own and the wider team’s 
experiences: and their confidence in giving a view in a multidisciplinary team context. 
However, less experienced staff with an interest in participating was not seen as a 
reason to exclude anyone as they may offer some useful questions or insights to 
challenge and stimulate group discussions. The disciplines of interest were 
experienced nurses, doctors, dieticians and pharmacists as these professionals have 
particular knowledge in the components of care relevant to glycaemic control.
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Although this sampling technique does not enable generalisable findings, it is 
commonly used in social research and organisational studies where findings are 
linked to other published research (Bradbury-Jones et al, 2009).
I
4.4.2.1. Recruitment and Ethical Considerations
Evaluation research is non-therapeutic, and frequently the only benefit is altruism 
(Brody, 2001). This benefit is denied if participants are not autonomously choosing to 
participate. Informed consent must be meaningful, and clear. Farsides (2003) 
suggests that indirect interpersonal methods are seen as more acceptable ethical 
method of recruitment. The researcher thus made use of naturally occurring 
specialist team and ward meetings to recruit and inform potential participants for the 
focus groups. A ‘snowball’ approach to recruitment was taken using these meeting 
opportunities. This is a form of convenience sampling where the researcher makes 
initial contact with a small group of people and then uses them to establish contact 
with others (Bryman, 2004). Participant information packs were given out as part of 
this strategy. This was to ensure opportunities were afforded to those who may be 
interested but were unknown to the researcher. Field notes were made during this 
period to capture comments or attitudes that were expressed. These responses 
ranged from surprise that the topic was even considered to enthusiasm that it was 
being addressed.
The chief pharmacist and principal dietician were briefed individually on the project 
verbally and through written information and their views were sought as to whether 
they felt their own discipline’s contribution to the focus groups would be relevant. 
Both disciplines agreed that they should be represented and were pleased to help 
with recruitment. Participants from these disciplines were self-selecting from their 
own team meetings and made themselves known to the researcher.
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4.4.2.2. Consent and Confidentiality Relevant to Focus Group Research
The focus group method can potentially present complex confidentiality issues that 
evaluators should address as participants are often employees within the 
organisation (Brody, 2001). Farsides (2003) emphasises that the participant 
information sheets (see appendices) should to be honest, detailed and be clear about 
the risk and outcome of inadvertent self-disclosure. This may occur where emotion 
may override normal self-control and may have both emotional and legal 
1 consequences if inappropriate or unlawful practices are surfaced. Follow up 
resources within the organisation were made known for any ongoing emotional 
support. Clarity about the rules of disclosure of other participant’s views outside of 
the focus group setting was made clear as part of the recruitment and conduct of the 
focus group process.
4.4.2.2.1. Confidentiality Procedures for Electronic Data
The use of a digital audio recorder was used and the data collected was stored on an 
encrypted memory stick for transportation to the University for analysis, and 
encrypted files were saved on NHS password protected intranet and home computer. 
The digital recordings on the recording device were deleted. The transcriber is a 
medical secretary and familiar with information governance ethical and legal issues. 
Recordings and transcriptions were uploaded and saved on the same encrypted 
memory stick supplied by the trust for such purposes. All transcribed data has been 
coded and participants anonymised according to respondent number in the focus 
group, professional group and focus group number (1-4). Therefore ‘R1.DR1.FGT 
identifies the person as ‘respondent 1 doctor number 1 from focus group 1 (see page 
114 for full professional group key).
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4.4.3. Validity and Reliability and Trustworthiness’
Focus groups generate qualitative data and the validity and reliability issues can be 
described according to the principle of ‘trustworthiness’ if well conducted to ethical 
principles and good practice guidelines. These criteria were summarised in box 3.0 
 ^ in terms of ‘confirmability’ (or objectivity) ‘credibility’ (internal validity) and 
dependability (reliability). Attention to these issues are presented, but the 
terminology ‘validity and reliability’ will also be used for succinctness.
4.4.3.1. Confirmability and Dependability
Although focus group methods tend to be informal, objectivity may be greater than 
that obtained through individual interview as researcher bias can be minimised This 
is because focus groups present an opportunity to share in a broad perspective of 
experiences that can be challenged, agreed or refuted by others. Validity and 
reliability are enhanced through participant’s interaction and challenging facts or 
practices raised by others (Wilkinson, 1999, Barbour, 2007, Bradbury-Jones et al. 
, 2009). This process may have the effect of diluting the researcher influence, and 
helps make collective sense of differing individual experiences through their 
interactions (Wilkinson, 1999; Lambert & Loiselle, 2008; Green & Thorogood, 2009). 
Further, conducting a series of focus groups allowed a range of perspectives to be 
collected and thus increase the confidence in emerging data patterns (Patton, 2002; 
Kidd & Parshall, 2000).
4.4.3.2. Credibility (Internal Validity)
The moderator opened all of the focus groups and all consent forms were signed at 
the start. Following introductions of group members, the research objectives were 
outlined and ground rules agreed by the participants, with emphasis on the 
/ confidentiality issues. Opportunities for questions were afforded, and light 
refreshments provided.
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The development of the semi-structured topic guide was informed by the review of 
the literature and data collection against this aimed to enable a degree of validation 
from the process (Bryman, 2004), and ensures reliability (dependability) or 
consistency of data collection across the focus groups. A handout (prompt sheet -
, see appendices) with the research question, objectives and question topic areas 
were circulated, and participants were encouraged to review and reflect on these for 
triggering relevant clinical memories if thought applicable. An individual notebook to 
write ideas and to avoid interruptions was provided. The role of the moderator 
ensured validity and reliability by enabling discussion towards participants to provide 
checks and balances on each other and challenge false or extreme views (Patton, 
2002). At the close of each focus group, the participants were asked to identify 
themes that they perceived had emerged from the discussion and comment on what 
guidelines were needed. This was considered an important contribution to the 
credibility of the theme development. This was further enhanced through the role of 
the co-facilitator and transcriber.
I
4.4.3.S. Limiting Researcher Bias
A co-facilitator and transcriber comprised part of the focus group to enable support 
for its conduct and credibility during for the data analysis strategy (Kidd & Parshall, 
2000). The co-facilitator made notes about the key points made and interaction of 
the group and validated the emerging themes during the early data analysis stage. 
The transcriber was present to facilitate the accuracy of transcription scripts for 
content and attributing individual participant’s contribution accurately. Both co­
facilitator and transcriber contributed to a post-group debriefing to discuss and 
validate impressions and themes as part of the early data analysis process and 
reflections for the next focus group. This strategy enhances the validity and reliability 
through reduction of subjective bias that may be attributed by the researcher. The
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co-facilitator validated the themes post analysis using the final transcript from focus 
group four to generate themes separately and then comparing and discussing 
findings to agree the themes. Further, the focus group chapter was read for face 
validity and agreement of themes by the co-facilitators (one experienced focus group 
lead, one qualitative researcher).
The objective was not to generate theory, or phenomenological perspectives, but in 
the spirit of pragmatism, describe the practice perspectives and processes as part of 
the evaluation research objectives.
4A 3.4. Pilot Group
The pilot group comprised the palliative care specialist group (n=7) who had agreed 
in advance to reconvene a second time if required. During the planning phase with 
the co-facilitator, the strategy was outlined as above. The rationale for the prompts 
was to document the research questions, maximise data collection and avoid 
prolonged discussion in just one area resulting in a rushed closure. The prompt 
sheet enabled participants to trigger ideas and focus on the research question and 
stimulate a wider group discussion to limit prompting from the moderator. A notebook 
to ‘park’ questions and comments in was given to everyone to facilitate non­
interruption by other participants.
The focus group (see table 4.4 for summary of participants) was arranged in a large 
circle in a patient day room. This room was the only venue available on the day that 
all the team were able to be present. Unfortunately, there was a lot of unanticipated 
noise from building work on the ward that day. Limited interruption was negotiated 
with the builders who needed access to the day room, which was being used to store 
all their tools to prevent undue noise. The research topic, objectives and ground 
rules were summarised, and the role of the research team outlined along with
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confidentiality requirements. Discussion from the group was restrained and inhibited. 
Everyone contributed, however; there was a lot of prompting from the researcher. 
The themes that emerged from the discussion were summarised by the group, 
confidentiality was reminded and the group was thanked in appreciation of their 
contribution and the meeting was then formally closed.
4.4.3.4.1. Reflection on the Pilot Focus Group Conduct
It was clear that the environment was critical in data collection in terms of its impact 
on distractions and clarity of sound. The practical issues of running the group had a 
steep learning curve. This included the size and location of the room. The large 
echoing day room affected the ability to hear clearly, what people were saying as the 
palliative team were quietly spoken and this diluted the sound considerably. The 
external sounds of the ward bells, lunch trolley, dishwasher in the kitchen next door, 
and talking outside the room limited clarity of communication during the discussion as 
well as in transcribing resulting from the poor sound quality. The practical issues of 
having a table in the middle of the group were important for managing lunch and the 
handouts. The role of the co-facilitator for supporting administration was a clear 
strength (Hyden & Butow, 2003) for time management. Further, the validation of data 
and observations about the focus group was invaluable for completeness of data 
collection.
4.4.3.4.1. Revision of the ‘Prompt’ Sheet Handout
Many of the moderator questions focussed on the varying contexts of monitoring, 
such as impact on the family of treatment withdrawal, impact of blood glucose on 
symptoms, diabetes classification issues and duration of diabetes. Therefore, in 
order to reduce the moderator prompting and stimulate discussion, the ‘prompt sheet’ 
was revised to include a series of vignettes for triggering discussion (see appendices 
for version 2.0).
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4.5. In Summary
Two complementary research methods were used that were associated with a range 
and depth of ethical concerns and validity and reliability issues. The inherent 
strengths and weaknesses for the research inquiry were enhanced to enable the 
illumination of the inherent ‘truths’ available from each of the research approaches.
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CHAPTER FIVE QUANTITATIVE DATA ANALYSIS
5.0 Introduction
This chapter reports the findings from the retrospective medical notes review and 
begins by describing how the data analysis was approached. The results arising 
from research objectives summarised in chapter 4 (section 4.2) are the focus of this 
chapter. The patient sampling frame is presented and explained in section 5.1. The 
medico-socio-demographic dataset findings are then presented which contextualises 
the acute care admission and patient characteristics in section 5.2.-5.4. The capillary 
blood glucose dataset and variables influencing the end-of-life glucose values are 
presented in section 5.5. There were limited findings in the medical notes for the final 
objective that explored shared decision making with patients and their family. Only 
two cases were reported where this was documented, one case reflected a patient 
initiated discussion (type 1 diabetes - see section 5.5.4), and the other was initiated 
by a junior doctor for patients with type 2 diabetes. Both these cases directly 
addressed diabetes management.
5.0.1 Data Management
Data were collected from 71 medical health records from which 4 datasets 
(demographics, blood glucose and vital signs, symptoms, and drug therapy) were 
compiled using Statistical Package for the Social Sciences’ (SPSS version 19) 
software. Analysis of these four datasets were iterative and time consuming as each 
of the 71 case note studies were diverse and required different strategies that 
facilitated data immersion and ‘sense-making’.
Relationships within and between the variables in the four datasets were explored 
using cross tabulations in SPSS, and by combining variables in data sub-sets using
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Microsoft Excel (2007). This facilitated a range of questions to be explored and 
patterns in the data to be tested, reflected on and described. The excel workbooks, 
enabled larger numbers of variables to be viewed directly and be placed strategically 
together (for example, cancer status, diabetes type, number of days on the LCP, 
days without food, days without diabetes medicines) and examined column by 
column through the ‘sort data’ tab to establish potential relationships and data 
patterns. The findings from this strategy of data immersion were then discussed with 
the statistician for statistical evaluation using SPSS using the statistician’s expertise 
with the software programming.
/
5.1.0. Hospital Deaths for Diabetes and Sample Characteristics
This section describes the sampling frame which arose from the total number of 
patients who had a hospital death during the period January to 31^ December 
2008 in patients who had a comorbidity of diabetes (n=229). The research sample 
(n=71) was drawn from this cohort in a purposive manner (see chapter 4, table 4.3) 
and represented 31% of total hospital deaths in patients with diabetes.
All three patient recruitment sources were compared and duplicates excluded (using 
the DSN database list as the master) which yielded 100 cases. Seventy-one cases 
met the research criteria, these medical notes were obtained, and data were 
 ^ abstracted. Table 5.1 summarises the inclusion and exclusion of cases.
Table 5.1 Summary of Cases Included and Excluded
Summary of Cases Sourced Summary of Exclusions
Source Total
cases
found
Duplicate
cases
Total
minus
duplicates
Missing
Data
Not
Diabetes
Not a
Hospital
Death
Died
2009
Total
exclusions
Total
notes
sampled
DSN 23 0 23 0 0 1 0 1 22
HES 35 10 25 5 1 0 0 6 19
PCDB 55 3 52 0 4 8 10 22 30
Total 113 13 100 5 5 9 10 29 71
DSN = Diabetes Specialist Nurse: HES = Hospital Episode Statistics: PCDB = Palliative Care Database
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5.1.1 Sample Summary and Characteristics
The total number of deaths in the hospital in 2008 was 1257 patients of whom 229 
(18.2%) had a comorbidity of diabetes. The Hospital Episode Statistics (HES) 
database identified 223 patients and a further 6 cancer patients who were not coded 
for diabetes in HES, were found in the Diabetes Specialist Nurse (DSN) referral list. 
More cancer patients (63%) from HES were found on the palliative care team 
database than on the DSN database (4.5% n=1); and less than two patients from 
palliative care and HES were common to DSN database.
From this total dataset of 229 patients, the age, sex and cancer characteristics were 
compared for representativeness with the 71 patients in the purposive sample (see 
figures 5.2, 5.7). The age range from the total sample was found to be between 35 
and 99 years of age. There was a clear incremental trend in age for female (almost 
two fold) which peaks in the 8th decade. In the male population, there is a steep 
‘step’ pattern, with the majority of patients in the older ages of between 70-89 years. 
Figures 5.2 and 5.3 reflect similar patterns suggesting ‘representativeness’ in the 
research dataset to the total hospital diabetes cohort.
Total Hospital Diabetes Deaths 
Age & Sex Profile
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Figure 5.1: Total Diabetes Deaths Age-Sex 
Characteristics
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Figure 5.2: Research Dataset Age-Sex 
Characteristics
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5.1.2 Cancer and Non-cancer Profile of Total Hospital and Sample
The HES database reported 14.4% (n=33) patients who had a diagnosis of cancer 
and diabetes, whereas the actual percentage found was 17.9% (n=41). The total 
hospital deaths for patients with diabetes reflect higher survival by a decade in the 
non-cancer group particularly in the female population (see figures 5.4 and 5.5). The 
research dataset reflect similar distribution with slightly more male cancer patients 
compared with the total hospital sample (see figures 5.6 & 5.7).
In summary, the majority of patients who died in the hospital were over the age of 70 
years, and presented with non-cancer comorbidities. Table 5.2 summarises the 
cancer survival by site and shows 59% died within 6 months of diagnosis of which 
32% of patients died within first month of diagnosis. Survival over 6 months to 17 
years occurred in 41% of patients and reflects different time perspectives for patients 
to consider end-of-life planning.
Table: 5.2 Cancer (n=41) Survival from Diagnosis
Number of 
patients
Cancer survival from date of 
diagnosis time period
Cancer Sites
13 1-30 days Lung (8); UGI (2) ; Metastatic (3).
11 1-6 months Lung (4): UGI (3); LGI (2); skin (1); Adrenals (1).
7 7-24 months Haematology (2) ; UGI (2); LGI (1); Bladder (1) : Renal (1).
8 8-17 years Breast (2); Haematology (2); Multiple Myeloma; (1) Prostate; (1); LGI (1); Skin (1).
2 unknown Haematology (1); LGI (1).
Glossary: LGI (lower Gastro-intestinal tract) UGI (Upper Gastro-lntestinal Tract)
Total Hospital Deaths 
Diabetes and Cancer n=33
I  Male Cancer N=16 I  Female Cancer N=17
3 3
5 5
80.
I
90-99
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Figure 5.5: Male Cancer Diagnosis by Age Figure 5.6: Female Cancer by Age
5.2.0. Disease and Symptom Characteristics Triggering Admission
This section reports the reason for the hospital episode to ‘map out’ factors affecting 
end-of-life planning capacity, advocacy, factors impacting on symptoms 
discrimination and perceptions through polypharmacy and comorbidity burden.
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5.2.1. Reason for Admission
In the 2008 HES database (n=223) the recorded hospital deaths for all patients with 
diabetes was reported as vascular diseases (40%) infections (27%) non-vascular 
(18%) and cancer related diagnosis (15%). In the 71 sampled patients, the medical 
reasons for admission are summarised in Figure 5.11. The medical notes listed two 
admission diagnoses in most patients, which gave 133 diagnoses from 71 cases; for 
example, heart failure and chest infection may be documented as co-occurring for the 
same admission.
Two thirds of patients were admitted with acute serious illness and one third with non­
specific illness symptoms such as ‘unwell’ ‘not coping’ ‘dizzy’ ‘fell’. Patient-reported 
symptoms on admission were documented as a single entity or as a cluster of 
symptoms. Symptoms that were commonly reported as a single entity were chest 
pain (n=4) and ‘unresponsive’ or ‘collapsed’ states (n=5). A notable feature about the 
non-specific nature of some of the admission symptoms was the seriousness of the 
underlying conditions that emerged as the clinical problem. This may have 
implications for the psychological preparedness of patients and their families for a 
declining prognosis and end-of-life discussions.
The most common reason for admission was infection, which was associated in a 
third of the cases, with dehydration. Chest and cardiac related conditions were the 
most common systems affected. If chest infections were included, the total chest 
related condition increased to 29 cases and accounted for 40% of the sample. Heart 
failure was the most common cardiac condition at the end-of-life in the patient 
sample. Upper and lower gastric tract conditions included dysphagia, bleeding, 
constipation and diverticulitis. Liver disorders were alcohol and cancer related. Both 
failed discharges were due to unrecognised imminence of death as hospital length of 
stay was brief.
Reason for Admission
11XI i 1 1 1
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Reason for Admission:Primaryand Secondary Diagnosis n=133 from Total Sample n=71
Figure 5.7 Reasons for Admission to Hospital
Diabetes & Non Cancer • Total Comorbidities & Prescribed 
Drugs
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Figure 5.8 Non-cancer Patient 
Comorbidities & Prescribed Drugs
Diabetes & Cancer • Total Comorbidities & Prescribed Drugs 
I  cancer prescnbed drugs I  cancer comorbidity
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Figure 5.9 Cancer Patients 
Comorbidities & Prescribed Drugs
Eleven admissions (26%) were directly related to the primary cancer site, such as 
pleural effusions with lung cancer. Nine admissions were secondary to cancer 
complications such as hypercalcaemia or general physical deterioration.
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Comorbidities are an important reason for admission in cancer and non-cancer 
patients.
5.2.2. Comorbidities & Prescribed Medicines.
Cancer patients had a mean of 5.2, comorbidities (SD=1.9) and non-cancer patients
5.8 comorbidities (SD =1.9) (see figures 5.12 and 5.13). A non-paired t-test showed 
there was no statistically significant (p=0.227) difference between co morbidity 
burden in cancer and non-cancer patients. Cancer patients had a mean of 9.4 
prescribed medications (SD=4.0) and non-cancer 9.5 prescribed medications 
(SD =4.1). There was no statistical correlation between cancer status and number of 
prescribed medicines (Unpaired t-test, P = 0.923). The number of prescribed 
medicines was independent of age at admission, no statistically significant correlation 
was found between age at admission and number of prescribed medicines 
(Pearson’s correlation co-efficient = - 0.023; P = 0.852).
5.3.0. Diabetes and Advocacy Variables
The following section report’s findings from the research sample of 71 patients, for 
factors influencing the patient’s potential competence that may inform their end-of-life 
glycaemic decisions if asked. These include diabetes duration, diabetes drug 
therapy, HbAic, mental capacity, terminal phase on admission and socio­
demographic background for advocacy from others.
5.3.1. Diabetes Type & Duration
As summarised in figure 5.8, the majority (87.3 %) of patients had type 2 diabetes of 
which 11.2% (n=8) were diet controlled. Patients with type 1 diabetes accounted for
9.9 % (n=7) of the sample which reflects the population prevalence of type 1 
diabetes.
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Diabetes Duration
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Figure 5.10: Summary of Diabetes Duration
Duration of diabetes ranged from 0-30 years for type 2 diabetes, and 30-60 years for 
type 1. Fifty percent of patients with Type 2 diabetes had been diagnosed within the 
last 10 years; only two patients had been diagnosed with diabetes for less than 1 
year (see figure 5.8). Many would be familiar with the medical message that diabetes 
is important to manage well.
5.3.2. Treatment of Diabetes
Diabetes Therapy During Admission
(n -71 Patients)
■  Number of Patients
I
Insulin,oha llk e c lln s u tin  B a s a l/b o l'i j  sul|'bonytu i«a N o n e p ie s tr ib e d  f .le tfo im ln  dual/oha Triple,-oba
Figure 5.11: Summary of Prescribed Diabetes Treatment During Admission
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In 76.1% of patients, treatment was with tablets and/or insulin therapy. Only 18% 
patients were not on any diabetes medicines during their final admission (see figure 
5.9). In six cases diabetes treatment had not been prescribed on admission as the 
patient was not eating or was unresponsive on admission. Four patients with type 1 
diabetes were treated with basal-bolus, and three with mixed insulin analogue 
regimes. In patients with Type 2 diabetes most were on insulin analogue basal-bolus 
regimes (n=16). Gliclazide as monotherapy was the most common oral 
hypoglycaemic agent prescribed. The majority of patients and their families were 
likely to be familiar with self-monitoring of blood glucose, glycaemic symptoms and 
management of diabetes.
5.3.3. Blood Glucose Control Pre-Admission HbAic Summary
Sixty-five HbAic records were found and six were not available. These six patients 
may have been from out of area, exempted from testing by the general practitioner 
(GP) due to terminal status, or the test may not have been taken or processed in the 
researcher’s hospital. Eight patients (six diagnosed with cancer) did not have their 
HbAic measured within the previous 14-31 months prior to their final admission. It is 
not known whether the test was withheld based on patient preference or professional 
judgement.
Eighty-seven percent of patients had an HbAic test within the last 12 months of life of 
which 69% were in the previous 6 months prior to admission. This suggests that 
blood glucose management was regarded as important in the majority of the sampled 
group; however, the assessment that the patient was in the final year of life may not 
have been recognised. The last reported HbAic data are summarised in figure 5.10. 
These results imply that the majority (66%) of patients were reasonably well 
controlled with results in the equal to, or less than 58 mmol/mol (7.5 %) ranges within 
the previous 6-12 months.
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Summary of last recorded HbAic
(n=6S)
I last 6 months ■ last 7 12 months >12 months
" 2 ■
42 mmol/mol 43-58
(<6.0%) mmol/mol
(6.1-7.5%)
13
I
60-68
mmol/mol
(7.6-8.4%)
69-85
mmol/mol
(8.5-9.9%)
86 mrnol/mol 
(>10.0%)
Figure 5.12: Summary of Last Recorded HbA1c
5.3.4. Factors Potentially Supporting Self-Advocacy
Data on social support were analysed to identify self-advocacy and potential 
advocates to act on the patient’s behalf if they were unable to do so for themselves. 
Type 1 diabetes has a higher mortality risk in the short-term from DKA and these 
risks are likely to be known by both patients and family. Thus, cross tabulation 
searches were run in SPSS to identify the type of diabetes with social variables and 
are summarised in table 5.3 and reported below.
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Table 5.3 Gender, Diabetes Type, Social Support and Self Advocacy
Variable Diabetes Type
Diabetes summary Type
1
Type
2
Steroid Not
Clear
Total
n=7
(9.9%)
n=62
(87.3%)
n=1
(1.4%)
n=1
(1.4%)
n=71
(100%)
Support n= %
Lives alone Male 1 5 1 7 (9.5%)
Female 11 11 (15.4%)
Lives with spouse Male 26 1 27 (38%)
Female 4 6 10 (14.8)
Lives with relative Male 3 3 (4.2%)
Female 3 3 (4.2%)
Lives in care home Male 1 3 4 (5.6%)
Female 1 5 6 (8.4%)
Mental capacity to make decisions 
On admission:
Yes 6 46 52 (73%)
No 1 15 1 17 (23.9%)
Unclear 1 1 2 (2.4%)
Mental capacity to make decisions 
last 72 hours of life
Yes 2 27 29 (40.8%)
No 5 33 1 40 (56%)
Unclear 1 1 (1.4%)
Terminal phase apparent 
On admission
Yes 1 7 8 (11%)
No 6 55 1 1 63 (89%)
5.3.4.1. Social History
The majority of patients were married (52.1%) and only a few (8.5%) lived with a 
relative. The rest either lived alone (25.4%) or were in a care home (14.1%). All 
notes indicated family contact except for one patient. When analysed by gender, two 
thirds of males were living with their spouse or family member and one third were 
living either alone or in a care home. In contrast, just over one third of females were 
married or looked after by family member, and two thirds were living alone or in a 
care home. Potential patient advocacy in this sample appears to be more favourable 
for the male population. Most patients with type 1 diabetes had support in place.
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5.3.4.2. Mental Capacity
Patients with mental capacity were those who, on admission, gave an account of their 
presenting complaint, were reported as independent and not classed as confused, 
muddled or having a history of dementia. 73% of patients had mental capacity and 
thus were potentially able to provide a glycaemic and symptom history. However, 
documentation of a structured glycaemic history was not standard practice on 
admission. At the end-of-life phase (last 72 hours), fifty six percent of patients did not 
have mental capacity, therefore opportunities to know patient preferences for blood 
glucose management could not be known.
5.3.4.3. Terminal Phase on Admission
On admission, 11% of patients were clearly identified as being in the terminal phase 
and would probably not be able to act as their own advocate. Diabetes was not 
raised as a concern in any of these notes. There were no patients who lived alone, 
possibly, because they were more likely to alert someone earlier in the deterioration 
phase or died at home.
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S.3.4.4. Deterioration trajectory across whole dataset
Preadmission period Post admission period
Stable
Trajectory 1 
Acute deterioration death
Acute
deterioration 
Comfort care 
point
Stable
Trajectory 2 
Acute illness
death
Figure 5.13 Deterioration trajectory
The pilot work identified two admission trajectories, where admission was related to 
an acute deterioration that was not reversible and those who responded to acute 
reversible treatment. The entire dataset was reviewed and the following patient 
admission characteristics of those who died within 72 hours of admission were 
summarised. In total 20% (n=14/71) of patients died within 72 hours of whom 64% 
(n=9/14) were female, and 57% (8/14) had a non-cancer diagnosis. The reasons for 
admission were mostly acute events (n=5) (myocardial infarction, confusion 
secondary to pneumonia, stroke, haematemesis and heart failure exacerbation). 
Three were for generalised chronic deterioration. For patients with cancer (n=6) two 
patients had acute events (generalised swelling with cancer diagnosed on admission, 
and rectal bleeding in liver failure). One patient was admitted electively for palliative 
surgery. The other three deaths were due to ongoing deterioration with one patient 
actively dying pre-admission. The pilot work trajectories were supported, although not
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all were predictable. Advanced care planning for glycaemic preferences may not 
have been appropriate for all patients admitted.
5.4.0. Management at the End of Life
This section reports wards where end-of-life was supported and the referral patterns 
for palliative care and diabetes end-of-life advice.
5.4.1. Wards Managing Patients with Diabetes at the End-of-Life
The majority of patients were managed by the medical wards and the least by the 
diabetes ward (see table 5.4). The diabetes ward comprises one of six medical 
wards and the proportion of patients with diabetes at the end-of-life appears 
comparatively low. People with diabetes tend to have high medical comorbidities, 
which may account for the spread of specialties caring for patients with diabetes at 
end of life.
Table 5.4 Diabetes Type and Ward Caring for Patients at the End-Of-Life
High Acuity Areas Medical “Surgical Diabetes Total
Emergency 
 ^n=3
ITU
n=1
H^DU
n=2
wards
n=5
wards
n=5
wards
n=1 n=71
Type 1 0 1 0 5 0 1 7
Type 2 5 2 2 42 9 2 62
Steroid
Induced
0 0 0 0 0 1 1
Not clear 0 0 0 1 0 0 1
Total % 12.6% 67% 12.6% 5.6% 100%
I^ncludes A/E and medical/surgical assessment units 
 ^High dependency units 
‘‘general and orthopaedic
5.4.2. Diabetes Specialist Nurse (DSN) Referrals
A total of 25 patients were referred. These were analysed relative to the proximity to 
the end of life or the period when the ‘do not attempt resuscitation’ (DNAR)
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notification was made, and for the reason for referral. Figure 5.14 summarises the 
reasons for referral.
The majority of the referrals (n=18) were made prior to DNAR status notification; and 
the remaining 7 patients were referred during the early DNAR period (2-14 days) and 
9-40 days pre-death (average 20 days). Two patients were seen by the DSN within 
72 hours of death in this subgroup of patients. No referrals for end of life blood 
glucose management were found in the post DNAR period. Of the 25 patients seen, 
six patients blood glucose had normalised at the end of life, 5 died unexpectedly 
within 2-7 days of initial referral; and the remaining patients, blood glucose had 
moved into episodic hypoglycaemic and hyperglycaemic ranges, were not referred for 
glycaemic guidance when there may have been some comfort-based benefit to do 
so.
Reasons for DSN referral
■  Referred n 25
H y p o g lv c a e m ia Erratic blood 
glucose
In s u lin  a d ju s t m e n t  E n te ra l  fe e d s  &  
g lu c o s e  
m a n a g e m e n t
Figure 5.14 Nature of requests for referral In patient in final hospital 
admission.
5.4.3. Palliative Care Team Referrals
Sixty percent (n=44) of patients with diabetes were referred to the palliative care 
team. However 50% (n=26) were requested within the last 72 hours of life (see figure 
5.15). In 28% (n=7) of cases the hospital length of stay was less than 72 hours which
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limited earlier notification. Two thirds of referrals were for management of the 
imminently dying patient on the LCP.
In this research, 90% of patients had a ‘DNAR’ notification in place. Referrals to 
palliative care were made within 72 hours of DNAR notification in 38% (n=17) of 
patients with 17% (n=8) being referred on the same day. Figure 5.15 summarises a 
higher proportion of patients with cancer referred to palliative care team and non 
cancer cases to the diabetes team.
Referral Patterns to Palliative and Diabetes team
c(U0)V)
Cancer N=41
» Non Cancer N=30
Diabetes
Jteam »
2
Palliative 
Cate 
19
Neither
Figure 5.15 proportion of specialist referrals by cancer diagnosis
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5.4.4. Symptom Burden in the Last 72 Hours of Life
The medical notes review abstracted any documented symptom written in the 
medical or nursing notes within the period of deterioration in last 72 hours of life. 
These data reflect those symptoms thought important enough to document. No 
relationship can be made to causality. Figure 5.16 represents a ‘symptom count’ 
rather than number of times they were reported.
Cancer patients (63.4%) experienced 6 or more symptoms over the last 72 hours, 
whereas non-cancer patients experienced less (46.6%). Table 5.5 lists the 
symptoms and cancer status during the last 72 hours. There were many similar 
symptom experiences between cancer and non-cancer patients. The role of blood 
glucose management may be important given the high gastro-intestinal, confusion 
and neuro-psychiatric symptoms. Cancer symptom profiles may reflect side effects 
of analgesia.
Symptom Burden in Last 72 hours by Cancer & 
Non Cancer Patients
■  Non Cancerns30 #  Cancer n=41
14
12
10
' l i E l n n0 ^  11 11
1 2 3 4 5 6 7 8 9 10 11 12
Number of Symptoms Documented in Last 72 hours
Figure 5.16 Number of Symptoms Reported in the Last 72 hours and Cancer Status
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Table 5.5 List of Symptoms in Last 72 Hours and Cancer Status
System Symptom Cancer n=41 Non-cancer
n=30
Respiratory Short of breath 11 (26.8%) 7 (23.3%)
Chesty 4 (9.7%) 5 (1 6 .6 % )
Both *9 (42.8%) 1(3.3% )
Gastro-intestinal Dry mouth *7 (17.7%) 2 (6.6%)
No Appetite 14(34.1% ) 13 (43.3%)
Unable to swallow 13(31.7% ) 9 (30%)
Vomiting 4 (9.7%) 2 (6.6%)
Nausea *7 (17.7%) 3(10% )
Nausea & Vomiting *5 (12.1%) 1 (3.3 %)
Lower Gl Diarrhoea 5(12.1% ) 4(13.3% )
Constipation *8 (19.5%) 3(10% )
Both 1 (2.4%) 0
Pain Abdominal *11 (26.8%) 3(10% )
Other pain *9(21.9% ) 4 (14.3%)
Other Feeling cold 2 (4.8%) 1 (3.3%)
Sweating 2 (4.8%) 0
Neuro-psychiatric Confusion 6 (14.6%) 7 (23.3%)
Confusion + agitation /  
anxiety / distress / 
restlessness
*9(21.9% ) 4 (14.3%)
Anxiety 1 (2.4%) 0
Distress 1 (2.4%) 5(16.6% )
Restless 0 1 (3.3%)
Agitated 0 1 (3.3 %)
Energy Weak/lethargic/sleepy *17 (41.4%) 8 (26.6%)
Consciousness Unresponsive 11 (26.8%) 10 (33.3%)
Comfortable 23 (56.1%) 18(60% )
^Greater differences compared with non-cancer patients probably opiate related side-effects
5.5.0. Capillary Blood Glucose (CBG) Management
5760 timed and dated capillary blood glucose (CBG) recordings were collected from 
70 patient medical records in total. One imminently dying patient did not have any 
CBG data recorded.
The total CBG monitoring events recorded for each patient episode ranged from 0 to 
721 CBG readings in a cohort of patients whose hospital length of hospital stay 
ranged between 1 and 84 days.
The CBG dataset on blood glucose management was sourced from a diverse case 
series. Support from the statistician was lent to write command syntax programming 
within SPSS software to facilitate statistical modelling and for exploring potential
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trends or patterns with other variables across all four of the SPSS datasets (CBG, 
demographics, symptoms, drug therapy).
From the four main SPSS datasets multiple combinations of variables were compiled 
and integrated using Microsoft excel (2007) software to explore, analyse and 
synthesise data to establish the factors influencing blood glucose management. The 
following findings from the analyses are reported as outlined in 1-4 below. The 
influence of cancer and non-cancer diagnosis was a common thread throughout all of 
the analyses.
1. The whole hospital episode is summarised and statistical differences between 
cancer and non-cancer diagnosis
2. Monitored and non monitored variables
3. Hypoglycaemia variables
4. Type 1 diabetes
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5.5.1. CBG during Entire Hospitalisation Episode
The CBG dataset was interrogated across the entire admission period to establish 
any differences in CBG in cancer and non-cancer patients. Due to the skewed long 
right-hand tail nature of the distribution of the CBG variables, the non-parametric 
Mann-Whitney U tests were run in SPSS to test the association of cancer on CBG 
test values (see table 5.6).
Table 5.6 Summary of CBG distribution in cancer and non-cancer for entire hospital 
episode
Patients n =
Hypoglycaemia 
{<4.0 mmol/l)
Normal 
(4.0 - 9.9 mmol/l )
Hyperglycaemia 
(>10.0 mmol/l )
Median IQR Median IQR Median IQR
Cancer 40 5.1% 0-9.8% 71% 50.7-92.4% 19.2% 3.0-42.3%
Non­
cancer 30 5.6% 0-12.4% 56.2%
44 .0 -
72.6 31.4%
20.5-
52.9%
P = 0.699 NS P = 0.022 P = 0.014
For hypoglycaemia there was no statistically significant between cancer and non­
cancer patients. However, cancer patients had a statistically significant higher 
proportion of CBG in the normal range, whereas non-cancer patients had more CBG 
in the hyperglycaemic range than cancer patients.
5.5.1.1. CBG in Cancer and Non-Cancer in the Deterioration Phase Data 
Analysis
Table 5.7 summarises the variation in blood glucose monitoring in the last 72 hours in 
the cancer and non-cancer diagnosis groups. Seven patients had a hypoglycaemic 
event in the last 72 hours of 1.3-2.9 mmols occurring on 1-2 occasions. Patients who 
had hyperglycaemia in the >15 mmols range were due to inadequate management of 
intravenous insulin or enteral feedings.
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5.5.1.2. CBG in Acute and Deterioration Phase
Table 5.6.1 below summarises the CBG dataset according to the acute and 
deterioration phase. The mean CBG is higher in the deterioration phase (10.8 
mmols) compared with the acute phase (8.7mmols). However, it is difficult to 
conclude on relevance, as the number of tests in the deterioration is much lower.
Statistics for all Glucoses taken in 
Acute Phase
glucose test result
Statistics for all Glucoses taken in 
Deterioration Phase
glucose test result
N Valid 5151 N Valid 546
Missing 125 Missing 64
Mean 8.707 Mean 10.825
Std. Deviation 4.7331 Std. Deviation 5.2570
Minimum 1.3 Minimum 1.5
Percentiles 25 5.400 Percentiles 25 6.900
50 7.400 50 9.600
75 10.700 75 13.825
100 36.000 100 32.100
Table 5.6.1 Description of the blood glucose in the acute and deterioration phase
5.5.2. Blood Glucose Monitoring
The ‘deterioration to death’ time variable was used as a reference point for end of life 
monitoring practice to evaluate when a decision to stop or continue monitoring was 
made. This section will characterise those contexts and patients that were, or were 
not monitored to the day of death -  see table 5.7.
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Table 5.7: Summary of characteristics of those who were monitored or not 
monitored
Monitored to day of death Not monitored to day of 
death
Number of patients 68% (n=48) 32% (n=23)
Cancer 30 11
Non-cancer 18 12
Type 1 diabetes 29% (2/7) 71% (5/7)
IV insulin on day 
CBG withdrawn 5 1
CBG less than 3.0 
mmols/l 72 hours 
prior to monitoring 
stopping
7 patients (5 cancer) 3 patients (1 cancer)
CBG >15 mmols 9 patients (5 cancer) 7 patients (3 cancer)
5.5.2.1 CBG Monitoring Continued or Withdrawn Contexts
Sixty eight percent of patients were monitored until the day of death of which 12 were 
on the LCP. Patients managed on the LCP are discussed further below and data 
summarised in figure 5.18. Seven patients died suddenly and unexpectedly and 
represented the total cohort of patients who did not have a DNAR notification in situ. 
A higher proportion of cancer patients were incidentally monitored to the end of life 
compared with the non-cancer cohort due to rapid deterioration and death (see table 
5.7). Patients were still receiving active treatment with intravenous insulin therapy at 
the decision points for ‘comfort care’ when insulin was discontinued. Patients with 
type 1 diabetes were not selectively monitored and treated and will be reported later. 
Figure 5.18 summarises the deterioration to death time frames for diabetes medicine 
withdrawal and the relationship of food stopping to the final blood glucose reading.
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Figure 5.18 shows that ninety percent of patients died in the first 72 hours in 
monitored patients, of which 71% died in the first 24 hours. The short survival time 
from deterioration to death probably accounts for why patients are monitored. Only 
10% of patients survived beyond 4 days in the monitored group. In contrast, in those 
who were not monitored 78% died within 72 hours and 22% survived beyond 4 days. 
The average time unmonitored was 7.9 days. The final CBG was not influential in 
continuation of monitoring behaviour despite their wide-ranging variation and lack of 
food intake. The final CBG in the unmonitored were slightly higher as nutrition and 
treatment were continued slightly longer.
5.5.2.1.1. CBG in last 72 hours
M e a n  CBG last 72 hours
14 13
12
10 ---------------------
o o
I I
4 .1-6.0 6.1-8.0 8 .1- 10.0 10.1- 12.0 > 12.0-14.9 > 15.0mol/l mol/l mol/l ml mol/l mol/l
«  M onitored Patients n=48 ■
Figure 5.19 Mean CBG in patients monitored to day of death
Figure 5.19 reports the averaged CBG readings per in-patient in the last 72 hours, 
are variable. Hyperglycaemia was iatrogenic in origin secondary to enteral feeding 
and unskilled management of insulin.
Table 5.8 summarises the range of CBG values in the monitored patient to the day of 
death. These data are compared with the final 72 hours prior to stopping monitoring 
to note the influence of the final readings for discontinuation. The majority of 
readings in the unmonitored patients were in the normal range but 18% of cancer
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patients and 42% of non-cancer patients had blood glucose in hyperglycaemia 
ranges in the fewer than 15.0 mmols range. Depending on the patient’s sensitivity to 
hyperglycaemia, these readings were unlikely to contribute to symptom burden at the 
point where they were stopped. However, in the unmonitored group 22% survived 
beyond 72 hours for up to 18 days and may have been symptomatic. The number of 
symptoms listed in those who died within the first 72 hours, were less compared with 
those who survived beyond 72 hours. Fewer symptoms were listed, particularly for 
low energy states compared with those surviving beyond 72 hours, who had more 
neuropsychiatrie type symptoms such as agitation, distress, restlessness.
Table 5.8: Summary of last 72 hours of CBG readings pre death and re withdrawal of 
monitoring
>50%
readings 11- 
14.9 mmol
>50%
readings 15 
mmols/l
<25% in 
$normai 
range
>75% in 
normal range
"Number of 
patients CBG 
<3.0 mmols/l
Non-cancer (n=18) 4 (22%) 3(17%) 3(17%) 8 (44%) 2
Cancer (n=30) 5(17%) 4(13%) 1 (3%) 20 (67%) 5
Non-cancer. (n=12) 5 (42%) 0 0 7 (58%) 3
"Cancer (n=11) 2(18%) 0 0 8 (72%) 1
*1 patient never 
monitored
"Maximum recorded number of events was 2 per patient 
$mix of high and low end readings
S.5.2.2. Food and Diabetes Medicines (DM) Withdrawal
Table 5.9 provides a detailed report on the withdrawal of diabetes medicines prior to 
food being stopped according to monitoring status and recorded episode of 
hypoglycaemia during entire hospitalisation period. In the majority of cases 44% of 
monitored patients had food and medicines stopped on the same day. In the
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unmonitored, this was in 35% of cases. Most patients had their diabetes drugs 
stopped the day after food was stopped (23% in monitored and 30% in unmonitored). 
Less than 20% of patients were not on treatment in both monitored and unmonitored 
cohorts. There were no obvious differences between cancer and non-cancer 
patients.
Table 5.9 Diabetes drug withdrawal relative to food stopping in monitored and
unmonitored
monitored to RIP n= 48 not monitored to RIP n=23
whole
group total by hypo status
whole
group total by hypo status
diabetes drug 
withdrawn
n=48 hypo n=31
non
hypo
n=17
n=23 hypon=15 non hypo n= 8
same day as 
food stopped 21 (44%) 13(42%) 8 (47%) 8 (35%)
5
(33.3%) 3 (37%)
days after food 
stopped 11 (23%) 9 (29%) 2 (12%) 7 (31%)
5
(33.3%) 2/4 (25%)
days before food 
stopped 7 (14%) 6 (19%) 1 (6%) 4 (17%)
3
(20%) 1 (13%)
no drugs 
prescribed 9(19%) 3 (10%) 6 (35%) 4 (17%)
2
(13.3%) 2 (25%)
cancer 3/18 (17%)
4/12
(33%)
1/7
(14%) 1/4 (25%)
days without food 
cancer 3-4 days 1-4 days
non-cancer 0/13
1/5
(20%)
1/8
(13%) 1/4 (25%)
days without food 
non-cancer nil 4 days
NOTE: table does not discuss the hypo at end o f life but discussed the group who experienced or never 
experienced hypoglycaemic events during entire hospitalisation (RIP- date of death)
5.5.2.3. Patients Who Were Managed on the LCP
Patients who were not monitored were managed exclusively on the LCP and most 
had stopped eating on the same day the LCP started. Those who were monitored on 
the LCP were noted to still be on enteral feeding or taking nutrition. There were no 
obvious trends between diet and drug therapy to account for the variable range of 
CBG values (see figure 5.18). For example, the variable ‘length of time without food’ 
and blood glucose level were not linear with some values being normal and others 
being elevated regardless of time variables. This factor is likely to be attributable to 
disease variables or documentation variables.
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The last blood glucose levels recorded ranged from 4.8 to 18.3 mmol/l and were 
reported in section 5.5.2.1.
The length of time patients were managed on the LCP ranged from a few hours to 18 
days. In this sample 35 patients were managed on the LCP; of whom 88.5% (n= 31) 
were supported by the palliative care team, where 45% (n=14) were referred on the 
same day the LCP was initiated; and 35% (11) were referred 24-72 hours after 
patients were established on the LCP. The rest were referred earlier between 5-19 
days pre LCP initiation. Therefore, in the majority of patients managed on the LCP, 
referral to palliative care for symptom advice was late. This limited sufficient time to 
address CBG management wishes of the patients or their families.
5.5.3. Hypoglycaemia Analyses
The CBG database was analysed to establish hypoglycaemia events across the 
hospitalisation period and in the end-of-life phase. Those patients who had a 
recorded hypoglycaemic event and those who did not were analysed separately and 
are summarised in table 5.10 below. The hospital episode and end-of-life findings 
are briefly presented.
Table 5.10: Summary of patient contexts for hypoglycaemic events
Contexts Hypoglycaemic event recorded No Hypoglycaemic event recorded
Total n=70
(1 patient never monitored)
46 (64%) 24 (36%)
Cancer diagnosis 25 (54%) 9 (38%)
Non-cancer diagnosis 21 (46%) 15(62%)
Admission context
• Acute-on-chronic 14/46 (30%) 11/24 (46%)
• new acute event 18/46 (40%) 7/24 (29%)
• infection 14/46 (30%) 6/24 (25%)
Type 1 diabetes 5 2
Average hospital length of stay 22.1 days 7.8 days
Monitored until day of death 31/46 (18 cancer) 17/24 (12 cancer)
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5.5.3.1. Hypoglycaemia and Weight
Using Spearman’s rank correlation test, no statistically significant association was 
found between a patient’s weight and:
1. percentage of CBG tests in Hypoglycaemic range
2. percentage of CBG tests Normal (hospital) range (4.0 -9.9 mmol/l)
3. percentage of CBG tests > 10.0 mmol/l
4. percentage of CBG tests >15.0 mmol/l
5.5.3 2. Admission Contexts -  Non-Hypoglycaemia Group
The majority of patients who never had a recorded hypoglycaemic event were 
admitted in an acutely ill and distressed state and the average hospital length of stay 
was short (see table 5.10). One third died in the early admission period. The 
majority presented with cardiopulmonary events (respiratory failure arising from a 
variety of pathology such as collapsed lung, pulmonary embolus, pulmonary effusion, 
pulmonary oedema, acute renal failure, sepsis and ruptured aortic aneurysm) and the 
rest were related to acute upper gastro-intestinal conditions and end-stage liver 
disease. These acute admission contexts were exacerbated by other comorbidities 
such as dehydration and other infections.
5.5.3.2.1. CBG Findings in the Non-Hypoglycaemic Cohorts
Twenty-five percent had normal CBG, and two thirds had up to 50% or more readings 
in the hyperglycaemic range. The higher readings were seen in patients treated with 
steroid therapy (n=7) enteral feeding (n=1) and sliding scale intravenous insulin 
therapy (n=1) or who were on no diabetes medications (n=13). Some patients had 
one or more of these variables in combination which were inadequately adjusted and 
were variably managed, even within the same ward. Patients were monitored in the 
deterioration period with no clear management plan.
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5.5.3.3. Admission Contexts -  Hypoglycaemia Group
The reasons for admission reflect a wider spectrum of causes compared with the 
non-hypoglycaemia group (table 5.10). These ranged from planned admissions (2) to 
emergencies related to new acute events (18) such as fractures, stroke, and 
myocardial infarction and first presentation for diabetic foot disease. Only two 
patients were admitted for general deterioration and poor coping. The remaining 
patients were admitted with acute exacerbations of existing problems. Thirteen 
patients had presenting complaints that were non-specific such as falls (7) unwell (2) 
drowsy (2) which may not have signalled a terminal phase of illness for some patients 
and their families. Only five patients in the cancer group had a short hospital length 
of stay of 24-72 hours.
5.5.3.3.1. CBG Findings in the - Hypoglycaemic Cohorts
In total, 64% of patients (n=46) had 466 recorded hypoglycaemic events (4.0 mmol/l 
or less) of which 48.2% (n=208) were recorded in 8 individuals who experienced 20 
or more hypoglycaemic events during their entire hospitalisation episode. The 
unskilled use of intravenous insulin ‘sliding scale’ was contributory in seven patients 
and Gliclazide in one patient. Analyses of the CBG dataset indicate that episodes of 
hypoglycaemia had been recorded continuously without treatment over several hours 
in patients on the sliding scale intravenous insulin protocols. This suggests that 
hypoglycaemia may be overlooked as a glycaemic emergency.
5.5.3.3.2. Intravenous Insulin
During the whole hospitalisation episode, more people had hypoglycaemic events 
below 2.5 mmol/l on sliding scale (n=12) compared with other insulin therapy. 
Patients with blood glucose below 2.5 mmol/l were found in those on mixed insulin 
(n=4): Long Acting insulin (n=5); Gliclazide (n=4).
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5.S.3.4. Last 72 hours and Hypoglycaemia Events
The majority of causes were iatrogenic and could be attributed to synchronisation of 
insulin and sulphonylureas with food. Only two patients (cancer) were low risk for 
hypoglycaemia (diet controlled or metformin) experienced hypoglycaemia in the 
range of 2.7-S.8 mmol/l. This was probably related to low glycogen reserves in one 
patient who had not eaten for 4 days and low caloric intake in the patient prescribed 
metformin. Two non-cancer patients who stopped diabetes medicines for 7-10 days, 
and not eaten for up to 9 days had only 2 recorded hypoglycaemia events suggesting 
non-iatrogenic causes that corrected naturally. Table 5.11 summarises three time 
frames in the deterioration phase and hypoglycaemia contexts. The non- 
hypoglycaemic group had more iatrogenic hyperglycaemia and shorter length of stay. 
No clear relationship between diabetes drug withdrawal, stopping food and final CBG 
was found. This may reflect the variation of diabetes disease and underlying 
pathology.
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Table 5.11 Summary of Variables in the Deterioration Period in the Continuously 
Monitored Patient ( n=45)
D eterioration -  
death
Non hypoglycaemic Group n=17 Hypoglycaemic group n=28
Cancer (n=12) Non-cancer (n=5) Cancer(n=18) Non-cancer
(n=10)
41% (n=5) 80% (n=4) 63% (n-12) 54.4% (n=5)
Hospital length 
o f stay
1-6 days
(average 2.2 days)
0-9 days 
(average 4 days)
1-52 days
(average 11.5 days)
13-81 days 
(average 35.6 
days)
Days w ith o u t 
food
1-4 days (average 
2.4 days)
0-1 days
(average 0.75 
days)
0-6 days
(average 2.4 days)
0-6 days
(average 2.4 
days)
Last Blood 
Glucose Value
5.2 -15.1 m m o l/l 9 -13.9 m m o l/l 4.1-14.9 m m o l/l 5.1-17.3 m m o l/l
Days since last 
diabetes drug
0 days 
(3 patients not prescribed)
0-1 days
(2 patients not 
prescribed)
0-5 days
(average 1.4 days)
(2 patients not 
prescribed)
0-5
(average 1.6 
days)
50% (n=6) Nil patients 26.3% (n=4) 36.3% (n=4)
Hospital length 
o f stay
3-19 days 
(average 7.5 days)
Nil patients 7-84 days 
(average 41 days)
7-29 days
(average 13.25 
days)
Days w ith o u t 
food
0-2 days
(averagel.33 days)
Nil patients 0-3 days
(averagel.75 days)
0-9 days 
(average 2.4 
days)
Last Blood 
Glucose Value
5.2 -18.8 m m ol/l 5.3-11.3 m m o l/l 4.8-11.6 m m o l/l
Days since last 
diabetes drug
0-18 days
(average 1.25 days)
(1 patient not 
prescribed)
Nil 0-1 days 
(average 0.75 days)
(1 patient not 
prescribed)
O-lOdays 
(average 5.5 
days)
8.3 % (n= l) 20% (n = l) 10.5% (n=2) 9.09% (n = l)
Hospital length 
o f stay
5 days 12 days 27-41 days 17 days
Days w ith o u t 
food
2 days 4 days 1-5 days 0 days
Last Blood 
Glucose Value
5.8 m m ol/l 9.3 m m o l/l 12.6-18.3 m m o l/l 11.0 m m o l/l
Days since last 
diabetes drug
2 days Not prescribed 0-2 days 0 days
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5.5.4. Management of Type 1 Diabetes
All were managed on the medical wards except one, who was managed in the 
intensive care unit, only two patients were monitored to the end-of-life and insulin was 
withheld from 1-7 days. This section will discuss the care of those who were 
monitored to the end of life and those who were not.
5.5.4.1 Monitored Patients with Type 1 Diabetes at the End of Life
Only two patients were monitored to the end of life. The first patient died suddenly 
during active treatment for infection, and was managed on a sliding scale insulin 
infusion with blood glucose in the high OKA risk range of 23-32 mmol/l range during 
the last 24 hours. The symptoms reported for this patient on the day were; dry 
mouth; poor appetite, difficulty in swallowing, nausea and vomiting abdominal pain, 
restlessness, anxiety and confusion. These symptoms have similar characteristics to 
DKA. No testing for Ketonuria was carried out to differentiate potential symptoms of 
DKA or other reasons.
The second patient (aged 57 years) was managed in ITU for overwhelming multiple 
infections and poor intravenous access. Although her blood glucose was monitored, 
insulin was withheld for 4 days. The ITU consultant had recorded her diagnosis as 
type 2 diabetes possibly because she was overweight. However, the medical notes 
summarised her 37 year type 1 diabetes medical history in one thin volume. The last 
blood glucose reading was 11.2 mmol/l. Her baseline readings were in the high-end 
of normal wherein DKA is still possible. Artificial feeds had stopped 3 days prior to 
death. Symptoms reported at the end of life were; sleepy, unresponsive and poor 
appetite.
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S.5.4.2. Unmonitored Patients with Type 1 Diabetes at the End of Life
Five patients were managed on the Liverpool Care Pathway (LCP) for the last 1-4 
days of life. Insulin was stopped in all cases at different time points. These were at 
24 hours (2) 2 days (2) 3 days (1) and 7 days (1). Only one set of medical notes 
reported anxiety over insulin omission. This patient was aware of her poor prognosis 
and feared her subcutaneous basal insulin may be omitted, as she was not eating. 
Insulin was discontinued when she became unresponsive and was managed on the 
LCP.
The patient whose insulin was omitted for 4 days had been re-admitted with recurrent 
DKA. There was scant documentation on symptoms or care for this patient and the 
only symptom recorded at the end of life was thirst.
The range of symptoms reported in the medical and nurse’s notes in these 
unmonitored patients were thirst, weakness, distress, difficulty swallowing, chesty, 
short of breath, distress, agitation, confusion, nausea, sleepy, poor appetite, 
comfortable, chest pain. Whilst these symptoms cannot be attributed directly to blood 
glucose derangements or DKA in any retrospective study, some may be suggestive.
5.5.5. Summary
The whole hospital episode CBG dataset has been analysed and was found that 
cancer and non-cancer patients have an equal chance of hypoglycaemic events. 
CBG in cancer patients are more likely to be normal and in non-cancer, patients are 
likely to be in hyperglycaemic range. The causes of glycaemic extremes are 
iatrogenic in nature. The majority of patients are incidentally monitored to the day of 
death as the deterioration to death time is less than 72 hours, with the majority (71%) 
occurring in first 24 hours. The withdrawal of diabetes therapy and food intake 
occurs mostly on the same day or after food is no longer taken.
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Continuation of monitoring is not associated with a clinical plan to treat 
hyperglycaemia. Patients who were hyperglycaemic were poorly managed; this was 
most evident in enteral feeding and intravenous insulin and use of steroids.
Those who were not monitored were all managed on the LCP and the final CBG 
reading was not influential in continuation of monitoring. Once the decision to stop 
CBG monitoring is made, it is no longer revisited. The diagnosis of type 1 is not 
prioritised for continued monitoring or insulin therapy.
The management of CBG at end-of-life is managed across the entire trust with fewer 
patients seen on the diabetes wards and referrals to the diabetes team for advice are 
limited after the DNAR period. Patients and relatives are not routinely consulted 
regardless of the years of experience with diabetes. Taking a glycaemic history is not 
standard practice.
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CHAPTER SIX FOCUS GROUP DATA ANALYSIS
6.0. Introduction
This chapter will report on the data analysis processes (6.01) and themes arising 
from the focus groups. The thematic analyses are discussed in two sections. The 
first section (6.1) will summarise the common themes raised across all four groups, 
and includes the observational data on group contribution and interaction. The 
second section (6.2) will report the thematic structures arising from analyses of the 
transcripts.
6 . 0 . 1 . Data Analysis
The transcriber who attended all of the meetings transcribed the digital recording 
promptly. The researcher checked the transcript for accuracy. Transcribed data 
were copied into Microsoft Excel 2007, and used to both familiarise the researcher 
with the data, and to import data into NVivo (version 8.0), qualitative research 
software.
The stages and approaches to data analysis of the transcripts are summarised in box
6.0. This iterative examination of the data relative to the research question enabled 
theme and category development which resulted in two overarching themes. These 
addressed clinical context and organisational context. The constant review of the 
data ensured that data saturation for the identified themes across all focus groups 
were maximised. The objective was to explore clinical practice processes and issues. 
The development of theory or interpretation of motive was not sought. For example, 
all the reasons to continue CBG monitoring and treatment was initially themed under 
‘importance’ and situations where it was seen as less relevant was themed under ‘not
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important’. The key denominator was found to be related to the level of 
consciousness, and proximity of death, for which ‘importance’ and ‘not important 
reasons were clinically related.
The ‘factors influencing’ research question component addressed a range of reasons 
that were linked to decision-making factors and were initially coded individually, such 
as ‘LCP’ ‘attitudes to palliative care’ ‘"those” conversations’ ‘knowledge’ ‘information 
flows’ ‘inconsistency of consultant decisions’ ‘relatives’ ’hierarchy’ ‘time’. These 
themes were inter-related and it was particularly challenging to single out a dominant 
theme which allowed a clear categorisation that flowed under it comfortably and 
succinctly. An overarching theme that evolved was underpinned by knowledge 
variables, but was finally contextualised to organisational factors related to the acute 
care setting.
Familiarisation strategies included use of highlighting key words, and organising texts 
into potential themes within the workbooks (excel). The unique data contributions of 
each focus group were noted as well as the common themes across all groups. All 
transcribed data were then managed and themed using NVivo 8 (Edhlund, 2009) to 
support the analysis processes.
Thematic analysis was undertaken based on the three-stage process suggested by 
Auerbach (2003) (see box 6.1). Each stage deals with a different level of analysis. 
These processes were both iterative and non-linear. Auerbach (2003;p38) defines a 
theme as ‘an implicit topic that organises a group of repeating ideas’. This model of 
analysis offered a flexible pragmatic approach that situates well within an evaluation 
research framework. Box 6.0 summarises the process of data saturation for theme 
development.
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Box 6.0 Focus group transcript analysis
Research questions
1. Is blood glucose managem ent an important component o f end-of-life care in patients with 
diabetes?
2. W hat factors influence the clinical management in the acute care setting?’
Stages Processes
1 Focus group generated A t the end o f the focus group, participants suggested 
emerging themes discussed in the group
Transcript validation
Manual handling o f data
Electronic
data
handling of
Transcripts were validated through checking narrative and 
listening to the digitalised audio-tapes. During this process 
emerging themes reflecting the research question are m ind- 
mapped and m em o’s placed in M icrosoft ‘One note’ 2007
Individual mind maps are generated from each focus group 
to organise data reflecting specialist and generalist and 
common views, relative to the research questions.
All transcripts reviewed to produce in-depth mind maps 
generated by the data to answer the research question. 
Question 1 ‘importance’ was key in sorting clinical data. 
Question 2, factors influencing are applied to situational 
context that may influence perception o f ‘im portance’. These 
produce 2 overarching themes.
Data are finally managed and systematically coded using 
NVivo 8 Software to analyse the data, m em o’s noted to 
ensure that coding is reliable. Them es & categories were 
structured using ‘tree nodes’ All data is linked to research 
question as outlined in Auerbach (2003) Them atic Process 
(see Box 6.1)
Box 6.1 Auerbach (2003) Thematic Process
1. ‘Making the text m anageable’ by working at the level o f the text itself. This is a 
filtering process where selection o f relevant text, which reflects the research, 
concerns, and discards text that does not.
2. Hearing what was said ’ where the researcher works at the level o f the subjective 
experience o f the participants. Relevant text is ordered according to repeating ideas.
3. ‘Developing a theory’ where the level o f analysis moves to a more abstract level and 
evolves towards grouping themes into more general concepts (theoretical constructs) 
which are then used to create a theoretical narrative.
A theory is defined as ‘a description of a pattern that you find in the data’ 
(p31).
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The familiarisation process was enhanced using excel and overcomes the problem 
noted by Kidd & Parshall (2000) about qualitative software where the researcher can 
become distanced from reflective engagement with the data. At stage one and two of 
Auerbach (2003) different methods of iterative engagement with the data occurred 
through various processes including validating the transcripts, repetitive listening to 
digital recordings, using Microsoft ‘excel’ and ‘NVivo’ software, modelling ideas 
through diagramming and organising themes for possible relationships. Stage three 
of Auerbach describes the themes as they relate to the research inquiry.
6.1. Summary of Focus Groups Convened
Four focus groups were convened. The pilot group was formed from the palliative 
care team who had agreed to act as the pilot and to participate in a fourth group. 
Group two were convened from medical and surgical wards, and group 3 from the 
diabetes speciality. Group four were convened from all three focus groups to 
enhance validity and reliability through data triangulation. Casey & Murphy (2009) 
report that the literature identifies two purposes for triangulation: confirmation of data 
and completeness of data. Confirmation consists of examining and comparing data 
gathered from several sources to identify the extent that findings converge or are 
confirmed.
6.1.1. Coding of Participants
Individual focus group and respondents were assigned a six digit alphanumeric code 
that correlated to respondent number, professional group, and focus group number. 
The following is an example of the code structure used: ‘R1.SN1. FGT means 
‘respondent 1, staff nurse 1, in focus group T (to identify professional group coding 
see table 6.0 below).
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Table 6.0 Alpha-numeric code key for disciplines
Professional Code Key (alpha-component) Key (numeric - component)
Dr. M edical Doctor Serialised individuals w ith in  stated
CNS Clinical Nurse Specialist discipline
DT Dietician e.g. DR3 is th ird  docto r in en tire  sampie
M M atron
SL Spiritual leader
SN Staff Nurse
OT Occupational the rap is t
PH Pharmacist
NM Nurse M anager
6.1.2. Focus Group Conduct
Each focus group was one hour long except for focus group four, which overran by 
30 minutes by mutual consent, with two people leaving after the first hour. The 
researcher moderated all four groups as outlined in the methods section, and was 
supported by a transcriber and a facilitator for each group. Overall, each group 
presented professionally, were respectful of each other’s contributions, ground rules, 
and engaged well with the topic. No-one was visibly upset or required emotional 
support either immediately or following the focus group attendance. The majority of 
the groups were female and everyone contributed a view.
6.1.3. Common Themes and Observations Across all Four Groups
There was a general appreciation for the role of the blood glucose management at 
the end of life in the conscious patient and limitations of blood glucose management 
in the unconscious patient. An individualised approach to care based on this criteria 
was prized by all groups. However, it became evident that the concept of 
‘individualised care’ was situated around the medical context, versus the 
‘personalised preferences’ informed by the inclusive views of patients or their 
families. It was generally felt that it was important to avoid Diabetic Ketoacidosis and 
hypoglycaemia episodes, but that high blood glucose in patients with type 2 diabetes 
at the end of life was acceptable. A core element across all groups was that few 
participants were able to draw or reflect on experience around the nature of typical
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blood glucose values, conversations and patient’s viewpoints around treatment of 
blood glucose at the end of life. Excluding the diabetes group, the majority of focus 
group participants did not directly address any of the vignettes. The vignettes were 
addressed predominantly by diabetes doctors.
The topic that evoked the most discussion was of the role and management of the 
LCP and its impact on decisions for monitoring blood glucose. Comparatively less 
was said about the blood glucose management issues per se. The majority of nurses 
agreed with most of the doctor’s viewpoints, but individualised the exceptions to the 
rule. The doctors supported each other, and never directly contradicted another’s 
view, but expanded on them. Doctors presented principles of practice, whereas 
nurses tended to detail their arguments with individual patient vignettes. All agreed 
that the majority of the clinical decisions are made by doctors and this ‘decision 
distance’ (principles versus patient complexity) may be an important factor influencing 
the clinical management of blood glucose in the acute care setting. Hierarchy and 
cultural issues were raised as important factors that emerged in various examples of 
practice dilemmas. This hierarchy was observed within the focus group behaviour by 
what was challenged by whom. The dieticians and pharmacist contributed data 
directly relevant to their discipline and did not contribute a principled (ethical or 
personal) view on the subjects discussed.
6.1.4. Individual Analysis & Summary of Focus Group Findings
This section briefly summarises the education, professional role and experience of 
participants in each focus group, and the ‘unique’ contribution that emerged from 
each focus group. The unique aspects are important as they represent both general 
and specialist professional perspectives, and to set a context of ‘objectivity’ to reduce 
readers perception of ‘selectivity bias’ when evidencing transcript data. The pilot 
group findings are reported first.
I l l
6.1.4.1 Pilot Focus Group
The pilot group comprised the palliative care team and their experience is 
summarised in table 4.4. This group had a broad range of end-of-life specialist 
expertise within the palliative care speciality and limited diabetes expertise. Although 
everyone contributed to the discussion, the majority of data arose from the doctors 
and the more experienced specialist nurses. The pharmacist was the only group 
member to have participated in any formal diabetes education.
The focus group contributed a large portion of data around the specialist objectives of 
palliative care. In particular, the difficulties arising from limited understanding of the 
palliative philosophy and ‘comfort care’ options for patients in the acute setting. The 
issue of blood glucose management was situated in this context. Imminence of death 
was important to care decisions. Discussion of the role of hypoglycaemia as a 
‘natural process’ in dying and the concern around the risk of additional distress and 
increasing the iatrogenic symptom burden in the management of blood glucose 
aberration particularly in the unconscious patient was seen as important issue.
6.1.4.2. Focus Group 2
This senior multidisciplinary team recruited from a range of medical and surgical 
wards is shown in table 4.4. This group had limited formal education in diabetes or 
end of life care. Ten people were recruited and seven were able to attend. Apologies 
were due to ward pressures, date change for the focus group and sickness.
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The hierarchy was balanced in this group for seniority and previous working 
relationships; with two doctor/nurse dyads that had pre-existing good working 
relationships. The HES database reported high respiratory related deaths, thus 
representation from the respiratory ward was important.
The focus group contributed unique data around the ‘benefit versus burden’ of finger 
pricking for CBG. This point was well argued between the doctors, where the 
burdens of disturbing the dying and patient distress for finger tip discomfort was 
balanced against the benefits of appropriate treatment decisions and clarity that DKA 
had been avoided through a minimal testing regime. No view was changed or 
compromised probably because the principles of clinical practice (heuristics) were 
firmly set, or professional autonomy was valued. There was a strong element of 
‘devil’s advocate’ to the argument from the surgeon.
This group contributed unique data for hospital versus community contexts, 
fragmentation of clinical information, lack of medical consistency in end of life 
decisions and the issues and dilemmas in blood glucose management. Anyone 
reading the transcripts may conclude this group was aggressive and challenging, 
however, the tone and energy in the room was positive, provocative with an edge of 
humour and irony. This may reflect the balance of hierarchy for challenging decision­
making based on existing working relationships. There was no negative feedback 
after the group had dispersed.
6.1.4.3. Focus Group 3
This comprised the diabetes multidisciplinary team, with a broad-ranging expertise 
with representation from the high dependency unit, ward based and outpatient areas. 
Notable was the limited formal education in the end of life care as indicated in table
4.4. All recruited participants attended. This focus group transcript was the shortest
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and most focussed of all groups; and was the only one to address and systematically 
review the vignettes on the prompt sheet.
The medical team contributed the most data about the blood glucose management. 
There was very limited contribution given by the diabetes specialist nurses and 
dietician whose expertise were clinic based; or by the newly qualified staff nurse. 
This may have reflected the influence of usual working practices where this clinical 
problem may not arise, and the normal communication authority structures within the 
diabetes team. The majority of nurse input was via the senior ward staff and the 
nurse working in the high dependency care area. The latter challenged and 
moderated the group response and enabled a lively debate.
The focus group contributed a large portion of unique and detailed data around the 
complex issue of diabetes management strategies and patient attitude contexts for 
monitoring, and the complexity of individual issues relative to their experiences and 
behaviours as a person living with diabetes.
6.1.4.4. Focus Group 4
This group reconvened from a combination of previous focus groups participants from 
groups one and two and are summarised in table 4.4. Apologies were received last 
minute from the ‘focus group three’ participant due to ward level pressures. Three 
new group members were recruited who had not participated in any of the focus 
groups in the series. These new participants were the clinical practice educator who 
had significant diabetes ward experience; the spiritual advisor who has substantive 
end of life experience; and an experienced staff nurse from the medical ward. All 
members contributed to a lively discussion. The palliative care doctor was interested 
in the views about the LCP and the perceptions at the interface of care, and 
commented on practice dilemmas but gave no new data. There was a general 
consensus that the group’s diabetes knowledge was limited with regards to knowing
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or interpreting symptoms and confidence with insulin and treating abnormal blood 
glucose.
The focus group contributed unique data around organisational and hierarchical 
influences on clinical decision-making in the acute care setting. Other influences 
raised were time pressures, experiences and attitudes to palliative care as important 
factors in end of life care for patients with diabetes.
6.1.4.5. Importance as Summarised in Focus Groups
In the summing up period at the end of all the focus group discussions, participants
were asked to answer the research question and their views on what the themes
were. Most felt that CBG management was important at the end-of-life and the
excerpt below summarises the key reasons.
R8.SL.FG4: Yes, SO in answer to the first question, about blood glucose measures, 
are we not saying actually, every single patient should be considered 
individually? And if they are a known diabetic then the issue has to be addressed, 
it can’t jus t be ignored.
The management of blood glucose in palliative patients was seen as generally 
important up to a point of days to hours, with caveats that will be reported in this 
chapter.
6.1.4.6. In Summary
All groups contributed similar and unique perspectives on the research question. 
Therefore, the report will reflect this variation when selecting evidence from 
transcripts. All groups identified clear areas where blood glucose was important and 
where it was less important. Decisions were multi-faceted and were influenced by 
physiological and ethical variances, individual patient situations, natural and 
iatrogenic factors, diabetes type, lack of guidelines, LCP, education in palliative care
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and diabetes, personal and professional values and organisational factors within the 
acute care setting.
6.2.0 Focus Group Themes
The two themes that emerged were ‘clinical’ (theme 1) and ‘organisational’ contexts 
(theme 2) as discussed in 6.0.1. These two themes had intrinsic factors that were 
influential in helping or hindering the delivery of personalised care. Figure 6.1 
summarises theme 1 which are organised around the categories of the level of 
consciousness in patient’s thought to be dying.
Figure 6.1. Theme 1 Patient C linical Context
Yes
Clinical Decision Context 
Is the patient conscious?
No
Monitor CBG
Patient Role
reporting
Professional Role
interpretation
Stop Monitoring CBG
if blood glucose not cause of 
unconsciousness & dying is 
imminent
Reasons Not to Monitor
no evidence base / not 
knowing
Figure 6.2 summarises ‘theme 2’, which reflects the organisational contexts or 
‘factors influencing’ the delivery of individualised holistic care. The findings from both 
these themes are synthesised in figure 6.3.
Time & Opportunity Specialist Knowledge Acute Care Culture
Figure 6.2: Theme 2 Organisational Contexts
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6.2.1. Knowing and Not Knowing
Implicit to all themes was an overarching factor of either ‘knowing’ or ‘not knowing’ 
that ‘spiralled through’ or appeared to be a ‘root cause’ of the variations, dilemmas 
and complexities in clinical practice. For example, glycaemic symptoms may or may
not be known, patients may or may not know they are hypoglycaemic; staff may or
may not know how the LCP works.
6.3.0 Theme 1 Patient Clinical Contexts
Clinical decisions were based on the patient’s level of consciousness and proximity to 
death. This theme will present the conscious state (6.3.1) and then the unconscious 
state (6.3.3). These two excerpts below summarise the various distinctions.
R4.CNSi.FG4: With our two Categories of patients there are those that are
unconscious and actively dying, which are a different group of people to the 
people who are moving towards that, because those people are awake, they’re 
able to have conversations; they know about their past medical history, they and 
their families need to be engaged in this (palliative) conversation.
R2.DR2.FG4: And certainly the patients are conscious, there is a cut off of
conscious and unconscious, but if somebody is conscious, then you really have 
to look and see, what have their blood sugars been ?, and if their blood sugars go 
outside of whichever range, are they likely to become symptomatic ? That is 
what your decision-making is on.
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Figure 6.3 Summary of Focus Group Themes and Key Points
Patient Clinical Contexts & Decision Making
r
Importance of 
monitoring in conscious 
patients
^  J
 I_ _ _ _ _ _ _ _ _ _ _ _ _
Importance of monitoring in 
unconscious patients
Patient
responsibility
Healthcare professional (NCR) 
responsibility
Unimportant to monitor in 
unconscious or dying 
patients
Withdraw of glucose 
management is 
appropriate because:
i i i
Report glucose 
symptoms 
because they
Not routinely 
assessed 
Not known by 
all Health 
care
professionals
Test when acute change 
occurs - drowsiness, loss of 
consciousness o confusion
Accountability for patient 
safety
Proactive management of 
hypoglycaemia risk during 
withdrawal of treatment 
when active dying 
recognised
Ethics and symbolic 
implications concluded by 
patient and family for not 
monitoring
I
Continue 
treatment in 
Type 1 
patients
Rule out and 
treat
iatrogenic
hypoglycaem
ia
Challenging to manage
a) Undue patient and 
relatives distress
b) Impossible to know if 
patient is suffering
Non Iatrogenic hypos are 
a natural process of 
existing disease states 
and dying
LCP -  ‘end o f acute 
treatment
Type 2 diabetes is low 
risk if hyperglycaemic : 
no known benefit for
Organisation Factors Influencing Knowing and Managing the Clinical Importance or 
Unimoortance of Blood Glucose Monitorino
Time & Opportunity
I
Specialist Knowledge Acute care culture
I I
Patients too sick or too late 
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Fragmented information 
flows
Inexperience to take the 
opportunity
Privacy in ward setting
Time to think or 
nersonalisfi carp.
Awareness of glycaemic symptoms 
and their relevance by patients, 
relatives and healthcare
Pre-existing specialist knowledge of 
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management from OPD
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6.3.1. Conscious‘Knowing’ Patient
There were two situations related to conscious patients where end-of-life CBG 
monitoring importance was identified and the roles of patient and health care 
professionals defined. This was a patient-led responsibility to report their 
symptoms, and a professional-led responsibility to respond to an acute clinical 
change to define the cause.
6.3.1.1. Patient Responsibility
The responsibility to report idiosyncratic symptoms of deranged blood glucose lies 
with the patient as these examples explain.
R2.DR6.FG3: If someone is not able to complain, we would never be able to 
interpret the symptoms. It depends on the stage (of dying) or how sedated they 
are.
R1.DR1.FG1: Well, you know, ... this is their own decision, and because even 
though they are in the last few days, they would still be able to... you know, ... 
they are the ones who lived with diabetes all their lives, I mean, it’s in 
communication with the patient, if it is possible, .... and saying that, you know, 
these are the main (symptoms) - thirst and confusion - true, it needs managing 
because it lessens the burdens, but, it depends on their views. Because very 
often this is what happens, if their sugars are unstable, you get symptoms and 
they know that’.
R2.DR2.FGi: I suppose in practice we have thought a lot about eating and 
discussions here, but, their prognosis has been raised, a lot of those patients 
aren’t going to be eating, and I would doubt, not really communicating effectively 
about their diabetes and maybe that’s where it becomes more tricky.
Although it is seen as the patient’s responsibility to report their symptoms, the routine 
assessment of patient’s blood glucose comfort threshold or preferences for
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monitoring and treatment are not part of a routine assessment in clinical practice in all 
cases.
Moderator.FG2: Do you think W0  Should ask patients what their blood glucose 
preference range is? Or do you think we set it as a profession?
R5.NM3.FG2:1 think it could be better but we do tend to ask people.
R3.NM2.FG2: Yeah we do, we try a lot.
R5.NM3.FG2: We don't ask as much as we should, but we do ask.
R5.CNS3.FG3: Do we ask them what they want to do?
R2.DR6.FG3:1 ju s t..., we should, that’s, ideally that would be, ideally we should 
ask them their opinion about what they want.
Moderator.FG3: Do we ? Is that routine to practice?
R7.NM4.FG3: Yes, we do ask but as R1.DRS.FG3: Said, it is tailored to individual 
patients.
R3.CNS2.FG4: I Can’t Say I’ve had that many conversations, about diabetes 
management with people.
6.3.2. Healthcare Professional Responsibility
The role of CBG at the end-of-life was allied to legal and ethical decision parameters. 
CBG monitoring was an important criterion for defining deterioration due to reversible 
causes or to define the transition point for terminal care. The role of CBG was also 
perceived as best practice in patients with type 1 diabetes. These contexts are 
articulated below.
6.3.2.1. Acute Symptom Interpretation
The role of CBG monitoring is important to differentiate acute changes in the patient 
who is thought to be dying versus deterioration to acute causes. The ethics of 
allowing someone to die with diabetes symptoms, or the short-term complications of 
DKA or hypoglycaemia were raised as a concern. The acuity of the change was an 
important prompt for CBG testing and the difficulty of differentiating the natural dying 
process versus glycaemic symptoms was identified as a dilemma.
120
R2.NM1.FG2: That IS What I am vacillating about, I absolutely take on board what 
you are saying because, to stab somebody every hour, is not necessarily kind, 
but is it kind to let them die with the symptoms of diabetes ?, I don’t know. Also, 
how do we know what it is that is actually precipitating their death? Is it the 
diabetes not being managed properly? Or is it their underlying condition?
R4.CNSi.FGi: I have a worry about the bit about the connection between the upper 
limits and the drowsiness with blood glucose when we are talking about someone 
who is dying so they are going to necessarily be often sleepy. So it, ... I don’t 
know that it is necessarily going to be due to the opiods or due to blood glucose 
levels.
Moderator.FGi: Do you think it makes a difference to know?
R4.CNSi.FGi: It is important to know that they are started opiods or that they are 
diabetic and that there are things that you can think about when you are planning 
the care of the patient.
R5.NM3.FG2: If the patient has been confused before, maybe it is something, that 
is norm for the patient, but if the patient suddenly becomes confused then you will 
have to investigate.
R6.SNi.FG3: One of the things, is to keep an eye on the vital symptoms, and then 
maybe before you get to the end, I would just check what their BM is; and keep 
an eye on the signs and symptoms, and make sure they are not going into 
ketosis, or dropping and going hypo or just needing monitoring, it just depends on 
the patient.
6.3.2.2. Professional Accountability
CBG monitoring was linked to clinical accountability, or being held accountable for 
acts of omission. The non-nursing members of the group made it quite clear that 
there were family expectations for accountable care and that CBG should form part of 
the patient assessment. This was linked to quality of life and enhancing 
communication with family when little time was left.
R6.SN3.FG4: With this situation, I kept thinking ‘my registrations on the line with 
this. If this went to court, would I be able to stand up and justify why I wasn’t 
doing the blood sugars?’
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R7.0T1.FG4: If the person is conscious, then that is the last available time that
you have got the opportunity to speak to them, and if something could be done 
about it, (unconsciousness due to hypoglycaemia) I would actually be very angry 
if something wasn't done.
R8.SL.FG4: Similarly, I think as an outsider, I would clearly agree with that
comment, and that relatives find it distressing if they think that’s the cause of 
confusion.
Although the monitoring and recording of CBG was seen as important from an 
accountability perspective, there was limited knowledge for conducting a glycaemic 
history and symptom assessment. It was found in the final group that the detail of 
symptom attribution was not known sufficiently well to form part of an assessment. 
The symptoms of hyperglycaemia were less well known than those of 
hypoglycaemia.
R6.SN3.FG4: I think they (other staff members) are probably more aware of low
symptoms of low blood sugars than of high blood sugars, but we rely on, especially 
on the busy wards, we very much rely on information that other people are giving you 
about blood sugar, and I have been on the ward and someone else had done it and 
not told me that someone had a blood sugar of 2.4 or whatever. So I think, it is more 
education is needed there, and knowing the symptoms, especially of high blood 
sugars.
Ri.CPEi.FG4: I think that cause (symptoms) is attributed to other things and not the
... in reality, on the wards that it isn’t, it isn’t attributed to any ... I don’t think any notice 
is taken about what the blood glucose is doing.
R4.CNSi.FG4: .... one thing that I hadn’t fully appreciated up until recently, was that
just the general discomfort of the patient who might be hypoglycaemic, that might not 
be confused or particularly anything else. But the dry mouth, actually, myself hadn’t 
appreciated.
6.3.2.3. Knowing the Symbolic and Psychological Impact of CBG 
Withdrawal
A common concern about stopping CBG in the conscious patients was that it may be 
ethically insensitive and psychologically distressing to patients and relatives. 
Consideration to the impact of withdrawing the patient’s daily routines was
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recognised as important. The first excerpt evidences this distress, and its 
management needs sensitivity.
R4.CNS1.FG4: I’ve had lots of conversations with people who have been appalled 
at me because I have suggested that they have full fat milk, and they’ve always 
had skinny, because of all the fats and, you know, cholesterol and all of that. I’ve 
had loads and loads of questions like that and I don’t think it is any different really 
(stopping blood glucose monitoring) that the diabetes kind of thing as well. And 
we have said to people ‘If you want a piece of chocolate, have it, it won’t do you 
any harm’
The importance of hope and ‘life value’ may be symbolically removed along with the 
blood glucose monitoring. In addition the comfort of usual routines, that CBG 
management may convey may be greater than its glycaemic value. This is 
highlighted in giving the patient the message ‘this is the end’ and may reflect the 
culture of death as a taboo.
Ri.DR5.FG3: I think there would be potential to get over enthusiastic about
‘everything has to be removed, everything typical has to be taken away’, because 
actually someone who has monitored multiple times per day, injecting multiple 
times per day, for years or decades, may have a different view to that, as you 
alluded to, compared to someone whose diabetes may be relatively new...
R6.SN3.FG4: As a diabetic it is quite psychological for the patient suddenly, I 
mean, some patients are quite well, aren’t they? Well not necessarily ‘quite well’, 
but they sometimes still quite ’with it’, and suddenly stop doing their blood sugars 
to them must be quite frightening and disheartening R7.0Ti.FG4: You don’t know 
do you? R5.wsi.FG4: They think ‘this is the end’.
Ri.DR5.FG3: I can’t imagine anything worse when you always maintain control and 
is still with it enough to understand that, and then someone just goes, ‘well you 
are dying now, we are not doing it’, that would be just hideous.
R8.SL.FG4: I think then it leaves relatives feeling, that actually the person, I mean, 
if the person themselves can’t articulate this, but they have actually managed 
their diabetes really, really well, over the years and it would be such a very 
distressing sense at the end that it all ‘goes to pot’, that’s in ‘inverted commas’; 
that’s a perception.
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6.3 .2A  Managing the Transition to the Terminal End of Life Phase
When the decision to implement ‘comfort measures’ is made, the management of 
CBG in the ‘transition’ period was seen as important. This comprises proactively 
managing the hypoglycaemia risk or adjusting any intravenous insulin to achieve a 
non-symptomatic CBG. Both dietician and doctor raised issues in the management 
of withdrawal of enteral feeding. Patients who are receiving treatment at the point of 
transition to active dying should be monitored until the risk of hypoglycaemia is 
removed.
R7.DT1.FG1: W0  may see them so that they don’t get rebound hypos in the same 
way, so once the decision for the TPN decision has been made to stop then we 
screen at that point but after that it wouldn’t be checked I would imagine. We 
would still encourage them to review the cause of the rebound hypos so we will 
try and prevent that, by the end of the round we would step down the rate of the 
TPN kind of by half and then a quarter rate, then off over a period of a few hours 
to last the time, and the TPN would be stepped down in line with the blood 
sugars, just that time, for that period....
R2.DR6.FG3: If patient is not eating and if you stop the feed then they will have 
hypo sooner or later wouldn’t they?
R3.DT3.FG3: So surely, if you stop the feed you stop the insulin?
Ri.DR5.FG3: It'S really a question of whether you withdraw the feed.
R5.NM3.FG4: I think it depends a lot, if the patient until that point was on a sliding 
scale and things like that, you can’t stop it all together, you would do a blood 
sugar just to see what happened after sliding scale. Its common sense, I think, 
that everybody perceives this as common sense, and what they think is best in 
that situation for each individual.
R2.DR6.FG3: But like all treatment at the end of the day, we need to assess the 
risk and benefit outweigh, if there is a risk the patient may go hypo, we don’t 
detect, but you have to outweigh the benefit you would get from not checking the 
BM’s very regularly.
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R2.DR2.FG4: Well, I would like to think that you wouldn’t get into a situation like 
that hypo, because as soon as they had stopped eating as much, then there 
should be an adjustment (to treatment), but then sometimes that thought process 
doesn’t happen does it?
R2.DR2.FG4: If you have got an iatrogenic cause, so basically, ... if you have got
somebody who is semi-conscious, and you have given them insulin, and they go hypo 
and they become unconscious, then that would need reversing because you have just 
caused them to become unconscious by giving them a drug. Whereas, if actually 
their blood sugar is fine, and then as part of the dying process they become 
unconscious at that point I wouldn’t do a BM.
6.3.2.S. Type 1 Diabetes
It was generally agreed that type 1 diabetes was important to manage right to the end 
of life. The management principle was ‘keep it simple and minimal’ to avoid the 
discomfort and mortality associated with DKA. Diabetes as a cause of death was to 
be avoided. The exception to this was in imminently dying patients where it may be 
possible to be intervention free if deterioration was clear.
R1.DR5.FG3: It would take a particular set of circumstances, for me to withdraw all 
insulin from a Type 1 patient. Because that patient and that family will know the 
consequence of that. I may well modify the insulin regime to minimise the 
number of injections that they may have and the monitoring, and any risk of 
hypoglycaemia, but I wouldn’t necessarily remove all....If somebody is 
unconscious; I’d still probably not remove it entirely in a long standing type 1 
patient, unless there was an active request to do so.
R2.DR6.FG3: I think we need to consider, you know, how imminent death is, you 
know, if we can predict, if it is quite imminent; giving insulin should not be an 
issue. I am going to consider if, ... what, ... we don't want to accelerate the 
process on the other hand, that’s all...l think like Ri.DR5.FG3: said, if you modify 
and just minimum insulin, I don’t think monitoring would be a big issue. Because 
if you, if they are getting the minimum dose, we don’t really worry about going too 
high, or too low, I don’t know that we should have the heart, you know, too 
reduce the distress from testing, we should keep the monitoring to minimum 
level.
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R2.NM1.FG2 : ......but Type 1 diabetics especially, I feel very uncomfortable saying
‘We are not going to give anything, let’s just go with ‘to stopping everything,
Liverpool Care Pathway oomph!’ I think everyone recognises the difference
between Type 1 and Type 2 and that the need is much greater perhaps in Type 
1, because it is much more acute, but further than that, I don’t know.
R4.DR4.FG2 : OK how long would I keep a Type 1 off Insulin? To be honest I don’t 
think I would keep them off Insulin.
R6.SNi.FG3: They Often get quite upset though, the family, when you start to withdraw 
treatment in patients with type 1.
Ri.DRi.FGi: I would just like to pick up what R2.DR2.FGi: said, if someone is what we 
would call, dying, and dying; and by which I mean almost unconscious, looked very 
comfortable, then, we might think that there isn’t much point in doing anything about 
that, seeing them over, time, when we knew that yesterdays blood sugar was OK, and 
the day before was ok, then I don’t think that we would, advocate any intervention.
6.3.3. The Unconscious ‘Unknowing’ or imminently Dying Patient
Several contexts for not managing blood glucose at the end of life were highlighted 
and included:
1. Medical challenges associated with the unconscious patient.
2. Hypoglycaemia as a ‘natural process’.
3. Hyperglycaemia in type 2 diabetes.
4. Patients on the LCP
6.3.3.1. Clinical Challenges Associated with the Unconscious Patient
The common theme underlying this decision context by physicians was ‘not knowing’ 
at the practical knowledge level, the benefits of actively managing CBG in the dying 
patient. This was due to limits of what is accessible to research and the available
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evidence based knowledge to know what the comfort benefit would be for the 
patients during the dying experience. Participants opted for choosing not to risk 
unskilled intervention and causing unnecessary distress. This area of practice was 
considered an area where ‘we will never know’. From the nursing perspective, the 
role of CBG monitoring was seen as futile because treatment would not be acted on.
R2.DR2.FG4; Nobody would ever really know (what a dying person is going 
through), but to actually start putting drips up on an absolutely unconscious 
patient, I think that would be quite challenging, and to give insulin to an 
unconscious patient and then risk them going hypo, while the family are around 
them, dying, and you’re doing all these interventions. That’s why I said, as long 
as it’s not an iatrogenic cause of the hypo’ that’s made them unconscious - then I 
would feel completely comfortable not doing a BM on an unconscious patient 
who’s dying. I suppose you would never quite know would you?
R4.DR4.FG2 : Well for the patient, it is really to prevent DKA so if they were on a 
large dose, or just something in the background, but it is quite difficult when 
somebody who is on a long acting; who’s dying, who’s not eating but they are still 
going hypo. Now what are we going to do? We are just chasing the blood sugar, 
we are making the patient feel uncomfortable with the hypo, they’re sweaty - we 
are now going to give them a dose of ‘hypostop’, glucagon so I think...
R4.DR4.FG2: Not enough skill. And when someone comes in and you know that 
they are not eating and drinking and they are dying, how do you really know what 
their metabolism is going to be like?
R3.NM2.FG2: I think again that is where it comes into assessing your patient, I 
mean, as far as I am concerned if somebody is unconscious, what are you going 
to gain by sorting out their diabetes? You can see that thev-are-qoinq-to-die!
R1.CPE1.FG4: I think it’s a big debate and it comes up on the wards, quite
frequently, and the nurses are usually governed by what the Doctors, are 
prepared to do. Usually, that means withdrawal; they are not going to monitor it 
because they’re not going to treat.
The excerpts below highlight differing views on treatment between the doctors and 
nurses that may lead to professional and ethical dilemmas in practice. Selective
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decisions for treatments of hypoglycaemia and type 2 diabetes may be potentially 
contentious and professionally uncomfortable.
Moderator.FG2: And you wouldn’t have a threshold for treatment for Type 2 on a 
oral hypoglycaemic?
R4.DR4.FG2: No, I Wouldn’t.
R2.NM1.FG2: Again, I think it has got to be very individual.
R3.NM2.FG2: The whole picture.
R2.M1.FG2: And consciousness.
R4.DR4.FG2: No, we know we can’t because we can’t allow patients to die of a hypo, 
sorry. I am that really strong about it, we can’t let someone die of a hypo.
R1.DR3.FG2: Why?
R4.DR4.FG2: Because it is reversible! if you have something that is reversible... 
R3.NM2.FG2: But If they are going to die I
R2.DR2.FG4: ...So that’s actually treatment that you’re giving them, whereas doing 
BM isn’t actually up to me, I would see the treatment.
R5.NM3.FG4: And sometimes it’s just, not fighting and you all know what I mean, 
on (x-ward) we have ‘Doctors’ and’ Doctors’. Some are more challenging than 
others, sometimes it’s a matter of what’s the best for the patient and doing stuff 
when the particular difficult doctors have gone.
6.3.3.2. Hypoglycaemia Due to ‘Natural Causes’ and Iatrogenic Causes.
Hypoglycaemia that is not related to diabetes treatments were not seen as important 
at this stage due to the complexity of diagnosing true hypoglycaemia with CBG 
monitoring, and differentiating symptoms from those of dying with limited perceived 
benefit of treating. The probability that the patient is not suffering unduly as the body 
is ‘shutting down’ in the dying process justifies non-intervention - for which there is 
cited legal support, and is seen as a grey area of medical knowing.
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R2.DR2.FG1: I suppose then comes the question of are we medicalising dying 
completely? And if we tr... and at some point, the body undergoes changes 
because it’s ‘the dying process’, blood chemistry - and seeing all the biochemical 
changes and (indistinct) and if we at some point - and no-one will never know -  
and in that situation if the patient has a very low blood sugar, and they become 
more drowsy, you know, that is part of the dying process and, what the patient is 
exactly going through at that moment no-one will really ever know.
R2.DR6.FG3: One thing we need to consider is this the natural disease process ? 
and of natural disease process like hypoglycaemia could be a disease process of 
dementia. If it’s natural disease process, I don’t think we should intervene either, 
because by law we are not allowed to act, actually not allowed, omission is 
allowed legally. In a case like a 92 year old with hypoglycaemia - could be a 
natural disease process. I don’t think we get much benefit by interfering. Having 
said that, we need to get the family and other health care professionals involved 
in the decision-making.
Ri.DR5.FG3: ... There is another consideration with capillary blood glucose 
monitoring and that is the fact that they are likely to be less accurate, and that 
patient may not be hypo if you did formal venous blood glucose.
R7.NM4.FG3: We have a patient like him, who is 90 odd, where he’s not eating 
obviously, so he ends up having blood sugar of 2’s, so the Consultant decided to 
stop everything after all because we were not achieving anything except 
(indistinct) and the family did agree we need to stop and give up, so he end up 
on LCP. Because it is just a discomfort for the patient during the night, if his 
blood sugar drops again we need to call the ‘On-Call’ stick 50/50 and everything, 
the next day it will go down again because he won’t eat. He is end stage 
Dementia; he is a 96-year-old chap, so we end up withdrawing everything and 
implementing LCP and syringe driver. I think the Macmillan nurse was involved 
as well during that time.
6.3.S.3. Type 2 Diabetes
High blood glucose in Type 2 diabetes patients who were thought to be actively dying
were not seen as important due to decreased relevance to preventing long-term
complications and low perceived risk of symptom benefit.
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R6PH1.FG1: Obviously control is going to be quite different in palliative care, 
control is going to be a lot higher than your average diabetic patient, but this isn’t 
you looking at long time complications’ you know, to get confusion in.
R1.DR5.FG3: Practically, because the majority of the, people who we look after in 
this sort of situation tend to have type 2 and this is likely artificial discussion 
because we don’t do this (give background insulin) terribly often. But I think we 
all would know how to adjust somebody’s insulin regime to make sure they 
wouldn’t go hypo ....And of course once you remove the intent to any form of 
glycaemic control and complications avoidance, it does ... liberate us to quite a 
degree...
R4.DR4.FG2 : Yes, When the blood sugar is running high, there is hypo’s, there is 
no point in bringing the sugars down to normal because they would have an awful 
hypo even though it’s within the normal range.
R4.dr4.fg2:...To monltor, ? I don’t think that is fair on the patient as I understand 
with high sugars you feel uncomfortable, but in a dying patient, we do not know, 
we know from the palliative care research, they’ve shown that patients who are 
dying are not thirsty.
6.3.3.4. The Liverpool Care Pathway
Blood glucose management is seen as unimportant if the patient is on the LCP. The 
term ‘comfort care’ was seen as a euphemism for ‘syringe driver’ and the blanket 
withdrawal of all treatment including blood glucose management. The generalised 
perception of the LCP as a ‘single model of care’ was a common theme across all 
groups, where pharmaceutical pan-symptom palliation through the syringe driver 
emerged as its assumed purpose. The LCP was seen as a tool to avoid 
uncomfortable conversations about death and dying and details of medically 
managing end of life. Only a few participants showed understanding of its subtleties 
as a tool for personalised care. The importance of blood glucose management on 
the end of life care pathway was influenced by this perception.
R7.OTi.FG4: It’S like the LCP is one size fits all, this is all you do when this, this, 
this, tick, tick, tick.
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R4.CNS1.FG4: I Went to See a patient the other day who had a patch on her, and
she was very comfortable; and I was asked ‘should we go onto syringe driver’ 
and I said ‘I don’t see any reason why you would need to have a syringe driver, 
so ‘no’ ; and the day after, somebody else on the team went and they were asked 
the same question, because they didn’t - they don’t - feel comfortable that 
someone was ‘end of life ‘ and not on a syringe driver. It ‘has to be’.
R6.SN3.FG4: As someone who works on the ward, quite regularly, as soon as that 
‘TLC’ title is given or ‘palliative’ title is given and everything is stopped, I think it is 
just the automatic reaction for the Nurses, to stop blood sugars as well, and I’m 
not sure, if that’s how appropriate that is in some cases.
R9.NM5.FG3: I think we are given this perception of the Liverpool Care Pathway 
that you’re on it, you’re dying; you have nothing. When actually that is not what 
the Liverpool Care Pathway says. It says to ‘personalise’ the care plan for the 
patient and remove what you feel is inappropriate treatment at that time, it 
doesn’t say remove everything, and I think it's the perception of what the 
Liverpool Care Pathway is, and I think the common perception is you’ve got days 
to live therefore you don’t need anything, we’ll, just you know, ‘syringe drive’ 
midazalam, morphine, etc, and that’s it! It’s quite interesting, as everyone here 
comes from a diabetes background, that they are all saying ‘oh give them insulin’ 
because that was my perception, but I don’t think that’s going to be trust wide, I 
think the group probably needs to spread to general medical wards. Whereas 
diabetics there will be people who will be brought in with other diseases and have 
diabetes as a sideline, it’s not what they are brought in with and I think if you had 
this chat with them, it would be really different, I think they would be more 
towards not bothering to give insulin and not bothering to do the end. That my 
personal perception.
R8.SL.FG4: I think, and I am speaking as a relative, in terms of individual
consideration at the LCP, it’s not specifically diabetes, but I think it makes the 
same point. I have experienced a relative being put on the LCP, with the family 
being told what is going to happen. But actually no discussion about why it was 
going to happen, and what the options are within it. and it’s not with this Trust, no 
discussion whatsoever, and three siblings the only person among us who 
understood the LCP was, was myself, but there was no further discussion, and 
then the following day when my relative was taken off the LCP, just as suddenly.
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there was no discussion then either. Now, I actually don’t feel that that is 
untypical. So, and that was not with this Trust.
R5.NIVI3.FG4: This happens, let’s face it, this happens on a daily basis with the
majority of relatives.
R6.SN3.FG4: I think the Medical Team used the LCP as a sort of a ‘back out 
clause’ from having to have the discussion, and the uncomfortable discussion of 
it.
R5.NM3.FG4 : In reality, to be honest, I think from what I see every day the doctor 
just goes and signs and says this is partly up to you’, and so the patient ‘we are 
going to keep your relative comfortable’ ‘make sure he is comfortable and not in 
pain’.
wioderator.FG3: Do you think it inhibits people from testing sugars if they’re on it? 
R6.SN1.FG3: Definitely.
R9.NM5.FG3: I think it Can, I think it moves towards not causing distress to the
patient so the nurses probably then feel they can’t inject, they can’t do BMs 
because it’s discomfort, etc. So I think it might be how the Pathway’s structured 
or how it’s perceived by the staff that stops them doing that.
R2.DR6.FG3: I don’t think the Liverpool care pathway is specifically deciding for the 
diabetic patients you have some consideration for that.
R6.SN3.FG4: I would usually take the LCP to the patients’ relatives if they are
susceptible to it, I go through the actual LCP with the relatives, and go through 
the care plans and what we do, but I must admit I’ve never actually asked about 
diabetes because generally, in my mind, I am told to stop. You know, we stop 
monitoring it.
R6.SN3.FG4: I have never been questioned by a family or, well relatives generally 
aren’t, not relatives - patients generally aren’t awake when they’re on the LCP - 
about why we’re not doing blood sugars anymore or why we’re not doing obs 
or.....
Moderator.FGi: So a syringe driver would ... the cocktail you put in there would 
probably cover it without you having to do blood glucose monitoring -  is that the 
suggestion?
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R3.CNS2.FG1: Possibly, at the very end of life.
R4.DR4.FG2: I am not SU re exactly how it works, but I am hoping the syringe driver 
or whatever is in the ‘cocktail’ will cure.
Part of the reason for this ‘single-model’ perception was thought to be in the 
management of the medical notes with the focus purely to the care pathway. 
Previous assessment documentation is filed away in the notes. All documentation is 
via the LCP where there is no perceived place to document any blood glucose.
R1.CPE1.FG4: But the notes are all wrapped up I .... And they are bound together 
I  ‘don’t go near me again’ ! (laughter)
R2.DR2.FG4: And that is a problem isn’t it?
R2.DR2.FG4 :Yes but it’s like it’s locked, it’s almost like saying that what’s gone 
before doesn’t matter and actually it just supports what we are saying about 
BM’s then being stopped.
R9.NM5.FG3: I think it then perhaps makes people think they can’t make a
medical decision anymore, because the notes are sealed with this big band, so 
therefore we don’t do anything anymore. I think that is the perception of it.
R6.SN3.FG4: There’S actually a box on the LCP that says ‘other problems ‘or
‘other’. I’ve never actually seen ‘diabetic’ ‘diabetes’ ever written in that ‘other’ 
box. They haven’t actually taken that into account.
R1.CPE1.FG4:... and all assessments get removed, so there’s no further 
assessment because the paperwork. Waterlow is gone, minimal handling is 
gone, there is no assessments, and we still have to minimal handle or manual 
handle those patients, and we still have to assess skin integrity, and you know, 
surely even if they’re not eating very much and maybe that is a bit more 
acceptable, but surely you still have to be looking at that as an individual, you 
still need to be making some kind of assessment, even if you’re not gonna...., 
but because it all gets bound up in those notes, that’s it, it’s gone for good, and 
the LCP is it.
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6.3.3.S. Complexity in Individualising Care
There are clear reasons to stop monitoring in the unconscious patient with diabetes 
and clear reasons to continue monitoring in conscious patients. However, the patient 
context does not always present so neatly, as some patients may have never been 
conscious in the acute admission period; and not everyone on the Liverpool Care 
Pathway are imminently dying, or unconscious. Although there was a unanimous 
agreement that an individualised approach must be taken for each patient, most 
participants responses can be categorised as ‘medical situations’. Very little data 
were generated that articulated blood glucose management issues for patients with 
diabetes at the end of life or with their relatives.
6.4. Contexts of Care within the Acute Care Setting
Factors within the acute care context were identified that may optimise or 
compromise an individualised approach to blood glucose management decisions as a 
component of end of life care. Themes emerged that raised opportunities and 
limitations for individualising care by ‘knowing the patient’ across a wide range of 
levels and contexts. Theme 2 contexts were outlined in figure 6.2. and are reported 
below.
6.4.1. Time and Opportunity
Time and opportunity to get to know the patients and their concerns and wishes can 
be limited within the acute care setting unless the patient has an existing pre-hospital 
relationship with the diabetes or palliative care team. Although time and opportunity 
may be present, the importance of blood glucose management at the end of life may 
still not be discussed, and knowledge of how important blood glucose management is 
to individual well-being at a holistic level may still not be known. Referral to the 
palliative care or diabetes team may not be made and ‘knowing the patient’ and their
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wishes may not be recognised as this information is not available for other healthcare 
professionals to be made aware.
6.4.1.1. Pre-Hospital Knowledge of Patient
In the pre-hospital period, diabetes and specialist teams may know their patients well 
and provide continuity of care into the hospital.
R4.CNS1.FG1: In the hospital, palliative care they may have only been here a few 
days anyway, so it is difficult to know what their past history is. If they have been 
known to the community team and I always liaise with them and the family as 
well, to find out what has been happening.
Ri.DR5.FG3: ...Often we get to know our patients very well over many, many, 
years, so the people known to us particularly, we may have quite long standing 
relationships with them; and obviously that will help to try and be as considerate 
to their requirements at that the time as possible.
R4.DR4.FG2: I think, HbA1C, is a guide, to know what the blood sugar has been
running for the past 3 months, (getting) Information from the Diabetes Team, but 
this takes time, this takes time, and we don’t really have that much time to make 
someone comfortable. So I don’t know, sorry. I don’t know how to make it 
easier.
Establishing the patient’s attitude around blood glucose management in the pre­
hospital stage when there is time and opportunity is not an area that may be routinely 
addressed in palliative care, particularly in patients with type 1.
Mod.FGi: Do you think when you have patients coming to a palliative phase when 
they are well, is it worth putting in their care plan, the trajectories for when they 
come into the hospital, so it's quite clear about what patients want in terms of 
their diabetes management?
R2.DR2.FGi: I think that even just doing this that absolutely kind of makes it, you 
think, actually at that point you are having an end-of-life discussion with a patient, 
and you see they are on insulin, it is worth bringing up that action pattern of you 
know, ‘monitoring may change’ and how do they feel about that and it's part of
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their end-of-life care discussion, if they are for exampie, in fact a type 1, so 
actuaily you know I think that is compietely valid.
R4.CNS1.FG4: And although it’s not a..., I think that’s why it’s important to have
conversation early in the disease trajectory.
Moderator.FG4: You don’t have Conversations about diabetes much though do you? 
R3.CNS2.FG4: No.
6.4.1.2. In-Patient Time and Opportunity
The hospital environment is limited in terms of privacy and time compared with the 
community. Patients may be too sick to relate their preference and information flows 
between primary and acute care are discontinuous. A range of skill in recognising or 
relating to patients end of life needs competently and confidently are important 
factors.
R7.0T1.FG2: I work a iot in the community at the Hospice and you find that there is 
more time, and opportunity in peopies’ own homes, to actuaily sit with them and talk
about what they do want, which you don’t have that iuxury of, You don’t have a
nice environment to do it in, you’ve got people listening on either side of the bed, and 
it’s very difficult to have to have that final sort of conversation with peopie.
R3.NM2.FG2: I think also the time, sometimes by the time the patient comes into 
hospital, they are already dying, and you know perhaps at that point where you can’t 
ask them anything. It is quite difficult.
R4.DR4.FG2: I mean you say these things are being discussed in the community but it 
takes so long for it to feed back into the hospitai; so that’s very hard when managing 
patients because you don’t know what’s there so when you taik to relatives it’s very 
hard, it’s a hard discussion, because you don’t know what the ‘party line’ is in inverted 
commas.
R2.NM1.FG2: And if it’s hard for you, you can imagine junior nurses they just don’t feei 
comfortabie, they don’t know how to approach it or so then you miss an opportunity 
there as weil.
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6.4.1.3. Time to Think
The pace of work in the acute care setting presents limitations in time and space to 
think or discuss blood glucose management. The following observations around 
thinking were made by the final focus group.
R8.SLFG4: ‘Individualised care’, but where the person is a known diabetic, whatever 
their situation may be at the end-of-life and these issues have to be raised and 
addressed, and what we’ve been talking about is the thinking that goes with it, and I 
think what we’ve demonstrated this afternoon is that actually there is a place for that 
thinking to take place. Part of that thinking has to take place outside the immediate 
context because in the immediate context, there is not time, or room, or energy, or 
whatever, so actuaily this kind of debate contributes to that context.
R5.NM3 1.FG4: ‘Thinking’ - briefly I would say, because you have to think to do 
something but we don’t think as much as we shouid actuaiiy.
R3.CNS2.FG4: Classicaiiy, people stop using their own inteilect, don’t they? And just 
use that. They don’t know what they’re going to do, without actuaiiy stopping and 
thinking ‘right, iet’s look at how it fits that patient, how that patient feels’. It’s the doing 
things with thinking.
6.4.2. Acute Care Culture
Within the acute care setting, the participants describe a culture of care that is based 
on professional hierarchies with the medical hierarchy as the dominant clinical 
decision-making authority. The division of knowledge and care responsibilities lies 
within a range of specialities, which contribute towards the holistic care of patients in 
a multi-disciplinary and multi-specialist way. The focus of all these energies and 
knowledge is for the management and optimisation of reversible causes for acutely ill 
patients.
R4.DR4.FG2: I think if they are on the Liverpool Care Pathway, they have an 
irreversible condition, that’s why we are going with the Liverpool Care Pathway.
R5.Nivi3.FG2: That’s the end.
R3.NM2.FG2: That’S it.
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The provision of holistic individualised care needs for dying patient in this complex 
climate relies on good and skilled communication, a common vision of care and wide 
education requirements. The acute care context appears to be subtly incompatible 
with palliative care with the prevailing culture of ‘disease reversal’. The transferable 
knowledge of reversible symptom management associated with comorbidities 
appears to be lost in the context of dying patients, along with the perception of what 
palliative care aims to achieve. The categories that are situated under this theme are 
attitudes to palliative care; hierarchy and cultural differences. All of these factors are 
thought to influence the individualised management of blood glucose in the acute 
care setting at the end of life.
6.4.2.1. Attitudes to Palliative Care
Within the context of acute care, ‘comfort’ plans signified ‘end of everything and a 
limited view of personalised care. The LOP is thought to be too subtle for its 
appropriate application within a non-palliative specialist setting, to cover a range of 
symptomatic management contexts to which diabetes is illustrative. Culture of care 
may not be transferable on a paper document.
R3.CNS2.FG4: There are different degrees of Paiiiative Care; you’ve got people, 
who I think agree with you, that there is a misunderstanding that if a patient is 
titied ‘Paiiiative’ then there is nothing else that can ever be done for them. I think 
you probably go in and stir that a little bit because we are saying ‘hang on a 
minute, you’re not doing anything active for this patient’s disease but you still 
have an obligation to make sure that their other diseases are managed, that there 
is nothing reversible that could be managed effectively’ which doesn’t fit in with 
that idea of ‘palliative’ being ‘end of.
R9.NM5.FG3: When the Liverpooi Care Pathway was trialled, were these things not 
brought up? Because obviousiy I have not got the whoie research thing on the 
LCP, but when it was brought up it was written for cancer patients, but they didn’t 
just have cancer did they? So did they not have this probiem in the first place 
when they devised it?
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R1.CPE1.FG4: But that is the argument you have with the doctors, is the constant 
battle about, you know, first getting them - if it is out of hours - getting them to 
come and review the patient, and then what actions are there going to be from 
that ? if you have taken it (biood sugar) and you’ve alerted someone, how long do 
you leave it before you think ‘Weii actually, we ought to get them making this 
more urgent, they ought to come down’ and because the minute they hear it’s 
paiiiative they don’t rush.
Parallels were drawn to other ‘components’ of end of life care that may be important 
to individualised holistic care. The complexities of managing basic care needs as 
‘simple’ as keeping an oxygen mask on a dying patient or treating a ‘temperature’ can 
lead to practice dilemmas that make ‘blanket’ decisions an attractive way of coping 
for avoiding more practice dilemmas. The apparent opposing values of acute and 
palliative care are well illustrated with the decision to maintain oxygen.
R3.CNS2.FG4:.But you need to observe your patients and know them weii. Then 
you can take a measure of what you know as normai, and then react, and it’s 
absolutely fine then to say ‘let’s check your temperature and see if you have got a 
temperature’ and again, it’s back to what are you going to do about it when 
they’ve got a temperature? If it’s just a matter of giving them something to bring 
their temperature down and that’s perfectly appropriate, or do they need more?
Do they need antibiotics and then you are opening a whoie’ hornet’s nest’ aren’t 
you? Because you have then got to taik about the benefits of having or not 
having antibiotics. So you can understand why decisions are made, it is much 
easier to have a blanket decision than to be actually, be faced with those kind of 
dilemmas.
R9.NM5.FG3: A patient in (x)-ward who was a respiratory patient and well known to 
the respiratory team, she was end of life and she, the nurse said to me, ‘she is on 
the LCP now, shali I stop her oxygen and take away her nebuliser?’ I said ‘no’, 
because it’s comfort, leave her, because it won’t prolong her life but it wili give 
her comfort because that’s what she knows. So I think it does happen in iots of 
different...
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G.4.2.2 Role of Hierarchy and Cultural Differences
Culture and the medical hierarchy appear to be an important factor and was 
illustrated from this case discussion. The situation involved a non-diabetic patient 
who had rapidly deteriorated over the last 48 hours, and who was distressed, 
persistently hypoglycaemic. There was no clear end of life plan in place at ward or 
family level, and the doctors were not prepared to discuss or treat the blood glucose 
concerns of the nursing staff. This case illustrates the impact of the multi-disciplinary 
hierarchy on clinical decision-making and patient advocacy for end of life care.
R6.SN3.FG4: They did at one point say to me well we’ll get the specialist nurses 
invoived and I thought ’weil is not what I’m saying not good enough’.
R4.CNS1.FG4: As a speciaiist nurse, you are in a better position, because we are 
actually writing in the notes, and so it can’t or it shouldn’t really be ignored. 
Whereas, if you are saying something to a doctor, it could be easily ignored.
R4.CNSi.FG4: But what I wonder is, if you don’t feel comfortable, you know that if 
you talk to one of the junior doctors that you are going to be told ‘just to forget it’ 
but if you go and talk to one of the senior doctors wouid that stiii be the same? I 
mean we should all have full access to the senior doctors too.
R6.SN3.FG4: Because the situation that me and r i .c p e i .f g 4: were taiking about 
earlier, when we went to the juniors he said ‘Well we are just following the 
instructions of the seniors, the Reg’ and the consultant. It was actually the Reg’ 
and the Consultant who told us to stop BM’s and stuff’. So, I think in a way, I 
think it is a hierarchy with them as weil, and they’re just following their orders.
R2.DR2.FG4: There just seems to be a huge discrepancy between all the wards, 
general wards, the nursing staff and the medical team, just from what I’m hearing, 
and maybe our palliative care team with the medical teams, I don’t know. There 
just seems to be these, demarcation of what understandings and approach are 
really, which is quite interesting hearing you talk about, you know, how 
disempowered you are in a sense, when the medical teams are making one 
decision and you’re seeing something else and that’s ..I think we have debates 
and ethical dilemmas all the time. But I think in that situation I wonder if the 
dilemma is inexperience?
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R1.CPE1.FG4: I don’t think a lot of nurses make that link anymore because I think 
we are disempowered, and we don’t have, an assessing and sort of anaiytical 
nursing approach that we used to have, I think somehow that ievel of 
understanding, from nurses, has deteriorated over time which is really quite sad 
because we used to be more autonomous. I mean, as senior people - don’t get 
me wrong - we are a bit more autonomous, but, a lot of the junior nurses will just 
do as they are told because of the culture, the background, the very hierarchical - 
and that actually has a huge impact; because even if there is something that they 
don’t think is quite right, they don’t agree with, and they wouldn’t have done that 
where, in their own country or, you know, or where they previously worked, if 
that’s what their to id now by someone senior they take that as given, they don’t 
chalienge senior people anymore. It’s just accepted and they, it’s aimost;’ we wiil 
do as we’re told’. That’s very sad.
R3. CNS2.FG4: It’S a Cultural thing that’s changed and not to take the risk of
stepping over the mark because it’s not good for me, and that’s reaily sad.
Ri.cPEi.FG4: It’S, some of it is culturai, it is that almost as though we won’t look 
you in the eye because that is a cuitural thing, you know, and over time you can 
get over that, but because we are so muiti culturai now, that does, from what I 
see as practice development when I go around the different wards, that is 
definitely having an impact on nursing care regardiess of what the type of care is.
R8.SL.FG4 : But it also may be that more senior, more experienced nursing staff 
have dealt with it all the time that actually, their opinions their views are not taken 
into account or valued, and so that, that, erodes you, so then you don’t want to 
present your views.
R7.OTi.FG4: There are a iot of reiatives that implicitiy trust the medical profession 
and wouid never question, and that doesn’t necessariiy mean that it’s right or 
wrong.
The dominance of medical staff for clinical decision making within the acute care 
setting has an impact on individualised holistic care. There may be a context where 
the doctor stops all treatment without consulting the patient or relatives who may 
have been comforted to know their blood glucose was still important to those caring 
for them, even though it may not be medically relevant. Participants reported that
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consultation with relatives occurred but not often, and in most cases, it was to tell 
them what the doctors had decided.
R7.0T1.FG4: The thing is that a iot of people don’t know that family don’t have
some knowledge or that these people do have a lot of knowledge and can go 
away and find out and then actually could then say ‘I don’t agree with’, because 
people do have a lot more knowledge and they can turn around and said that you 
didn’t give us this and this; and I don’t think that we do communicate well enough,
I don’t think, not ali of us, but as a team we don’t go to the family and say’ we’re 
not doing this because, because, because’ and then peopie wiii often accept that, 
but we don’t talk enough, and we don’t explain because there stiii is an 
assumption where people won’t understand it, and I don’t think that’s true, and I 
think peopie do understand, and aren’t daft.
R4.DR4.FG2: But there again, if I hear it from the reiatives how can I trust them? 
R2.NM1.FG2: That’S right, yeah, it’s difficult.
R4.DR4.FG2: So it wouid be nice for information, from clinic visits, to know what the 
person is like, that would be good. That would be more evidence for me, 
personally, to manage a patient.
6.4.3. Specialist Knowledge
Blood glucose management at the end of life requires skilled knowledge around 
diabetes and palliative care and its treatment objectives. Ward staff report that 
making decisions around these parameters of care may be difficult and more 
education is needed. Patients who are knowledgeable may not be listened to.
Ri.DR5.FG3: This again comes back to the education doesn’t it? about the
incomplete understanding of what the LCP is actually trying to do, I think the 
‘education’ probiem is widespread as R2.dr6.fg3: and I saw two Type 1 diabetes 
patients on ITU, on Tuesday both of whom had Actrapid pumps stopped before 
any subcut’ insulin had been given, which I know none of you guys would do 
(laughs). So I mean as a general diabetes information, LCP information, there is 
always that sort of need to keep everybody fresh on those knowledge’s.
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R6.SN3.FG4 : That’S as if to say ‘OK we carry on doing it 4 times a day, we carry 
on doing it once a day or we’ve got to stop completely, because I wouldn’t feel 
comfortable as a nurse making that decision, and I don’t think any of my last lot of 
doctors would have either.
R3. CNS2.FG4: I think knowledge of insulin as well is all tied up with that, so, you 
know I am the first to hold my hand up and say I am not expert in the different 
insulin’s that are out there. But hopefully I would know who to ask, and I think 
that is part of it. I have patients who continualiy have their insulin given to them 
and actually, their situation has changed and that needs to be considered but 
nobody has thought to consider it, so again, it is not just the blood (glucose), it is 
the whoie thing.
R1.CPE1.FG4: I Can See sometimes why that is the case because I think
sometimes there is lack of education, in nursing, because there are so many 
things to get you head round so, sometimes it is because of our lack of 
education.
R2.NM1.FG2: I think there is an element for training and that invoives Palliative 
Care as well.
R5.NM3.FG2; It’S interesting I did Palliative Care course in this hospital, and they 
don’t mention insulin.
R2.NMi.FG2: No I did the (institution name) one and they didn’t seem to have it.
R6.SN3.FG4: I think a iot of it on the ward is, that this patient is diabetic, they can’t 
have sugar. They can’t have. But if someone has a bar of chocoiate a day at 
home their insuiin or whatever is monitored, they adapt it, due to that, if they have 
a bar of chocolate, that’s fine. I feel what the patient’s do know a lot more than 
nurses who are caring for them about their blood sugars and about their insuiin 
routines, quite often you get a patient with, is prescribed by the doctors 15 units. 
‘I would normally have like 18 when my blood sugar is this when I’m at home’, 
and because you are already prescribed 15, you can only give 15.
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6.5. In Summary
The qualitative data have reported that patients who are conscious should be 
monitored, and those on the LCP should not be, unless they have type 1 diabetes, 
iatrogenic hypoglycaemia or have symptomatic hyperglycaemia. The knowledge and 
skills to deliver care and the time and opportunity factors within the acute care 
settings pose challenges to the delivery of palliative care for patients with diabetes at 
the end-of-life. The avoidance of DKA and iatrogenic hypoglycaemia seems to be the 
baseline of care. The limited skill set to manage insulin and lack of clinical guidelines 
and evidence base are influential in permitting the values of the senior team to limit 
the voice of the patient’s families and other disciplines. The hierarchy is an influential 
factor for enabling shared decision opportunities.
144
CHAPTER SEVEN DISCUSSION
7.0. Chapter Outline
This study sought to establish whether blood glucose management was an important 
component of end of life care in patients with diabetes and what factors influenced 
their clinical management in the acute care setting. An evaluation research inquiry 
approach was taken that utilised both quantitative and qualitative data collection 
methods to explore the nature and management of blood glucose at the end of life. 
This approach was time intensive but enabled the collection of rich data that allowed 
a comprehensive exploration of the research question. The retrospective medical 
notes review has enabled a detailed background to be known about the patients, 
medical, advocacy, palliative and diabetes management contexts; and the focus 
groups has provided a depth of insight to enable a rich picture to emerge on the 
complexities of individualising end of life care in patients with diabetes.
The research findings from the qualitative and quantitative data will be discussed and 
evaluated using the relevant published literature. The findings will address the 
following three components of practice; these are the patient clinical and population 
characteristics (7.1); CBG monitoring and treatment contexts (7.2) and the influence 
of acute care culture on individualised care decisions (7.3). The organisational 
factors within the acute care setting that help and hinder individualised care for 
patients with diabetes will then be discussed.
7.1. Patient Clinical and Population Characteristics
The characterisation of the patient population and clinical problem structure is an 
important aspect for planning and implementing quality end-of-life services. 
(Cardenas-Turanzas et al. 2006). Both quantitative and qualitative data suggest that 
patients are not routinely involved in the end-of-life decisions for the continued
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management of their diabetes care. This section describes and compares the 
population characteristics to the literature review and explores the advocacy potential 
of patients admitted in the final hospital episode.
7.1.1. Patient Admission Characteristics
The sample represented the normal population distribution for type 1 (10%) and type 
2 (90%) found in the United Kingdom (UK) (Diabetes UK, 2010). Patients who died in 
hospital with a comorbidity of diabetes accounted for 17.4% of the total hospital 
deaths in 2008. Since no published data were found to enable benchmarking, an 
audit of the HES database for the years 2009 and 2010 was undertaken. The annual 
incidence over the last 3 years was found to be stable between 17.4-17.7%. 
Diabetes as a comorbidity comprises an important patient population for research 
and practice in end-of-life care management processes.
The retrospective medical notes review found the majority of patients to be over 
seventy, with multiple comorbidities and presenting with serious acute-on-chronic 
conditions. The admission profile of the sample was similar to other studies that 
investigated end-of-life care in the hospital setting (Fins et al, 1999, Middlewood et al, 
2007, Abel et al, 2009). Most patients were admitted with serious acute care 
requirements requiring good CBG control. The opportunity to involve the support of 
the diabetes team on admission and in the terminal phase was not routine.
7.1.1.1. Cancer and Non-Cancer Cohorts
There were more patients with chronic illness and few with cancer related 
admissions. There was a similar distribution between cancer and non-cancer for 
comorbidities and prescribed medication burden. The polypharmacy issues and their 
potential for blurring the perceptions of symptom origin (pharmacy versus glycaemia 
origins) may be equivalent for both cancer and non-cancer. The findings from the
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symptoms listed at the end-of-life suggest that cancer patients may have more 
analgesia side-effect related symptoms (for example constipation, nausea) than non­
cancer patients. These side effects may be influential on appetite variables for 
sleepiness and gastro-intestinal effects and subsequently impact on the CBG values.
The patients with cancer and diabetes accounted for 14.6% of hospital deaths and 
this was comparable with the study findings of McCoubrie et al (2004) who noted the 
higher proportion of cancer hospital deaths compared with the general population. 
This compares with the audit by Abel et al. (2009) who reported in their United 
Kingdom (UK) hospital-based study that the percentage of all patients with cancer 
who died in hospital in a one year period was 11.8%. As reported by van de Poll- 
Franse et al (2007) patients diagnosed with cancer were diagnosed late into the 
disease process in patients with diabetes. In the retrospective medical notes review 
the mortality was high for many cancer patients (59%) in the first 6 months.
There were significant differences in the proportion of CBG values between patients 
with and without cancer diagnosis. A higher proportion of patients with cancer had 
normal CBG values, whereas non-cancer patients had higher CBG values. There 
were no significant differences in the risk for hypoglycaemia. The role of acute care 
in supporting patients and their diabetes management may be important when DNAR 
status is recorded. Consideration for reviewing their diabetes plan, ideally in 
collaboration with the palliative and diabetes care team could be initiated at this 
juncture.
7.1.2. Patient Advocacy
The ability for patients to be their own advocate is suggested in the retrospective 
medical notes review data. Forty percent of patients were physically independent on 
admission, while others required some (50%) or total support (10%). On admission, 
73% of patients had the mental capacity to provide their own admission history. Most
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patients had diabetes for greater than 10 years and were on active diabetes 
treatment, and may be familiar with fluctuations in their glycaemic profiles and 
associated symptoms. The majority were well controlled in the preadmission period 
by their HbAic standards, suggesting patients were managing their diabetes 
effectively at home. These data imply that a large proportion of patients may have 
been independent enough to have anticipated discharge home and may not have 
been mentally prepared for death. The knowledge to support their diabetes where 
prognosis is unexpectedly poor is lost if data on their diabetes are not collected in a 
timely way.
Field notes from the retrospective medical notes review indicated that no systematic 
data on the patient’s normal glycaemic control, hypo-awareness or self-management 
practices are routinely collected on admission clerking. In some cases, the correct 
type of diabetes was not documented, and required a detailed search through the 
clinic correspondence and past medical history to verify the diagnosis for data 
collection. Therefore, baseline knowledge of the patient’s glycaemic thresholds and 
(DKA risks) symptoms are not always known for professional-led advocacy. The 
patient’s attitude to diabetes could be inferred from this history (choosing not to CBG 
test, never complying with diet recommendations) and may inform the approach to 
end-of-life decisions based on an initial assessment that could be referred back to if 
the patient could not advocate for themselves.
These data suggest that most patients who were admitted could potentially contribute 
to end-of-life discussions about their diabetes management preferences. However, in 
the hospital setting where the immediate context may be uncertain and adaptation to 
new or worsening illness may be realised (Watts, 2000); their diabetes management 
may not be felt to be a priority. It is not known whether patients had concerns around 
their diabetes, as these views were rarely documented; but clinical experience in the
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acute care setting reflects most patients worry about their blood glucose and its 
management.
Supported self-management in the hospital setting and early referral for diabetes 
specialist support is advocated by Diabetes UK (2009) and NICE (2008) guidelines. 
Collaboration with patients for self-management of glycaemic treatment decisions has 
been shown to be safer than those decisions made independently by hospital care 
providers on behalf of the patient (Gangopadhyay, et al 2008). This tension between 
patient and healthcare professional authority was alluded to by the focus groups 
where the liberalising of dietary restrictions in those with poor appetites was variably 
allowed by some ward staff. Shared decision-making should be encouraged in those 
patients that are able to self-manage because it empowers the team to provide and 
promote holistic care as the patient views and attitudes are more likely to be known in 
the terminal phase. The hospital length of stay for the majority of patients (average 
22 days) was sufficient to gain this level of personalised knowledge and support.
The focus group suggests the normal role of the patient to be passive and to report 
symptoms to the team as the quotes below suggests. However, it is not routine 
practice to encourage patients to enquire for their symptoms when abnormal readings 
are obtained.
R2.DR6.FG3: If someone is not abie to complain, we wouid never be able to 
interpret the symptoms. It depends on the stage (of dying) or how sedated they 
are.
R1.DR1.FG1: It needs managing because it iessens the burdens, but it depends on 
their views. Because very often this is what happens, if their sugars are unstable, 
you get symptoms and they know that’.
In a sense there is a hierarchy extending to the bedside with the patient being the 
least empowered.
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Over half the patients were married, and whose spouse may be familiar with their 
daily CBG fluctuations and symptom experiences. The strength of feeling of relatives 
was suggested by the non-nursing and non-medical participants as shown in this 
view.
R7.0T1.FG4; If the person is conscious, then that is the last available time that 
you have got the opportunity to speak to them, and if something could be done 
about it, (unconsciousness due to hypogiycaemia) I would actually be very angry 
if something wasn't done.
Those who were living alone or in a care home may be less likely to have anyone 
advocate for their wishes and preferences around their diabetes management. In the 
latter, the hospital staff caring for them may be their only source of advocacy. Implicit 
to the role of advocacy is a good working knowledge of diabetes and palliative care 
principles. Spollett (2006) reported that studies, which investigated basic diabetes 
knowledge in nurses in a variety of clinical settings, found their knowledge to be poor. 
This has implications for practice as the retrospective medical notes review data 
found that patients at the end-of-life had reduced mental capacity to contribute to 
clinical decisions compared to admission (73% versus 43%).
The need to educate the palliative care team and ward staff was suggested across 
the focus groups. The excerpt below is a reminder of the insight from the focus group 
about the role of CBG in symptoms.
one thing that I hadn’t fully appreciated up until recently, was that just the general 
discomfort of the patient who might be hypoglycaemic, that might not be 
confused or particularly anything else, but the dry mouth actually, myself hadn’t 
appreciated (Palliative Care Specialist Nurse).
Focus group data implied that patients and their family were rarely involved in 
decisions for CBG management, even when overt ‘comfort measure’ discussions with 
the LCP occurred.
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R7.0T1.FG4: but 3S 3 team we don’t go to the family and say, ’we’re not doing this 
because, because, because’ and then peopie will often accept that, but we don’t 
talk enough, and we don’t explain because there stiii is an assumption where 
peopie won’t understand it, and I don’t think that’s true, and I think people do 
understand, and aren’t daft.
R4.DR4.FG2: But there again, if I hear it from the relatives how can I trust them? 
R2.NM1.FG2: That’S right, yeah, it’s difficult.
R4.DR4.FG2: So It wouid be nlce for information, from clinic visits, to know what the 
person is like, that would be good. That would be more evidence for me, 
personally, to manage a patient.
The qualitative study by Jack et al (2003) reported that withdrawal of routine 
assessments of CBG was a symbolic message for relatives that enabled the removal 
of ‘false hope’. However, within the current study findings, the focus groups 
commonly cited withdrawal of monitoring as custom and practice associated with the 
LCP as the reason. There was a consensus that patients and relatives should be 
more involved, but that the physician or the multi-disciplinary team made most 
decisions.
Both specialist focus groups raised the point that the specialist team within the 
outpatient setting may know patients with diabetes. The patient’s views and attitudes 
to diabetes may be known through a pre-existing relationship with the team, enabling 
a professional advocate role, which may be lost when referrals are either not made or 
occur late in the terminal phase. The retrospective medical notes review showed that 
few patients are managed on the diabetes ward and that referral for support at the 
end-of-life is less common in the post DNAR notification period. Referrals for 
palliative care are often delayed to the last minute and this all colludes towards 
decreased knowledge of the patient and the ability to provide professional-led 
advocacy.
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The palliative care team have lamented the narrow perception of acute care to 
palliative care service provision.
R3.CNS2.FG4:... that there is a misunderstanding that if a patient is titied ‘Paiiiative’ 
then there is nothing else that can ever be done for them ... you still have an 
obligation to make sure that their other diseases are managed, that there is 
nothing reversibie that couid be managed effectiveiy’ which doesn’t fit in with that 
idea of ‘palliative’ being ‘end of.
The early referral for the skilful assessment of selective treatment withdrawal that 
supports symptom management was thought to promote the role of advocate. 
However, the palliative care team have alluded to a limited scope of insight 
themselves to the blurring of pharmacologic treatment versus glycaemic symptom 
origins experienced by patients with diabetes. Several participants reported limited 
awareness of the similarity of glycaemic symptoms to the common end-of-life 
symptom profiles and reversibility of them through diabetes management.
Advocacy for people with diabetes relies on knowing glycaemic symptom effects and 
the assessment of their importance to the patients comfort and well-being. For 
example, some patients are not troubled by a dry mouth but are fearful of 
hypoglycaemic events and would prefer not to have hyperglycaemia treated. Others 
may be distressed by the increased frequency of incontinence exacerbated by the 
osmotic effects of hyperglycaemia and would prefer to have CBG managed to 
promote dignity, and reduce the discomfort and burden of effort associated with 
incontinence and wet beds.
Radwin, (1996) observes from her literature review that the concept of ‘knowing the 
patient’ is central to personalised care, which is implicit in the LCP. ‘Knowing the 
patient’ is related to clinical decision making and is an essential element of clinical 
judgement found in many qualitative nursing studies on individualising patient care. 
Radwin (1996) concluded that the core component of ‘knowing the patient’ was the
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relevance of the nurse's knowledge and appraisal of specific patient perceptions of 
their situation, thoughts and concerns to care practices. Within the hospital setting 
where the relationships are episodic, random, and focussed within the ward 
speciality: the relevance or understanding of patient’s attitudes and feelings towards 
their diabetes at end-of-life management may not be fully appreciated. Time and 
opportunity to know the patient may be the limiting factor in acute care. ‘Knowing the 
patient’ is important as it creates the possibility of beneficence and patient advocacy 
and may counter the patient’s dependent and passive role in the decision making 
process (Bryon et al, 2010).
The opportunities to discuss the preferences and treatment withdrawal in advance of 
an acute admission are an ideal of the National End-of-Life Strategy (DH, 2008). 
This enables the thoughts and feelings to be articulated outside of the high emotional 
space that is often associated with the terminal few days of life, particularly when an 
acute illness has absorbed the energies of the patient and family. De Berardis et al 
(2011) compared patients with and without diabetes to establish the burden of 
diabetes on hospitalisations. Their findings reported diabetes increased the 
likelihood of hospitalization by two to six times, for the different causes examined. 
Field notes from the medical notes review suggest that a large percentage of patients 
had multiple réadmissions in the last year of life. Opportunities for discussion of end- 
of-life preferences are ideally the domain of primary care that has a role in co­
ordinating care needs. The increased use of health resources may be marker for 
these discussions to occur. Seale & Cartwright, (1994) note that the development of 
multi-partner practices in line with national health policy has diluted the role of the 
family doctor in ‘knowing the patient’. This can limit continuity and recognition of 
these markers of deterioration in the last year of life that single-handed general 
practitioners enabled.
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7.2. Blood Glucose Monitoring and Treatment
The focus group reported on the different surveillance roles for the conscious patient 
and healthcare professionals in the management of diabetes during the end-of-life 
period. The role of glucose monitoring (summarised in box 7.1) was to identify the 
cause of sudden changes in mentation, consciousness, and to know whether 
hyperglycaemic symptoms such as thirst were present. This was perceived as an 
important component of end-of-life care to enable treatment for reversible symptoms 
or provide evidence for acute deterioration that was not related to diabetes.
Box 7.1. Focus group data summary for CBG monitoring importance contexts 
Reasons to continue monitoring
• Conscious patients abie to report symptoms
• Type 1 diabetes
• Iatrogenic hypoglycaemia
• Symptomatic hypergiycaemia (>15 mmois)
• Proactive hypoglycaemia prevention during transition to ‘comfort measure’ with 
enteral feeding or intravenous insulin protocols
• Acute changes in consciousness or mental status
• Patient requests 
Reasons to withdraw monitoring
• Unconscious state
• Imminence of death
• Transfer to the LCP
• Type 2 diabetes
A consistent finding observed in the field notes across the full admission period was 
that references to the CBG were randomly noted in the medical or nursing record. 
Notably, vital signs were always recorded on medical ward rounds even if they were 
normal. However, symptoms of deranged blood glucose readings were rarely 
reported, nor were glycaemic management outcomes or targets reviewed in those in
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whom hypoglycaemia had occurred. This suggested a certain ‘blindness’ to the 
importance of diabetes across all ward specialities and may reflect the limitations of 
diabetes knowledge and competing priorities of episodic specialist-led care.
7.2.1. The Nature of the Blood Glucose Patterns and its Influences
The HbAic analysis shows that most patients were optimally controlled with a mean 
HbAic of 55 mmol/mol (7.2%) within the last 6-12 month period prior to the final 
admission. A large retrospective study by Huang et al (2011) reported that an HbAic 
in the 42 -  64 mmol/mol (6-8%) range in patients aged over 65 years was appropriate 
and maintained the lowest rates of complications, mortality and lower risk of 
hypoglycaemia. The CBG dataset showed that during the final hospital episode this 
stable pre-hospital glycaemic control was variably unstable across the sample. The 
causes of unstable blood glucose were predominantly due to the underlying acute 
disease process and the unskilled management of diabetes.
Analysis of CBG database compared cancer and non-cancer patients CBG trends. 
Blood glucose values were statistically more likely to be normal in cancer patients 
compared with non-cancer patients (P=0.022). This finding reflects the anecdotal 
observation in the palliative care literature that CBG normalises at the end of life 
(Poulson, 1997, Ford-Dunn et al, 2006). Only one other study reported normal CBG 
values in the last 72 hours of life in 18 patients (Ford-Dunn et al 2004). However, 
non-cancer patients were more likely to be hyperglycaemic compared with patients 
who had a diagnosis of cancer. Patients who did not experience hypoglycaemia 
throughout their admission had a higher proportion of hyperglycaemia readings. 
These results will be discussed further.
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7.2.2. Hypoglycaemia
According to the focus group data, the importance of blood glucose management at 
the end-of-life was contextualised towards avoiding the risk of hypoglycaemia as 
illustrated below.
R2.DR2.FG4: If you have got an iatrogenic cause, so basically, if you have got 
somebody who is semi-conscious, and you have given them insuiin, and they go 
hypo and they become unconscious, then that wouid need reversing because 
you have just caused them to become unconscious by giving them a drug. 
Whereas, if actually their blood sugar is fine, and then as part of the dying 
process they become unconscious at that point I wouidn’t do a BM.
This approach is consistent with the palliative care literature (Poulson, 1997, Quinn et 
al, 2006, Ford-Dunn 2005) and in the principles of management of diabetes across all 
guidelines (Rowles et al. 2010; NICE, 2008; NSF, 2001). The fear of hypoglycaemia 
is an accepted limiting factor in achieving euglycaemia (Cryer, 2002) for both patient 
and providers due to its significant risk of inflicting harm (Fowler, 2011). The CBG 
database found no significant difference between cancer and non-cancer patients for 
hypoglycaemic events.
7.2.2.1. Frequency of Hypoglycaemic Events for Entire Hospital Episode
Data analysis from the CBG dataset indicated that although the frequency of 
hypoglycaemia events was low (8.1%) across the total dataset, 68% of patients 
experienced at least one recorded hypoglycaemic event during their hospitalisation. 
The cut-off point for defining hypoglycaemia was set at 4.0 mmol/l and below, which 
is the threshold set within the hospitai protocols. Although the clinical significance of 
exposure to glucose concentrations of 3.5-4.0 mmol/l is probably minor (Swinnen et 
al, 2009) it was considered to be an appropriate threshold for an evaluation research 
design. The higher cut-off points (3.5-4.Ommol/I) for the hypoglycaemia threshold
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may increase the reported frequency of hypoglycaemia considerably (Swinnen et al, 
2009) and in this study, accounted for 47.3% of the recordings.
In contrast, 25.6% of total hypoglycaemic readings were below 2.9 mmol/l; with a 
small percentage (7.9%) of hypoglycaemia recordings found in the ^ 2.0 mmol/l 
range. The latter readings were commonly seen in patients managed on intravenous 
insulin protocols, which are associated with wide glycaemic variations (Queale et al, 
1997, Baldwin, 2005, Umpierrez et al, 2007).
Limited published data were found to satisfactorily benchmark these findings in the 
total in-patient cohort (critical and non-critically ill). This was because most hospital 
based research has studied a broad range of sample sizes, glycaemic thresholds, 
clinical outcomes and patient populations such as elderly, non-diabetic, stroke and 
cardiac patients. However, two hospital-based studies were found.
Wexler et al, (2007) survey of 44 hospitals, reported hypoglycaemia in the 2.5 mmol/L 
range that was reported in fewer than 5% of patients. The CBG database was 
analysed and CBG in the 2.5 mmols/l range was found in 32% of patients. Schnipper 
et al (2006) reported less than 1.2% of patients with CBG readings in the under 3.3. 
mmol/l range. The CBG database was analysed and compared using the same 
criteria of 3.3 mmol/L/l and 56% of patients were found in this range. The higher 
incidence of hypoglycaemic events in the lower values probably reflects the end- 
stage disease cohort of the diabetes hospitalised patient, and the fact that the entire 
CBG readings for the whole patient episode were measured. In addition the numbers 
from the CBG database were small (n=70). The hypoglycaemia risk is thus common 
in hospitalised dying patients. The importance of monitoring during active treatments 
is implied.
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The routine use of intravenous insulin protocols caused greater fluctuations than any 
other treatments including subcutaneous insulin protocols, this finding was also noted 
by Wexler et al (2007) and Schnipper et al, (2006). Patients with fluctuations in the 
hyperglycaemic (and lower) ranges were most often those on enteral feeds and this 
finding was supported in the study by Pleva et al, (2009). The need for guidelines 
and practical support is required from dieticians and the diabetes team to proactively 
management hypoglycaemia risk.
R7.DT1.FG1: W0  may see them so that they don’t get rebound hypos.... by the end 
of the round we would step down the rate of the TPN kind of by half and then a 
quarter rate, then off over a period of a few hours to last the time, and the TPN 
would be stepped down in line with the blood sugars, just that time, for that 
period....
7.2.2.1.2. Hypoglycaemic Events at the End-of-Life in Monitored 
Patients
Of those patients (67%) who were monitored to the end-of- life, 23% (n=11) had a 
reported hypoglycaemic event below 3.5 mmol/l on one or more occasions. The 
expressed belief that hypoglycaemia is a ‘natural process’ in the dying patient was 
not shown in this study as low readings were episodic and random, mostly occurring 
in the fasting state rather than continuously. Five had no diabetes medications 
prescribed and six had all diabetes medication stopped the day prior to death. These 
episodes can be attributed to both iatrogenic and non-iatrogenic origins.
7.2.2.1.3. Factors Linked to Hypoglycaemia Risk
The complexity of managing diabetes at the end of life was clear from the 
retrospective medical notes review. Given the known difficulties of predicting eating 
patterns, appetite for hospital menu on the day, and managing the diabetes treatment 
skilfully in the acute care setting, this may be more complex in the slowly or rapidly 
deteriorating patients, blood glucose monitoring and management at the end of life 
may be important. An interesting observation was that 40% of patients were still
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conscious and taking in nutrition within the last 24 hours of life. The perception of 
patients dietary intake and conscious level as a barrier to discussion was raised in 
the focus group. The data indicated a wide variation of nutritional intake at the 
terminal phase.
R2.DR2.FG1; I suppose in practice we have thought a lot about eating and 
discussions here, but, their prognosis has been raised, a lot of those patients 
aren’t going to be eating, and I would doubt, not really communicating effectively 
about their diabetes and maybe that’s where it becomes more tricky.
This dataset reflected variable permutations of nutritional intake, diabetes treatment 
withdrawal and CBG readings in all types of diabetes. There was no discernible 
relationship between the times food intake was stopped or treatment withdrawn to the 
CBG values. For example, food may have been stopped for 7 days and tablets 12 
days and the CBG would be high, whereas the expectation may be for it to be in the 
lower ranges. This raises a clear argument for monitoring and taking an individual 
approach to each patient’s situation.
This lack of a clear relationship between the glycaemic variables and their apparent 
non-linear relationship to recorded CBG values may be due to documentation 
variables. In particular, the qualitative variables (recording nutrition) are subjective in 
contrast to the more objective data abstracted from structured documentation for 
medicines and blood glucose data. It may also reflect different insulin resistance 
variables or islet cell secretory function relevant to the advancement of their 
underlying diabetes pathophysiology. Although the distribution of end of life CBG 
readings ranged across the continuum from low to high readings (see figure 5.5), the 
vast majority of abnormal readings were episodic and likely to be clinically 
insignificant with regard to symptoms. However, there was a small cohort of patients
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where the management of CBG may have been important and would have benefitted 
from an individualised review from the diabetes team.
The causes of hypoglycaemia were mostly iatrogenic, and were related to the 
misalignment of food, insulin and diabetes drug therapies. To unskilled management 
of intravenous sliding scale protocols (Smiley & Umpierrez, 2008) Bellam & 
Braithwaite (2010) provide guidelines for the principles of dosing of subcutaneous 
and intravenous insulin that may limit the hypoglycaemia risk and effectively manage 
hyperglycaemia in a range of common clinical contexts. These include situations 
such as varying nutritional absorption and intake, diminished renal and liver function 
and corticosteroid contexts that are relevant to the end of life situations found in 
hospitalised patients. The principles outlined are based on significant clinical 
experience, and may appear complex to implement by the novice physician or nurse. 
Therefore, diabetes team support may be important to support in the hospital setting 
(Puig et al, 2007).
7.3. Special Diabetes Situations at the End-of-Life
Although diabetes was not usually the primary reason for admission, blood glucose 
derangements are known to be associated with acute illness, and have been linked to 
significant morbidity and mortality outcomes (Clements et al, 2004, Lansang & 
Umpierrez, 2008). The management of type 1 diabetes and avoidance of significant 
hypoglycaemia has been cited in all the literature as important. In this section the 
management of type 1 diabetes and patients in the unmonitored state for prolonged 
time periods will be discussed.
7.3.1. Type 1 Diabetes
The retrospective medical notes review, focus group data, national guidelines 
(Rowles et al, 2010) and world literature (Poulson, 1996; Ford-Dunn et al, 2006),
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McCoubrie, et al, 2004; Quinn et al, 2006) suggest that end of life management of 
diabetes can be challenging, complex and should be individualised. There is general 
agreement that the management of type 1 diabetes is a priority as treatment is 
important for survival, and avoidance of Diabetic Ketoacidosis (OKA) and the 
symptomatic discomforts associated with it. However, there did not appear to be any 
consistent evidence for this consideration in the data analysis.
The only patient who was managed with insulin to the end of life was by the staff on 
the diabetes ward. Only one patient was documented to express concern about the 
continued management of her diabetes in the deterioration period when she no 
longer had the reserve to be her own advocate. To ensure she was receiving 
appropriate care, she asked for intravenous insulin to be started to ensure its 
continued use. This was stopped when she became unconscious.
For those patients with type 1 diabetes who were managed on the LCP (n=5) there 
was no documentation about the type of diabetes, or references made to any 
discussion with relatives or patients about their preferred management of diabetes. 
Patients on the LCP who died within 72 hours (n=4) had insulin last administered 1-3 
days pre-death in 5 patients; and was withheld for longer than 6 days in 2 cases. The 
majority had documented symptoms that could be associated with Diabetic 
Ketoacidosis (DKA) but the association is tenuous as the data collection method was 
not sensitive enough.
Four patients were unable to be their own advocate in the last 72 hours due to their 
confused or unresponsive state. Focus group data suggest that knowledge and 
experience is the limiting factor in managing the patient with diabetes at the end of 
iife. Most participants agreed that type 1 is important, and most did not feel confident 
in managing insulin. However, the role of the LCP as a trigger to stop all diabetes 
care was the most common reason reported across all focus groups. There were no
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plans in place to cover a time frame for reassessment of treatment or monitoring in 
any of the notes. This supports the general finding of Quinn et al, (2006). Version 12 
of the LCP now has a 3-day review point in place where the diagnosis of dying can 
be reassessed (Ellershaw et al, 2010). The importance of blood glucose assessment 
is not specifically recommended for review however. The management of diabetes 
seems to take a generic stance with all the other chronic diseases on the LCP.
These data suggest that non-specialists in the acute care setting are not sufficiently 
sensitive in clinical practice to the physiological and ethical issues of insulin 
withdrawal in type 1 diabetes. The focus group data were clear about the importance 
of managing type 1 diabetes in theoretical terms. Neither was there any 
documentation for further advice sought, which reflects the findings of Quinn et al 
(2006) and Jacobs et al (2002) where reluctance to seek expert advice was a 
common finding.
The ethical issues of premature insulin withdrawal in type 1 diabetes in the absence 
of any patient, family or diabetes expert consultation may be complex. Ford- Dunn et 
al (2006) who surveyed expert opinions from diabetes and palliative care consultants 
on diabetes end of life decisions found that only 25% would stop treatment. It was 
concluded that continuation of insulin therapy in patients with type 1 diabetes implied 
ethical uncertainty for withdrawing a life sustaining medication where clarity of benefit 
versus burden of treatment was unknown. However, difficulties in predicting time of 
death is well known (Glare et al, 2008) and in this subgroup of patients with type 1 
diabetes, just over half died within 72 hours of insulin withdrawal and 43% were over 
72 hours. The retrospective medical notes review recorded that within the whole 
sample, six percent (n=4) of patients had the LCP withdrawn as the terminal phase 
was judged prematurely. Thus, a review of insulin (minimal dose) should be part of 
the ‘comfort care plan’.
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The LCP is considered to be a best practice initiative in the government’s ‘End of Life 
Care Strategy’ (DH, 2008), and is hailed as the mechanism for ‘importing’ the culture 
of hospice care into a range of healthcare settings (Ellershaw & Murphy, 2005). A 
recent Cochrane review (Chan & Webster, 2010) concluded that while the LCP care 
pathway lacks a full evidence base, it is recognised to be the gold standard. They 
further conclude that there is no reported harm to contra-indicate its use (Chan & 
Webster, 2010). However, a situation such as type 1 diabetes where withdrawal of 
insulin may cause death is an example of harm, which may persist in the minds of the 
bereaved family after death.
A key value in the palliative model of care in the terminal phase is to manage the 
dying process without hastening death (Regnard & Dean, 2010). Yet in their book 
(6*^  edition) on the palliation of symptoms in advanced disease, the chapter on 
management of the terminal phase recommends to stop all diabetes medicines. 
There is no caveat with respect to the type of diabetes, and the potential benefits in 
the suppression of ketosis with minimal dose insulin as a symptom management 
strategy. With the exception of brain death, there are no guidelines for the use of life- 
sustaining treatments for patients who may be near the end of life, (Larochelle et al, 
2009). It may be useful to list the drugs that sustain physiological functions and affect 
comfort - such as cortisol in Addison’s disease, insulin in type 1 diabetes and 
Parkinson’s disease medicines - directly on the pathway to remind the (often junior 
medical staff) hospital team of their importance to consider them for comfort 
measures.
It is difficult to draw firm conclusions as to why patients managed on the LCP, or 
patients with type 1 diabetes were not shown more consideration but it is likely to be 
multifactorial. In a widely cited report based on data from America and the 
Netherlands, Grol & Grimshaw (2003) reported that 30-40% of all patients do not
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receive healthcare based on current relevant knowledge and an estimated 20-25% of 
all patients receive harmful or unnecessary care. The opportunity to clarify the type 
of diabetes clearly on admission would be beneficial. Notably, a third of patients with 
type 2 diabetes were treated with insulin and the term ‘IDDM’ (insulin dependent 
diabetes mellitus) was commonly used in both type 1 and type 2 diagnosis 
categories. The recognition of type 1 can be blurred with such documentation (NHS 
Diabetes, 2010).
7.3.2. Prolonged Survival on the LCP
The LCP was used to manage 49% of patients with diabetes sampled in the medical 
notes review. Over a third of patients died suddenly, (38%) and were not managed 
on the LCP. The claimed benefits for using the LCP lie in the following features: the 
provision of guidance on comfort measures, discontinuation of inappropriate 
interventions, anticipatory prescribing for common symptoms present in the terminal 
phase and holistic care during and after death where bereavement support is implicit 
(Jack et al, 2003, Preston, 2007).
The majority of patients managed on the LCP had the last CBG readings in the 
normal to high range where clinical symptoms were unlikely or transitory. However, 
35% of patients survived over 72 hours on the LCP for up to 18 days without further 
monitoring, where the last CBG value was either significantly in the hypoglycaemic or 
hyperglycaemia range. This survival beyond 72 hours is higher than McCoubrie et al 
(2004) findings where only 24% survived to 16 days. The CBG was not checked 
again suggesting diabetes management was no longer important in the terminal 
phase of life. Once this diagnosis is established, then it seems implicit that there is 
no further obligation to review even at an ethical level. Analysis of the symptoms 
database found those who died within 72 hours of the LCP management had at least 
one symptom of distress, anxiety and agitation, whereas those on the LCP longer
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than 72 hours had several recordings of distress similar in characteristics to 
hypoglycaemic symptoms. The number of symptoms listed in these patients was six 
or more. These were commonly mental stress (anxiety, agitation, and restlessness), 
tiredness and lethargy. These symptoms cannot be attributed to hypoglycaemia due 
to the limits of retrospective data collection, and the lack of data reporting prior 
symptom load. These symptoms certainly merited a review of the CBG to rule out 
glycaemic origin. The perception of greater symptom load may be related to data 
artefact for two reasons. The LCP documentation symptom tick list may improve the 
documentation, and the involvement of the palliative care team for the LCP may 
reveal a more skilled documentation of symptoms profiles.
This generic attitude to the management of the dying through the ‘blanket withdrawal’ 
of treatment reported in the focus groups was seen to originate from the ‘yellow card’ 
that officially closes the medical notes and nursing assessment documents. At the 
point of diagnosing dying, the line is drawn, marking the point of irreversible disease 
progression to the reversible symptom management care focus. This was perceived 
as a symbolic closure to all that was relevant to the patient in terms of their medical 
history, assessments, biometric observation charts and blood glucose monitoring 
documentation.
Thus, the care was focussed to that outlined on the LCP protocol. This was thought 
by the focus groups to have the effect of ‘authorising’ insulin or blood glucose 
monitoring to be stopped and this practice was supported in the majority of cases in 
the notes review. The ‘blanket’ approach to withdrawal of routine observations and 
treatments was suggested as a way of overcoming complex decision escalation back 
towards active treatment and enabling ‘drawing the line’ for interventions. If the blood 
glucose is measured, there is an implied obligation to treat it, which may escalate into 
ambiguous outcomes of care.
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R3.CNS2.FG4: ... 'le t'S chsck youf temperature and see if you have got a
tem perature’ and again, it’s back to w hat are you going to do about it when 
they’ve got a temperature? If it’s jus t a matter o f giving them something to bring 
their temperature down and that’s perfectly appropriate, or do they need more? 
Do they need antibiotics and then you are opening a whole ’ hornet’s nest’ aren’t 
you? Because you have then got to talk about the benefits o f having or not 
having antibiotics. So you can understand why decisions are made, it is much 
easier to have a blanket decision than to be actually, be faced with those kind o f 
dilemmas.
Further, decisions to treat may be compromised by lack of knowledge and skill to 
judge the dosing of insulin. Knowledge and skill in the management of insulin and 
diabetes is becoming well documented in the research literature (Knight et al, 1984, 
Thorne et al, 2000, Quinn et al, 2006, Derr et al, 2007, George et al, 2011). These 
studies indicate a need for all healthcare professionals working in acute care (and 
palliative care) to receive education. Limitations in knowledge of diabetes care in the 
acute management also pose limitations in the skills for palliation of those at the end- 
of-life.
A frequently touted benefit of clinical guidelines is the delivery of consistent practice 
patterns; however, this may come at the expense of reducing individualised care for 
patients with special needs (Woolf et al, 1999). The LCP framework can be likened 
to an algorithm (tick-box) that reduces patient symptoms into a sequence of binary 
(yes/no) decisions. This approach can potentially do injustice to the complexity of 
clinical practice decisions and limit the use of thought processes inherent in clinical 
judgment (Woolf et al, 1999). The palliative care group recognised that the subtleties 
of the LCP were not necessarily fully appreciated in generalist clinical practice.
Several focus group participants remarked that the end-of-life symptomatic care 
‘cocktail’ in the syringe driver was likely to manage all the symptoms arising from 
glycaemic derangements. The difficulties of managing the glucose were also blurred
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by ‘not knowing’ what the patient was experiencing as part of the dying process. This 
uncertainty is probably counter-balanced by what is known about the drug effects 
. within the syringe driver, and the ethics of ‘not suffering at the end’ and enabling a 
peaceful death.
McCarthy & Grumley (2010) argue that the introduction of evidence based practice 
and evidence based medicine focuses on the ‘evidence’ itself and the clinician, but 
fails significantly to focus upon the user. The ultimate aim of evidence-based 
medicine is to improve the service quality and this is a partial function of care 
pathways. However, these authors argue that a clinical pathway caters for the 
majority to the detriment of the minority. In the process, although variances are 
incorporated in pathways, the development of clinical reasoning may be diminished. 
The patient values are not considered when ‘blanket’ decision approaches are used 
instead of personalising care to the patient’s situation. The importance of team 
working, which is inclusive of patients and relatives, may be the most effective way to 
provide symptom management (Connor et al, 2002). Consideration to pre-LCP 
planning for withdrawal of treatment was seen as important, particularly by the 
palliative care nurse specialists. This was compromised by late referrals to the team. 
Reasons for this may be found in the study by Jacob et al (2002) that indicated 
continuity of care by the admitting team was shown to be important to physicians 
because they preferred to take responsibility and authority to the end. The emphasis 
on evidence-based medicine versus values based care may also impact on 
practitioners decisions (McCarthy & Rose, 2010). The liberation from the 
responsibility to treat CBG is enhanced through the reduced relevance of long-term 
complications. Thus evidence-based data for prevention of long-term complications 
is probably the most influential factor in the decisions to stop CBG monitoring and 
treatment even though it is out of the context of the original intent of the study
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outcomes. Its application to decision making at the end-of-life is inappropriate. 
These decisions require a different evidence base than those for long-term issues.
The focus groups suggested that the transition period from active to comfort care 
should be proactively managed in terms of preventing hypoglycaemic events. 
Suggestions for this included gradual reduction of enteral feeds, and checking sliding- 
scale insulin readings to ensure they were normalised prior to stopping. In practice, 
this was not standard according to the retrospective medical notes review data; but is 
a useful guideline for practice.
From these data, it can be concluded that blood glucose is not perceived as an 
important component of end-of-life care in terminally ill patients on the LCP. The 
need for further research, inter-professional education, practice support and 
resources has been seen as a fundamental requirement for quality implementation of 
the LCP (Mellor, et al, 2004, Mirando et al, 2005, Walker & Read, 2010, Di-Leo et al, 
2011) in chronic illness and particularly in diabetes.
7.4.0. Influences within the Organisational Context
Cultural values and organisational systems within the hospital were viewed as 
complex and influential in care decisions around diabetes management at the end-of- 
life. Principally nurses within the focus groups raised these issues.
The cultural values of the hospital, primary care, patients, families and the influence 
of the differing epistemology underpinning healthcare provider decision-making were 
found to be a source of tension. In the study by Jacobs et al (2002), these cultural 
issues were shown to be related to variations in personal values, beliefs, education, 
spiritual orientation and other factors of all individuals involved, as well as the 
particulars of the situation itself. In this thesis, the issues of ‘time and opportunity’
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and the role of the hierarchy were viewed as a disempowering structure within the 
hospital setting.
7.4.1. Time and Opportunity
Focus group data identified a range of factors that limit the opportunity to ‘know the 
patient’ and their wishes around withdrawal of blood glucose management. The time 
elements discussed were multifactorial. These included the moribund condition of 
the patient, and the imminence of death at the time of admission. Staffing level limits 
on time available for end of life conversations (Schreiner et al, 2004, Tsaloglidou et 
al, 2007); difficulties in predicting prognosis; time to research the medical volumes of 
notes to assimilate data of previous discussions; and the randomness of having 
experienced professionals with the requisite communication skills at the time when it 
was needed. The latter were supported by Jacobs et al, (2002). In addition, the 
issues around the ward environment and privacy for such conversations to occur 
were considered important limitations. This lack of privacy has been shown to reduce 
disclosure by patients on matters that may be important (Malcolm, 2005). All these 
factors impact on time and opportunity for individualising care around patients 
diabetes concerns.
7.4.1.1. Recognising the Dying Patient
The majority of patients (71%) died suddenly and were monitored within the 72 hours 
of death. This rapid deterioration to death has been previously reported in the acute 
care end-of-life literature (Gibbens et al, 2009, van der Heide et al, 2010). This 
observation suggests that there was uncertainty in the prognosis as the LCP data 
indicate monitoring is permanently stopped when dying has been confidently 
diagnosed. Randall (2011) observes in acute care that daily decisions are made in 
the ‘now’ context rather than the future. Therefore time, space and energy in the 
’now’ moment are influential in decisions around personalising end-of-life diabetes
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care. The acute care context may be limited in terms of time and opportunity for 
some patients and their family to have the emotional space to realise the terminal 
state of their chronic illness. Forty percent of the patient sample who were admitted 
was self-caring and independent pre-admission, and anticipation of survival may 
have been the expectation.
Taylor & Johnson (2011) discuss in great length the dilemma of knowing the true 
prognosis of elderly patients with multiple comorbidities. They argue that recognising 
dying is complex and difficult and has been subject to controversy within the wider 
literature. This thesis found that a degree of recognition and opportunity to 
proactively manage the end-of-life phase was evidenced in the high percentage 
(89%) of ‘do not attempt resuscitate’ (DNAR) notification in the medical notes. These 
DNAR notifications can be described as ‘critical junctures’ as outlined by Strauss et 
al. (1985) where opportunities to review the treatment plan should be made, but are 
not always recognised. The lack of documentation around end-of-life planning is 
common (Fins et al, 1999, Becker et al, 2007) even when DNAR decisions have been 
made (Jacobs, et al, 2002). This was supported in the medical notes review where 
‘comfort care’ was likely to be documented within the last 72 hours of life, and where 
certainty of prognosis could be confidently concluded.
7.4.2. Hierarchy
National diabetes guidelines for end-of-life for care have been recently published 
(Rowles et al, 2010). They recommend multi-disciplinary and user group involvement 
across the primary and secondary care sector to advocate for the patient’s wishes. 
The leadership role of the physician in decision-making on the patient’s behalf has 
been cited as a source of conflict and dissatisfaction in other team members including 
the family (van der Heide, et al, 2010. These issues will be discussed in the next 
section regarding hierarchy as an influencing factor.
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Connors et al, (2002) note that no individual team member alone can meet the highly 
complex needs of patients and families at the end-of-life. However, the ultimate legal 
authority to intervene and prescribe treatment lies with the medical team, who have 
overall accountability for the clinical treatment plan.
There were multiple factors that contributed towards decisions for doctors to 
intervene or not intervene. These include the lack of practical clinical guidelines, the 
overarching influence of the evidence-base for long-term complications of glycaemic 
control perceived as futile in the dying patient and limited skill with insulin 
management at the end-of-life were cited as the source of variation in the practice. In 
addition, some junior medical staff were seen to be more sympathetic to intervening 
for treatment of blood glucose but were disempowered to act according to senior 
physicians view. Referral for advice to the clinical nurse specialists for review was 
perceived as devaluing the ward nurse’s assessment at the bedside, rather than 
supporting it. This ‘decisional distance’ from the bedside by the senior hierarchy was 
a source of tension for those delivering care at the bedside who had a closer, and 
probably more knowledgeable insight. This issue has been recognised in other 
studies where the role of end-of-life care has been seen as a nursing domain 
(Tsaloglidou et al, 2007, Oberle & Hughes, 2001). This ‘decisional distance’ from the 
patient may be influential in the degree of quality of care perceived by the patient. 
Foucault (1990) defines ‘decisional distance’ as:
‘the optimal distance between a decision made and the individuai it 
concerns, in such a way that the individual has a say in what is done and 
in such a way that the decision is inteliigibie to him, whiie at the same time 
being geared to his situation (p168) ’ .
It would seem, the further from the individual the decision is made, the less ‘geared to 
the situation’ it is likely to be. This may cause a degree of tension between those 
who are closer to the patient and family and those who have the decision authority.
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There may be dissonance between the problem perception and the adequacy of the 
decision to solve it satisfactorily. The issue of hierarchy was discussed passionately 
by nurses in the final focus group, and their views are supported in other studies 
(Oberle & Hughes, 2001; Willard & Luker 2006). Hierarchical barriers to decisions to 
continue or withdraw diabetes management was reported to be multi-factorial and 
included failure of some doctors to listen to nurses who have greater personal 
knowledge of patients and families (Oberle & Hughes, 2001). The lack of experience 
and power of some junior doctors to support nurse’s requests to respond to glucose 
monitoring results was reported (Kelley et al, 2006). Some doctors (Hanratty et al. 
2006) perceived palliative needs as low priority. Furthermore, difficulties in building 
and maintaining working relationships with individual doctors are hindered through 
the constant rotation through consultant teams (Tsaloglidou et al, 2007). These 
issues may variably contribute to limiting the advocacy role of nursing.
An interesting observation by the non nursing participants in the focus groups was 
the reference to being ‘outsiders’ when discussing end of life decision involvement 
from the relatives perspective.
R8.SL.FG4: Similarly, I th ink as an outsider, I would clearly agree with that
comment, and that relatives find it distressing if they th ink that’s the cause of 
confusion.
One of the key principles of palliative care is to involve the relatives in the process of 
care and decision making. Focus group and field note data implied that this was not 
common practice; relatives are usually informed about care decisions, rather than 
discussing options. Qualitative research studies report this lack of discussion as a 
source of dissatisfaction with relatives for the end-of-life care in the hospital setting 
(Veerbeek, et al, 2008; van der Heide, et al, 2010). Van der Heide et al (2010) note 
that the acute care setting tends to transition therapeutic intervention from ‘cure’ to 
‘care’ very close to death which limits the opportunity for any realistic discussion.
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This finding was supported in this study. Although the role of the family is espoused 
as important, the focus groups did not contribute much data other than medical-led 
decision-making as to why there was less involvement.
In summary, there is great variation and inconsistency in patient empowerment 
practices that occur in response to the professional-led culture and care structure of 
acute care in conscious patients. In the unconscious patient thought to be dying, the 
patient's context and wishes should be considered and promoted inter-professionally 
and in open dialogue with the patients family to ensure that morally valid 
perspectives, other than patients’ biomedical perspective are considered (Connors et 
al. 2002;Jones, 2005).
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CHAPTER EIGHT CONCLUSION AND IMPLICATIONS 
FOR PRACTICE
8.0. Introduction
This chapter will summarise the review of the literature and conclude the key findings 
from this thesis and the implications for practice. The strengths and limitations of the 
methodologies used is summarised and recommendations for future research are 
made.
This thesis has argued in the review of the literature that good diabetes control is 
important in both type 1 and type 2 diabetes from the point of diagnosis. This has 
been shown in randomised control-led trials to substantially reduce life threatening 
and life limiting consequences arising from the metabolic derangements from 
inadequate management. The view in the end-of-life literature indicates that these 
outcomes are no longer relevant in both the pre-terminal and terminal phases of 
advanced disease.
However, attention to the short term complications can be ethically debated based on 
the research evidence shown for the effects of symptoms of diabetic ketoacidosis, 
hyperglycaemia and hypoglycaemia on the daily quality of life. It has been argued 
that supported self-management through a patient empowerment model is the 
aspiration of primary care colleagues and supported by the health policies through 
which healthcare is commissioned. The patients role in CBG monitoring and lifestyle 
is an integral part of diabetes care. This enables patients who have the capacity, to 
give their own glycaemic history and outline their symptom awareness at the point of 
admission, or for their family to advocate on their behalf on admission to hospital.
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Because hospitalisation is due to a compromised health state that exceeds the 
patient’s capacity to self-manage, the care paradigm changes to expert-led specialist 
care. The expertise of the patient for their medical history and management should 
remain an important part of the in-patient care process. This is important as the 
literature points to limited opportunities to ‘know the patient’ and a collaborative 
approach to supporting patient’s autonomy in acute admission phase may be 
beneficial. This collaboration may enable better understanding for the patients view 
and values and preferred glycaemic thresholds if they deteriorate and cannot self 
advocate. The hospital environment limits informed decision making due to the 
episodic nature of acute care and the rapid turnover of trainee doctors and varying 
staff member’s clinical rotas.
The end-of-life research to date has been initiated by palliative care professionals 
who have recognised the complexity of managing diabetes in advanced and declining 
disease states. This complexity is primarily due to changes in metabolic and caloric 
requirements and the consequences of this for diabetes therapy management in all 
diabetes categories. Several small studies have been undertaken which have been 
opinion-based (Ford-Dunn et al, 2006, Quinn et al, 2006) or audit based (Ford-Dunn 
et al, 2004, McCoubrie et al 2004) due to the exploratory nature, pragmatic and 
ethical limitations for this sensitive research area.
The findings from other studies are that liberalising the diet and medication is 
common practice. Continued monitoring of patients with steroid induced diabetes 
and type 1 diabetes is normally prioritised, and is perceived as less important in type 
2 diabetes. Blood glucose monitoring frequencies are variable across different 
organisations, but a common theme was the lack of treatment planning to support 
monitoring results. Although guidelines were seen as important to support care, few 
palliative care specialists undertook any diabetes continuing professional education
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and did not refer to diabetes specialists for advice. Many saw the management of 
blood glucose as important but practice was experience-led and variable and many 
lacked confidence. The obvious finding from the literature review was the lack of 
research from generalists in the community or hospital setting, where the problem 
has either not been recognised or considered important enough in the end-of-life 
context.
Common to all these research publications is the de-contextualisation of the patient 
situational variables that influence the CBG, and the lack of linkage of healthcare 
attitudes and practice perceptions from the survey or audit setting.
This thesis has situated the research context to the hospital setting, and, using a 
mixed method approach, has examined both the documentation of care, patient 
advocacy variables and the views of diabetes, palliative and generalists in three 
separate specialist focus groups, and one combined specialist group. This mixed 
approach enabled analysis of documented clinical practice to be evaluated according 
to clinician based perceptions. This has mutually enlightened data findings from the 
different methodologies. The objective of this work is to generate a better 
understanding of the factors that influence the management of diabetes at the end of 
life to inform clinical practice guidelines and the educational needs to improve the 
quality of care and this has been accomplished.
8.1. Key Thesis Findings
This study is the first to report the entire CBG dataset for the management of 
diabetes at the end-of-life and to examine patient and professional advocacy contexts 
of all patients admitted to, and who died in the acute care setting. The key findings of 
this thesis are that CBG are not routinely managed as part of the end-of-life pathway, 
and diabetes is treated generically with no apparent differentiation for type 1, or 
preceding CBG readings at the point when CBG monitoring, enteral feedings or
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diabetes treatment is stopped, individualised personalised care is compromised 
through the hierarchy, LCP and time and opportunity factors within the acute care 
setting which limits ‘self or ‘other’ advocacy; the knowledge and skill for professional- 
led advocacy for palliative care philosophy and diabetes management limits the 
ability to define a management plan or refer for expert opinion. These three findings 
will be discussed and the implications for research and practice concluded.
8.1.1. Blood Glucose Management at the End-of-Life.
This thesis found that in the majority of cases the CBG is not actively managed as 
part of the end-of-life care. Most patients deteriorate and die very quickly at the point 
when routine ward CBG data collection and treatment is part of standard care. Most 
patients who were monitored within the 72-hour period from deterioration to death 
probably reflect those cases where the reversibility of the deterioration may not have 
been confidently known.
When the diagnosis of dying is definitively made and LCP procedures are initiated, 
the type of diabetes was not clarified in the documentation, and a generic approach 
to diabetes seemed to occur, where the routine withdrawal of all monitoring and 
treatment appears to be standard practice. The heuristics and perceptions of the 
focus group for monitoring were not reflected in the documentation. Patients with 
type 1 diabetes were apparently not prioritised.
In a limited number of cases some patients were monitored on the LCP, which 
contrast with the focus group perceptions of care. This may have been a coincidental 
finding since most of these patients died in the initial 24-hour period of the LCP. A 
similar finding to Quinn et al, (2006) was that in both monitored and unmonitored 
patients there were no treatment plans in place for glycaemic management. In 
unmonitored patients whose survival extended between 72 hours up to 16 days, the 
final CBG reading was not influential in the comfort care plan. In this group the final
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CBG, value was seen in the extremes of high and low readings, which were not 
reassessed. In this group, the symptom burden was slightly higher (average 8.6 
symptoms per patient versus 6.9 symptoms) than those who survived less than 72 
hours. A limitation of the retrospective medical notes review is the difficulty in making 
associations for cause and effect. Further research through prospective research 
methodologies are needed to investigate the patients experience directly.
The implications for practice are that there is a clear need for practical guidelines 
since patients were managed across the trust in the same way. The LCP may need 
some minor adjustments to trigger further consideration in those long-term conditions, 
such as type 1 diabetes that may impact on comfort care or patient and relatives 
wishes. Patients with type 1 diabetes may have a greater risk for discomfort 
compared to those with type 2 diabetes. However, the symptoms perception 
between both types of diabetes is not known and ethically they should be assessed 
and ruled out for glycaemic cause. The research evidence that cited the 15 mmols/l 
threshold (Warren et al, 2003) was referring to the median value, whereas the range 
for symptom perception began at 8.0mmols and extended to 30mmols. There is a 
clear gap in the research literature to assess this in clinical practice. The LCP could 
be adapted to collect this information in terms of the patient’s diabetes management 
wishes and glycaemic threshold for symptoms, this question may begin to be 
answered through audit of the care pathway.
There was a significant difference between cancer and non-cancer patients in CBG 
values across the whole hospital episode. Cancer patients were more likely to have 
normal CBG values whereas non-cancer patients were significantly more likely to 
have CBG in hyperglycaemic range. Both cancer and non-cancer patients were 
equally likely to have hypoglycaemic episodes. The implications for practice is non­
cancer patients may be at risk for unstable CBG and risk assessments should be part
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of end-of-life decision making on treatment continuation and withdrawal. Although 
the majority of CBG readings were situated in the normal range in the last 72 hours of 
monitored care, most patients experienced at least one episode of hypoglycaemia in 
the last 72 hours of monitoring. Most causes of CBG derangements could be 
attributed to iatrogenic causes, although some were non-iatrogenic and occurred 
episodically. Recognition of low CBG through monitoring may have triggered nurses 
to encourage patients with some nutrition and reduce any potential symptoms. It was 
noted in the diabetes focus group that non-iatrogenic hypoglycaemic episodes were 
associated with disease states such as dementia and treatment may cause excess 
distress to patient and family. In these instances, professional judgements should be 
made in collaboration with the patient’s family in non-symptomatic patients to 
withhold invasive treatments. The belief that diabetes patients blood glucose settles 
to a natural state of hypoglycaemia at the end-of-life phase was not fully borne out in 
the acute care setting.
8.1.2. Patient Advocacy
This thesis found that both clinical and organisational factors were influential in 
helping or hindering the time and opportunity provision for patient self-advocacy or 
advocacy by those who know the patient’s diabetes habits well enough to support 
their wishes. Within the acute care setting it was noted that practitioners work mostly 
in the ‘now’ moment (Randall, 2011). The rapid deterioration to death trajectory in 
the majority of patients has been commonly observed in this study and this will very 
likely place limitations on meaningful end-of-life conversations around monitoring and 
management. Particularly in situations where diabetes may not be the presenting 
cause for admission, and where the average length of stay was extremely variable.
However, the retrospective medical notes review indicated that the majority of 
patients had over ten years experience with diabetes, most were on treatment
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probably requiring monitoring of CBG, where they were likely to be familiar with their 
own CBG profile. The opportunity to document their diabetes type accurately, their 
glycaemic control profiles, and symptom thresholds was lost because it was not 
standardised admission data. Knowledge from this history would benefit the whole 
admission and inform the team of the patient’s sense of importance about their 
diabetes, and trigger early referral for diabetes support. The use of the term ‘NIDDM’ 
and ‘IDDM’ is still used to document diabetes type and can be misleading.
The opportunity to empower patients to manage their diabetes was not routine to 
practice in the medical notes or focus group reports. These data could be used to 
inform the management of patients at the end-of-life in a more personalised way if 
they were already documented in the notes. Within the hospital setting, the single 
assessment document used on admission for collecting baseline details for patient 
care could be extended to include these data. These data could be used to judge 
patient ability to self manage dose adjustments, and support ‘knowing the patient’ as 
outlined by Radwin (1996) in terms of the patients perception of symptoms and the 
thresholds at which they occur and are tolerated. The focus groups suggest that it is 
the patient’s responsibility to report their symptoms, but it is equally important to ask 
patients when an abnormal CBG value is found, if any symptoms are perceived at the 
time. Further, the patient’s attitude to their diabetes can be gleaned through paying 
attention to it during the acute phase and thus enable advocacy on the patient’s 
behalf if they deteriorate unexpectedly. A key observation from the focus group data 
was the inability to draw on practice experience to comment on the CBG trends at the 
end-of-life. This may be partly due to the fact that patients in this phase are not 
monitored, and are not assessed routinely.
The inclusion of the patient’s wishes for continued monitoring or treatment is not 
currently worded well in the current LCP document. The inclusion of the patients and
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relatives view on the continuation of the diabetes management may also not be direct 
enough. The focus groups confirmed that both patient and relatives are not 
consistently involved in these decisions and the LCP suggests a passive (‘inform’) 
versus active advocacy role for relatives.
8.1.3. Professional-Led Advocacy
The thesis found that professional-led advocacy predominated for decisions on the 
end-of-life diabetes management. The lack of clinical guidelines, limited diabetes 
knowledge, the perception of prevention of long-term complications seen as no 
longer relevant, the assumption of CBG normalising on nutrition withdrawal by the 
patient, the lack of management skill for insulin dosing, fear of iatrogenic 
hypoglycaemia and the difficulties in prognostication were key factors influencing the 
end-of-life management of diabetes. The focus group suggested that the blanket 
withdrawal of all diabetes care liberates the professional from the dilemmas of 
treating the CBG result. Blood glucose monitoring may oblige the practitioner to ‘do 
something’ that may cause iatrogenic hypoglycaemia and add to further complication 
for its reversal which may be complex in a patient whose system is physiologically 
shutting down. Treatment was thought to potentially lead to overt distress to patient 
and families, as treatment may need to be intrusive where there is likely to be limited 
intravenous access.
The reliance on the LCP drug formulary for amelioration of all symptoms may enable 
any ethical qualms of ‘doing no harm’ to be managed comfortably. The professional 
advocate role was strongly based on the irrelevance of the long-term complications 
data in the setting of the terminal phase and fear of iatrogenic hypoglycaemia, and 
was less sensitive to the short term complications of hyperglycaemia on the patients 
symptoms, diabetes type and management preferences.
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The provision of multi-specialists on the hospital premises allows patients to access 
an expert opinion fairly promptly, and the reticence to refer for diabetes support at the 
end-of-life may reflect the impact of evidence-based medicine on clinical decision 
making. The epistemology that relies on evidence-based randomised controlled trials 
has a fundamental weakness in the assumption of its generalisability to all 
populations. This may also limit an individualised view. Implicit to the evidence based 
philosophy is the value placed on professional judgement and values-based care 
(McCarthy & Grumley, 2010). Professional judgement relies on experience, and the 
majority of end-of-life care in the hospital is provided by trainee medical staff (Kelly et 
al, 2006). The switch to ‘values-based’ care may be difficult as the time factors for 
establishing what the patient values comprise may be limited. The limited knowledge 
of the short-term consequences of glycaemic symptoms and the reliance on the LCP 
protocol enables short cuts in thinking in the busy time pressured acute care setting. 
Knowledge and ‘thinking time’ were notable reasons for lack of attention to diabetes.
The sense of ‘decisional distance’ between those prescribing and authorising 
treatments was perceived as a source of tension from within and between disciplinary 
hierarchies. This has led to uncomfortable moments and practice dilemmas for 
nurses delivering care at the bedside. What has emerged from the data analysis is 
that there is no clear practical guidance or hospital policy structure for the 
management of diabetes at the end-of-life. Therefore, practice is variable and reliant 
on the personal ethics, knowledge and values of the individual professional who is 
accountable for the care, and may contribute to limiting the patient and family 
involvement.
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8.2. Implications for Practice
The implications for practice are drawn from the thesis findings and their co- 
terminosity with the relevant literature and applied in the following suggestions for in­
patients in the hospital setting. This policy should directly address diabetes in the 
following practical way:
All patients should have a structured glycaemic history on admission and a self 
management policy for administration of diabetes medication, especially where 
insulin therapy is concerned. When patients are reviewed for palliative support, a 
joint assessment with the palliative care teams should be sought with the diabetes 
team to enable patient’s wishes to be safely supported with a diabetes treatment 
plan. The minimum CBG monitoring and simplest treatment plan should be 
implemented in agreement with patients or their relatives when possible at the 
following transition points when:
(a) DNAR status is declared -  a palliative referral should be initiated if not in place 
already.
(b) Deterioration due to dying is recognised
(c) The LCP protocols are initiated.
The management plan should be based on the following assessments:
1. Clear diagnosis of the type of diabetes
2. Patients preferred glycaemic target based on assessment of
o patient symptom threshold 
o recent CBG profile and trends
o The patients preferred frequency to have CBG sampling -  
prioritise testing to those times of day when it's been lowest or 
highest
3. Review and manage continued use of drug / enteral therapy likely to 
increase CBG values or induce rebound hypoglycaemia
o e.g. Insulin dosing. Steroids and Octreotide, PEG feeds -  
referral to dietician for titration of feed guidelines
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o implement protocol to assess for and reduce rebound 
hypoglycaemia
o referral to diabetes team
4. Patients or relatives expressed wishes for further CBG testing.
8.3 Study Limitations
The study was limited by its small sample size and single organisation context and 
therefore cannot be generalised. However, readers can decide what data are 
relevant to their organisation.
The limitations to the retrospective medical notes review are the difficulties in 
generalising practice from a heterogeneous group of case studies. The reliance on 
what was documented may not be reflective of the complex issues at the level of the 
individual case study or the quality of care given. But is influenced by the writer’s 
values interests and biases in determining what was important. This was strength in 
terms of the research question but may be limitation for drawing firm conclusions.
The limitations of the focus groups were that they reflect the experience and views of 
a small number of people who work within the organisation and may not be 
representative of the views of all health care providers. The majority of the views 
were obtained from senior doctors and nurses as these professionals were thought to 
be influential in practice, and their experience cumulative. Further, most people have 
worked in other care organisations and their experience has likely been consolidated 
from many sources of practice exposure.
The accuracy of reporting by participants is unknown. The degree to which the focus 
group may have incidentally been provided an environment to discuss these issues at 
a theoretical level rather than clinically relevant level is difficult to determine.
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8.4 Conclusion
Although individualised care approach was commonly cited, its delivery is 
compromised by limited patient and family involvement for end-of-life decisions 
around treatment withdrawal for diabetes management. Individualised care was 
reported to be influenced by the organisational culture of acute care and the differing 
professional, ethical, knowledge, and decision accountabilities of the multi­
disciplinary team. The need to structure and develop this knowledge and incorporate 
it within clinical guidelines is evidenced from both the focus groups and retrospective 
notes review data. Without such guidance, individualised care will continue to be 
defined consistently as medically situated versus person situated. What people think 
they do in practice and what actually happens are not linear. Knowing what someone 
wants is different from having the skills and knowledge to deliver it. There are both 
physiological and ethical reasons to address end-of-life preferences for glycaemic 
management in patients with diabetes.
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Participant Information Sheet
Hospital LOGO removed for theses appendix
Study Title: Is blood glucose management an important component of end-of-life 
care in patients with diabetes? Factors influencing clinical management in the acute 
care setting.
Introduction
You are being invited to take part in a 
research study. Before you decide 
whether or not to take part it is important 
for you to understand why the research is 
being done and what it will involve.
Please take the time to read the following 
information carefully. Talk to others about 
the study if you wish.
Ask me if there is anything that is not clear 
or if you would like more information.
Take time to decide whether or not you 
wish to take part.
Researcher Contact Details:
Debbie Hindson: Voicemail: 2844 / Pager 
8230
What is the purpose of the study?
The purpose of the study is to explore the 
views of experienced healthcare 
professionals about the end-of-life 
management of blood glucose in people 
with diabetes or steroid-induced 
hyperglycaemia.
The aims of the study are to gain an 
understanding of the practice issues 
influencing the clinical decisions to 
continue or withdraw diabetes treatment 
and blood glucose monitoring.
Currently not much is known about the 
factors that influence management of 
blood glucose in the terminal phase of life 
in people with diabetes in the hospital 
setting.
It is hoped that this research will provide 
insight into service and development 
needs and the generation of clinical 
guidelines.
This study also forms part of an 
assessment in an academic program of 
study at Surrey University.
Do I have to take part?
No, it is up to you to decide whether or not 
to take part. It is entirely voluntary.
Why have I been chosen?
Because you are an experienced 
healthcare professional and your views 
are of interest.
What will happen to me if I take 
part?
This research seeks only your views.
No questions will be directed to you 
individually, but instead will be posed to 
the group. You may choose to respond or 
not respond at any point during the 
discussion.
The focus group discussion will occur 
during working hours and conducted in a 
seminar room in the Trust. The group 
interview will last for one hour and will be 
audio-taped for transcribing purposes. All 
written reports will be presented in an 
anonymised manner.
The confidentiality of your responses is 
guaranteed by the researchers and will be 
expected practice from you and the other 
group participants as part of the code of 
professional ethics.
What are you asking me to do?
You are invited to participate in a group 
discussion (focus group) with other 
colleagues from a range of professional 
disciplines who work in the hospital. There 
are three focus groups planned:
• Palliative care specialty
• Diabetes care speciality
• General ward speciality.
If you decide to participate in the study you 
will be asked to discuss your perception 
and practices around end-of-life care in 
patients with diabetes or steroid-induced 
hyperglycaemia.
09/Hl 109/93 Participant Information Sheet Version I./ 10.11.09 (see over)
Participant Information Sheet
A clinical vignette (patient situation) may 
be used to focus a group discussion about 
the issues that may influence your 
approach to diabetes management at the 
end-of-life.
You will be required to sign a consent form 
and complete a very brief questionnaire 
outlining years of experience and 
professional background. The 
questionnaire will be used to describe the 
professional characteristics of the focus 
group.
What are the possible benefits of 
taking part?
In taking part you contribute to accurate 
documentation of the issues as they occur 
in clinical practice and these may inform 
the development of clinical guidelines.
What are the possible 
disadvantages of taking part?
Discussion relating to a particularly 
problematic experience may cause undue 
distress. In this instance I would 
recommend that you contact the 
Occupational Health Department on ext. 
2404 or 2626.
If evidence of any practice of a criminal 
nature is disclosed, I will be obliged to 
refer the incident to the Trust’s HR 
Department.
What happens when the research 
study stops?
The research will involve a group 
discussion. There is no further 
participation required. The anonymised 
results of the study will be written up, and 
an executive summary will be reported 
back to each participant on request.
A full report will be produced detailing all 
the study findings this report will be 
submitted for academic examination. 
Findings from the study may be published 
in relevant professional and academic 
journals. Confidentiality and anonymity is 
assured.
What if I have a concern?
Any concern about the way you have been 
dealt with during the study or any possible 
harm you might suffer can be addressed 
either directly with the researcher, or by
contacting the academic supervisor 
detailed below.
o Dr. Patricia Colliety 
o 01483-684613
Will my taking part in this study be 
kept confidential?
Yes, all the information about your 
participation in this study will be kept 
confidential by the researcher.
Comments made during the focus group 
session should be kept confidential, it is 
possible that participants may repeat 
comments outside of the group at some 
time in the future. Therefore, we 
encourage you to be as honest and open 
as you can, but remain aware of our limits 
in protecting confidentiality.
No comments made during the group 
interviews (formal or opportunistic) will be 
attributable to any individual. All 
procedures for handling, processing, 
storage and destruction of your data will 
comply with the Data Protection Act 1998.
What will happen if I don’t want to 
carry on with the study?
You are free to withdraw from the study 
without prejudice. You are kindly 
requested to ensure you are able to 
commit for the whole hour if you decide to 
participate.
Who is organising and funding the 
research?
The research is self-funded and forms part 
of an academic qualification.
Who has reviewed the study?
This study has been favourably reviewed 
for conduct in the NHS by the Surrey 
Research Ethics Committee, Surrey 
University Ethics Committee, and the 
Acute Trust Research & Development 
Committee.
Thank you for taking the time to read 
this information
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R E S E A R C H  C O N S E N T  F O R M
Title of Project:
Is blood glucose management an important component of end-of-life care in patients 
with diabetes? Factors influencing clinical management in the acute care setting
Researcher: Debbie Hindson
REC. Reference No: 09/H1109/93 
R&D Reference No: 2009DH01
Contact details of researcher 
Pager 8230 Voicemail 2488
Please Initial 
Box
1. 1 confirm that 1 have read and understand the information sheet 
dated November 2009 (version 1.0) for the above study.
2. 1 have had the opportunity to consider the information and to ask 
questions, and have had these answered satisfactorily.
3. 1 understand that my participation is voluntary and that 1 am free to 
withdraw at any time without giving any reason, without my legal rights 
being affected.
4. 1 agree to the interview focus group consultation being audio recorded
5. 1 agree to maintain the confidentiality of comments and views 
expressed in the focus group as part of my professional ethical code of 
conduct.
6. If the research study is published, 1 consent to the anonymised use of 
direct quotes.
7. 1 agree to take part in the above study.
Name of Health Professional Date Signature
Researcher Date Signature 
Debbie Hindson
When completed, 1 for health professional: 1 for researcher file;
Many thanks for volunteering to participate in this focus group, your contribution is
highly valued.
09/H 1109/93 Consent Form Version 1 10.11.09
U N IV E R S IT Y  O F
. . SURREY
Please complete the following short questionnaire:
This data is used to summarise the characteristics of the focus group
Participant Experience Questionnaire
1. Gender: Male □ Female □
2. Ward /Subject Specialty___________________
3. Occupation:
□ Ward Pharmacist □ Dietician
□ Ward Manager □ Consultant
□ Deputy Ward Manager □ Registrar
□ Senior Staff Nurse □ SHO
□ Staff Nurse □ Foundation Year 2
□ Specialist/Consultant Nurse □ Foundation Year 1
4. Year first registered to practice.....................................
5. Years in current specialty...............................................
6. Years experience in providing I advising end-of-life care............
7. Have you received formal education in any of the following specialties in the last 3 years? 
(please tick as appropriate)
□ Diabetes
□ Palliative care
□ End-of-life care
□ Oncology
Thank you very much
09/Hl 109/93 Participant Experience Questionnaire version 1 10.11.09
Ashford and St. Peter's HospitalsU N IV E R S IT Y  O F
N H S  T r u s t
Questions and prompts
1. What would you define as a 'comfortable' death ?
a. Explore the concept of finger stick pain
b. Explore the concept of injecting insulin
2. When someone has deteriorated into the terminal phase at the end-of-life what 
influences your decision to stop or continue blood glucose monitoring
a. Blood glucose level -
b. In your view does blood glucose contribute to symptom burden ?
c. Hypoglycaemia risk -  is this more or less important than high
d. Should monitoring be reviewed -  criteria for review
e. Do you consider there are issues specific to corticosteroid 
induced diabetes that are different from pre-existing diabetes
3. What do you think the issues are for the patient and their family in terms of 
stopping monitoring and treatment for blood glucose ?
4. To what extent does the LCP influence management of blood glucose and diabetes 
treatment? Does it need to address diabetes specifically ?
5. What information or support regarding aspects of diabetes management at the end 
of life would be helpful to have available ?
09/H1109/93 Focus Group Topic Guide Version 110.11.09
When patient has been admitted to the acute care setting either in a deteriorated state or 
whose state has deteriorated during the course of their admission either from a long term 
condition or cancer related illness and their prognosis is estimated to measureable in days 
from ANY cause ...............
Researdigueste
1) i s M m lg iu m s m j i im a g e m m L m J m
2 ) Factors influencing clinical management in the acute care 
setting.
Objective is to
a. Discuss the decision to  continue/stop blood glucose monitoring and 
withdrawal of diabetes treatments.
b. Explore the contextual issues to this decision within the acute care 
setting.
c. Perception of end-of-life care endpoints and where priorities of 
managing diabetes is situated within palliative care framework.
Prompts only - not an exhaustive list
What is your experience and views on objective (a)?
What would be the consequences of not measuring ?
Have things ever turned out different than you expected ? have you been surprised by 
anything ?
Would the decision be altered if the patients were on steroids ? -  are there any caveats on 
this ?
Would the decision be altered if TPN /feeds running up until this point?
Context = Cachexia and hypoglycaemia ?
What is your view on ideal care for patients with diabetes?
What sort of symptoms would you consider important enough to manage at end-of-life 
related to diabetes
What would be your glucose /  treatment parameters in the diabetic patient who is dying
How would you interpret section on LCP for people with diabetes - would you modify or 
quantify it
1 I P a g e
Research question
Is blood glucose management an important component of end-of-life care In patients with 
diabetes?
Factors influencing clinical management in the acute care setting.
End-of-life - prognosis is thought to be days and comfort measures are treatment objectives
Objective is to
1. Discuss as a group whether or not we should continue/stop blood glucose monitoring and
withdrawal of diabetes treatments.
2. Explore the contextual issues to this decision within the acute care setting.
3. Perception of end-of-life care endpoints and where priorities of managing diabetes is
situated within palliative care framework -  holistic - comfort measures focus on 
'réversibles' for symptom management=
Prompts
Does blood glucose monitoring and diabetes treatment matter when there are days to live 
What factors are important ?
What difference would it make if we stopped all diabetes treatment ?
What difference would it make if we didn't stop monitoring /  diabetes treatment 
Who should make the decision and when ?
What are the issues for patients or their family for stopping blood glucose monitoring ?
How are these decisions normally made ?
What do patients typically think or say about it -  are they asked ?
What symptoms are important?
How does LCP influence decisions ?
Have you ever been surprised by anything when patients have a short prognosis ?
Version 2 used with group 2 3 4
2 I p a g e 
Prompts
Issues that may /  not impact on clinical decision to stop or continue
Patient specific / Ethical /  fam ily  /hosp ita l se tting /  ward issues /reso u rce /you r know ledge / sources 
o f support /concern  about pain from  finger s tick / concern o r competence w ith  use o f insu lin / biood 
glucose levels th a t you consider o f significance -  low  o r high /L iverpoo l care pathw ay started /  
stero id therapy
Vignettes to prompt discussion -  factors influencing decisions -  similar or different in importance? 
does context matter at the last few days ?
1. 45 year o ld type 1 patien t h is tory o f d iabetes fo r  35 years w ho has excellent con tro l pre­
hospital has de te rio ra ted  unexpectedly and rapid ly and is no longer com peten t to  make 
decisions, eating only spoonfuls period ica lly b iood glucose levels 12-15 m m o i/l
2. 92 year old diet controlled w ith  persistent hypoglycaemia secondary to  cachexia (42 kgs) -  
b lood glucose is less than  2.6 mmols on no diabetes therapy, weak and confused /to le ra ting  
sips
3. 65 year o ld type 2 diabetes on dexamethasone 8 mgs fo r  last 3 m onths w ith  blood glucose 
at 12 mmols on 6 hourly Actrapid insulin managing sips o f fo rtis ips fo r  last week
4. 72 year old w ith  type 2 on NG feeds type 2 w ith  biood glucose a t 15m m ols
5. 55 year old type 2 w ith  diabetes eating and drinking small am ounts biood glucose norm al, 
measures own biood glucose religiously norm ally and is now  on Liverpool care pathw ay
6. Your own v ignettes o r contexts th a t influence your approach
Version 2 used with group 2 3 4
amendment point 3c Deborah Hindson H112222 Post viva (9/2/2012) amendments
Respondent Narrative Focus /  issues Themes
Mod.FG2: When someone has deteriorated and the terminal phase 
looks apparent,and you think that this person has only got 
48 or 72 hours to live if that, what influences you to stop or 
continue monitoring?
R2.NM1.FG2 Whether they are conscious, unconscious, semi-conscious, 
that sort of thing.
conscious level clinical context
professional
responsibility
Mod.FG2: Anything else from anybody, about that?
R2.NM1.FG2 How 1 feel about it is; I'm quite keen that diabetic 
management continues right the way through; and the 
reason 1 say that is because, 1 think that diabetes not 
managed properly can make them feel so lousy, and what 
you are trying to do is improve their quality as long as you 
possibly can. (aside -1  am prepared to be shot down in 
flames)
continue observations 
to improve their quality 
of life
clinical context -
professional
responsibility
R5.NM3.FG2 Even if they are on the Liverpool Care Pathway, you come 
to that point where the policies in the hospital are not in 
agreement, 1 am not in disagreement with you, but once 
you place the patient on the Liverpool Care Pathway the 
rules a re ....
consistency of use of 
LCP, rules for practice
organisational 
context - attitude to 
palliative care - 
specialist knowledge
R2.NM1.FG2 Yeah, 1 think at the moment it is.
R2.NM1.FG2 That is the understanding that everything stops the 
minute they go onto the Liverpool Care Pathway, all 
monitoring stops, all everything stops, 1 don't know that 
that is necessarily right, and 1 think that there is maybe a 
call to look at the Liverpool Care Pathway and say 'Yes you 
are prepared to stop all of those' but are you actually 
making things worse, are you making the patient feel lousy, 
1 don't know.
LCP key influence 
ambiguous - practice 
dilemmas and 'knowing'
Organisational 
context, acute care 
culture, specialist 
knowledge
R4.DR4.FG2 But if that was the case, you are continuing diabetes 
treatment the IV fluids, IV Insulin and hourly blood sugar 
monitoring.
invasive treatment via iv 
and CBG
clinical context - 
imminently dying 
ethics
R5.NM2.FG2 Yes, that's an issue, yes
R4.DR4.FG2 Now is that fair, that the patient is dying. ethics clinical context 
ethics of care
R2.NM1.FG2 That is what 1 am vacillating about, 1 absolutely take on 
board what you are saying because, to stab somebody 
every hour, is not necessarily kind, but is it kind to let them 
die with the symptoms of diabetes ?, 1 don't know. Also, 
how do we know what it is that is actually precipitating 
their death? is it the diabetes not being managed properly? 
or is it their underlying condition?
pin pricks are a source 
of discomfort, dilemmas 
in practice, ethics and 
'not knowing'
clinical context - 
imminently dying 
ethics of care - 
complexity of 
accountability
R5.NM2.FG2 Yes, you have usually addressed all the issues and you 
know the person is dying.
known context clinical context - 
clarity of'dying' 
diagnosis
R4.DR4.FG2 Yes, At that point there is a irreversible process going on so 
you have to accept that.
accepting dying 
irreversible
clinical context - 
ethics of care
R4.DR4.FG2 So do you think it is irreversible... to monitor ?, 1 don't 
think that is fair on the patient as 1 understand with high 
sugars you feel uncomfortable, but in a dying patient, we 
do not know, we know for the palliative care research, 
they've shown that patients who are dying are not thirsty.
not knowing and limited 
research data - 
principled reasoning 
versus personalised
clinical context - 
professional 
responsibility, 
professional led 
decision
amendment point 3c Deborah Hindson H112222 Post viva (9/2/2012) amendments
R2.NM1.FG2 1 take on board that again, and you are absolutely right but 
we don't know a nd 1 think that is the issue that 1 am slightly 
uncomfortable with.
not knowing clinical context - 
professional 
accountability 
implied
R4.DR4.FG2 1 don't think we will ever know. not knowing clinical context
Mod.FG2: What are you meaning about irreversible, are you talking 
about things that are reversible of things about at the end 
of life are reversible, and of things that aren't, so what is 
not reversible?
R4.DR4.FG2 1 think if they are on the Liverpool Care Pathway they have 
an irreversible condition that's why we are going with the 
Liverpool Care Pathway.
clinical condition clinical context, 
professional-led 
decision
R5.NM3.FG2 That the end end o f clinical context
R5.NM2.FG2 That's it
Mod.FG2: It would be good to explore that end bit there really 
because that is really of interest. It's about comfort 
measures at the end there isn't it?
R1.DR3.FG2: Do you have to be so dogmatic and propatic, saying 'Yes 
we want this' or 'No we don't do that' can't you treat each 
person as individual....
individualised approach clinical context - 
professional led 
approach
R5.NM2.FG2 Yes as an individual
R1.DR3.FG2: and say 'Yes you're on the Liverpool Care Pathway, but in 
your case it is appropriate that we do carry on and manage 
your diabetes and get more involved in that and other 
people say.......
professionai led care clinical context - 
professional led 
approach
Lots of chat yeah
R5.NM2.FG2 what about the family yes we have done that 
yes
R5.NM3.FG2 1 think there is Type 1 diabetic there will be an issue with 
not giving Insulin because 1 don't think anyone will not give 
Insulin, because of the risk of going into DKA as well as 
their condition deteriorating, so 1 think that is going to be 
an issue and difficult, 1 think, 1 know for me, difficult but in 
my experience I've left people on IV Insulin, because they 
are Type 1 diabetic
type 1 is important -DKA 
risk, complexity, 
professional 
responsibility
clinical context - 
type 1 diabetes 
important
R1.DR3.FG2: yep
R5.NM2.FG2 That's what 1 would say.
R4.DR4.FG2 But my fear to put someone on IV Insulin you need to 
monitor blood sugars and they're in this comatose state, 
we haven't been there, and we are waking them up and 
that bit is hard to deal with.
disturbing the dying- 
ethics
clinical context - 
unconscious state - 
not knowing-ethical 
dilemma
R1.DR3.FG2: Sure
R5.NM2.FG2 Yes 1 agree with that
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Introduction
This paper summarises the research journey experience and the governance issues 
that were undertaken during the research project. The conceptualisation of the 
research to its fulfilment and the governance issues are addressed. The common 
thread to all the doctoral assessed work concerns some element for the management 
of care pathways and working with the multi-disciplinary team. The idea for this 
research project emerged from a clinical incident and a request to present diabetes 
management at the end-of-life at the palliative care journal club. The multi­
disciplinary palliative care team, including, consultants, specialist nurses from 
community and hospital, therapists, pharmacist, dietician, chaplain and the team 
secretary, attended the journal club. The work of Ford-Dunn et al. (2006) was 
presented and some questions for discussion were posed (see appendix 1). The 
following questions were.
1. How representative were the scenarios to base guideline development?
2. Do you agree with the guidelines?
The outcome of the discussion was that this was a complex area and efforts were 
made to accommodate patient wishes. There was a need to do more work for the 
hospital setting as the team had little insight to its management. Initially I had 
planned to do work for the thesis on the stroke care pathway to analyse care delivery 
in the acute brain unit for patients with diabetes. The review of the literature had 
been started and three months work accomplished, however, no links had been 
established with the stoke team as work was exploratory for research gap analysis. 
The enthusiasm from the palliative care team, who made it known they had a patient 
database which could be accessed for audit and were willing to support the research 
was worth considering. Based on complexity theory, which was tested in my service
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development project, establishing connections was pivotal to the success of 
innovation and project work. Having thought about it, and searched the literature, I 
approached the team and discussed my early ideas for the research, which were 
based on doing a medical notes audit and focus group approach. The team agreed 
this was a useful start to establishing practice. It was then established those who 
wished to be part of the focus group, and a consultant physician who was interested 
in ethics and audit agreed not to be in the focus group, but to act as a mentor for the 
retrospective medical notes review.
The ethical principles were outlined in detail in the thesis and all the ethical 
governance procedures are shown in the research governance log. This log attached 
in the appendices below includes all the research skills development and processes 
including supervision, for research governance.
The Research Question
At the start of the project, I felt this was an important question at many levels:
1) From the micro level of the CBG^ itself, (natural history in dying phase to know 
if stopping monitoring may be contributory to symptoms potentially).
2) From the meso level of the patient (was their personal perspective 
considered? Were patients expecting to die? what was their level of 
deterioration on admission?, were in fact these patients inappropriately 
coming to hospital as the end-of-life strategy (DH, 2008) suggests, in a 
position to advocate for their own of place of death?, were they sufficiently 
experienced with diabetes to perceive the origins of their symptoms, or know 
about their diabetes what was their potential for self advocacy?).
Capillary Blood Glucose
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2a) the meso level of the hospital environment (factors affecting the management 
at the end-of-life; the role of hospitals in caring for the dying).
3) From the macro level of adherence to palliative care principles and NHS end- 
of-life strategy. The need to keep focussed and tethered to research question 
in exploratory research was important. The potential to be drawn into 
principles of end-of-life care at a general level was always there. The work of 
Quinn et al (2006) was sufficiently detailed to cast doubt I would find unique 
data. As the research progressed and the uniqueness of the data became 
more apparent, confidence in the question was assured.
Targeting the Research Question through Methods Choice
This research question should ideally be approached through prospective 
methodology to incorporate all stakeholders’ views; and a mini-ethnographic 
approach would have been ideal. However, this would be time intensive as a lone 
researcher and practitioner whose hospital workload is unpredictable and time- 
pressured as bed capacity is an ongoing priority. This fact would compromise patient 
care and therefore a pragmatic approach through evaluation research was taken to 
‘map’ the care processes and attitudes. Evaluation research data may influence or 
contribute to the shaping of the LCP  ^documentation as it applies to acute care where 
the subtleties of the pathway may be spelled out more clearly; and where audit data 
would capture this collectively to inform further research.
The research design was a mixed method approach that examined what was done in 
practice and what the perceptions of the multi-disciplinary teams in diabetes, 
palliative care and the general ward settings. The focus groups needed to be 
separated as Quinn et al (2006) did not distinguish the individual specialists focus on
 ^Liverpool Care Pathway
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diabetes, but summarised them collectively. This was done separately and 
collectively. The fourth (integrated) focus group was more comfortable discussing the 
issues. Perhaps they had reflected and discussed the content from the initial focus 
groups with colleagues, or thought about the issue in the interim. The new focus 
group members were also challenging and energised. Unexpected data was 
collected and contributed important information as well as validated earlier focus 
group data.
The theoretical framework was informed by the palliative care philosophy and focus 
group work and objectives of care. The end-of-life strategy (DH, 2008) is influenced 
by this philosophy and the LCP has been seen as a vehicle for importing palliative 
care principles to the hospital setting.
The retrospective medical notes review was influenced by my own experience on 
managing patients with diabetes in the hospital setting, and the objectives of care as 
stated in the National Service Framework for diabetes (DH, 2001). This informed the 
fact that the majority of patients and their families are able to provide a diabetes and 
glycaemic history. My work in primary care and membership to local implementation 
teams for the national service frameworks informed me reliably about the self 
management education programmes and work within practices for developing 
diabetes self advocacy. However, the knowledge held by patients with type 2 
diabetes was not always reliable, most are aware of the complications, and most are 
able to report their symptoms.
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Data Management and Analysis
On reflection, while this method was valid, and produced an amazing amount of rich 
data, it was extraordinarily time consuming. The generation of the abstraction form 
was iterative and took the best part of a year to accomplish and validate through two 
pilot projects. Ensuring the operational definitions were measured consistently was 
helped by using SPSS directly. It was disheartening when the ethics committee 
demanded more to be on the form, as the validity of this extra work was not fully 
appreciated by the statistician or me. None-the-less it was collected. Over 200 hours 
of work was spent on abstracting the data over weekends and evenings.
The decision to collect all the CBG data was key to understanding the natural 
progression of CBG. A third of patients did not have monitoring to the end-of-life and 
it was important to look at both groups of monitored and unmonitored contexts, and to 
review the timing of drug withdrawal and when patients no longer wanted to eat, and 
review it against the CBG result. The reliance on the statistician time (30 hours) was 
due to dated and timed material within the four databases. The time it took to write 
the programme in SPSS and run it at meetings with the statistician soon mounted up. 
The decision to analyse the hypoglycaemia data at 4.0mmols or 3.5mmols where it 
would be more likely to be symptom inducing was discussed at lengths. The view of 
Dr. Gonder-Frederick, who is a world-renowned expert in hypoglycaemia research, 
was kindly provided on request for her opinion, (see 17 Jan 2011 in research 
governance log).
The support of the co-facilitators and the focus groups members to cite what they 
thought were the themes enabled the voices of the data contributors to be heard. 
The use of the NVIVO software was particularly helpful, however I still needed to use 
excel to ‘see’ the data in its wholeness. There was a degree of difficulty when
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searching by professional group to analyse different perspective to model. Much of 
the analyses were through data immersion, reflection, and iterative work.
The issue of subjectivity raised in the ethical opinion letter was reflected on 
particularly closely and continuously throughout all stages of the research from the 
point of ethical review. The conclusion drawn is that subjectivity has been part of the 
analysis and has been influenced by years of experience which has been processed 
through substantial reading of others work. Further, the views of other experts have 
been consulted and has informed and shaped the whole process, including those 
subjective views of all three ethics groups who gave a favourable opinion. The 
guidance of supervisors, and expertise within the faculty of health and medical 
science, the librarian, the clinicians, the attention to end-of-life care that formed part 
of my own professional role to patients, relatives, staff members and the observers in 
attendance at the focus group have all been influential to the final piece of work.
My conclusion is that the subjectivity of this work can be characterised as an 
informed opinion. This opinion has evolved over two years of continual engagement 
with the data. In daily life, the amount of attention we give to the discourse of others 
in its entirety and completeness of meaning is minimal. In this research, the 
engagement has been substantial. Subjectivity will also be challenged by the 
‘communities of practice’ in the literature, who will critique the work and publish their 
views. This is the nature of research; it cannot be separated from the researcher, for 
the researcher is not an empty vessel, or untouched by the world around them.
Conclusion for the Whole Research Project Process
The ability to write a thesis on such a seemingly small aspect of care is not only 
surprising, but is a testament to the complexity within clinical practice. There exists 
within this research question, profound physiological and ethical reasons why this 
small aspect of practice is important. The data suggests that most practitioners are
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doing what they feel is right, and may be limited in the availability of clinical and 
evidence-based guidelines, time, knowledge, the limitations to what can be known in 
the dying patient to inform the ‘right’ approach, and the hierarchical and 
organisational barriers that help and hinder individualised care.
In conclusion, this work has been a major quest that took a great deal of energy, 
discipline, self-belief and hard work. I hope it will benefit patients and colleagues in 
the long term. At the end of the process, I believe I have done justice to the topic, 
mined the question for all it's worth and to a consistent and high standard.
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This paper provides an overview of how the taught elements of the doctorate in 
clinical practice programme have contributed to the integration of research and 
knowledge into clinical practice. The taught elements of the course were accessed 
through Kings College London (KCL). Following a process of accreditation, the 
research thesis was accomplished within the University of Surrey. This paper will 
reflect the work completed at KCL to the module structure within the University of 
Surrey.
My clinical practice role at the start of this journey was as a long terms conditions 
lead in the primary care setting and was reflected in the taught component elements. 
My current role as a Lead Diabetes Specialist Nurse within the acute care setting was 
reflected in the thesis. The doctoral level studies were undertaken to both 
consolidate and advance my professional and research expertise and support clinical 
leadership roles for service development and education. Undertaking the projects 
within my employing organisation has enabled the credibility and value of the 
professional doctorate to be recognised within the practice setting rather than be 
considered purely as an academic research activity that is traditionally associated 
within a university faculty.
The taught elements of the course have enabled personal development and networks 
with other scholars. The testing of ideas and discussions within seminar groups has 
contributed to a wider understanding of the health service practice and service 
development issues of others. This has enhanced the knowledge and perspective of 
my own practice development.
1. Introduction to Doctoral Studies
This important module enabled me to reflect on my own abilities and motivations for 
undertaking this level of study. This multi-disciplinary module was attended by 
students from other departments in the university, primarily the school of dentistry
229
and education. This enabled a greater appreciation for the ‘blue print’ policy and it's 
wider application across the public sector strategy, and insights for the common and 
unique issues for implementing policy and research into practice development.
2. Communities of Practice
This module for me, on reflection was a keystone for the entire doctorate, for it 
explored the sociological perspectives of professional knowledge, epistemologies and 
ontology that underpins and legitimises the ‘value’ of knowledge within different 
disciplines. Having grasped this fact, a deeper understanding of the ‘connectedness’ 
of the modules for advanced research methods, professional ethics, policy, politics 
and power, organisational development and leadership issues was gained. The 
perspectives of nursing as a profession and the issues that interface with inter­
professional working for service development have been important to my own 
practice as a nurse and manager, and my scholarly development.
The integration of knowledge from the taught component into the practice setting has 
been an iterative process of exploring a range of change and management theory 
and then applying it to understand and direct service developments. The taught 
component had elements of theory assignments, followed by applied assignments. 
For communities of practice the art and science of professional knowledge was 
analysed in detail, where the work of Emuf (1997) was influential in developing my 
knowledge to a higher level where its application could be seen from a wider strategic 
viewpoint in education and practice. The application was conducted through the 
completion of a one-year organisational service development project, and a specialist 
practice portfolio in health care. Both these works were related to the development of 
care pathways for chronic disease management in primary care.
 ^Eraut, M. (1997) Developing Professional Knowledge and Competence, London, Palmer Press
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My clinical role has been primarily managing the inter-professional and managerial 
perspectives supporting the development of several care pathways. These were a 
post myocardial infarction care pathway developed from the coronary care unit back 
to primary care and through to the cardiac rehabilitation phase; and respiratory care 
pathway to prevent unnecessary admissions to hospital. The understanding of 
different communities of practice and their perspectives was integral to managing the 
change and education processes sensitively. For example, when process mapping 
for the pathway development, many general practitioners (GP’s) were not aware of 
what the district nurse role were in the post myocardial infarction patient. The 
surprise and implications of this role were variable between different GP’s. The 
support role had been in place for over 5 years and it was surprising that it was 
unknown. An important learning was the appreciation for the different knowledge’s 
from within the team were these ‘communities’ were integrated to ensure smooth 
transitions of care.
The development of CHD pathway was instrumental in gaining a secondment with 
Commission of Health Improvement to review local implementation progress of the 
National Service Framework for Coronary Heart Disease.
The learning from developing this pathway enabled the relevance of complexity 
science to be realised in the taught component and tested in the organisational 
development project. This was a one-year project, where the role of macro level and 
micro level perceptions of practice innovation were mapped and evaluated in the 
development of the pathway. The complexity approach for developing the respiratory 
care pathway through self-organisation was limited by the bureaucratic mindset of 
some managers who had difficulty in surrendering their own power in exchange for 
collaborative working. Key learning arising from managing practice innovation 
through the lens of complexity science was my own blindness to this bureaucratic
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model that was situated within myself. I slowly realised that my own values had been 
influenced through this socialisation process within the healthcare system and was a 
powerful insight into my own development processes. It was also a liberating 
process where I realised the extent and limitations of my own power. From this 
experience I am now more able to appreciate the ‘art of the possible’, and able to re- 
contextualise ‘failure’ to system issues rather than to personalise or take complete 
ownership of ‘blame’. I feel more able to predict and manage the potential for 
projects success and failures from experimenting with different models of thinking 
inherent in mixed communities of practice.
3. Advanced Research Methods
The research training received was reflected on through several assignments that 
critically analysed quantitative and qualitative research. The strengths of 
weaknesses of both paradigms were critically reviewed. The key learning was that 
searching for answers in practice required the right tools, and refinement of the 
research question. Opportunities to gain skills in theming with peers were particularly 
useful as a class exercise. The realisation of validity and reliability and perceptions of 
data meaning and interpretation was an important learning point. Two assignments 
were completed around proposal development for quantitative research and 
qualitative research.
An opportunity to participate in a research steering group to submit a research 
proposal for funding to explore the ‘expert patient’ role in diabetes self-management 
was influential in developing knowledge and skills in evaluation research 
methodology. This experience as practitioner and research student facilitated the 
knowledge and importance of the integration of policy research and practice 
outcomes. The theory of evaluation research as a perspective for policy and practice 
evaluation was influential developing the research design to explore the end-of-life
232
management of patients with diabetes in the hospital setting. I have been successful 
in writing funding bids for specialist nurse support in primary care from the British 
Heart Foundation and the British Lung Foundation.
(4) Policy Politics and Power (5). Leadership in Health Care 
Organisations (6) Service Development
Within all my roles in the doctoral programme, I have actively undertaken a 
leadership role through using transformational change and to a lesser extent, 
transactional change management. The health policies that I have been directly 
involved in implementing in practice are the National Service Framework (NSF) for 
diabetes and Coronary Heart Disease (CHD), and to a lesser extent, the Expert 
Patient Programme.
Reflective writing on change management processes allowed deeper learning and 
evaluation of different strategies for change management. The organisational 
development in the public sector project reviewed and evaluated several change 
process tools. Through this process, the difficulties of evaluating change were found 
as emergent and planned outcomes that were difficult to attribute to cause and effect. 
This was partly because of the perception of speed of change, and the sense of 
incompletion of one set of policy, which was shortly followed by another. The political 
nature of healthcare has strengths and weaknesses that enable service development 
on the one hand, and undo it on the other. This has influenced the motivation of 
practitioners to take on service development. There is much reticence from the more 
experienced practitioners for change as what has been learned in practice, is that all 
will change again.
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The ‘speed of change’ was considered in the organisational development (service 
development) project where the work of Stensaker ®et al (2002) was influential. 
These authors argue that planned and emergent change arises from a perceptual 
mismatch between macro and micro levels within and between organisations. 
Excess change was found to be perceived differently between macro, middle and 
micro levels of the organisation. This is because top managers were working in 
different time zones (future) where they had time to grasp and accommodate the 
plan, and as it devolves through the organisation, top management are then onto the 
next project. The application of this theory to practice through a complexity lens was 
energy and time intensive. It encompasses a bottom-up approach, which is idealised 
in theory, and in my experience valued by practitioners. However, it also requires 
‘top down’ support. The ‘top’ and ‘bottom’ were found to be interdependent and 
essential for successful change management and innovation programmes. The key 
learning from this work was the limitations imposed by the ‘Russian doll’ effect arising 
from the multi-macro levels (for example, government level. Chief executive. 
Directors, senior multi disciplinary teams) that are devolving policies, practices and 
expectations themselves. The net result is complexity. Complexity theory argues that 
order cannot be credited to a single person but emerges from the properties of the 
system, from the people within it and their capacity and willingness to connect to 
other systems and co-evolve with each other in a dynamic way.
This state of complexity in the system is recognised by most practitioners, but the 
value of complexity science insights are less well known explicitly. The learning I 
accomplished in ‘communities of practice’ on craft knowledge, which emerges from 
experience and personal knowledge development. The uniqueness in the way 
knowledge’s are integrated with academic theories to practice by practitioners is
 ^Stensaker e t al (2002) Excessive change, coping mechanisms and consequences. Organizational Dynamics 31 (3) 
296-312
234
important to knowledge development. The integration of research methods to make 
‘public’ this knowledge for practice development was influential in the research 
project. The utilisation of evaluation research and the implementation of mixed 
methods has required and tested all my knowledge and experience to know what 
needs to be known. To be able to be self-directed, to know where to look for the 
knowledge and skills, to assimilate and reflect on the taught components outcomes of 
learning and then consolidated within the research process. The starting point for 
leading and managing change through research and practice should be from paying 
attention to what is really there rather than what ought to be there, less time should 
be spent on trying to find out what we are supposed to do and more time on creating 
meaning through dialogue, interpretation observation and reflecting on experience.
The end-of-life care for patients with diabetes for the research project has now been 
incorporated into the ‘essentials of palliative care’ course, which is run within the 
trust. The referrals for end-of-life advice have increased from the ward based nurses 
and an invitation to present at ‘grand rounds’ for practice development has been 
received.
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Thesis Part 2 
Introduction
The academic papers in this section were completed at Kings College London. The 
application for accreditation against the Doctorate in Clinical Practice at Level D was 
approved and confirmed in writing letter by the examination department, Faculty of 
Health & Medical Sciences at the University of Surrey on 10^  ^September 2008.
During the years of study at Kings College London, I was employed as a project 
manager / clinical lead for enabling leadership for whole systems transformational 
change for long term conditions within and between primary and secondary care 
services. Academic work submitted reflected these work stream objectives and these 
are presented in Part 2. The published research paper reflects the work completed 
for Part 1.
The research thesis was based on my role as a senior specialist diabetes nurse in 
secondary care, and therefore there is no linear research continuity between 
academic work in part 1 and part 2 as a consequence of employment changes. The 
core themes that link the academic work streams in part 1 and part 2 are related to 
organisational development processes (exploratory research), diabetes and the 
expert patient and policy evaluation research methodology, and leadership for 
specialist practice that inform the knowledge and development and critical analysis 
of clinical pathways and transformational change processes. The Liverpool 
integrated care pathway and evaluation research methodology are clear links to Part
2.
The work submitted for Policy Review explores the Expert Patients Policy and the 
role of evaluation research in supporting the research methodology for evaluating this 
health policy. The patient group explored through a research proposal critique was for 
the evaluation of supported-self management for patients with diabetes. Reflection 
on a leadership issue explores the role of advanced practice and dissemination of 
relevant knowledge and skills across primary, secondary and tertiary care to embed 
quality care for post myocardial infarction patients. The Service Evaluation Critique 
presents a critical reflection for organisational development and the effectiveness of 
change management tools and techniques.
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Policy Review
An Evaluation of the Expert Patient Approach in Diabetes Self-Management 
Education Programme within a Primary Care Trust
Module: Selecting Research Methods
This assignment will explore various research methods to evaluate the effectiveness 
of a predominantly lay-led expert patient diabetes self-management education 
programme within a primary care trust using an evaluation research approach. The 
idea to explore this research area arose from being on a steering group to bid for 
research funding from the ‘Diabetes UK’ charity to implement the ‘Expert Patient’ 
initiative (Department of Health, 2001) at Surrey University. The research question 
has been modified and the author has been self-directed in this assignment.
To provide a context and background to the research, a brief review of the literature 
on the issues of diabetes, supported self-management education programmes and 
the expert patient initiative is covered. Quantitative and qualitative methods will be 
explored and their relevance evaluated to explore their appropriateness within the 
evaluation research framework.
Background literature
A review of the literature indicates that the prevalence of diabetes is increasing 
globally with many considering it as an epidemic (King, Albert & Herman, 1999). 
Diabetes is an angiopathic disease, that is, it is extremely toxic to blood vessels and 
is contributory to micro vascular complications (small vessel disease) to eyes 
(retinopathy) nerves (neuropathy) and kidneys (nephropathy), leading to blindness, 
neuropathies and renal failure; and macro vascular (large vessel disease) 
complications such as cerebrovascular, cardiovascular and peripheral vascular 
disease. There is compelling evidence, based on the Diabetes Control and 
Complications Trial (DCCT) (1993) and the United Kingdom Prospective Diabetes 
Study (UKPDS, 1998) that tight control of glucose levels can significantly reduce the 
risk of complications, particularly from microvascular disease. Given the increasing 
burden of diabetes, and the potential costs to the health system, strategies aimed at 
promoting diabetes self-management education are essential to enable effective 
control thus optimising positive health and social outcomes (Norris, Engelgau & 
Narayan, 2001).
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There is an abundance of literature indicating that effective diabetes self­
management significantly improves health outcomes. A systematic review of the 
randomised controlled trials on the effectiveness of diabetes self-management in type 
2 diabetes revealed that in the short term, self-management could positively impact 
on glycaemic control and dietary management (Norris, Engelgau & Narayan, 2001). 
They also reported that interactive educational sessions were more likely to produce 
positive self-management outcomes compared with didactic methods. A meta­
analysis by (Brown, 1999) concluded that interventions that combined both education 
and behavioural strategies produced better outcomes than either strategy alone. 
This was particularly successful in small groups compared with larger groups. 
Finally, Eakin et al. (2002) reviewed the literature on the outcomes of diabetes self­
management education interventions aimed at difficult-to-reach and under-serviced 
people to evaluate the overall public health impact. Using the ‘RE-AIM’ framework 
Glasgow & Vogt, (1999) found that studies that explicitly addressed social-contextual 
issues were more likely to be effective.
Several exploratory qualitative studies focusing on the learning needs and 
experiences of people with diabetes have reported that individuals have unique 
responses that cannot be ‘predicted by textbook cases and universal norms’, 
(Paterson & Thorne, 1999). People with diabetes have practical knowledge that is 
largely inaccessible to those without diabetes (Bonnet, Gagnayre & d’lvernois, 2001; 
Dietrich 1996; Hunt, Arar & Lanne, 2002; Paterson & Thorne, 1999).
In 2001, the Department of Health published the ‘Expert Patient’ recommendations 
reflected in the findings of the Expert Patient Task Force. The remit given was to 
design a new programme that would unite the work of clinical and patient 
organisations in developing self-management initiatives as part of a strategy for 
chronic disease management. ‘The Expert Patient’ programme emerged from this 
task force and a six year plan (2001-2006) to implement lay-led self-management 
programmes was produced. This report proposed eight recommendations that focus 
around patient empowerment, networking and integrating programmes within the 
NHS infrastructure and quality initiatives, commissioning and resource developments. 
Specifically, the key outcomes of the programme were to educate people with long 
term conditions to effectively self manage their condition to reduce its progression, 
manage symptoms; and to be actively involved in decision making with health 
professionals related to their treatment and health services development. A three-
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year period for implementation and evaluation of pilot programmes was set, with a 
view to these programmes becoming main-stream by 2007 within all NHS areas.
This assignment aims to explore an evaluation research approach that may be taken 
to investigate whether the expert patient approach educational programme to 
improve diabetes self care within a Primary Care Trust is effective.
Evaluation Research
The term ‘evaluation’ has a multitude of contexts ranging from informal subjective 
assessments to formal systematic assessments of a planned social intervention as 
undertaken by a professional evaluator. Central to any evaluation is establishing the 
merit, worth or value of whatever phenomena is being appraised. A key 
characteristic of evaluation research is that it aims to study the effectiveness of 
existing knowledge. This is used to inform and guide existing practice, and may not 
necessarily engender the creation of ‘new’ knowledge. However, the idea of 
evaluation research is not just to discover whether a programme works, but to explain 
how it works. Evaluation research is a form of applied research that aims to generate 
information about the implementation, operation and ultimate effectiveness of policies 
and programmes to inform the direction of change to improve social conditions 
(Rossi, Freeman & Lipsay,1999; Clarke, 1999).
Clarke (1999) notes that the difference between academic and evaluation research is 
that evaluation is primarily concerned with determining the merit, worth or value of an 
established policy, and in this sense is seen as a type of policy research. A key 
objective to commissioning evaluation research is to provide practical knowledge to 
aid the decision-making process regarding policy. Compared with academic 
research, the political agenda is overt. This has important implications for the 
relationship between the researcher and the researched in that the researcher may 
encounter a range of diverse viewpoints reflecting conflicting interests, thus 
compared with most other social scientists who presume an audience of peers, 
evaluators must negotiate whose questions will be addressed and whose interest will 
be served by their work (Green, 1994; p531). Therefore, careful consideration to the 
ethics in terms of whose interests are served, and use of appropriate methodology is 
especially important.
A methodology defines how one will go about studying any phenomenon (Silverman, 
2000). Research methods relate to techniques of collecting data to establish
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answers to questions posed about phenomena. Within an evaluation research 
framework there is scope for a wide range of questions and by implication, a wide 
use of research methodologies that may be used concurrently. A distinguishing 
characteristic of evaluation research is that its methods cover the breadth of 
prevailing research paradigms (Clarke, 1999). Therefore, consideration of the 
research approach must consider the nature of the question and the theoretical 
framework of the programme which may influence methodological considerations.
Evaluation research and developing the research question
The nature of the question is integral to the choice of research method and is 
important to epistemological and ontological considerations in the research approach. 
(Rossi, Freeman & Lipsay, 1999). Within the evaluation research framework, the 
questions need to be generated and developed into researchable questions by the 
evaluator. This can be achieved by using focus groups. The source of the questions 
should come from discussions with the evaluation sponsor and other key 
stakeholders and must establish the intended outcomes concretely, identify 
observable indicators, and specify what success looks like. Good evaluation 
questions identify a distinct dimension of programme performance that can be 
credibly assessed using the best available research methodology (Rossi, Freeman & 
Lipsay, 1999).
This sets the basis of consideration of the programme theory, or defining the 
hypothesis of how the programme will meet the outcomes specified by the 
stakeholders. The evaluator should construct a conceptual model or programme 
theory, (how the programme is expected to work and the relationships assumed 
between its various activities and functions and the social benefits it is intended to 
produce). This model can then be used to identify aspects of the programme most 
essential to effective performance as well as evaluation-related questions about 
whether the key assumptions and expectations are reasonable and appropriate; and 
whether the programme is enacting them in an effective manner. The importance of 
programme theory as a basis for formulating and prioritising evaluation questions, 
designing evaluation research, and interpreting evaluation findings cannot be 
underestimated (Birckmayer & Hirschon Weis, 2000). Issues of validity are reliant on 
this, since programme impact evaluation needs to be able to distinguish whether 
program theory or implementation issues have impacted on the outcome.
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Programme failure may be due to issues with implementation or with the programme 
theory, therefore data on both needs to be evaluated.
Having negotiated the research questions, the evaluator needs to address the issues 
of epistemology and ontology. Data collection can be categorised into two
ontological positions, the qualitative and quantitative paradigms. These paradigms 
will be briefly compared, and then their methodologies reviewed for their
appropriateness to this project.
Quantitative Paradigm - application to evaluation research
The quantitative paradigm has historically been the dominant paradigm and
incorporates only questions and phenomena that can be controlled, measured,
counted, and analysed by statistical methods (Malterud, 2001). Therefore, is self­
limited by the research questions that are amenable to verifiable observations 
(Singleton, Straits & Straits, 1993). Its methodological approach is the hypothetico- 
deductive approach, where causal explanation and prediction predominantly follow a 
deductive form of logic (Cohen et al. 1999). The method most associated with the 
‘scientific’ approach, is the experiment where the key characteristic is manipulation 
and control. To test hypotheses, the research deliberately introduces changes into 
the environment and measures the changes. A reason for carrying out an 
experiment is to test a hypothesis that one variable causes a change in another 
variable, therefore ‘cause and effect’ are inferred (Singleton, Straits & Straits, 1993). 
The hypotheses to be tested in this research (or programme theory) would be: 
‘increased exposure to medical knowledge of diabetes management is likely to 
promote effective self-management strategies resulting in better glycaemic 
monitoring and control’. Here a relationship and theory are made explicit (deductive) 
prior to starting the research, and the question is verifiable. The methods used may 
validate this relative to its ability to reduce bias and confounding variables.
To this end, the ideal method to evaluate this hypothesis is the randomised control 
group design since it is the strongest in determining cause and effect relationships. 
In this design, there are two groups, one who receives the treatment (expert patient - 
led education) and another, the control, (usual care group) who do not receive the 
treatment. Except for the experimental manipulation, the treatment and control are 
treated exactly alike to avoid introducing extraneous or confounding variables. The 
problem facing the evaluator is that causal effect cannot be directly observed but 
must be inferred; this can be done more confidently with randomisation. The
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assumptions supporting random assignment methods are that the confounding 
variables are evenly distributed between each group. Consequently, fair 
comparisons can be drawn between the two groups. Threats to internal validity 
issues are low in this design. A second strength of random assignment is that the 
evaluator’s confidence can be stated in statistical terms.
Although randomised experiments are of proven scientific merit, problems may 
emerge when attempting to introduce this research design into natural settings 
(Jensen, Hoagwood & Trickett, 1999). Ethical concerns may be associated with 
limiting or withholding beneficial treatment, particularly in light of current research 
findings in diabetes self-management programmes. Ethical considerations can 
undermine the commitment of programme staff to random assignment, staff may 
deviate from random assignment on basis of need, or by pacifying vocal clients 
(Rossi, Freeman & Lipsay, 1999). Even when random allocation procedures are 
successful, there is no guarantee that the comparability assumed between the groups 
will be sustained. Differing rates of attrition between the two groups may impose 
differences between the two groups. Further, randomisation may lead to potential 
inequalities between groups (Lee, 2000; Singleton, Straits & Straits, 1993). 
Individuals cannot be prevented from making comparisons between the ways they 
are treated compared with the treatment group. Randomisation may therefore be 
providing the highest levels of causal inference, but may present potentially serious 
implementation problems and are costly and time consuming to conduct (Rossi, 
Freeman & Lipsay, 1999).
Quasi-experimental designs provide an alternative to the randomised experimental 
methods where full experimental control may not be possible. An example may be 
for ethical reasons, where a treatment is known to be effective and denying patients 
the opportunity to be selected may be morally compromised; thus a quasi- 
experimental research design provides an alternative. Issues related to internal and 
external validity become more prominent in quasi-experimental designs because the 
benefits of randomisation are lost and bias is more difficult to control. However, a 
distinction can be made between weak and strong designs. In this regard, what 
distinguishes one quasi-design from another is the method of drawing comparison 
groups, such as matched control, statistical control, regression discontinuity and 
generic controls (Clarke, 1999). However, within the context of evaluation research, 
several issues with experimental designs need to be considered in addition to those 
noted in randomised experiments.
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The methodological requirements of experimental designs to maintain controlled 
conditions may be an issue. By ensuring group equivalence, the evaluator is 
focussed on discovering whether the programme is effective but loses the opportunity 
of evaluating the impact of the characteristics of the people that are subjected to it. 
As Pawson & Tilley (1997) point out, programme effectiveness is subject to variables 
linked to motivation, involvement, commitment and resources; programmes should 
not be conceived as externally imposed forces that elicit defined responses. Further, 
experimental approaches may prevent examination of factors that make the 
programme work (Pawson and Tilley, 1997). Causal explanations cannot be 
achieved by merely observing the relations between phenomena; the researcher 
needs to look beyond those initial events that produce change to explain the very 
process of change itself. This is the great value of evaluation research. Therefore, a 
balance of ontology and epistemology considerations is important.
In considering a design within the quantitative paradigm, and the findings within the 
literature review, it is likely that groups of fifteen patients per program would be ideal. 
However, this would mean a small sample size and may limit the ability to test for 
significance. According to Stewart (2000) statistical significance testing provides a 
convenient method for identifying those empirical outcomes that should receive 
further attention. He argues that without a test of statistical significance, researchers 
are left with the question of what results should be reported in detail and which 
effects require further analysis and reporting. He notes an alternative to significance 
testing is estimation of effect size, since, unlike significance testing, effect size is not 
dependent on sample size. Effect size is generally reported as some proportion of 
the total variance accounted for by a given effect (Stewart, 2000). Although effect 
size is not independent of other factors, total variance may be controlled in a variety 
of ways including making the samples more homogenous and through the reliability 
of measures and other properties of scales (Fern & Monroe, 1996: cited by Stewart,
2000).
Given the above, attention to sampling is important, since randomisation is 
inappropriate in this setting. An alternative strategy may be to use a wait-list control 
condition instead (Jensen, Hoagwood & Trickett, 1999) using matched groups from 
the waiting list to the intervention group. Although matched groups may reduce bias, 
the reality may be that recruitment may be focussed to those who have the least 
glycaemic control and may mitigate against this, but should be aimed for if possible. 
As Daly & McDonald (1992) point out, strict adherence to a method deemed to be
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strong may result in the wrong problems becoming the focus of the evaluation purely 
because the right problems are not amenable to analysis by the preferred method.
Evaluation of programme outcomes can be measured quantitatively using highly 
structured questionnaires (or instruments) or interview schedules, which contain 
predetermined standardised categories into which individual responses are recorded. 
Several validated instruments can be used in combination to give several 
perspectives. In these instruments validity and reliability issues are tested for 
extensively, and data from this can be compared and contrasted across various 
studies. Use of these instruments are reasonably quick to administer and enables 
pre-coded information to be converted to statistical data and produce graphical 
representation of results; the impact of which is a good visual summary of key results 
that can be easily digested.
In this proposed study, it may be useful to use the The Diabetes Care Profile’ (DOR), 
a validated instrument designed to measure the social and psychological factors 
important in a patient’s adjustment to diabetes and its treatment. These factors are 
related to a patient’s self-care behaviour and thus may influence an individual’s ability 
and willingness to provide diabetes self-care (Glasgow & Osteen, 1992). 
Additionally, assessment of pre and post programme knowledge of diabetes can be 
assessed using the Diabetes Knowledge Scale (Dunn et al. 1984). Statistical 
measures using correlation coefficients and factors analysis methods may be applied 
to assess relationships between variables to determine what, if any, variables 
influence outcomes that are being looked for within the programme. Use of a 
computer and the advice of a statistician would be a definite asset.
Evaluation research -  qualitative paradigm
In contrast to the quantitative paradigm, the qualitative approach provides insight into 
the social processes that account for the changes observed within a programme. It 
offers answers to questions as to why observed results occur. Clarke (1999) argues 
that an evaluation should describe the perception and experiences of those 
individuals or groups involved in a particular programme since lack of understanding 
of the subjective experiences may lead to the formulation of inappropriately designed 
programmes. The questions of interest that would be pursued would include areas 
around what difference the expert patient approach made compared with usual 
professional-led care as perceived by the participants, what added value was there to 
lay-led education? Exploration of the experience of having diabetes and the concerns
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that need to be addressed in setting up the programme, and evaluating whether they 
were met at the end; what processes (social or educational) were helpful in problem­
solving issues of living with diabetes; what aspects of the programme made a 
difference to the participants? These questions cross areas within phenomenology 
and ethnography approaches and are amendable to methods of interviewing and 
participant observation methods.
According to Marshall and Rossman (1999), qualitative research is a broad approach 
to the study of social phenomena. Its various genres are naturalistic and 
interpretative and their methodology draws on multiple methods of enquiry. The use 
of multi-method or triangulation reflects an attempt to get an in-depth understanding 
of the phenomenon, and the combination of multi-methods adds rigor, breadth and 
depth to any investigation. The naturalistic approach rejects the view that the social 
world can be understood by applying scientific modes of enquiry since social 
phenomena are clearly distinct from natural phenomena and need to be dealt with 
differently. Field & Morse (1985) note that the basic distinction between qualitative 
and quantitative approaches are that the qualitative methods develop theory 
inductively from the data. Theories and propositions are generated mainly from data 
collected during and at the end of the research, rather than before the study starts as 
in quantitative methods.
Qualitative research privileges no single methodology over any other and it has no 
theory or paradigm that is distinctly its own, neither is it allied to any particular 
discipline although it is used by many disciplines (Denzin & Lincoln, 1998). 
Therefore, the research approach or strategy is determined by the nature of the 
question. Each qualitative strategy offers a particular and unique perspective that 
generates a view of reality more easily than other methods. Denzin and Lincoln 
(1998:84) suggest that if the question concerns ‘meaning of phenomenon’, then the 
method suited would be phenomenology; if the questions concerns the nature of 
phenomenon, then ethnography would be a good approach; if the question concerns 
an experience and the phenomenon in question is a process, then the method of 
choice would be grounded theory. Given that an evaluation research is process 
oriented, grounded theory may seem to be the best way forward, but it generates 
conceptually dense theory. However, given time constraints of the program, this may 
not be the most cost effective option since the approach uses the constant 
comparative method for generating data and theory, and is very detailed and time 
consuming and therefore expensive.
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The purposes of qualitative methods are ‘to understand, to develop or to discover’ 
(Marshall and Rossman, 1999). Within the context of evaluation research, qualitative 
research should be used to explore the dimensions of what makes a particular 
programme work. Qualitative methodologies can also be used prior to the 
programme to establish outcomes being looked for by various stakeholders to ensure 
that the ‘should do’ aspects are explicit and explored. Methods to enable this would 
typically be use of focus groups, individual interview or questionnaires.
Focus groups are group discussions where the group is focussed in some kind of 
collective activity (Kitzinger & Barbour, 1999) and are useful in exploring people’s 
experiences, opinions concerns and wishes. It offers the advantage of gathering a 
wide variety of information over a larger number of subjects (Marshall and Rossman, 
1999). In the context of this proposed research, focus groups may enable answers to 
questions such as ‘what is the lived experience of having diabetes like? What are the 
daily issues that influence problem solving and symptom recognition? What 
difference has the expert patient approach made to you?’
Focus groups are not the same as group interviews; the distinguishing factor is the 
explicit use of group interaction to generate data through talking with each other and 
the researcher. Kitzinger and Barbour (1999) note that any group discussion may be 
called a ‘focus group’ as long as the researcher is actively attentive to group 
interaction. Other group methods include nominal groups (group specially convened 
to perform ranking exercises to establish priorities and concerns); Delphi groups 
(selected panel of experts responding to results from complementary research); and 
consensus panels (designed to develop agreed protocols or principles). All of these 
methods reflect purpose of intent, and knowledge of them is important in selecting the 
appropriate approach.
Kitzinger and Barbour (1999) suggest that the researcher is mindful that all data is 
context bound, and the same individual is likely to answer the same question 
differently in different data collecting scenario’s such as individual interviews, groups 
convened, or in groups occurring naturally. Consideration to the method used to 
access verbal views should look at how the group context and broader cultural and 
institutional features operate to suppress or express points of view. Composition of 
the groups should consider group size, demographic diversity, homogeneity and 
heterogeneity issues, using strangers or non-strangers.
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Practical issues such as finding a venue, reimbursing travel expenses need to be 
considered as well as issues related to recording and transcribing focus group 
discussions. Transcribing data may be challenged by issues such as recognising 
who the speakers are on tape, and use of additional observers to take notes may be 
necessary. The number of focus groups used may be dependent on the availability 
of time and resources to conduct and analyse them.
Focus groups can be combined with quantitative methods such as questionnaire 
surveys to enable construction of questionnaires in terms of relevance and use of 
participant’s language. They would be useful in validating interpretations made from 
the questionnaires used in the quantitative approach outlined above to add another 
dimension of evaluation to the interpretation of data.
The use of in-depth interviews enables the researcher to explore topics and allows 
the participant to express and structure responses as they see it. The strength of the 
interview is that it may generate large amounts of data quickly. The weakness of the 
method relate to the personal nature and co-operation of the subjects to gather valid 
data. Participants may not be willing to share all their thoughts and feelings. 
Interviewing skills that are sensitive to language issues (phrasing, expression and 
cultural variables) are also influential in tapping good data. Interviewing skills are 
important to a range of situations including ethnographic interviewing, 
phenomenological and focus group interviewing.
Use of questionnaires and surveys are another method used in qualitative data 
collecting. The survey method has the advantage of collecting a small amount of 
information from a large number of subjects, and offers a way to measure politically 
or ethically sensitive areas. Marshall and Rossman (1999) note that the assumption 
underlying questionnaires and surveys is that self-report methods can be measured 
accurately The researcher relies totally on the honesty and accuracy of the 
participant’s responses. Some respondents may be perceive this method an invasion 
of privacy. Although it is simple to administer and is convenient, the researcher 
needs to be wary of questionnaire overload that may lead to disinterest in completing 
them. Therefore, consideration to the absolute need and value of additional 
questionnaires may be critical.
Participation observation is to some degree an essential element of qualitative 
research since immersion in the setting allows the researcher to see, hear and 
experience the reality as the participants do (Denzin & Lincoln, 1998). Systematic
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noting and recording of events and behaviour such as body language, interactions 
with other participants, the nature of the questions asked within and external to the 
classroom and informal views or reactions to classroom sessions can be collected.
Within the research proposed these methods offer an opportunity to validate or 
contextualise and clarify data received from other methods. Observation can range 
from highly structured, detailed notation of behaviour guided by checklists, to holistic 
description of events and behaviour. Marshall and Rossman (1999) note that initially, 
the researcher may not have predetermined goals, but as patterns develop and 
evolve, the researcher may become more focussed in their observations. Its strength 
as a method is to discover complex interactions in natural social settings.
Proposal outline
A range of methods used in qualitative approaches has been discussed. Research 
methods are merely tools that can be used in a variety of ways. The nature of the 
questions and the perspective of the research shape these uses. For example, 
ethnographic methods may use participant observation more frequently that surveys. 
Selection of methods is also contingent on the resources available to the 
researcher/evaluator.
Within the evaluation research framework, a range of these tools that the author 
would use are as follows. Focus groups would be necessary to ensure that 
stakeholders’ views are taken into account, particularly those who are the key 
decision makers (Rossi, Freeman & Lipsay, 1999). Focus groups are also likely to be 
used at the beginning and end of the evaluation to assess the processes of the 
programme from the perspective of participant and facilitate relevant adaptations to 
programme. Participation and observation methods would also be necessary at key 
points (determined by the resources available to the researcher) to monitor change 
and issues emerging during the programme. These may be pertinent in determining 
aspects influencing the quantitative approach (recruitment and attrition issues) as 
well as gaining data on the interactions occurring within the group that help or hinder 
the programme aims. The use of surveys may be used to gain a view from the 
referring centres within the Primary Care Trust to gain their perceptions of change in 
the patient’s self-management strategies as a means of triangulating the data.
Ethical considerations within the qualitative paradigm are seemingly more prolific in 
terms of the individual nature of relationship with the researcher. Confidentiality is
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critical, and temptation to ‘gossip’ about any data must be curtailed. However, in a 
focus group situation, setting ground rules about confidentiality is important, but does 
not necessarily guarantee it being honoured. There is always a risk of misinformation 
occurring in focus groups, and the researcher has a responsibility to ensure that this 
is addressed. Issues of informed consent and confidentiality need to be overt and 
considered.
Summary & Conclusion
The strengths and weaknesses of the scientific and naturalistic paradigms have been 
discussed. It has been shown that expressed in their pure forms the paradigms are 
seemingly logically incompatible. This is, because they are based on fundamentally 
different philosophical premises, and represent mutually exclusive ontological and 
epistemological positions. The quantitative approach assumes reality as ‘singular, 
convergent and fragmentable’ whereas the qualitative paradigm subscribes to the 
view that reality is multiple, divergent and interrelated. Therefore, differences exist 
between quantitative and qualitative approaches, particularly in relation to the type of 
data collected and analytical procedures used.
In the context of evaluation research, the range of data that needs to be collected is 
wide and implicitly requires a multi-method approach. Both paradigms offer the 
evaluator a range of tools that can provide the sponsors and stakeholders with a 
range of relevant information to show the effectiveness from a range of perspectives. 
Knowledge that a programme works cannot be achieved by a single philosophical 
stance. Human beings are not inert; they are complex and have a range of 
influences within a programme. Methods that describe and interpret these 
complexities are important to the evaluation.
Limitations to the use of research methodologies within evaluation may be linked to 
time and available resources and represent a ‘best effort’ approach. This contrast 
with academic research whether qualitative or quantitative methodologies are used 
because the purposes of the knowledge differ. In order to make informed decisions 
concerning method choices it is essential that evaluators understand the 
characteristic features of the major methodological pluralism in evaluation research 
and the value of using a mixed methods design.
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Critical Reflection on a leadership Issue
Advancing Healthcare Practice th rough  Developm ent and Im plem enting  Integrated Care 
Pathways fo r Post M l Patients in Primary Care
Section One
Concept of Advancing Health Care Practice
This section of the portfolio will discuss the concept of advanced practice. A 
historical perspective is reviewed to distinguish between advanced practices in terms 
of developing autonomy, and advancing the boundaries traditionally associated with 
nursing and advanced knowledge related to medical developments. As healthcare 
environments have changed, advances in the role of the nurse have emerged and 
the lack standardisation of term has confused the picture regarding the roles of 
advanced nursing practice and specialist nursing. The dimensions of expertise and 
the limitations of competencies are reviewed briefly and the lack of compatibility of 
competence and expertise are alluded to. It is concluded that advancing practice is a 
complex activity that incorporates a unique range of roles and dimensions of 
knowledge, personal attributes, expertise and skills. There is an overlap of these 
roles, skills and processes and attempting to separate them detracts from the holistic 
nature of advanced practice.
Historically, nursing has developed and evolved around the developments of 
medicine, which have been influenced by technological innovations and advancing 
medical sciences. Arguably, early advances in nursing practice for example, have 
been around adapting practices related to patient care as they have pertained to 
medical innovations. However, these advances have been guided, and influenced by 
the medical profession, in a predominantly paternalistic manner, where the 
boundaries of nursing have not been transcended or advanced (Dingwall & Allen
2001). There is much debate in the literature about the essence and nature of 
nursing, and the complexities of defining the uniqueness within nursing practice. 
Whatever definitions have been used, a key constant in nursing has been the 
domination of medicine in the major decision-making processes around patient care, 
and the lack of autonomy in this respect for the nursing profession.
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In reviewing the literature, and reflecting on the issues of advanced or advancing 
nursing practice, there seems to be a recurring theme linked to advancing traditional 
boundaries and the enhancement of autonomy in nursing practice. These advances 
have been defining unique roles that seem to link around the concept of holism and 
unmet patient needs and have arisen from the socio-political and economic issues 
impacting on the healthcare systems. A consequence of this has been that the 
boundaries between doctors and nurses role has become less distinct with the 
evolving role of clinical nurse specialists and the consultant nurse.
Within the recent literature on role innovation and developments within the practice of 
nursing, there emerges a plethora of role titles that are not linked to a standardised 
definition of role and purpose. This has had an impact on evaluating and defining the 
nature of advanced nursing practice. Concepts such as expert practice and specialist 
practice can be seen to be components of advanced practice, but may in some 
studies be defined as either of the above. For example, expert practice may be 
described as advanced practice or specialist practice depending on the researchers 
or authors definitions. According to Conway, (1996) in her extensive review of the 
literature on advanced nursing practice, the only demarcation in the literature 
between the specialist and advanced nursing practice appears to be the level of the 
degree undertaken, that is, first degrees level for specialist practitioner and masters 
degree for the advanced practitioner. She concluded that two models clearly emerge 
in terms of advanced practice and notes that tensions arise between them. These 
are described as the medical model of advanced practice and ‘a nursing-focused 
approach to developing care based on a reflective paradigm’ (p6). The latter 
paradigm having emerged from early work in nursing development units.
Conway (1996) raises a concern that this polar distinction of advanced practice 
moving toward a ‘mini-doctor’ model or ‘maxi-nurses’, should evolve away from the 
medical model. In my view, this concern misses the crucial point that nurses are 
where patients are, and experts excel mainly in their own domain (Chi, Glaser & Farr 
et al. 1988) that can be found anywhere on the health continuum from wellness, 
illness and dying. The descriptor of ‘mini-doctor’ overlooks the fact that what nurses 
believe about nursing explicitly or, more probably, implicitly, is constitutive of nursing 
(Greenwood, 1995) and is always patient centred and nursing focussed in a ‘patient 
needs’ contexts. The challenge inherent in the medical model or substitution of the 
medical role (usually within secondary care) is that the scope of practice is defined
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only as that part that overlaps medicines’ scope of practice. The full scope of the role 
may not be fully recognised, and the nurses’ role risks becoming undervalued.
Advanced practice is defined by the UKCC (United Kingdom Central Council, 1994) 
as that in which a practitioner is engaged in ‘adjusting the boundaries for the 
development of future practice, pioneering and developing new roles responsive to 
changing needs and with advancing clinical practice, research and education, to 
enrich professional practice as a whole’ (UKCC, 1994:20). The UKCC further 
elaborates that ‘advanced practice will also make a contribution to health policy and 
management and in the determination of health need. This is not an additional layer 
of practice to be super-imposed on specialist practice. It is rather, a description of an 
important sphere of professional practice, which is concerned with the continuing 
development of the professions in the interests of clients, patients and the health 
services’ (UKCC, 1994). The Council therefore sees the advanced practitioner as 
working at the frontline of the profession, innovating and leading nursing practice. It 
is recognised by the Council that this requires considerable professional knowledge 
and expertise, plus advanced education to masters degree level and that only a small 
number of nurses will undertake this kind of practice.
McGee (1998) criticises this definition because it implies a certainty about advanced 
practice that in reality does not exist anywhere in the world literature. She argues 
‘what is certain is that some forms o f nursing transcend speciaiisation even though 
they may be based in it. There is something beyond the possession o f high levels o f 
knowledge and expertise that enables the individual practitioner to function in a 
different way’ (pi 77). The elusive nature of this difference has created difficulties in 
articulating its nature. Hamric (1996) proposes that, as with the nurse specialist, it is 
possible to identify a range of core elements within the advanced role. These are 
multifaceted and in her opinion ‘advanced nursing practice is the application of an 
extended range of practical, theoretical and research based therapeutics to 
phenomenon experienced by patients within a specialised clinical area of the larger 
discipline of nursing’ (p47).
This multifaceted nature of advanced nursing is reflected in the observations of 
advanced nurse practitioners. Elliott (1998) observes that advanced practice is the 
integration of practice, education, leadership, research and consultancy coupled with 
the individual practitioner’s scope of practice and personal qualities. Overton-Brown
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(1998) sees advanced practice as more than ‘specialist nursing’, which tends to be 
based on the medical model. Whereas advanced practice is ‘about what drives the 
individual, what motivates them, it is more than a set of skills it is a way of thinking 
and viewing the world based on clinical knowledge rather than composition of roles’. 
She further suggests that it demands an enquiring articulate mind with the ability to 
lead, sow creativity, be flexible and take risks, therefore is as much about individual 
characteristics as professional expertise. McGee (1998) sees several roles and 
characteristics linked to the advanced practitioner. These include those of an expert 
coach offering guidance and developing others in their practice, clinical and 
professional leadership to act in the best interests of the patients, being able to see 
possibilities and opportunities in situations (vision). Leadership is seen as presenting 
new ways of looking at everyday events and drawing people’s attention to new 
horizons and crossing boundaries to forge alliances with other members of 
professional groups. It could be concluded that advanced practice is more than a set 
of skills or roles; it’s about a way of seeing and thinking and individual characteristics 
as well as professional expertise. The author concurs with McGee’s view that 
‘becoming an advanced nurse practitioner could be seen emerging from the 
development of a specialist nurse and expertise growing sufficiently to blur the 
interface between nursing and medicine with significant overlaps in terms of decision 
making, diagnostic and therapeutic skills, problem solving research and education.’
Expertise is central to advanced practice and is multi dimensional. These dimensions 
encompass a range of expertise within the domain of clinical practice and leadership 
ability for merging challenges and expectations of the healthcare system. Analysis of 
research studies on expert performance by Chi et al (1988) suggested seven generic 
characteristics of expert performance. They found that experts excel mainly in their 
own domain, and were no more competent than anyone else outside of it. Experts 
perceive large meaningful patterns in their domain, (schemata), and were able to 
access data (knowledge) quickly; they were faster than novices at solving problems, 
reflected longer, and were more likely to use principles and theory to solve problems; 
experts have superior, short-term, and long-term memory and have strong self­
monitoring skills. The latter relates to double checking the facts, solutions, and have 
an increased awareness of their errors.
The standardisations of competencies required for higher levels of practice have 
been recognised in recent work done by the UKCC (2002) with regard to developing
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a standard and assessment system for the regulation of a higher level of practice in 
nursing, midwifery and health visiting. This work was initiated by the UKCC - which 
has now transformed to become the Nursing and Midwifery Council (NMC) - in 
response to a need to modernise the regulation of practice in the public interests.
Seven competencies with supporting criteria have been developed that characterises 
higher-level practice. The competency based framework approach has a role in 
terms of accountability and quality. This approach has been criticised by Elliot (1991) 
who argues that good practice cannot be discerned through national performance 
criteria but through peer review and supported self-reflection. Expertise is predicated 
on learning from experience so that future practice is enhanced. Using a 
competency-based approach does not offer insight into how an individual develops 
competence or what contribution experts make to performance outcomes (Manley & 
Garbet, 2000). In conclusion, advanced practice is a complex activity incorporating 
several roles underpinned by a wide variety of knowledge, personal attributes, 
expertise and skills. There is an overlap of these roles and attempting to separate 
them detracts from the holistic nature of advanced practice.
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Section 2
A Critical Account of Advancing Healthcare Practice
The following discussion examines how in my previous role as a project manger I 
was able to advance healthcare practice and will briefly reflect on how this work has 
influenced further advances and developments in healthcare practice for chronic 
disease management within a Primary Care Trust (POT). The focus of the discussion 
will reflect on how facilitating the implementation of an integrated care pathway 
contributed to advancing the healthcare practice of others; enabled inter-professional 
working and embedding evidence based practice for post Myocardial Infarction (Ml) 
patients.
Background
My role at the time was that of a project manager for the National primary Care 
Collaborative (NPCC) working for the modernisation agency. The rationale for the 
NPCC was to implement management systems within primary care to enable the 
development of a ‘primary care-led NHS’ in line with government policy changes. 
The key aspect of the role was to deliver improvements in primary care that optimises 
the experience of the patients within the National Health Service (NHS). The role 
was primarily that of a change-agent.
The three areas of the project for development were first, to improve access for 
appointments with the GP or practice nurse; second, to actively engage with 
secondary care and primary care to reduce the waiting lists with the greatest demand 
by utilising a ‘whole system’ approach to ensure sustainable capacity in the future. 
Third, to systematically manage chronic disease to reduce the number of acute 
events, and maintain stability and functional status of the patient using evidence 
based practice. The project focused on implementation of the Coronary Heart 
Disease (CHD) NSF as a platform for learning the skills of systematic management of 
CHD through building disease registers, maintaining them and using ‘recall and 
review’ strategies (mostly nurse-led) to systematically review all patients for 
education and evidence-based prescribing of medicines to improve survival and 
functional capacity of cardiac patients. The idea of ‘Collaborative’ working is to
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reduce trial and error in improving healthcare by sharing successful solutions and 
ideas from other NHS providers, nationally and locally. Tools and techniques were 
disseminated using strategies similar to action research methodology of collecting 
data, trialling solutions using short-term evaluative strategies, workshops and project 
managers to guide and facilitate change. The process of developing new behaviours 
in the context of real life experiences enables individuals to adapt or co-evolve with 
new situations, thus supporting the transition from individual competence to personal 
capability (Fraser & Greenhaigh, 2001).
Capacity for Advancing Practice
Inherent within the role was the capacity to network and to advance healthcare 
practice in a way that could improve patient care. This method aimed to reduce work 
related stress through new ways of working; reducing daily hassles arising from poor 
systems; facilitate learning and develop inter-professional and collaborative working. 
Working directly with practices, over a period of two years helped establish 
relationships and credibility as a health professional. Further, close working with GP 
practices provided insights, issues and data arising within primary care practices, 
thus enabling joint problem solving and practice improvements. For the purposes of 
this portfolio, the focus of discussion will be on the development of the integrated 
care pathway.
Primary Care in Context
The term ‘Primary Care’ is used to describe the patient’s first point of contact with the 
health service. The main primary care provider organisations are general practice, 
community health services, pharmacists, opticians, dentists and accident and 
emergency departments. However, primary care is often equated simply with general 
practice. Gordon (1999) describes primary care as ‘complex, organic, small and 
local, it is multi-professional, multi-agency, multi-shaped and multi-sized’. Within 
primary care, there is great variation in the quality and structure of general practices. 
Practices are small-scale organisations and are often culturally variable in their 
approach to healthcare provision. A common denominator however, is that by 
definition, general practice offers primary care delivered by generalists. Although 
GPs and nurses may develop specialist interest roles along with their generalist roles, 
the systematic delivery of evidence-based cardiology is likely to be variable in quality 
across the PCG.
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The National Service Frameworks (NSF) aim to ensure equity of access and 
standardisation of NHS care for patients wherever they live. They reference the 
quality of care and health outcomes using the best available evidence of clinical and 
cost effectiveness and aim to reduce undesirable variation in healthcare. 
Implementing the NSF requires partnerships across a number of agencies such as 
social services, the wider local authority, the voluntary sector and other government 
departments (Swage, 2000). Given the context of primary care and the remit of the 
NSF, these aims present a considerable challenge to standardise and implement 
high quality secondary prevention strategy.
The decision to develop a care pathway for post Ml patients had been made prior to 
my working with the Primary Care Group (PCG) as a project manager. The PCG 
lead nurse had attended a workshop, saw the benefits of an integrated care pathway, 
and recognised this model as a solution to implementing the NSF for CHD within 
primary care. However, she lacked the skill and knowledge of CHD and pathway 
development and invited me to facilitate the team in its development. Having never 
developed a care pathway and having limited experience within primary care did not 
daunt me since I have extensive domains of knowledge and experience to draw from. 
These include extensive experience with cardiac patients from the specialism of 
cardiology, cardio-thoracic surgery and cardiac rehabilitation that is supplemented 
with a Masters degree in both cardiology and nursing. As an educationalist, I have 
knowledge and skills in accessing published information as well as skills in facilitation 
and practice development.
A conclusion drawn about developing expertise over the years is that in moments of 
uncertainty, a key skill is knowing the right questions to ask. Often this unlocks 
relevant personal knowledge to enable effective problem solving, or may stimulate 
others to reflect further and enabling them to develop better solutions. The value of 
having this knowledge in terms of developing the care pathway maintained 
confidence in my own leadership ability and expertise to get the information I needed 
from published work and colleagues in practice.
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Benefits of Integrated Care Pathways
Integrated Care Pathways (ICR) encompasses standardised clinical guidelines for the 
management of specific disorders aimed at optimising and streamlining patient care 
(Cannon & O’Gara, 2001). They are a useful tool to enable implementation of 
evidence-based practice and national guidelines in to daily practice. This places a 
big responsibility on the ICR development team to maintain currency and accuracy of 
evidence within the pathway by ensuring review dates. An integrated care 
management system focuses on the continuity of care by taking a whole system view 
on the organisation and management of patient care to facilitate smooth transitions 
between healthcare professionals (Wilson, 1997). Although conceptually, pathways 
are attractive and offer many advantages in managing the patient’s journey, concerns 
have been raised about their effect on patient outcomes, physician autonomy and 
malpractice liability (Cannon & O’Gara, 20110). Clinical guidelines are not a 
substitute for professional judgment or clinical accountability. Clinical guidelines are 
broad statements of principle that enable clinical decision-making. Used effectively 
they have the potential to reduce the level of complaints and litigation in healthcare 
by improving the communication process and the quality of care. (Tingle & Foster,
2002). Use of a care pathway can be valuable in terms of the nature of its systematic 
documentation. This allows similar data to be recorded, including reasons why care 
was omitted, and produces prospective audit data, on which to manage the 
commissioning process more effectively.
Development of the ICP
The development of an Integrated Care Rathway (ICR) was an opportunity to review 
current practice, identify the strengths and gaps in practice and professional 
knowledge and develop a basis for equity in patient care delivery across all GR 
practice’s within the RCG. This was achieved by convening a multidisciplinary 
subgroup from the clinical governance strategy team whose role was to advise and 
develop the pathway. Developments and draft work within the subgroup were fed 
back to the rest of the RCG through the full clinical governance strategy group 
meetings. This group had a representative (lead) from each practice who was 
responsible for feeding back comments on the developments of the ICR to promote 
ownership and implementation of it.
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A review of the published literature and an internet search of NHS and other web 
sites was undertaken to learn more about the process and seek examples. There 
were no examples found for use within primary care, but a plethora of examples for 
secondary care, which were useful to evaluate for presentation styles. Discussions of 
the findings were presented to the Clinical Governance Strategy Group to help clarify 
the focus of ICP development.
Key professionals from primary and secondary care who had a role in the care of the 
post Ml patients were invited to a weekend workshops facilitated by me for process 
mapping to identify current practices and service development needs. The NSF for 
CHD document was used as a reference point for key areas for service development. 
An important outcome of this process was the wider insight into the roles within the 
multi-disciplinary team by all attendees. For example, the district nursing team had 
been visiting patients within 24 hours of discharge post Ml for the last 10 years, much 
to the amazement of the GPs, who had no concept that this was usual practice. The 
concept of ‘role’ is widely employed in considerations for inter-professional work 
(Rawson, 1994). Rawson notes that it is essential to distinguish how the position of 
each professional group within an occupational structure specifies task 
characteristics from how the professional perspective shapes the job. The 
significance for inter-professional work is that roles have to be actively interpreted 
and negotiated between inter-professional collaborators rather than prescribed. In 
discussing the role perception along the current pathway and issues related 
duplication and shaping care around the patient, this prepared the way for protocol 
development that supplemented detail to the care pathway document.
The outcome of this workshop was the development of action plans for each group 
member. The areas for development were that GPs wished to be informed of patient 
admission with Ml early in the hospitalisation. This advance notice was seen as 
being helpful to relatives who sought the GP for advice regarding coping during this 
period. This was actioned via the cardiac rehabilitation nurse specialist, who would 
fax a copy of her referral using a confidential fax in the district nurse liaison office to 
the relevant GP practice. The development of a patient held record would be 
completed to meet the NSF requirement to provide written documentation to patients 
informing them of their cardiac risk factors. Additionally, this would facilitate the 
management of transitions between health professionals, as details could be kept up- 
to-date and reduce duplication of tests and procedures. A project plan to devise
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protocol development and resources to implement evidence-based secondary 
prevention was also outlined. This included scheduling a series of educational study 
days to educate nurses in the use of the patient held records; and attendance by at 
least one nurse per practice for the British Heart Foundation (BHF) CHD secondary 
prevention course (3 days) was actioned.
Patient Held Record
The development of the patient held record was in progress prior to my appointment 
as project manager. Work on the design had been ongoing for one year and the work 
had ground to a halt with it. A key reason for its lack of progress was uncertainty 
about the specialist content, function and implementation as well as lack of 
Information Technology (IT) skills. Essentially the patient held record was modelled 
on the BHF card supplied free to all health practitioners but was found to be too small 
for practical use. The content on the front contained data that were required by the 
GP in the early discharge period. However, in evaluating it I could see a lot more 
potential that could be drawn from it. I modified the design of the card and sought 
expert opinion on the content from pharmacists for drug therapy, secondary care 
cardiology team and the CCU nurses to agree the wording of chest pain symptoms 
before submitting it to the subgroup for further comment.
The card was modified to enable secondary care nurse specialists to record the 
patient’s risk factors and baseline data. These enabled a basis for assessment by the 
district and practice nurses and reduce the duplication of work in primary care and 
promote continuity. To facilitate patient information and standardisation of knowledge 
for practice nurse-led clinics, the normal values for risk factor management were 
included. This is the only patient held record I have come across that has made this 
information explicit. The idea is that the patient will be given an opportunity to 
understand and assess their progress. Key information about chest pain symptoms 
were added since this is an area of concern for patients post Ml, and is reassuring to 
have it written down. The first symptom descriptors relate to Ml, and the second 
section relates to unstable angina. It is important that the patients can distinguish 
between them, since early presentation to the accident and emergency department 
can abort a heart attack. The patient held record also has a section on medication 
with key information for patients. The idea of this is to enable self-management and 
adherence to therapy since the patient will see how their cholesterol is responding to
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the drug dose, or how their blood pressure medicine has impacted on the level of 
their blood pressure, and chest pain patterns settled in response to calcium channel 
blockers or beta blocker therapy.
The patient held record was a key tool to advancing healthcare practice because it 
provided a focus for benchmarking best practice and a practical tool for non-specialist 
nurses to use with reasonable confidence in delivering secondary prevention clinics. 
Best practice is referred to as a process-oriented concept to achieve improvements 
within individual agencies or settings over time. Best practice means doing things 
smarter, or those practices, which lead to superior performance, achieving constant 
quality in what is done and is evidence based (Perleth, Jakubowski & Busse, 2001). 
A ‘pre-test’ audit was carried out to assess the level of information available to nurses 
prior to the card being used so that the impact on practice could be measured. A 
post-test audit is pending, and was delayed due to complex reorganisation with the 
PCG. A patient evaluation (n=40) of the hand held record to evaluate acceptability 
revealed that most patients were happy with the design and data on it. There was a 
consensus about the clinical data on the front of the card that ‘whatever helped the 
doctor’ was valued by the patients.
Integrated Post Ml Care Pathway Document
The patient held record and the process mapping exercise informed the post Ml care 
pathway document. The first page conveys the handover details that were 
considered important and reflect the locally identified contexts of care in terms of 
transitional information. The data in green writing pertains to the ‘Read codes’ that 
enable CHD register development and maintenance. This supports audit and can be 
entered by either a health professional or a non-health professional post consultation. 
Phase 1 checks the processes that should have occurred at the local hospital prior to 
discharge. Variances are documented and these can be used in the monitoring and 
performance of the local Hospital by the PCT and can inform the commissioning 
process.
Phase 2 builds on the work carried out previously by the district nurses. This is 
where healthcare practice has been advanced in terms of clarifying the aims of the 
visit and providing a framework for assessment. Data can be written here that will 
give a good baseline data to provide continuous individualised care rather than focus
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on generic tasks. The patient held record should be with the patient from the hospital 
thus providing a rich source of current information to engage with the patient. The 
work done by the cardiac rehabilitation specialist regarding cardiac risk factor 
management is made explicit allowing the district nurse to focus on information needs 
which may not have fully covered as in-patients. Risk management such as chest 
pain management and DVLC guideline information ensures that patients access 
emergency care appropriately, and also documents advice on driving. If the patient 
chooses to drive, then liability lies with the patient. The management of follow up is 
also made explicit. Completion of documentation using a ‘tick box’ approach was 
added for patient convenience. Variances can be recorded that offer prospective 
audit data. Workforce planning is included as nurses are asked to write in the time 
taken to deliver the care. This will enable costs of care and outcomes to be 
evaluated in terms of clinical effectiveness monitoring.
Phase 3 is when the district nurse gives the ICP document (booklet form) to the 
practice to update the records and CHD register. The idea here is that if the data are 
entered onto the system early, and if the patient phones for advice, the GP, and 
practice nurse record will be up to date, thus saving time and increasing efficiency to 
the patients and health professionals benefit.
Phase 4 records the second district nurse visit. The ICP with the previous entry 
enables the nurse to anticipate the patients’ needs more fully. Pilot work of the ICP 
revealed that the next phase (practice nurse) would be smoother and less stressful 
on the patient if the blood form was given to the patient at this stage in advance of the 
practice visit for phlebotomy. Post visit, the ICP is returned to the practice.
Phase 5 is the handover period for future management of CHD secondary 
prevention. In contrast to previous practice, the nurse now has an opportunity to 
acquaint themselves with the patients’ story prior to seeing them in the nurse-led 
clinic. They are now able to target the patients’ needs in a more focused way that 
facilitates the sense that the patients’ recent history is known and is more likely to 
portray a sense of being cared for. Duplication of questions is less likely.
Phase 6 highlights a risk point of relapse in lifestyle habits. This section is left to 
professional judgement as to whether it is a face-to-face visit, telephone follow up or 
omitted.
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Phase 7 contains the annual review template to record on going care.
Development of an algorithm for evidence based management of hyperlipidaemia; 
hypertension was developed to supplement the use of the ICP. The team were 
supplied with a range of guidelines including the joint society guidelines, NICE 
guidelines and SIGN guidelines and we systematically reviewed each relevant 
section to amalgamate the evidence into one guideline.
Implementation Plan
The ICP was trialled at four practices and adjustments were made based on the 
feedback. The progress of the developments was fed back to the practices via the 
clinical governance strategy leads from each practice. The team proposed that an 
implementation pack, should be used to take around to all practices, and used to ‘sell’ 
the ICP ‘package’ (protocols and ICP document). The idea here was that each 
practice should have a multidisciplinary team meeting to hear the ICP presentation. 
The point of the implementation pack was to ensure consistency of delivery of 
information to each practice within the PCG. This idea was later delayed in favour of 
a half-day study day to launch the care pathway. This decision was taken by the 
CHD lead who was a district nurse and PCG board representative, and the team 
reluctantly agreed. The study afternoon was poorly attended, managed, and not 
universally well evaluated by those who attended. Sadly, the implementation pack 
was not developed and practices were not visited. This was partly due to much 
organisational instability due to unsuccessful mergers. Evaluation of the effect of the 
ICP revealed that despite the poorly staged implementation phase the nurses valued 
it. Time was saved particularly with the practice nurse, who previously spent most of 
the consultation period engaged with the computer in an effort to get everything read- 
coded to the detriment of the patient who was passively observing this interaction. 
Practice nurses now engage with the patient, tick the boxes, make brief notes, and 
then at the end of the clinic inputs data through the computer to update and read 
code the episode of care.
Personal Learning
A combination of perspectives learned from developing the care pathway has 
informed both my learning and current strategy to advance healthcare practice and 
develop inter-professional working in my current role as CHD and chronic disease
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management lead within a PCT. Key learning was around the facilitation role around 
processes within pathway development and producing the pathway documents; and 
project manager skills for clinical development projects.
As a project manager, I engaged with the practices discussing and facilitating quality 
improvements and updating on progress with the collaborative projects. Some 
nurses invited me to mentor them during early clinic developments and support their 
learning with the patient held record and cardiac assessments. In addition, working 
on other projects and networking with nurses in other PCGs and managers and 
nurses in both local hospitals allowed me to gain a great deal of information 
supplementary to the care pathway. Being a member of two PCTs before being 
merged into a third PCT allowed a rare insight into the CHD strategy (or lack of) in 
other organisations and provided insight into our own achievements. Interest from 
the diabetic nurse specialists, vascular nurse specialists and district nurses working 
with stroke care, facilitated insight into other spheres of chronic disease management 
projects. As a primary care project manager, I learned that GPs are overwhelmed 
with paper and are very selective readers. Therefore the development of professional 
relationships were key, to ensure written communication or protocols are prioritised 
by GPs as part of clinical engagement.
Learning drawn from these experiences has shown that integrated care pathways 
may be key to future management within a PCT. The development of inter­
professional work across primary and secondary care is crucial to advancing 
healthcare practice. Utilising the expertise of others and valuing or acknowledging 
their ideas is important for creating motivation to develop practice. Given the time 
constraints within primary care, I will be developing a vascular risk pathway which 
covers three disease areas of importance (diabetes, stroke and CHD) which have 
common management themes including lifestyle, diet and medications which can be 
integrated as a common hand held record supporting several separate pathways.
The original pathway is currently serving as a model for future development and I am 
visiting all practices (and canvassing the views of each practice) to get their views 
and ideas on this model of care. The response to date is very positive and I am 
motivated to develop the work further.
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To conclude I would like to draw on the work of Higgs and Jones (2000) who reflect 
my own perceptions of what expert practice comprises, and the approach to 
advancing healthcare practice. Higgs and Jones (2000) identified experts as 
practitioners who value the participation of relevant others (clients, caregivers and 
team members) in the decision making process, who use high levels of metacognition 
in their reasoning and recognise the value of different forms of knowledge and use 
this knowledge critically. Experts are patient centred and share their expertise to help 
develop expertise in others. They are able to communicate their reasoning well and 
in a manner appropriate to their audience, and demonstrate cultural competence in 
their reasoning well and in a manner appropriate to their audience, and demonstrate 
cultural competence in their reasoning and communication. It is likely that degrees of 
skill and ability within these domains defines whether someone is an expert 
practitioner (clinically) or as an advanced practitioner (innovating practice).
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Service Evaluation Critique
Managing change in access in primary care: A critical review of the process
M odule : Organisational D evelopm ent in the  Public Sector
Consider a process o f change th a t has taken place In your w ork  th a t you could use as a case 
study consider which process o f change you:
• W ould  be likely to  use m ost o ften?
• W ould  likely to  use sometimes?
• W ould  never use?
Introduction
The process of change that will be used as a case study to critically reflect on change 
management tools and techniques for Organisational Change, reviewed by lies and 
Sutherlands (2001), relates to the work of the National Primary Care Collaborative 
(NPCC) around access targets to a General Practitioner (GP) or primary care 
professionals. The assignment will first describe the background for the motivation 
for being part of the NPCC, the organisation and context of primary care and the 
relevant issues related to ‘Access’ to set the context within a public sector 
organisational change programme.
Having laid out the case study, a critically reflective account on the change 
methodologies used in the case study will be critiqued with regard to whether they 
would likely be used again, occasionally or not at all.
Case Study
The case study is set within a small Primary Care Group (PCG) that was comprised 
of eleven GP practices. The PCG was eighteen months old at the start of the project 
and was managed by the Chief Executive and Chair of the PCG. There were no 
other management employees during the first year of the project; a commissioning 
manager was employed during the last year of the project. The PCG has since 
dissolved and has been reorganised within another organisation and now forms part 
of a larger Primary Care Trust. To enable full discussion of the organisational 
context, the geographical details will be omitted to ensure anonymity of practices and 
individuals.
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This case study will reflect on the management of change conducted under the 
auspices of the modernisation agency. The perspective of change relates to the 
authors role of project manager for the national primary care collaborative. The key 
aspect of the role was to deliver improvements in primary care that optimises the 
experience of the patients within the National Health Service (NHS). The role of the 
author was primarily that of a transformational change-agent.
The national primary care collaborative project was tasked with three key change 
areas for organisational improvement. These were to: improve access to general 
practice (90% of patients could get an appointment to see a GP within 48 hours and a 
primary care professional with 24 hours); improve access to specialist care (hospital 
waiting lists) and to implement a systematic proactive approach to chronic disease 
management. The latter used the National Service Framework (NSF) for Coronary 
Heart Disease (CHD) as a platform for learning. The idea of collaborative working is 
to reduce trial and error in improving healthcare, by using systematic methodologies 
that are data driven, and through sharing successful solutions and ideas from other 
NHS providers, nationally and locally. These methods were facilitated by a primary 
care collaborative handbook, regular workshops, web-based materials and via a 
project manager supported by a centrally located development team.
National Primary Care Collaborative and Access 
Why is Access an Issue?
Because the NHS is a publicly accountable and funded service, the Department of 
Health (DOH) has conducted surveys on the views of the public and professionals to 
determine what service improvements the public and staff wish to see prioritised. 
This was published in the NHS plan (Department of Health, 2000), and one of the top 
three public responses was for improved access to primary healthcare services.
According to the National Primary Care Collaborative literature (National Primary 
Care Development Team, 2000), the main issue with access to primary care is 
‘gaming the system’ by patients and practices, (Murray, 2002; Freeman, Horder & 
Howie, 2002). The proposal is that, by systematically examining supply, demand and 
system variation effectively, general practices can manage their access more
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effectively. The outcome would be patients getting the appointments when they want 
them resulting in increased patient, staff and clinician satisfaction.
A framework for calculating capacity and demand was part of the access 
management package. The key theory was to reduce multiple queues (urgent and 
routines) to one manageable queue and then shorten the queues through a range of 
strategies such as telephone consultation and triage systems (Murray, 2000). 
Practices were required to produce monthly data and action plans. A project 
manager supported this process.
Primary Care in Context
Primary care has been defined by Heywood (2000;p26) as the ‘community based 
health services that provide preventive, primary, personal and continuing care to 
patients and their family, including responsibility for the practice population as well as 
individuals”. This definition relates to the role of general practice, where the 
accountability for healthcare lies primarily with the GP and the primary health care 
team. During the last fifty years within the NHS, general practice has undergone 
many reforms and has developed from an isolated, single-handed GP, 
organisationally peripheral focus, (secondary care being dominant) to a larger team 
based organisation that has an increasing, central focus within the NHS (Heywood, 
2000).
Primary care forms the infrastructure of most healthcare systems and it has been 
argued that a strong primary care system is both cost effective and is linked to better 
health outcomes (Sims, 1999). Gordon (1999; p3) describes primary care as 
‘complex, organic, small and local, it is multi-professional, multi-agency, multi-shaped 
and multi-sized.’ Within primary care there is great variation in the quality and 
structure of general practices services. Practices are small-scale organisations and 
are often culturally (how things are done) variable in their approach to healthcare 
provision. Given these definitions, any strategies for organisational development 
would have to be multi-faceted and sensitive to local context and history. It is likely 
that change management has been experienced to varying degrees by most GPs 
and may colour the perception of ‘top down’ approaches to quality improvement that 
may help or hamper actions to change future practice (Exworthy, Wilkinson and 
McColl, 2003).
275
The Organisational Context of the PCG
The decision to put in a bid for membership to the national primary care collaborative 
arose from the Chair of the PCG who was a local GP. Discussion with the Chair 
regarding his motivation for joining the collaborative, revealed that the significant 
lump sum of money available to participating practices for ‘pump priming’ change to 
improve the patient experience, and for covering travel and locum costs, was key. In 
addition, there was the added benefit of the national profile attached to the project. 
The perception of the PCG chair regarding the project outputs was that the PCG was 
doing comparatively well already. Although the practices were not meeting the 
access targets consistently, this was not perceived as a major problem since great 
confidence had been placed in the role of the project manager to ‘sort it out’.
The Chief Executive Officer (CEO) was happy to participate in the program, but 
expressed grave doubts to the author, regarding its success due to a long held belief 
that if you increase access you will increase and encourage demand. This doubt 
may have underpinned his anxiety that the added demand would increase pressure 
on limited resources to meet it. This concern represented the chief executive’s 
‘theory-in-use’, which Argyris (1996; p8) notes can significantly influence how 
individuals and groups make choices and solve problems. Argyris argues that 
theories-in-use link into organisation development through the concept of single and 
double-loop learning. Single-loop learning helps get everyday work problems solved 
that keeps the status-quo, whereas double-loop learning is conducive to 
transformational change through ‘changing the status-quo’. Therefore, at executive 
level, minimal support occurred in terms of integrating the project outcomes and 
learning into the PCG development. It was beyond the author’s skill to know how to 
manage this perception better, since attendance to all workshops, educational half 
days and data validation by local practices did not convince the CEO otherwise.
The collaborative was a two-year, two-stage project. The first year comprised six 
practices (core practices) that attended three workshops per year at the prestigious 
Belfry Hotel in Warwickshire, and were paid five thousand pounds per year. The 
second year would recruit ‘Spread’ practices who would be paid two thousand five 
hundred pounds, and learning would be from local and national core practice 
successes and would be facilitated by the project manager. In year one, the PCG
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organised post Belfry Workshop events with the PCG to discuss the learning and 
ideas from the national workshops. Financially, every cent was given to the 
practices; none was held by the PCG to secure central support for any project 
developments. This would have been helpful to the core practice in the deprived 
zone that had comparably limited additional funds to trial their ideas.
Selection of practices was not voluntary in that the chair of the PCG allocated them. 
Unfortunately the core practices had all been fund-holding practices and the spread 
practices had been non-fund holding. This fact was probably influential in the 
resentment and non-engagement of the spread practices to the project, two of the 
spread practices had expressed an interest in being core practices. The core 
practices comprised three practices that were interested in improving access and 
three who were comfortable with their current systems and did not seem to be 
receptive to improvement methodologies.
Within General Practice, GPs are independent contractors. This is relevant to the 
access project for two reasons. First, GPs are paid through capitation fees, fees for 
service and target payments and are thus paid to attract patients (Sheaff, Pickard & 
Smith, 2002). Second GPs regard themselves as small businesses (Heywood, 2000) 
and employ their own staff, and therefore have a great deal of influence regarding 
decisions about managing the practice and patient access strategies. The 
implications of this is that GPs have to be actively engaged by whatever means, in 
change management processes and educational events to allow ‘external’ people 
such as NHS managers to influence policy implementation and engage with their staff 
in systems improvement (Exworthy, Wilkinson & McColl, 2003).
Outcomes
At the end of the project, all core practices could offer forty-eight hours access to a 
GP and four out of six could provide access to a practice nurse. Work prioritised on 
GP access at the expense of nurse access and workload. Nurses were rarely 
involved in strategic decisions regarding access. Regarding the spread practices, 
receiving consistent data was problematic and conclusions regarding progress could 
not be fully assessed. Three out of the four practices were not able to meet NHS 
Plan targets. A frequent issue raised by the majority of practices was that there was 
no time to collect capacity and demand data. Moving practices from their comfort
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zone was a key challenge. Binney and Williams (1997; p3) suggests that ‘top-down’ 
Change Programmes do not often work. Instead of transforming organisations, they 
produce mediocre results and often do not shift corporate cultures in the way that is 
needed for sustainable results.
Critical Reflective Critique
This section introduces the framework of change discussed by lies and Sutherland 
(2001) to illustrate the classification of change being implemented as well as issues in 
assessing change particularly within the context of primary care, where multiple 
policies are being implemented across a range of services within similar time frames. 
The author will then review selected change processes outlined in lies & Sutherland 
(2001) that were either used, not used, or would be considered, by the author having 
reflected on the learning and outcomes of the case study.
lies and Sutherland (2001:14) comment that change can be either deliberate or 
emergent. Deliberate change is a product of conscious reasoning and actions, and is 
planned. Change that appears to unfold, that is apparently spontaneous and 
unplanned is referred to as emergent change. Emergent change may be related to 
planned change, but may not be apparently connected. Further, emergent change 
may be due to external forces impacting on planned change, seen from this 
perspective; it is clearly non-linear or fixed. This implies that evaluating change 
maybe complex and therefore, evaluating the change occurring relative to methods 
and tools used, is likely to be presumptive.
Change can also be viewed as a contextual phenomenon, occurring in episodes or 
as a continuous process. Episodic change reflects a revolutionary or radical change 
in the system where one strategy is replaced by another and is referred to as second 
order. Continuous change, or first order change is seen as incremental, evolutionary 
and reflective and linked to continuous improvement. The use of episodic and 
continuous change strategies were illustrated at the national primary care 
collaborative workshops on access, however, a major emphasis was on continuous 
improvement strategies that were focused on developmental change. According to 
Langley et al (1996:p77) second order change are required to improve the system 
beyond historical levels, and include redesign of parts of the system and
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fundamentally alter how the system works and what people do. This type of change 
underpins much of the work by the modernisation agency.
Change Processes: Organisation Development and Project Management
lies and Sutherland (2001) have organised the tools techniques and models they 
reviewed under four key questions. These were ‘How can we understand complexity, 
interdependence and fragmentation?’ ‘Why do we need change?’ ‘Who and what can 
change? and ‘How can we make change happen?’ These questions systematically 
assess organisational capacity and readiness for change as well as implementing 
change. On reflecting on the models and tools used in the case study, the majority 
were from the ‘How can we make change happen’ category, which probably reflects 
the modernisation agency perspective and priority towards implementation of change 
(policy). In this case study, this was probably the case for the sponsors, and to 
varying degrees by those responsible for implementing the vision. Only one 
technique used came from the ‘understanding complexity’ question (Soft Systems 
Methodology), and the other two categories were not addressed in the case study. 
On reflection, the tools, models and techniques for the first two categories would be 
considered as essential and would be used frequently in any future change project.
This section will begin with discussion of project management as a change 
management tool since entry to the change process journey started here for me as a 
project manager. Burke (2002) defines a project as:
‘an endeavour in which human, (or machine), material and financial resources 
are organised in a novel way, to undertake a unique scope of work, of given 
specification, within constraints of cost and time, so as to deliver beneficial 
change defined by quantitative and qualitative objectives’.
The project was to deliver an improvement methodology for managing primary care 
access that had been originally tested and found to be successful in one 
geographical location and was then used to implement the project nationally. The 
national team devised milestones, data collection tools that were distributed to 
participating practices. Monthly data and reporting were implemented and funding 
was given. National Workshops were put on to disseminate the experiences of
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practices that had used these techniques and validated their utility. Project 
management has been defined by Burke as:
‘the application of knowledge, skills, tools and techniques to project activities 
in order to meet stakeholders needs and expectations from a project’ (Burke, 
2002).
The life cycle of a project has distinct phases, these are:
The concept and initiation phase, where need is established.
• Design and development phase, where the feasibility and plans are 
established.
The implementation or construction phase where the plans are put into 
practice.
The commissioning and handover phase where the project is terminated and 
handed back to the sponsor (Burke, 2002).
In the context of the case study, the approach to change was ‘top down’. Unlike the 
author, the national team had an opportunity to explore perceptions about ‘access’ 
and then took a unilateral view on its definition and measurement. In order for the 
project to be implemented at a national level, it is likely that the measures for ‘access’ 
had to be ‘generic’. This may be problematic as ‘access’ can be a subtle concept in 
that it may have multiple perspectives (availability, intellectual access, and quality of 
services etc) however it is often the service utilisation rates that are used as a proxy 
measure of access (Goddard & Smith, 2001). The NPCC used proxy measures and 
this may have limited the project outcomes to those that could be measured, possibly 
at the expense of what was possible and desired at a local level.
As project managers, few were party to the discussions and insights from the first two 
phases of the project cycle. This misses a key area for successful implementation of 
the project. That is, a full and thorough understanding of the project. Although the 
national team put on training for project managers who came from a range of 
backgrounds, (both internal and external to the NHS and clinical and non-clinical), 
there was very thin coverage on the essential knowledge on understanding the 
access problem, the measures, aims and methods. In fact, project management 
training appeared haphazard and did not seem to integrate with the needs of the 
project managers. Much of my early interaction with practices was based on the
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hope that by parroting the words of the handbook, all would be crystal clear to those 
that do the work. On reflection, this was assumptive, since I later learned that 
practice managers knowledge of access was variable and had been limited to trial 
and error and advice from other practice manager who had been around longer. The 
body of knowledge and frameworks were not there to start with, so, they made no 
more sense of it than I did, except in few practices, who were not engaged with 
change, and who felt their system worked for them. Had I known exactly the issues 
related to access and the changes proposed and understood, I feel I would have had 
a greater opportunity to improve the support and outcomes of the project. However, I 
learned a lot in the process that was very valuable.
Reflecting on the project management approach in the context of the case study, I 
concluded that it assumes much about the process of change. Inherently there is the 
assumption that there can be a universal solution to the problem that can be 
delivered off the shelf. PIsek & Wilson (2001) noted that current organisational 
thinking is built largely on the assumptions that plans for progress must provide ‘best 
way’ completely specified in detail and consistently implemented in the same level of 
detail across the board, and thus fails to take advantage of natural creativity 
embedded in organisations. Problems may occur when learning is transformed into a 
recipe and attached to a centrally set target. On reflection, use of assessment and 
diagnostic tools for change reviewed by lies an Sutherland particularly the PESTELI 
(see below) and SWOT (Strengths, Weakness, Threats and Opportunities) analysis 
may be key it improving success within change management processes. The 
assessment of organisational readiness and context may have supported a project 
management model that enables integration of both a ‘bottom up’ and ‘top down’ 
project plan. Perhaps it would have been better if the Access issues had been 
articulated by the practices and ownership of the solution facilitated. I found (one 
year later in my journey) that the modernisation agency had reflected the issues to 
Access accurately, but I had ‘sold’ it as an outsider (essentially as a ‘this is the 
problem’) rather than facilitating it as ‘what is our problem with access’. Within the 
project management literature it is well recognised that the three reasons why 
projects fail, is due to lack of executive commitment, lack of knowledge about what 
they doing, and lack of knowledge on how to proceed (Van Der Men/ve, 2002; 
Pellegrinelli, 2002).
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The lessons learned from this experience are that I would have certain caveats about 
using project management as implemented in this case study, arising from a national 
initiative as an organisational change process. This is because implementing 
national models that comprise logical processes of modelling, in a superimposed way 
on often, irrational social processes, may be limited in their effective implementation, 
particularly in a time limited framework (Crawford, Costello & Pollack, 2003).
Soft Systems Management (SSM)
lies and Sutherland (2001:34) defines soft systems methodology as a ‘means of 
articulating complex social processes in a participatory way, allowing peoples 
viewpoints and assumptions about the world to be brought to light, challenged and 
tested.’ Crawford et al. (2003) suggest that soft systems management complement 
‘hard’ systems management of change such as project management by exploring 
aspects of situation’s that cause them to be problematic. The soft systems approach 
recognises that there is no ‘one’ best solution, and that there are many possibilities 
for action, each valued differently by other stakeholders. A notoriously difficult area 
of change is working-practices and culture. Often with the same practice, there were 
varying views on how things should be done, and attitudes to work and patient 
access. Crawford (2003) suggests that ‘grafting and embedding’ have been identified 
as ways to combine hard and soft methods. Add soft systems management to a 
stage of a hard process (project management) while embedding involves running the 
two processes concurrently and using soft systems management to structure the 
problem. Successful implementation of strategic change by projects requires a 
flexible process grounded in shared professional experience (Crawford, Costello & 
Pollack 2003). In the authors experience, the most important factor in managing 
change was found to lie in good working relationships and establishing trust within 
each general practice.
Organisational Development
Using project management as a tool for change had its limitations within this case 
study in that it was time limited and super-imposed. Taking an organisational 
development approach and applying project management tools may have overcome 
the limitations discussed above. This issue of Access taken from an organisational 
development approach may enhance continuity and ongoing support and 
sustainability of change.
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French & Bell (1999) defines organisational development as a long-term effort, led 
and supported by top management, to improve an organisation’s visioning, 
empowerment and learning and problem solving process, through an ongoing, 
collaborative management of organisation culture -  with special emphasis on the 
culture of intact work teams and other team configurations -  using the consultant- 
facilitator role and the theory and technology of applied behavioural science, 
including action research.
Analysis of this definition suggests that change takes time and there is no quick fix for 
lasting organisation development. The importance of top management support is 
seen as imperative along with visioning to clarify a viable coherent shared picture of 
the primary business agenda. The use of empowerment through leadership 
behaviours that enable others to use their talents fully and collaboration and shared 
learning to enable organisational learning to be embedded and shared is central. 
Collaborative management of the culture means that everyone has a stake in making 
the organisation work.
Looking to lies and Sutherland (2001) the approach I would most likely use that 
would embrace some of the organisation development philosophy of approach would 
be to tackle the question ‘how can we understand complexity, interdependence and 
fragmentation?’ Using the PESTELI (Political factors. Economic influences. 
Sociological trends. Technological innovations. Ecological factors. Legislative 
requirements. Industry analysis) checklist and a steering group comprising top and 
middle management and practice representatives and other stakeholders within 
primary and community care, the organisation could establish the issues related to 
provision of primary care access. This would take into account those services 
provided by the PCT to enable practices to improve their access. Services such as 
walk-in clinics, out of hours services, and ‘NHS Direct’ as a supportive infrastructure 
for practices and patients could be considered in an integrated way. This acronym 
(PESTLI) would provide a structure that took into account:
Politics, internal and National
Economics that would likely include incentive payments to enable baseline
work and improvement pilots to take place.
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Sociological trends would enable planning for different patient groups and 
their access needs,
Technological innovations would look at the use of telemedicine, telephone 
consultation and management of patient information given the different 
contexts of access.
Ecological issues would enable consideration to parking and access. 
Legislative requirements would enquire on factors such as confidentiality, 
location of patients notes etc and
Industry analysis would be on the customer needs, marketing, and so forth.
This has the advantage of involving the whole organisation rather marginalising (and 
defining narrowly) Access to the periphery by using project management alone.
Engaging the Practices
The PESTELI analysis may enable a legitimate point of entry into the practice that 
iooked at Access from a whole system view rather than imply the fault lies in the 
practice. The question posed by lies and Sutherland (2001) would be to ‘why do we 
need to change?’ is key to getting the ‘what’s in it for us?’ (would the change be an 
improvement?) view within practices to enable them to identify whether there is a 
need for change. Perhaps they have a good and equitable system from which we 
could learn. The S.W.O.T. analysis as discussed above was the tool reviewed to 
answer this question. This is helpful in looking at what they are doing well, what 
could be improved and factors helping and hindering the process. Ownership of the 
project then helps establish a need for change or to improve the current system. 
When going around the practices and ‘selling’ access from the logic of the national 
team the learning from this informed me that working from the ‘what’s in it for us’ is 
central to engaging people in the change process.
A project outcome was to generate learning to sustain a system that improved 
access. The method used was similar to Action Research methodology, through 
implementing the ‘Plan-Do-Study-Act’ cycles as discussed below. This localises the 
problem solving to individual practices and is a complementary model to facilitate 
organisational learning. Most practices preferred not to take the time to write PDSA 
cycles out; therefore I did it for them to help manage the targets for the project, but 
this meant the practices did not continue this technique at the end of the project. An
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action research model is cyclic and iterative and consists of identifiable processes 
reflected in PDSA cycles. PDSA cycles ensures that change activity is planned, 
including a plan for data collection, the plan was attempted (Do) and that time is set 
aside to analyse the data and study the results (Study) and action (Act) is rationally 
based on what was learned (Langley, Nolan and Nolan, 1996:p60). It also offers 
evaluation at each stage of change and in this sense it is a directional tool for change 
and as such is one tool I would use frequently. However, in managing change at a 
micro-level, conclusions may be drawn about outcomes that were emergent from 
other areas of the health service (increased demand for appointments due to early 
discharge from hospital) that may be more apparent from evaluating the whole 
system (macro-level).
In conclusion, a range of processes of change have been discussed and evaluated 
relative to their utility within the context of the case study. On reflection, I think that 
the national team should have taken a different approach to empower their project 
and the change management team. It has been argued that an organisational 
development approach supported by organisational assessment and diagnostic tools, 
with project management and soft systems methods using an action research model 
may have been a better strategy to promote sustainable change than by project 
management alone. National projects may be useful in providing workshops and 
celebrating the successful strategies and promoting shared learning between and 
within organisations.
Change management tools such as PESTELI and a SWOT analysis offer an 
assessment for the organisational readiness that enable the starting point for the 
project plan and strategy for change, and for this reason, I would use it frequently. 
Project management skills have a value and may be useful in managing a rapidly 
environment. In this sense, I would use it often to manage complex projects in the 
context of primary care as discussed above. However, I would use it with certain 
caveats in the context of change as noted above. Action research allows the 
organisation to test their theories-in-use and offers a directional tool, and for this 
reason I would use it frequently, although there was reticence in writing out PDSA’s 
which may limit its use in practice.
The process of change is multifaceted, complex and a variation of tools that enable 
change management are available. A key personal learning outcome within this
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study is that mutual understanding of the problem, processes, vision and direction is 
crucial for all concerned. Soft systems methods that build relationships with people 
enable multi-perspectives to be understood to direct change and learn, are core 
requirements to facilitate change. Organisational change is not a solo journey and 
requires the efforts of many. There are no short cuts, nor ‘off the shelf answers and I 
would argue after two year managing this project that ‘off the shelf answers are likely 
to be foolhardy and certainly not cheap.
286
References
Argyris, C. (1996) On Organisational Learning Blackwell Business, Oxford
Binney, G. Williams, 0. (1997) Leaning into the Future; Changing the Way People 
Change Organisations. Nicholas Brealey Publishing, London
Burke, R. (2002), Project Management; Planning and Control Techniques, third 
edition, John Wiley and Sons Ltd., Chichester.
Crawford, L. Costello, K. & Pollack, J (2003) Managing Soft Change Projects in the 
Public Sector International Journal o f Project Management 21, 434-443. 2003.
Department of Health. (2000) The NHS Plan. London, HMSO
Exworthy, M. Wilkinson, E.K. McColl, A.M. (2003) The Role of Performance 
Indicators in Changing the Autonomy of General Practice Professions in the UK. 
Social Science and Medicine 56, 7, 1493-1504)
Freeman, G. Horder, P. Howie J.G.K. (2002) Evolving General Practice Consultation 
in Britain, the Issues of Length and Context BMJ 324, 880-82.
French, W.L. & Bell, C.H. (1999) Organisation Development, 6th edition, Prentice- 
Hall International Ltd.
Goddard, M. & Smith, P. (2001) Equity of Access to healthcare Services: Theory and 
Evidence from the UK. Social Science & Medicine 53, 1149-1162.
Gordon, P. (1999) “Primary Care n Context”, in Primary Health Care Sciences, 
J. Sims, ed., Whurr Publishers Ltd, London.
Heywood, P. (2000) The Changing Character of Service Provision (Ch 2) in 
Contemporary Primary Care: The Challenges o f Change edited by Philip Tovey. 
Open University Press, Buckingham.
lies, V & Sutherland, K, (2001) Organisational Change: A Review for Heaith Care 
Managers, Professionals and Researchers, National Co-ordinating Centre for NHS 
Service Delivery and organisation R&D, London
Langley, G.J. Nolan, K.M. Nolan, T.W. Norman, C.L & Provost, L.P. (1996) The 
Improvement Guide Jossey-Bass, San Fransisco.
Murray, M. Modernising the NHS, Patient Care: Access. BMJZ20, 1594-1596.
National Primary Care Development Team. (2000) Primary Care Collaborative 
Handbook. Manchester, NHS.
Pellegrinelli, K.S. (2002) Shaping Context: The Role and Challenge for Programmes. 
International Journal o f Project Management 20, 229-233.
PIsek, P.E. & Wilson, T. (2001) Complexity, Leadership and Management in 
Healthcare Organisations. BMJ 323, 46-49.
287
Sheaff, R. Pickard, S. & Smith, K. (2002) Public Service Responsiveness to Users. 
Demands and Needs: Theory Practice and Primary Healthcare in England. Public 
Administration 80 [2]
Sims, J. (1999) Primary Health Care Sciences \Nhun Publishers Ltd, London.
Van Der Merwe, A.P. (2002). Project management & Business Development: 
Integrating Strategy, Structure, Processes & Projects. internationalJournai o f Project 
Management 20, 401-411.
288
PUBLICATION
An audit review of end-of-iife care for hospitalised patients with Diabetes
An audit review of 
end-of-life care 
for inpatients 
with diabetes
Debbie Hindson, Pat CoUiety, Jill Shawe, 
Peter W illiams
Article points
1. Th is  audit evaluated 
end-of-lifè  care decisions 
in  the management o f  
diabetes.
2. Data were collected 
fo r 71 cases to assess 
demographics, 
diabetes characteristics, 
m on ito rin g  and diabetes 
treatment w ithdraw al and 
the potentia l ab ility  fo r 
“self or other” advocacy 
fo r these decisions.
3. The findings suggest 
that most inpatients 
w ith  diabetes in  whom 
deterioration and death is 
rapid continue capillary 
blood glucose m onitoring 
to the end o f  life.
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glucose monitoring
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The decision to withdraw capillary blood glucose (CBG) 
monitoring and glycaemic treatment at the end o f  life in people 
with diabetes may have implications for comfort-care management 
in the dying individual in the acute care setting. The paradigm 
shift to the self-management o f diabetes through CBG monitoring  
enables patients or their relatives to contribute to decisions for 
the withdrawal o f CBG m onitoring or antidiabetes treatment. 
Although it is unknown whether glycaemic symptoms are 
perceived in dying persons in the same way as those in full health, 
there is still an obligation to consider their effects on comfort 
at the end o f life. In this article, the authors report the findings 
from a medical-notes audit in which they evaluated some key 
assumptions about advocacy (self or other) for end-of-life care 
decisions and the management o f diabetes.
Authors details can be found 
at die end o f this article.
T he decision to w ithdraw  capillary blood glucose (CBG) m onitoring and glycaemic treatment at the 
end o f life  in  people w ith  diabetes may have 
implications for comfort-care management 
in the dying individual in the acute care 
setting. The symptoms com m only seen in 
the term inal phase o f life (the last 72 hours) 
include pain, weakness, dyspnoea, nausea, 
vom iting, restlessness, dry m outh and 
dizziness (Tsai et al, 2006), and are sim ilar 
to symptoms seen in  diabetic ketoacidosis 
(D K A ), hyperglycaemia and hypoglycaemia.
The role o f CBG m on itoring may enable 
symptom dilferentiation and appropriate 
glycaemic treatment measures as part o f the 
comfort-care plan. The paradigm shift to 
the self-management o f diabetes through 
CBG m onitoring (W allym ahm ed, 2007) 
enables patients (or their relatives) who have 
the mental capacity and self-management 
knowledge to contribute to decisions for the 
w ithdrawal o f CBG m on itoring or diabetes 
treatment. Th is  may be im portan t as there 
is evidence that the perception o f  hypo- 
and hyperglycaemic symptoms varies in
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character, pattern and intensity, both w ith in  
and between individuals, and over time 
(Pennebaker et al, 1981; Cox et al, 1993; 
Weinger et al, 1995; M cAulay et al, 2001). 
A lthough it is unknown whether glycaemic 
symptoms are perceived in  dying persons in 
the same way as those in  fu ll health, there is 
s till an obligation to consider the ir effects on 
com fort at the end o f  life  (Ford-Dunn et al, 
2006).
Aim
In  this article, the authors report the findings 
from a medical-notes audit that formed part 
o f  an evaluation research study in which a 
favourable ethics opinion was received. The 
audit sought to evaluate some key assumptions 
about advocacy (self or other) for end-of-life 
care decisions and the management o f diabetes.
Sample
The total hospital deaths for the period between 
1 January and 31 December 2008 in a 450- 
bed acute hospital in Surrey was 1257. O f 
these individuals, 229 (18.2%) had a reported 
comorbidity o f diabetes. Am ong these, there 
were 22 referrals to the DSN team and 19 to 
the palliative care team. The Flospital Episode 
Statistics database was searched for additional 
adults w ith  a comorbidity o f diabetes and cancer 
(n=30). These 71 individuals were audited.
The age range for the cohort was 
52-95 years (mean age, 76.9 years). T h ir ty  
(42.2%) were female and 4 l (57.7%) had 
a cancer diagnosis (additional uncoded 
cancer cases were found). There were seven 
individuals (9.9%) w ith  type 1 diabetes and 
62 (87.3%) w ith  type 2 diabetes, which reflects 
the population ratio (Diabetes U K , 2010). 
O f  the remaining two individuals, one had 
steroid-induced diabetes and the other had 
diabetes o f  unknown type.
Data collection and analysis
Data were collected to assess individual 
and disease characteristics, including those 
suggesting ab ility  to be a self-advocate for 
end-of-life diabetes treatment withdrawal 
(socio-demographic data; ability to give one’s
own history on admission; documentation 
o f intact cognition; diabetes type, duration 
and treatment; and inclusion o f individual 
or relative views) and management variables 
(glucose m onitoring practices, cancer status, 
relationship between diabetes medication 
w ithdrawal and individuals’ nu trition intake, 
DSN and palliative care involvement and 
influence o f the Liverpool Care Pathway [LCP] 
at the end o f life). Descriptive and inferential 
statistics were used.
Individual and family advocacy variables
The literature reports that most individuals are 
w illin g  to discuss their end-of-life preferences 
(Heyland et al, 2003) and the opportunity to do 
so has been found to be im portant (Fallowfield 
et al, 2002). In  this study, only three individuals 
had any documented reference in the notes for 
their end-of-life diabetes management; two o f 
these had type 1 diabetes. One individual who 
knew that her prognosis was “ days” requested 
an intravenous insulin infusion to ensure her 
insulin needs were continuously met in the 
terminal phase; an im m inently dying patient 
admitted from  a clin ic explicitly stated no CBG 
m onitoring by the physician, w ithou t reference 
to the decision source. One person w ith  type 2 
diabetes requested CBG monitoring.
Expertise with diabetes
The m ajority o f individuals were like ly to have 
significant expertise to support shared decision­
making. A ll individuals w ith  type 1 diabetes 
had been diagnosed for >30 years. Among the 
people w ith  type 2 diabetes, ha lf had been 
diagnosed lo t >10 years. Most o f the cohort 
(76%) were managed w ith  tablets, insulin 
therapy or both and were likely to be fam iliar 
w ith  their own CBG profile. A  structured 
glycaemic history was not part o f the standard 
admission history by doctors or nurses for 
hypoglycaemic awareness or usual CBG 
profile. The majority o f the cohort (66%) were 
reasonably well controlled pre-admission, w ith  
a mean HbA| level o f 55 m m ol/m ol (7.2%) 
w ith in  the previous 6-12  months.
Table 1 summarises the socio-demographic 
profile for the study group. The data suggest
Page po in ts
1. There were 71 individuals 
audited: seven w ith
type 1 diabetes, 62 w ith  
type 2 diabetes, one w ith  
steroid-induced diabetes 
and one w ith  diabetes o f  
unknow n type.
2. O n ly  three individuals 
had any documented 
reference in  the notes for 
the ir end-of-life  diabetes 
management; tw o o f 
these had type 1 diabetes.
3. A ll indiv iduals w ith  
type 1 diabetes had been 
diagnosed fo r >30 years. 
A m ong the people w ith  
type 2 diabetes, ha lf 
had been diagnosed
for > 10 years. M ost o f  
the cohort (76% ) were 
managed w ith  tablets, 
insu lin  therapy or both 
and were like ly  to  be 
fam ilia r w ith  the ir own 
capillary blood glucose 
profile.
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Table 1. Ind iv idua ls ’ socio-demographic profile .
Diabetes type 
Type 1 Type 2 Steroid-induced Unclear 
«=7 (9.9%) «=62 (87.3%) «=1 (1.4%) «=1 (1.4%) Tota l
« (%)
Support
Lives alone Male 1 5 1 7 (9.9%)
Female 11 11 (15.5%)
Lives w ith  spouse Male 26 1 27 0&o%O
Female 4 6 10 (14.1%)
Lives w ith  relative Male 3 3 (4.2%)
Female 3 3 (4.2%)
Lives in  care home Male 1 3 4 (5.6%)
Female 1 5 6 (8.5%)
M enta l capacity to make decisions
- O n  admission: Yes 6 46 0 52 (73.2%)
N o 1 15 1 17 (23.9%)
Unclear 1 1 2 (2.8%)
—Last 72 hours o f life: Yes 2 27 29 0:&8%O
No 5 34 1 40 (56.3%)
Unclear 1 1 2 (2.8%)
Term inal phase apparent on admission Yes I 7 8 (11.3%)
N o 6 55 1 1 63 (88.7%)
who may have had available fam ily  who were 
knowledgeable about the patients’ attitude to 
the ir diabetes and could contribute to com fort 
care issues, and those who may have needed to 
rely on professional advocacy in  the hospital 
setting.
M an a g e m e n t o f  d iabetes 
at th e  end o f  l i fe
CBG m on ito ring
A total o f 5760 timed and dated CBG 
recordings for the whole admission period were 
collected from 70 individuals’ medical records. 
The number o f CBG tests per person ranged 
between 0 and 721 in a cohort whose length 
o f hospital stay ranged between 1 and 84 days. 
O w ing to the skewed nature o f the distribution 
o f the CBG variables, non-parametric M ann— 
W hitney U  tests were performed to test the 
association between cancer diagnosis and 
CBG test values. There was no statistically 
significant difference between people w ith  
and those w ithou t cancer for the occurrence
o f hypoglycaemia. However, those w ith  cancer 
had a statistically significantly (P=0.022) higher 
proportion o f CBG tests w ith  normal values 
(defined as 4.0-9.9 m m ol/L), whereas those 
w ithout cancer had a statistically significantly 
(P=0.014) higher proportion o f CBG tests 
w ith  values in the hyperglycaemic range 
(defined as slO  m m ol/L). The mean CBG 
values for the last 72 hours o f  life  (terminal 
phase) were variable, as shown in Figure 1. 
CBG in high and low ranges were mostly 
attributable to iatrogenic causes secondary to 
unskilled management o f intravenous insulin 
and enteral feeds. N o DSN referrals were 
received for glycaemic advice at the end o f life 
in these individuals. There was no evidence that 
hypoglycaemia was a “ natural” process in the 
terminal phase, as occurrences were episodic 
in nature. The CBG m onitoring may have 
prompted nurses to alter nutritional intake in 
patients w ith  lower CBG values.
Table 2  summarises the key characteristics 
o f those individuals who were m onitored from
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Figure 1. Mean blood glucose levels for last 72 hours in individuals ivho were monitored to end o f life.
CL,
'o
I
4.1-6.0 6.1-8.0 8.1-10.0 10.1-12.0 12.1-14.9 >15
M ean blood glucose level (m m ol/L )
Table 2. Characteristics o f ind iv iduals who were m onitored versus unm onitored.
M on ito red  to day o f death N o t m onitored to  day o f death
«=48 (68%) «=23 (32%)
Cancer 30 (63%) 11 (48%)
Non-cancer 18 (38%) 12 (52%)
Type 1 diabetes («=7) 2(4% ) 5 (22%)
Deterioration to death:
<72 hours 43 (90%) 16 (70%)
>72 hours 5 (10%) (range, 4 -1 2  days) 7 (30%) (range, 4-18  days)
Intravenous insu lin  given on day CBG w ithdraw n 5 (10%) 1 (4%)
the po int when irreversible deterioration was 
documented u n til the day o f death and those 
who were not.
Monitored individuals
The data for individuals whose CBG levels were 
monitored un til death suggest that the short 
survival time o f 24-72 hours was influential.
Unmonitored individuals 
In the 30% o f unmonitored individuals who 
survived beyond 72 hours, the average time 
unmonitored was 7.9 days. The final CBG 
value was not influential in continuation o f 
CBG m onitoring management despite their 
wide-ranging variation (3.5-22.0 mmol/L). 
A ll symptoms that were documented in  the 
notes were listed in the audit but frequency o f
recurrence was not counted. Those surviving 
beyond 72 hours had more symptoms listed 
than those who did not. The role o f CBG 
monitoring may be useful to determine 
symptom origin and guide reversible treatment.
Referral to the palliative care team for 
support w ith  com fort measures occurred 
in  62% o f the cohort, and 50% o f referrals 
were in the last 72 hours. These late referrals 
may lim it an integrated specialist approach 
to optim ising symptom management across 
palliative and diabetes specialisms.
Food and diabetes medicines w ithdraw a l
M any individuals (41%) were s till taking their 
diabetes medications and some nu trition  un til 
the day o f death. Diabetes drugs were stopped 
the day after food was no longer consumed
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Page po in ts
1. O n ly  two people w ith  
type 1 diabetes were 
m onitored to  the end 
o f life. One person was 
managed on intravenous 
insulin , w ith  capillary 
b lood glucose readings 
>15 m m o l/L . The other 
was managed in  the 
intensive care un it.
2. The findings from  
this audit suggest that 
most inpatients w ith  
diabetes in  w hom  
deterioration and death 
is rapid continue C B G  
m on ito ring  to the end 
o f  life.
3. The lack o f  glycaemic 
h isto ry-taking in  the 
hospital lim its  the 
professional advocate role 
and suggests “ blindness” 
to its importance at 
both a physiological and 
ethical level, particularly 
in people w ith  type 1 
diabetes, for
w hom  patients’ or 
relatives’ preferences 
were no t documented.
in 24% o f  cases (23% in  m onitored and 30% 
in  unmonitored individuals). Th is suggests 
that nurses were d iligent in  m onitoring 
patients’ nu trition  and diabetes medication 
management according to CBG values.
M on ito red  ind iv iduals w ith  type 1 diabetes
Patients w ith  type 1 diabetes were not selectively 
monitored for CBG and treated. This may be 
because the term “ insulin-dependent diabetes 
mellitus”  was commonly cited in  the medical 
notes and the differentiation o f diabetes type 
could not be made.
O n ly  two people w ith  type 1 diabetes were 
monitored to the end of life. One person 
was managed on intravenous insulin, w ith  
CBG readings >15 m m ol/L . The other was 
managed in  the intensive care un it. A lthough 
her CBG was monitored, insu lin  was w ithheld 
fo r 4 days. The notes reported her diagnosis 
as type 2 diabetes, possibly because she was 
overweight. However, the medical notes 
summarised her 37-year type 1 diabetes 
medical history in  one th in  volume.
U nm on ito red ind iv iduals 
w ith  type 1 diabetes
Five individuals were managed on the LCP 
for the last 1—4 days o f the ir lives. Insu lin  was 
stopped in  all cases at different tim e points 
ranging from  24 hours to 7 days before death. 
The ind iv idual whose insu lin  was om itted for 
3 days had been readmitted w ith  recurrent 
D K A , and scant documentation on symptoms 
or diabetes management was noted.
The symptoms listed in the notes in these 
unm onitored patients were th irst, weakness, 
distress, d ifficu lty  swallowing, chestiness, 
shortness o f breath, distress, agitation, 
confusion, nausea, fatigue, poor appetite and 
chest pain. A lthough these symptoms cannot 
be attributed directly to blood glucose level 
changes or D K A  in any retrospective study, 
some may at least be suggestive.
Discussion
The findings from  this audit suggest that most 
inpatients w ith  diabetes in  whom deterioration 
and death is rapid continue CBG m onitoring
to the end o f  life. The m ajority are monitored 
up to 72 hours, probably ow ing to uncertainty 
about the reversibility o f the medical situation. 
This is a common dilem m a in hospital settings 
in  people w ith  advanced disease (Gadoud and 
Johnson, 2011). The decision to discontinue 
CBG m on itoring is clear in  those individuals 
w ith  a prognosis o f  “ days” .
The literature is clear about the importance 
o f managing type 1 diabetes and symptomatic 
hyperglycaemia (Usborne and W ild ing , 
2003; M cCoubrie et al, 2005; Smyth and 
Smyth, 2005; Ford-Dunn et al, 2006; Q u inn  
et al, 2006; Tice, 2006; Rowles et al, 2011) 
at the end o f  life. There appears to be no 
due regard for the contribution o f the CBG 
profile to the ind iv idua l’s symptom profile in 
considering rechecking the CBG  level when 
the last known reading is abnormal. The lack 
o f glycaemic history-taking in  the hospital 
lim its  the professional advocate role and 
suggests “ blindness” to its importance at both 
a physiological and ethical level, particularly 
in  people w ith  type 1 diabetes, for whom 
patients’ or relatives’ preferences were not 
documented.
The LCP is very lim ited  in  its guidance for 
managing end-of-life conditions in which 
w ithdrawal o f  usual treatments fo r “ survival” , 
such as insu lin  in  the case o f  type 1 diabetes, 
has ethical and comfort-care implications. 
The knowledge, sk ill and confidence w ith  
which to manage insulin and diabetes w ith in  
acute care is well known (Spollett, 2006; Derr 
et al, 2007; Cook et al, 2008; George et al, 
2011). Shared decision-making for preferred 
glycaemic thresholds is lim ited  w ithou t such 
knowledge.
L im ita tions
As w ith  all medical-notes audits, the subjective 
nature o f the ind iv idual docum enting care is 
a known issue. Conversations are not always 
reported in the notes and therefore this audit 
can only report what was w ritten .
Concluding remarks
The importance o f documentation o f the type 
o f diabetes, glycaemic history and symptom
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profile for the management o f diabetes and 
supporting com fort care at the end o f  life  in 
the hospital setting is clear. The m ajority o f 
patients (90%) in  this evaluation had a “ do 
not attempt resuscitation”  notification in 
place. Th is may be a good po in t at which to 
consider revising a diabetes plan o f “m in im a l 
and simple” in  line w ith  the individuals’ 
wishes. Collaborative team work between the 
diabetes and palliative care teams to support 
end-of-life com fort care, and managing insulin 
therapy and CBG  testing preferences may 
be helpful. The need for more education and 
better com m unication is a consistent find ing 
in most c lin ical research and its application in 
this setting is clear. ■
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